Note: Descriptions are shown in the official language in which they were submitted.
CA 02412353 2002-12-13
WO 01/95911 PCT/USO1/19062
PROTEASE INHIBITORS
FIELD OF THE INVENTION
This invention relates in general to 4-amino-azepan-3-one protease inhibitors,
particularly such inhibitors of cysteine and serine proteases, more
particularly compounds
which inhibit cysteine proteases, even more particularly compounds which
inhibit cysteine
proteases of the papain superfamily, yet more particularly compounds which
inhibit
cysteine proteases of the cathepsin family, most particularly compounds which
inhibit
cathepsin K. Such compounds are particularly useful for treating diseases in
which
cysteine proteases are implicated, especially diseases of excessive bone or
cartilage loss,
e.g., osteoporosis, periodontitis, and arthritis.
BACKGROUND OF THE INVENTION
Cathepsins are a family of enzymes which are part of the papain superfamily of
cysteine proteases. Cathepsins B, H, L, N and S have been described in the
literature.
Recently, cathepsin K polypeptide and the cDNA encoding such polypeptide were
disclosed in U.S. Patent No. 5,501,969 (called cathepsin O therein). Cathepsin
K has been
recently expressed, purified, and characterized. Bossard, M. J., et al.,
(1996) J. Biol. Chem.
271, 12517-12524; Drake, F.H., et al., (1996) J. Biol. Clzem. 271, 12511-
12516; Bromme,
D., et al., (1996) J. Biol. ClZem. 271, 2126-2132.
Cathepsin K has been variously denoted as cathepsin O or cathepsin 02 in the
literature. The designation cathepsin K is considered to be the more
appropriate one.
Cathepsins function in the normal physiological process of protein degradation
in
animals, including humans, e.g., in the degradation of connective tissue.
However, elevated
levels of these enzymes in the body can result in pathological conditions
leading to disease.
Thus, cathepsins have been implicated as causative agents in various disease
states,
including but not limited to, infections by pneumocystis carinii, trypsanoma
cruzi,
trypsanoma brucei brucei, and Crithidia fusiculata; as well as in
schistosomiasis, malaria,
tumor metastasis, metachromatic leukodystrophy, muscular dystrophy, amytrophy,
and the
like. See International Publication Number WO 94/04172, published on March 3,
1994,
and references cited therein. See also European Patent Application EP 0 603
873 Al, and
references cited therein. Two bacterial cysteine proteases from P.
gingivallis, called
CA 02412353 2002-12-13
WO 01/95911 PCT/USO1/19062
gingipains, have been implicated in the pathogenesis of gingivitis. Potempa,
J., et al.
(1994) Perspectives in Drug Discovery azzd Design, 2, 445-458.
Cathepsin K is believed to play a causative role in diseases of excessive bone
or
cartilage loss. Bone is composed of a protein matrix in which spindle- or
plate-shaped
crystals of hydroxyapatite are incorporated. Type I collagen represents the
major structural
protein of bone comprising approximately 90% of the protein matrix. The
remaining 10%
of matrix is composed of a number of non-collagenous proteins, including
osteocalcin,
proteoglycans, osteopontin, osteonectin, thrombospondin, fibronectin, and bone
sialoprotein. Skeletal bone undergoes remodelling at discrete foci throughout
life. These
foci, or remodelling units, undergo a cycle consisting of a bone resorption
phase followed
by a phase of bone replacement.
Bone resorption is carried out by osteoclasts, which are multinuclear cells of
hematopoietic lineage. The osteoclasts adhere to the bone surface and form a
tight sealing
zone, followed by extensive membrane ruffling on their apical (i.e.,
resorbing) surface.
This creates an enclosed extracellular compartment on the bone surface that is
acidified by
proton pumps in the ruffled membrane, and into which the osteoclast secretes
proteolytic
enzymes. The low pH of the compartment dissolves hydroxyapatite crystals at
the bone
surface, while the proteolytic enzymes digest the protein matrix. In this way,
a resorption
lacuna, or pit, is formed. At the end of this phase of the cycle, osteoblasts
lay down a new
protein matrix that is subsequently mineralized. In several disease states,
such as
osteoporosis and Paget's disease, the normal balance between bone resorption
and
formation is disrupted, and there is a net loss of bone at each cycle.
Ultimately, this leads
to weakening of the bone and may result in increased fracture risk with
minimal trauma.
Several published studies have demonstrated that inhibitors of cysteine
proteases
are effective at inhibiting osteoclast-mediated bone resorption, and indicate
an essential
role for a cysteine proteases in bone resorption. For example, Delaisse, et
al., Bioclzezn. J.,
1980, 192, 365, disclose a series of protease inhibitors in a mouse bone organ
culture
system and suggest that inhibitors of cysteine proteases (e.g., leupeptin, Z-
Phe-Ala-CHN2)
prevent bone resorption, while serine protease inhibitors were ineffective.
Delaisse, et al.,
Biochenz. Bioplzys. Res. Comnzun., 1984, 125, 441, disclose that E-64 and
leupeptin are also
effective at preventing bone resorption in vivo, as measured by acute changes
in serum
calcium in rats on calcium deficient diets. Lerner, et al., J. Bone Min. Res.,
1992, 7, 433,
disclose that cystatin, an endogenous cysteine protease inhibitor, inhibits
PTH stimulated
2
CA 02412353 2002-12-13
WO 01/95911 PCT/USO1/19062
bone resorption in mouse calvariae. Other studies, such as by Delaisse, et
al., Bone, 1987,
8, 305, Hill, et al., J. Cell. Biochenz., 1994, 56, 118, and Events, et al.,
J. Cell. Physiol.,
1992, 150, 221, also report a correlation between inhibition of cysteine
protease activity
and bone resorption. Tezuka, et al., J. Biol. Clzem., 1994, 269, 1106, Inaoka,
et al.,
Bioclzern. Biophys. Res. Commurz., 1995, 206, 89 and Shi, et al., FEBS Lett.,
1995, 357, 129
disclose that under normal conditions cathepsin K, a cysteine protease, is
abundantly
expressed in osteoclasts and may be the major cysteine protease present in
these cells.
The abundant selective expression of cathepsin K in osteoclasts strongly
suggests
that this enzyme is essential for bone resorption. Thus, selective inhibition
of cathepsin K
may provide an effective treatment for diseases of excessive bone loss,
including, but not
limited to, osteoporosis, gingival diseases such as gingivitis and
periodontitis, Paget's
disease, hypercalcemia of malignancy, and metabolic bone disease. Cathepsin K
levels
have also been demonstrated to be elevated in chondroclasts of osteoarthritic
synovium.
Thus, selective inhibition of cathepsin K may also be useful for treating
diseases of
excessive cartilage or matrix degradation, including, but not limited to,
osteoarthritis and
rheumatoid arthritis. Metastatic neoplastic cells also typically express high
levels of
proteolytic enzymes that degrade the surrounding matrix. Thus, selective
inhibition of
cathepsin K may also be useful for treating certain neoplastic diseases.
Several cysteine protease inhibitors are known. Palmer, (1995) J. Med.
Clzenz., 38,
3193, disclose certain vinyl sulfones which irreversibly inhibit cysteine
proteases, such as
the cathepsins B, L, S, 02 and cruzain. Other classes of compounds, such as
aldehydes,
nitriles, a-ketocarbonyl compounds, halomethyl ketones, diazomethyl ketones,
(acyloxy)methyl ketones, ketomethylsulfonium salts and epoxy succinyl
compounds have
also been reported to inhibit cysteine proteases. See Palmer, id, and
references cited
therein.
U.S. Patent No. 4,518,528 discloses peptidyl fluoromethyl ketones as
irreversible
inhibitors of cysteine protease. Published International Patent Application
No. WO
94/04172, and European Patent Application Nos. EP 0 525 420 Al, EP 0 603 873
A1, and
EP 0 611 756 A2 describe alkoxymethyl and mercaptomethyl ketones which inhibit
the
cysteine proteases cathepsins B, H and L. International Patent Application No.
PCT/US94/08868 and and European Patent Application No. EP 0 623 592 A1
describe
alkoxymethyl and mercaptomethyl ketones which inhibit the cysteine protease IL-
1 (3convertase. Alkoxymethyl and mercaptomethyl ketones have also been
described as
3
CA 02412353 2002-12-13
WO 01/95911 PCT/USO1/19062
inhibitors of the serine protease kininogenase (International Patent
Application No.
PCTlGB91101479).
Azapeptides which are designed to deliver the azaamino acid to the active site
of
serine proteases, and which possess a good leaving group, are disclosed by
Elmore et al.,
Biochem. J., 1968, 107, 103, Garker et al., Biochem. J., 1974,139, 555, Gray
et al.,
Tetrahedron, 1977, 33, 837, Gupton et al., J. Biol. Chem., 1984, 259, 4279,
Powers et al., J.
Biol. Chem., 1984, 259, 4288, and are known to inhibit serine proteases. In
addition, J.
Med. Chem., 1992, 35, 4279, discloses certain azapeptide esters as cysteine
protease
inhibitors.
Antipain and leupeptin are described as reversible inhibitors of cysteine
protease in
McConnell et al., J. Med. Chem., 33, 86; and also have been disclosed as
inhibitors of
serine protease in Umezawa et al., 45 Meth. Erzzyzzzol. 678. E64 and its
synthetic analogs
are also well-known cysteine protease inhibitors (Barren, Bioclzem. J., 201,
189, and
Grinde, Biochezn. Biophys. Acta, , 701, 328).
1,3-diamido-propanones have been described as analgesic agents in U.S. Patent
Nos.4,749,792 and 4,638,010.
Thus, a structurally diverse variety of protease inhibitors have been
identified.
However, these known inhibitors are not considered suitable for use as
therapeutic agents in
animals, especially humans, because they suffer from various shortcomings.
These
shortcomings include lack of selectivity, cytotoxicity, poor solubility, and
overly rapid
plasma clearance. A need therefore exists for methods of treating diseases
caused by
pathological levels of proteases, particularly cysteine proteases, more
particularly
cathepsins, most particularly cathepsin K, and for novel inhibitor compounds
useful in such
methods.
We have now discovered a novel class of 4-amino-azepan-3-one compounds which
are protease inhibitors, most particularly of cathepsin K.
SUMMARY OF THE INVENTION
An object of the present invention is to provide 4-amino-azepan-3-one carbonyl
protease inhibitors, particularly such inhibitors of cysteine and serine
proteases, more
particularly such compounds which inhibit cysteine proteases, even more
particularly such
compounds which inhibit cysteine proteases of the papain superfamily, yet more
particularly such compounds which inhibit cysteine proteases of the cathepsin
family, most
4
CA 02412353 2002-12-13
WO 01/95911 PCT/USO1/19062
particularly such compounds which inhibit cathepsin K, and which are useful
for treating
diseases which may be therapeutically modified by altering the activity of
such proteases.
Accordingly, in the first aspect, this invention provides a compound according
to
Formula I.
In another aspect, this invention provides a pharmaceutical composition
comprising
a compound according to Formula I and a pharmaceutically acceptable carrier,
diluent or
excipient.
In yet another aspect, this invention provides intermediates useful in the
preparation of the compounds of Formula I.
In still another aspect, this invention provides a method of treating diseases
in
which the disease pathology may be therapeutically modified by inhibiting
proteases,
particularly cysteine and serine proteases, more particularly cysteine
proteases, even more
particularly cysteine proteases of the papain superfamily, yet more
particularly cysteine
proteases of the cathepsin family, most particularly cathepsin K.
In a particular aspect, the compounds of this invention are especially useful
for
treating diseases characterized by bone loss, such as osteoporosis and
gingival diseases,
such as gingivitis and periodontitis, or by excessive cartilage or matrix
degradation, such as
osteoarthritis and rheumatoid arthritis.
DETAILED DESCRIPTION OF THE INVENTION
The present invention provides compounds of Formula I:
N
,O
J
N
wherein:
R1 is selected from the group consisting of:
5
CA 02412353 2002-12-13
WO 01/95911 PCT/USO1/19062
O O O
R'
R4/N RsiX
R3 Rs
R
> > >
R' O R' O
4/N a./N
R R"" R
R3 ~ ~d ) n
R2 is selected from the group consisting of: H, C1_6alkyl, C3_6cycloalkyl-CO_
6alkyl, Ar-CO_6alkyl, Het-Cp_6alkyl, R9C(O)-, R9C(S)-, R9S02-, R90C(O)-,
N C(O) N~ CH2
R9R11NC(O)-, R9R11NC(S)-, R9(Rl1)NS02- I ~
Rs
Ra i N ~ Z ,.~
R8 , and R9S02R11NC(O)-;
R3 is selected from the group consisting of: H, C1_(alkyl, C3_(cycloalkyl-
CO_6alkyl, C2_6alkenyl, C2_galkynyl, HetCO_6alkyl and ArCO_6alkyl;
R3 and R' may be connected to form a pyrrolidine, piperidine or morpholine
ring;
R4 is selected from the group consisting of: H, C1_6alkyl, C3_6cycloalkyl-
CO_6alkyl, Ar-CO_6alkyl, Het-CO_6alkyl, R5C(O)-, R5C(S)-, R5S02-, R50C(O)-,
R5R12NC(O)-, and R5R12NC(S)-;
R5 is selected from the group consisting of: H, Cl_6alkyl, C2-(alkenyl,
C2_6alkynyl, Cg-6cycloalkyl-CO_6alkyl, Ar-CO_6alkyl and Het-CO_6alkyl;
R6 is selected from the group consisting of: H, Cl_6alkyl, Ar-CO_6alkyl, and
Het-
CO_6alkyl;
R~ is selected from the group consisting of: H, Cl_6alkyl, Cg_6cycloalkyl-
CO_6alkyl, Ar-CO_gallcyl, Het-CO_6alkyl, R10C(O)-, R10C(S)_, RlOS02_,
RlOpC(O)_~
R10R13NC(O)-, and R10R13NC(S)-;
Rg is selected from the group consisting of: H, C1_6alkyl, C2_galkenyl,
6
CA 02412353 2002-12-13
WO 01/95911 PCT/USO1/19062
C2_6alkynyl, HetCp_6alkyl and ArCp_6alkyl;
R9 is selected from the group consisting of: C1_6alkyl, Cg-6cycloalkyl-Cp-
6alkyl,
Ar-Cp-6alkyl and Het-Cp_6alkyl;
R1p is selected from the group consisting of: C1_6alkyl, C3_6cycloalkyl-Cp-
6alkyl,
Ar-Cp_6alkyl and Het-Cp_6alkyl;
R11 is selected from the group consisting of: H, C1_6alkyl, Ar-Cp_6alkyl, and
Het-
Cp_6alkyl;
R12 is selected from the group consisting of: H, C1_6alkyl, Ar-Cp_6alkyl, and
Het-
Cp_6alkyl;
R13 is selected from the group consisting of: H, Cl_6alkyl, Ar-Cp_6alkyl, and
Het-
Cp_6alkyl;
R' is selected from the group consisting of: H, C1_galkyl, Ar-Cp_6alkyl, and
Het-
Cp_6alkyl;
R" is selected from the group consisting of: H, C1_6alkyl, Ar-Cp_6alkyl, or
Het-
Cp_6alkyl;
R"' is selected from the group consisting of: H, C1-6alkyl, C3-6cycloalkyl-
Cp-6alkyl, Ar-Cp-6alkyl, and Het-Cp_galkyl;
R"" is selected from the group consisting of: C1_6alkyl, C3_6cycloalkyl-
Cp_galkyl
C2_6alkenyl, C2_6alkynyl, HetCp_6alkyl and ArCp-6alkyl;
X is selected from the group consisting of: CH2, S, and O;
Z is selected from the group consisting of: C(O) and CH2;
n is an integer from 1 to 5;
and pharmaceutically acceptable salts, hydrates and solvates thereof.
O
R'
R4/ N
3
In compounds of Formula I, when R1 is R
R3 is selected from the group consisting of: H, C1_6alkyl, C3_6cycloalkyl-
Cp_6alky1,C2_6alkenyl, C2_6alkynyl, Het-Cp_6alkyl and Ar-Cp_6alkyl;
R3 is preferably selected from the group consisting of: H, C3_6cycloalkyl-
Cp_6alkyl, C2_galkenyl, Ar-Cp_6alkyl, and C1_6alkyl;
R3 is more preferably selected from the group consisting of:
7
CA 02412353 2002-12-13
WO 01/95911 PCT/USO1/19062
H, methyl, ethyl, n-propyl, prop-2-yl, n-butyl, isobutyl, but-2-yl,
cyclopropylmethyl, cyclohexylmethyl, 2-methanesulfinyl-ethyl, 1-hydroxyethyl,
toluyl,
naphthalen-2-ylmethyl, benzyloxymethyl, and hydroxymethyl.
R3 is even more preferably selected from the group consisting of: toluyl,
isobutyl
and cyclohexylmethyl.
R3 is most preferably isobutyl.
R4 is selected from the group consisting of: H, C1_6alkyl, C3_6cycloalkyl-
CO_6alkyl, Ar-CO_6alkyl, Het-CO_6alkyl, R5C(O)-, R5C(S)-, R5S02-, R50C(O)-,
R5R13NC(O)-, and R5R13NC(S)-.
R4 is preferably selected from the group consisting of: R50C(O)-, R5C(O)- and
R5S02-.
R4 is most preferably R5C(O)-.
In some embodiments, R4 is preferably methanesulfonyl.
RS is selected from the group consisting of: H, C1_6alkyl, C2-6alkenyl,
C2_6alkynyl, Cg_6cycloalkyl-CO-galkyl, Ar-CO-6alkyl or Het-CO_6alkyl.
Preferably R5 is selected from the group consisting of: C1_6alkyl, Ar-
CO_6alkyl
and Het-CO_6alkyl.
More preferably, and especially when R4 is R5C(O)-, R5 is selected from the
group
consisting of:
methyl, especially halogenated methyl, more especially trifluoromethyl ,
especially
C1_6alkoxy substituted methyl, more especially phenoxy-methyl , 4-fluoro-
phenoxy-
methyl , especially heterocycle substituted methyl, more especially 2-
thiophenyl-methyl ;
ethyl, especially piperidin-1-yl-ethyl;
butyl, especially aryl substituted butyl, more especially 4-(4-methoxy)phenyl-
butyl;
isopentyl;
cyclohexyl;
pentanonyl, especially 4-pentanonyl;
butenyl, especially aryl substituted butenyl, more especially 4,4-bis(4-
methoxyphenyl)-but-3-enyl;
acetyl;
phenyl, especially phenyl substituted with one or more halogens, more
especially
3,4-dichlorophenyl and 4-fluorophenyl, especially phenyl substituted with one
or more
aryloxy or Cl_(alkoxy groups, more especially 3,4-dimethoxy-phenyl, 3-
benzyloxy-4-
CA 02412353 2002-12-13
WO 01/95911 PCT/USO1/19062
methoxy-phenyl, especially phenyl substituted with one or more C1-6alkyl
sulfonyl groups,
more especially 4-methanesulfonyl-phenyl;
benzyl;
naphthalenyl, especially naphthylen-2-yl;
benzo[1,3]dioxolyl, especially benzo[1,3]dioxol-5-yl;
furanyl, especially furan-2-yl, especially substituted furanyl, such as 5-
nitro-furan-
2-yl, 5-(4-nitrophenyl)-furan-2-yl, 5-(3-trifluoromethyl-phenyl)-furan-2-
yl,more especially
halogen substituted furanyl, even more especially 5-bromo-furan-2-yl, more
especially aryl
substituted furanyl, even more especially 5-(4-chloro-phenyl)-furan-2-yl, more
especially
C1-6alkyl substituted furanyl, even more especially 3-methyl-furan-2-yl, 4-
methyl-furan-2-
y1, 2,5-dimethyl-furan-2-yl, and 2,4-dimethyl-furan-3-yl;
tetrahydrofuranyl, tetrahydrofuran-2-yl;
benzofuranyl, especially benzofuran-2-yl, and substituted benzofuranyl, more
especially 5-(2-piperazin-4-carboxylic acid tert-butyl ester- ethoxy)
benzofuran-2-yl, 5-(2-
morpholino-4-yl-ethoxy)-benzofuran-2-yl, 5-(2-piperazin-1-yl-ethoxy)benzofuran-
2-yl, 5-
(2-cyclohexyl-ethoxy)-benzofuran-2-yl; especially C1_6alkoxy substituted
benzofuranyl,
more especially 7-methoxy-benzofuran-2-yl, 5-methoxy-benzofuran-2-yl, 5,6-
dimethoxy-
benzofuran-2-yl, especially halogen substituted benzofuranyl, more especially
5-fluoro-
benzofuran-2-yl, 5,6-difluoro-benzofuran-2-yl, especially C1-6alkyl
substituted
benzofuranyl, most especially 3-methyl-benzofuran-2-yl, 3,5-dimethyl-
benzofuran-2-yl,
and 3-ethyl-benzofuran-2-yl; also 5-fluoro-3-methyl-benzofuran-2-yl, 6-fluoro-
3-methyl-
benzofuran-2-yl, 5-methoxy-3-methyl-benzofuran-2-yl, 4-inethoxy-3-methyl-
benzofuran-2-
y1, and 6-methoxy-3-methyl-benzofuran-2-yl;
naphtho[2,1-b]-furanyl, especially naphtho[2,1-b]-furan-2-yl, alkyl
substituted
naphtho[2,1-b]-furanyl, especially 1-methyl-naphtho[2,1-b]-furan-2-yl;
benzo[b]thiophenyl, especially benzo[b]thiophen-2-yl; especially C1_6alkoxy
substituted benzo[b]thiophenyl, more especially 5,6-dimethoxy-
benzo[b]thiophen-2-yl;
quinolinyl, especially quinolin-2-yl, quinolin-3-yl, quinolin-4-yl, quinolin-6-
yl, and
quinolin-8-yl;
quinoxalinyl, especially quinoxalin-2-yl;
1,8 naphthyridinyl, especially 1,8 naphthyridin-2-yl;
indolyl, especially indol-2-yl, especially indol-6-yl, indol-5-yl, especially
C1_
6alkyl substituted indolyl, more especially N-methyl-indol-2-yl;
CA 02412353 2002-12-13
WO 01/95911 PCT/USO1/19062
pyridinyl, especially pyridin-2-yl, pyridin-3-yl, pyridin-5-yl, especially
C1_6alkyl
substituted pyridinyl, more especially 2-methyl-pyridin-5-yl, and oxy-
pyridinyl, especially
1-oxy-pyridin-2-yland 1-oxy-pyridin-3-yl;;
faro[3,2-b]-pyridinyl, especially faro[3,2-b]-pyridin-2-yl, C1_6alkyl
substituted
faro[3,2-b]-pyridinyl, especially 3-methyl-faro[3,2-b]-pyridin-2-yl;
thiophenyl, especially thiophen-3-yl, also thiophen-2-yI, especially C1_6alkyl
substituted thiophenyl, more especially 5-methyl-thiophen-2-yland 5-methyl-
thiophen-3-yl,
especially halogen substituted thiophenyl, more especially 4,5-dibromo-
thiophen-2-yl;
thieno[3,2-b]thiophene, especially thieno[3,2-b]thiophene-2-yl, more
especially
C1_6alkyl substituted thieno[3,2-b]thiophene-2-yl, more especially 5-tert-
butyl-3-methyl-
thieno[3,2-b]thiophene-2-yl;
isoxazolyl, especially isoxazol-4-yl, especially C1_6alkyl substituted
isoxazolyl,
more especially 3,5-dimethyl- isoxazol-4-yl;
oxazolyl, especially oxazol-4-yl, more especially 5-methyl-2-phenyl oxazol-4-
yl, 2-
phenyl-5-trifluoromethyl-oxazol-4-yl; and
1H-benzoimidazolyl, especially 1H-benzoimidazol-5-yl.
When R4 is R5S02, R5 is preferably pyridin-2-yl or 1-oxo-pyridin-2-yl.
R' is selected from the group consisting of: H, C1_6alkyl, Ar-CO_6alkyl, and
Het-
CO_6alkyl.
Preferably R' is selected from the group consisting of: H and naphthalen-2-yl-
methyl.
Most preferably R'is H.
R" is selected from the group consisting of: H, C1_6alkyl, Ar-CO_6alkyl, and
Het-
CO_6alkyl.
Most preferably R" is H.
R"' is selected from the group consisting of: H, C1_6alkyl, C3_6cycloalkyl-
CO_6alkyl, and Het-CO_6alkyl.
R"' is preferably selected from the group consisting of: H and C1_6alkyl.
CA 02412353 2002-12-13
WO 01/95911 PCT/USO1/19062
R"' is more preferably selected from the group consisting of: H, methyl and
6,6-
dimethyl.
R"' is still more preferably selected from the group consisting of: H and 6,6-
dimethyl.
Most preferably R"' is H.
R' O
N
R4~ R""
In compounds of Formula I, when R1 is R3 .
R3 is selected from the group consisting of: C1_6alkyl, C3_6cycloalkyl-
CO_6alkyl;
C2_6alkenyl, C2_6alkynyl, Het-CO-6alkyl and Ar-CO-6alkyl.
R3 is preferably C1_6alkyl.
R3 is more preferably selected from the group consisting of methyl, ethyl, n-
propyl,
n-butyl, isobutyl, t-butyl, cyclohexylmethyl, and toluyl.
R"" is selected from the group consisting of: C1_6alkyl, C3_6cycloalkyl-
Cp_6alkyl, C2_6alkenyl, C2_6alkynyl, HetCO_6alkyl and ArCO_6alkyl;
R"" is preferably C1_6alkyl;
R"" is more preferably selected from the group consisting of methyl, ethyl, n-
propyl, n-butyl, isobutyl and t-butyl.
R"" is most preferably methyl.
In such compounds, R~, R'~, R~~~, R4, and RS are as described above wherein
O
R'
R4/ N
R3
R' O
R4/ N
In compounds of Formula I, when R1 is
11
CA 02412353 2002-12-13
WO 01/95911 PCT/USO1/19062
n is preferably an integer of from 1 to 5; and
R~, R~~, R~~~, R4, and RS are as described above wherein
O
R'
R4/ N
R1 is Ra
n is most preferably 3.
The ring may be unsubstituted or substituted with one or more of C1_6alkyl,
C3_6cycloalkyl-CO_6alkyl, C~_galkenyl, C~_6alkynyl, HetCO_6alkyl, ArCO-6alkyl,
or halogen
The ring is preferably unsubstituted.
In compounds of Formula I, R~ is selected from the group consisting of:
H, C1_6alkyl, C3_6cycloalkyl-CO_6alkyl, Ar-CO_galkyl, Het-CO_6alkyl, R9C(O)-,
R9C(S)-,
c~o~
R9S02-, R90C(O)-, R9R11NC(O)-, R9R11NC(S)-, R9R11NS02-, I ~ ,
Rs
cH2 R~iN~Z~
R , and R9SO~,R11NC(O)-.
More preferably R2 is selected from the group consisting of: Ar-Cp_6alkyl,
Rs
R~iN~ZW
R9C(O)-, R9S02, R9R11NC(O)_, and Re
Even more preferably, R2 is selected from the group consisting of: Ar-
CO_6alkyl,
R9C(O)-, and R9S02.
Most preferably R~ is R9S02.
In such embodiments:
12
CA 02412353 2002-12-13
WO 01/95911 PCT/USO1/19062
R6 is selected from the group consisting of: H, C1_6alkyl, Ar-CO_galkyl, or
Het-
CO_6alkyl, preferably H.
R~ is selected from the group consisting of: H, C1_6alkyl, C3_6cycloalkyl-
CO_6alkyl, Ar-CO_6alkyl, Het-CO_6alkyl, R10C(O)-, R10C(S)_, R10S02_~ RlOpC(O)-
RlORI4NC(O)-, R10R14NC(S)-, R~ is preferably R100C(O).
R8 is selected from the group consisting of: H, C1_6alkyl, C2_6alkenyl,
C2,_galkynyl, HetCO_6alkyl and ArCp_6alkyl; preferably C1_6alkyl, more
preferably
isobutyl.
R9 is selected from the group consisting of: C1_6alkyl, Cg-6cycloalkyl-
CO_6alkyl,
Ar-CO_6alkyl, and Het-CO_6alkyl.
R9 is preferably selected from the group consisting of: C1-galkyl, Ar-
CO_6alkyl,
and Het-CO_6alkyl.
More preferably, R9 is selected from the group consisting of:
methyl;
ethyl, especially C 1-6alkyl-substituted ethyl, more especially 2-cyclohexyl-
ethyl;
propyl;
butyl, especially C1_6butyl, more especially 3-methylbutyl;
tert-butyl, particularly when R2 is R90C(O);
isopentyl;
phenyl, especially halogen substituted phenyl, more especially 3,4-
dichlorophenyl ,
4-bromophenyl, 2-fluorophenyl, 3-fluorophenyl, 4-fluorophenyl, 2-chlorophenyl,
3-
chlorophenyl, 4-chlorophenyl, especially C1_6alkoxy phenyl, more especially 3-
methoxyphenyl, 4-methoxyphenyl, 3,4-dimethoxyphenyl, especially cyanophenyl,
more
especially 2-cyanophenyl; especially C1_6alkyl substituted phenyl, more
especially 4-ethyl-
phenyl, 2-methyl phenyl, 4-methyl phenyl, especially C1_6alkyl sulfonyl
substituted
phenyl, more especially 4-methanesulfonyl phenyl, and 2-methanesulfonyl
phenyl;
toluyl, especially Het-substituted toluyl, more especially 3-(pyridin-2-
yl)toluyl;
naphthylene, especially naphthyl-2-ene;
benzoic acid, especially 2-benzoic acid;
benzojl,3]dioxolyl, especially benzojl,3]dioxol-5-yl;
benzo[1,2,5]oxadiazolyl, especially benzo[1,2,5]oxadiazol-4-yl;
13
CA 02412353 2002-12-13
WO 01/95911 PCT/USO1/19062
pyridinyl, especially pyridin-2-yl, pyridin-3-yl, especially 1-oxy-pyridinyl,
more
especially 1-oxy-pyridin-2-yl, 1-oxy-pyridin-3-yl; especially
C1_6alkylpyridinyl, more
especially 3-methyl-pyridin-2-yl, 6-methyl-pyridin-2-yl;
thiophenyl, especially thiophenyl-2-yl;
thiazolyl, especially thiazol-2-yl;
1H-imidazolyl, especially 1H-imidazol-2-yl, 1H-imidazol-4-yl, more especially
C1_6alkyl substituted imidazolyl, even more especially 1-methyl-1H-imidazol-2-
yl, 1-
methyl-1H-imidazol-4-yl, and 1,2-dimethyl-1H-imidazol-4-yl;
triazolyl, especially 1H-[1,2,4]triazolyl, more especially 1H-[1,2,4]triazol-3-
yl,
especially C1_6alkyl substituted 1H-[1,2,4]triazolyl, more especially 5-methyl-
1H-
[1,2,4]triazol-3-yl; and
isoxazolyl, especially isoxazol-4-yl, especially C1_6alkyl substituted
isoxazolyl,
more especially 3,5-dimethyl- isoxazol-4-yl.
When R2 is R9S02, R9 is most preferably selected from the group consisting of:
pyridin-2-yl and 1-oxy-pyridin-2-yl.
When R2 is R9S02R11NC(O)-, R9 is preferably Ar-CO_6alkyl, more preferably
Ar, most preferably substituted phenyl such as 2-methyl phenyl, 4-methyl
phenyl, 2-chloro
phenyl, and 4-fluoro phenyl.
When R2 is R9C(O)-, R9 is preferably selected from the group consisting of
C1_6alkyl, C3_6cycloalkyl-CO_6alkyl, and Het-CO_6alkyl, more preferably 1-oxy-
pyridin-2-
y1, cyclohexyl ethyl, and 3-methyl butyl.
R11 is selected from the group consisting of: H, C1_6alkyl, Ar-CO_6alkyl, and
Het-
CO_galkyl.
When R2 is R9S02R11NC(O)-, R11 is preferably H.
When R2 is Ar-CO_6alkyl, R2 is preferably phenyl, especially substituted
phenyl,
more especially halogen substituted phenyl, even more especially 2-
fluorobenzyl.
When R2 is C1_6alkyl, R2 is preferably selected from 1-propyl, 1-butyl, and 1-
pentyl.
14
CA 02412353 2002-12-13
WO 01/95911 PCT/USO1/19062
When R2 is Het-CO_galkyl, Het-CO-6alkyl is preferably Het-methyl, and Het in
Het-methyl is preferably selected from the group consisting of:
pyridinyl, especially pyridin-2-yl, especially C1_6alkylpyridinyl, more
especially 6-
methyl-pyridin-2-yl;
thiophenyl, especially thiophene-2-yl, more especially thiophen-2-yl or
benzo[b]thiophen-2-yl;
thiazolyl, especially thiazol-4-yl such as 1-(2-morpholin-4-yl-thiazol-4-yl),
and 1-
(isothiazol-3-yl);
1H-imidazolyl, especially 1H-imidazol-2-yl, 1H-imidazol-4-yl, especially
C1_galkyl substituted imidazolyl, more especially 1-methyl-1H-imidazol-2y1;
triazolyl, especially 3H-[1,2,3]triazolyl, more especially 3H-[1,2,3]triazol-4-
yl,
especially C1_6alkyl substituted 3H-[1,2,3]triazolyl, more especially 3-phenyl-
3H-
[1,2,3]triazolyl -4-yl;
quinolinyl, especially quinolin-2-yl, quinolin-2-yl;
furanyl, especially furan-2-yl, especially substituted furanyl, such as 5-
ethyl-furan-
2-Yh
thieno[3,2-b]thiophene, especially thieno[3,2-b]thiophene-2-yl, especially
C1_6alkyl substituted thieno[3,2-b]thiophenyl, especially 3,4-dimethyl-
thieno[3,2-
b]thiophene-2-yl.
R2 is also preferably:
H;
toluyl;
aryl substituted ethyl, especially 2-phenyl ethyl, 2-[3-(pyridin-2-yl) phenyl]
ethyl.
Compounds of Formula I where R" and R"' are both H are preferred.
More preferred are compounds of Formula I wherein:
R1 is
CA 02412353 2002-12-13
WO 01/95911 PCT/USO1/19062
O
R'
R4/ N
R3
R2 is selected from the group consisting of: Ar-CO_6alkyl, R9C(O)-, R9S02,
R6
R~iN~ZW
R9R11NC(O)-, and R8 ;
R3 is selected from the group consisting of: H, C1_6alkyl, C3_6cycloalkyl-
CO_6alkyl and Ar-CO-6alkyl;
R4 is selected from the group consisting of: R50C(O)-, R5C(O)- and R5S02-;
RSis selected from the group consisting of: C1_6alkyl, Ar-CO-6alkyl and Het-
CO_6alkyl;
R6 is H;
R~ is R100C(O);
Rg is C1_6alkyl;
R9 is selected from the group consisting of: C1_6alkyl, Ar-CO_6alkyl and Het-
CO_6alkyl;
R10 is selected from the group consisting of: C1_6alkyl, Ar-CO_6alkyl and Het-
CO-6alkyl;
R' is H;
R" is H;
R"' is H; and
Z is selected from the.group consisting of: C(O) and CH2.
Even more preferred are such compounds of Formula I wherein R2 is selected
from
the group consisting of: Ar-Cp_6alkyl, R9C(O)-, R9S02.
Yet more preferred are compounds of Formula I wherein:
R1 is
O
R'
R4/ N
R3
R2 is selected from the group consisting of: Ar-CO_6alkyl, R9C(O)- and R9S02;
16
CA 02412353 2002-12-13
WO 01/95911 PCT/USO1/19062
R3 is selected from the group consisting of: H, methyl, ethyl, n-propyl, prop-
2-yl,
n-butyl, isobutyl, but-2-yl, cyclopropylmethyl, cyclohexylmethyl, 2-
methanesulfinyl-ethyl,
1-hydroxyethyl, toluyl, naphthalen-2-ylmethyl, benzyloxymethyl, and
hydroxymethyl;
R4 is R5C(O)-;
RS is selected from the group consisting of:
methyl, especially halogenated methyl, more especially trifluoromethyl ,
especially
C1_6alkoxy substituted methyl, more especially phenoxy-methyl , 4-fluoro-
phenoxy-
methyl , especially heterocycle substituted methyl, more especially 2-
thiophenyl-methyl ;
ethyl, especially piperidin-1-yl-ethyl;
butyl, especially aryl substituted butyl, more especially 4-(4-methoxy)phenyl-
butyl;
isopentyl;
cyclohexyl;
pentanonyl, especially 4-pentanonyl;
butenyl, especially aryl substituted butenyl, more especially 4,4-bis(4-
methoxyphenyl)-but-3-enyl;
acetyl;
phenyl, especially phenyl substituted with one or more halogens, more
especially
3,4-dichlorophenyl and 4-fluorophenyl, especially phenyl substituted with one
or more
aryloxy or C1_6alkoxy groups, more especially 3,4-dimethoxy-phenyl, 3-
benzyloxy-4-
methoxy-phenyl, especially phenyl substituted with one or more C1-6alkyl
sulfonyl groups,
more especially 4-methanesulfonyl-phenyl;
benzyl;
naphthalenyl, especially naphthylen-2-yl;
benzo[1,3]dioxolyl, especially benzo[1,3]dioxol-5-yl;
furanyl, especially furan-2-yl, especially substituted furanyl, such as 5-
nitro-furan-
2-yl, 5-(4-nitrophenyl)-furan-2-yl, 5-(3-trifluoromethyl-phenyl)-furan-2-
yl,more especially
halogen substituted furanyl, even more especially 5-bromo-furan-2-yl, more
especially aryl
substituted furanyl, even more especially 5-(4-chloro-phenyl)-furan-2-yl, more
especially
C1-6alkyl substituted furanyl, even more especially 3-methyl-furan-2-yI, 4-
methyl-furan-2-
y1, 2,5-dimethyl-furan-2-yl, and 2,4-dimethyl-furan-3-yl;
tetrahydrofuranyl, especially tetrahydrofuran-2-yl;
benzofuranyl, especially benzofuran-2-yl, and substituted benzofuranyl, more
especially 5-(2-piperazin-4-carboxylic acid ter-t-butyl ester- ethoxy)
benzofuran-2-yl, 5-(2-
17
CA 02412353 2002-12-13
WO 01/95911 PCT/USO1/19062
morpholino-4-yl-ethoxy)-benzofuran-2-yl, 5-(2-piperazin-1-yl-ethoxy)benzofuran-
2-yl, 5-
(2-cyclohexyl-ethoxy)-benzofuran-2-yl; especially C1_6alkoxy substituted
benzofuranyl,
more especially 7-methoxy-benzofuran-2-yI, 5-methoxy-benzofuran-2-yl, 5,6-
dimethoxy-
benzofuran-2-yl, especially halogen substituted benzofuranyl, more especially
5-fluoro-
benzofuran-2-yl, 5,6-difluoro-benzofuran-2-yl, especially C1_6alkyl
substituted
benzofuranyl, most especially 3-methyl-benzofuran-2-yl, 3,5-dimethyl-
benzofuran-2-yl,
and 3-ethyl-benzofuran-2-yl; also 5-fluoro-3-methyl-benzofuran-2-yl, 6-fluoro-
3-methyl-
benzofuran-2-yl, 5-methoxy-3-methyl-benzofuran-2-yl, 4-methoxy-3-methyl-
benzofuran-2-
yl, and 6-methoxy-3-methyl-benzofuran-2-yl;
naphtho[2,1-b]-furanyl, especially naphtho[2,1-b]-furan-2-yl, alkyl
substituted
naphtho[2,1-b]-furanyl, especially 1-methyl-naphtho[2,1-b]-furan-2-yl;
benzo[b]thiophenyl, especially benzo[b]thiophen-2-yl; especially C1_6alkoxy
substituted benzo[b]thiophenyl, more especially 5,6-dimethoxy-
benzo[U]thiophen-2-yl;
quinolinyl, especially quinolin-2-yl, quinolin-3-yl, quinolin-4-yl, quinolin-6-
yl, and
quinolin-8-yl;
quinoxalinyl, especially quinoxalin-2-yl;
1,8 naphthyridinyl, especially 1,8 naphthyridin-2-yl;
indolyl, especially indol-2-yl, especially indol-6-yl, indol-5-yl, especially
C1_
6alkyl substituted indolyl, more especially N-methyl-indol-2-yl;
pyridinyl, especially pyridin-2-yl, pyridin-3-yl, pyridin-5-yl, especially
C1_6alkyl
substituted pyridinyl, more especially 2-methyl-pyridin-5-yl, and oxy-
pyridinyl, especially
1-oxy-pyridin-2-yland 1-oxy-pyridin-3-yl;;
furo[3,2-b]-pyridinyl, especially furo[3,2-b]-pyridin-2-yl, C1_6alkyl
substituted
furo[3,2-b]-pyridinyl, especially 3-methyl-furo[3,2-b]-pyridin-2-yl;
thiophenyl, especially thiophen-3-yl, also thiophen-2-yl, especially C1-6alkyl
substituted thiophenyl, more especially 5-methyl-thiophen-2-yland 5-methyl-
thiophen-3-yl,
especially halogen substituted thiophenyl, more especially 4,5-dibromo-
thiophen-2-yl;
thieno[3,2-b]thiophene, especially thieno[3,2-b]thiophene-2-yl, more
especially
C1_6alkyl substituted thieno[3,2-b]thiophene-2-yl, more especially 5-tart-
butyl-3-methyl-
thieno[3,2-b]thiophene-2-yl;
isoxazolyl, especially isoxazol-4-yl, especially C1-6alkyl substituted
isoxazolyl,
more especially 3,5-dimethyl- isoxazol-4-yl;
18
CA 02412353 2002-12-13
WO 01/95911 PCT/USO1/19062
oxazolyl, especially oxazol-4-yl, more especially 5-methyl-2-phenyl oxazol-4-
yl, 2-
phenyl-5-trifluoromethyl-oxazol-4-y1; and
1H-benzoimidazolyl, especially IH-benzoimidazol-5-yl.
R9 is selected from the group consisting of:
methyl;
ethyl, especially C1-6alkyl-substituted ethyl, more especially 2-cyclohexyl-
ethyl;
propyl;
butyl, especially C1_6butyl, more especially 3-methylbutyl;
ter-t-butyl, particularly when R2 is R90C(O);
isopentyl;
phenyl, especially halogen substituted phenyl, more especially 3,4-
dichlorophenyl ,
4-bromophenyl, 2-fluorophenyl, 3-fluorophenyl, 4-fluorophenyl, 2-chlorophenyl,
3-
chlorophenyl, 4-chlorophenyl, especially C1-galkoxy phenyl, more especially 3-
methoxyphenyl, 4-methoxyphenyl, 3,4-dimethoxyphenyl, especially cyanophenyl,
more
especially 2-cyanophenyl; especially C1_6alkyl substituted phenyl, more
especially 4-ethyl-
phenyl, 2-methyl phenyl, 4-methyl phenyl, especially C1_galkyl sulfonyl
substituted
phenyl, more especially 4-methanesulfonyl phenyl, and 2-methanesulfonyl
phenyl;
toluyl, especially Het-substituted toluyl, more especially 3-(pyridin-2-
yl)toluyl;
naphthylene, especially naphthyl-2-ene;
benzoic acid, especially 2-benzoic acid;
benzo[1,3]dioxolyl, especially benzo[1,3]dioxol-5-y1;
benzo[1,2,5]oxadiazolyl, especially .benzo[1,2,5]oxadiazol-4-yl;
pyridinyl, especially pyridin-2-yl, pyridin-3-yl, especially I-oxy-pyridinyl,
more
especially 1-oxy-pyridin-2-yl, 1-oxy-pyridin-3-yI; especially
C1_6alkylpyridinyl, more
especially 3-methyl-pyridin-2-yl, 6-methyl-pyridin-2-yl;
thiophenyl, especially thiophenyl-2-yl;
thiazolyl, especially thiazol-2-yl;
1H-imidazolyl, especially 1H-imidazol-2-yl, 1H-imidazol-4-yl, more especially
CI_6alkyl substituted imidazolyl, even more especially 1-methyl-1H-imidazol-2-
yl, 1-
methyl-1H-imidazol-4-yl, and 1,2-dimethyl-1H-imidazol-4-yl;
19
CA 02412353 2002-12-13
WO 01/95911 PCT/USO1/19062
triazolyl, especially 1H-[1,2,4]triazolyl, more especially 1H-[1,2,4]triazol-3-
yl,
especially C1_6alkyl substituted 1H-[1,2,4]triazolyl, more especially 5-methyl-
1H-
[1,2,4]triazol-3-yl; and
isoxazolyl, especially isoxazol-4-yl, especially C1_6alkyl substituted
isoxazolyl,
more especially 3,5-dimethyl- isoxazol-4-yl.
R' is H;
R" is H; and
R"' is H.
More preferred are compounds of Formula I wherein:
R1 is
O
R'
R4/ N
R3
R2 is R9S02;
R3 is isobutyl;
R4 is R5C(O);
R5 is selected from the group consisting of: 3-methyl-benzofuran-2-yl,
thieno[3,2
b]thiophen-2-yl, 5-methoxybenzofuran-2-yl, quinoxalin-2-yl, and quinolin-2-yl,
preferably
3-methyl-benzofuran-2-yl;
R9 is selected from the group consisting of: pyridin-2-yl and 1-oxy-pyridin-2-
yl,
preferably 1-oxy-pyridin-2-yl.
R' is H; and
R"' is H;
Most preferred is such compound wherein:
R5 is 3-methyl-benzofuran-2-yl; and
R9 is 1-oxy-pyridin-2-yl.
CA 02412353 2002-12-13
WO 01/95911 PCT/USO1/19062
An embodiment (IA) of the present invention provides compounds of Formula IA:
R\ ~R~~
N
~O
R»> N
~R2
IA
wherein:
R1 is selected from the group consisting of:
O N~ O ~ N~ O
R'
4/ 4/
Ra/ R R»» R
3 3
R , R , and ~ "
R2 is selected from the group consisting of: C1_6alkyl, Ar-CO_6alkyl, Het-
CO_6alkyl, R9C(O)-, R9S02-, R9R11NC(O)-, and R9S02R11NC(O)-;
R3 is selected from the group consisting of: C1_6alkyl, C3_6cycloalkyl-
CO_6alkyl,
C2_6alkenyl, C2_6alkynyl, Het-CO_6alkyl and Ar-CO_6alkyl, preferably
C1_6alkyl;
R3 and R' may be connected to form a pyrrolidine, piperidine or morpholine
ring;
R4 is RSC(O)-;
RS is selected from the group consisting of : C1_6alkyl and Het-CO_6alkyl,
preferably Het-CO_6alkyl;
R~ is selected from the group consisting of: C1_6alkyl, C3_6cycloalkyl-
CO_6alkyl,
Ar-CO_6alkyl and Het-CO_6alkyl; a
R11 is selected from the group consisting of: H, C1_6alkyl, Ar-CO_6alkyl and
Het-
CO-6alkyl, preferably H;
R' is H;
R" is H;
R"' is selected from the group consisting of: H and C1_6alkyl, preferably H;
21
CA 02412353 2002-12-13
WO 01/95911 PCT/USO1/19062
R"" is selected from the group consisting of: C1_6alkyl, C3_6cycloalkyl-CO-
6alkyl
C2_6alkenyl, C2_6alkynyl, HetCO-6alkyl and ArCO-6alkyl; and
n is an integer from 1 to 5, preferably n is 3;
and pharmaceutically acceptable salts, hydrates and solvates thereof.
O
R'
R4/ N
3
In embodiment IA, when Rl is R
R3 is preferably C1_6alkyl;
R3 is more preferably selected from the group consisting of: but-2-yl and
isobutyl.
R3 is most preferably isobutyl.
R4 is RSC(O)-.
RS is selected from the group consisting of : C1_6alkyl and Het-CO_6alkyl,
preferably Het-C1_6alkyl;
More preferably, RS is selected from the group consisting of:
piperidin-ethyl, especially piperidin-1-yl-ethyl;
benzo[1,3]dioxolyl, especially benzo[1,3]dioxol-5-yl;
furanyl, especially furan-2-yl, especially aryl substituted furanyl, such as 5-
(3-
trifluoromethyl-phenyl)-furan-2-yl, more especially C1_6alkyl substituted
furanyl, even
more especially 3-methyl-furan-2-yl, 4-methyl-furan-2-yl, 2,5-dimethyl-furan-2-
yl, and
2,4-dimethyl-furan-3-yl;
benzofuranyl, especially benzofuran-2-yl, especially C1_6alkoxy substituted
benzofuranyl, more especially 5-methoxy-benzofuran-2-yl, especially halogen
substituted
benzofuranyl, more especially 5-fluoro-benzofuran-2-yl, especially C1_6alkyl
substituted
benzofuranyl, most especially 3-methyl-benzofuran-2-yl, 3,5-dimethyl-
benzofuran-2-yl,
and 3-ethyl-benzofuran-2-yl; also 5-fluoro-3-methyl-benzofuran-2-yl, 5-methoxy-
3-methyl-
benzofuran-2-yl, 4-methoxy-3-methyl-benzofuran-2-yl, and 6-methoxy-3-methyl-
benzofuran-2-yl;
naphtho[2,1-b]-furanyl, especially naphtho[2,1-b]-furan-2-yl, C1-6alkyl
substituted
naphtho[2,1-b]-furanyl, especially 1-methyl-naphtho[2,1-b]-furan-2-yl;
benzo[b]thiophenyl, especially benzo[b]thiophen-2-yl;
quinolinyl, especially quinolin-2-yl;
22
CA 02412353 2002-12-13
WO 01/95911 PCT/USO1/19062
quinoxalinyl, especially quinoxalin-2-yl;
pyridinyl, especially pyridin-2-yl, pyridin-3-yl, pyridin-5-yl, and oxy-
pyridinyl,
especially 1-oxy-pyridin-2-yl and 1-oxy-pyridin-3-yl;
faro[3,2-b]-pyridinyl, especially faro[3,2-b]-pyridin-2-yl, C1_6alkyl
substituted
faro[3,2-b]-pyridin-2-yl, especially 3-methyl-faro[3,2-b]-pyridin-2-yl;
thiophenyl, especially thiophen-3-yl, and thiophen-2-yl, C1_6alkyl substituted
thiophenyl, especially 5-methyl-thiophen-2-yland 5-methyl-thiophen-3-yl; and
thieno[3,2-b]thiophene, especially thieno[3,2-b]thiophene-2-yl; and
1H-benzoimidazolyl, especially 1H-benzoimidazol-5-yl.
RS is more preferably selected from the group consisting of:
3-methyl-benzofuran-2-yl, thieno[3,2-b]thiophen-2-yl, 5-methoxybenzofuran-2-
yl,
quinoxalin-2-yl, and quinolin-2-yl.
i' O
R4~N R»»
In embodiment IA, when R1 is R3 .
R3 is selected from the group consisting of: C1_6alkyl, C3_gcycloalkyl-
CO_6alkyl,
C2_6alkenyl, C2_6alkynyl, Het-CO_galkyl and Ar-Cp_6alkyl.
R3 is preferably C1_galkyl, C3_6cycloalkyl-CO_(alkyl, and Ar-CO_6alkyl.
R3 is more preferably selected from the group consisting of methyl, ethyl, n-
propyl,
n-butyl, isobutyl, t-butyl, cyclohexylmethyl, and toluyl.
R"" is selected from the group consisting of: C1_6alkyl, C3_6cycloalkyl-
CO_6alkyl, C2_galkenyl, C2_6alkynyl, HetCO_6alkyl and ArCO_6alkyl;
R"" is preferably Cl_6alkyl;
R"" is more preferably selected from the group consisting of methyl, ethyl, n-
propyl, n-butyl, isobutyl and t-butyl.
Most preferably R"" is methyl.
In such compounds, R~ and R4 are as described above wherein
23
CA 02412353 2002-12-13
WO 01/95911 . PCT/USO1/19062
O
R'
R4/ N
R3
R' O
R4,N
In embodiment IA, when Rl is
n is an integer of from 1 to 5; preferably 3; and
R~ and R4 are as described above wherein
O
R'
R4/ N
R3
The cyclic ring may be unsubstituted or substituted with one or more of
C1_galkyl,
C3_6cycloalkyl-CO_galkyl, C2_6alkenyl, C2_6alkynyl, HetCO_6alkyl, ArCO_6alkyl,
or
halogen.
The cyclic ring is preferably unsubstituted.
In embodiment IA, R2 is selected from the group consisting of:
Cl_6alkyl, Ar-CO_6alkyl, Het-CO_balkyl, R9C(O)-, R9S02-, R9R11NC(O)-, and
R9S02R11NC(O)-.
More preferably R2 is selected from the group consisting of: Ar-CO_galkyl,
R9C(O)-, R9S02, and R9R11NC(O)-.
Even more preferably, R2 is selected from the group consisting of: Ar-
Cp_6alkyl,
R9C(O)-, and R9S02.
Most preferably R2 is R9S02.
24
CA 02412353 2002-12-13
WO 01/95911 PCT/USO1/19062
In such embodiment:
R9 is selected from the group consisting of: C1_6alkyl, C3_6cycloalkyl-
CO_6alkyl,
Ar-CO_6alkyl, and Het-CO_6alkyl.
R9 is preferably selected from the group consisting of: C1_6alkyl, Ar-
CO_6alkyl,
and Het-CO_6alkyl.
More preferably, R9 is selected from the group consisting of:
ethyl, especially C1_6allcyl-substituted ethyl, more especially 2-cyclohexyl-
ethyl;
propyl, especially prop-1-yl;
isopentyl;
butyl, especially but-1-yl;
phenyl, especially halogen substituted phenyl, more especially 3-fluorophenyl,
4-
fluorophenyl, 2-chlorophenyl; especially C1_6alkyl substituted phenyl, more
especially 4-
ethyl-phenyl, 2-methyl phenyl, 4-methyl phenyl, especially C1_6alkyl sulfonyl
substituted
phenyl, more especially 4-methanesulfonyl phenyl, and 2-methanesulfonyl
phenyl;
pyridinyl, especially pyridin-2-yl, 1-oxy-pyridinyl, more especially 1-oxy-
pyridin-
2-yl;
1H-imidazolyl, especially 1H-imidazol-2-yl C1_6alkyl substituted imidazolyl,
especially 1-methyl-1H-imidazol-2-yl; and
isoxazolyl, especially isoxazol-4-yl, C1_6alkyl substituted isoxazolyl,
especially
'3,5-dimethyl- isoxazol-4-yl.
When R2 is R9S02, R9 is most preferably selected from the group consisting of:
pyridin-2-yl and 1-oxy-pyridin-2-yl.
When R2 is R9S02R11NC(O)-, R9 is preferably Ar-CO_6alkyl, more preferably
Ar, most preferably substituted phenyl such as 2-methyl phenyl, 4-methyl
phenyl, 2-chloro
phenyl, 4-fluoro phenyl.
When R2 is R9C(O)-, R9 is preferably selected from the group consisting of
C1_6alkyl, Cg_6cycloalkyl-CO_6alkyl, and Het-CO_galkyl, more preferably 1-oxy-
pyridin-2-
y1, 2-cyclohexyl ethyl, and isopentyl.
When R2 is R9S02R11NC(O)-, R11 is selected from the group consisting of:
CA 02412353 2002-12-13
WO 01/95911 PCT/USO1/19062
H, Cl_6alkyl, Ar-CO_6alkyl and Het-CO-6alkyl. Preferably in such embodiment,
Ril is H.
R2 may suitably be selected from the group consisting of:
Cl_6alkyl, Ar-Cp_6alkyl and Het-Cp-6alkyl, preferably C1_6alkyl and Het-
Cp_6alkyl,
When R2 is Ar-CO-6alkyl, R2 is preferably phenyl, especially substituted
phenyl,
more especially halogen substituted phenyl, even more especially 2-
fluorobenzyl.
When R2 is C1_6alkyl, R2 is preferably selected from 1-propyl, 1-butyl, and 1-
pentyl.
When R2 is Het-CO-6alkyl, Het-CO_6alkyl is preferably Het-methyl, and Het in
Het-methyl is preferably selected from the group consisting of:
pyridinyl, especially pyridin-2-yl, Cl_galkylpyridinyl, especially 6-methyl-
pyridin-
2-yl;
thiophenyl, especially thiophene-2-yl;
benzo[b]thiophen-2-yl;
thiazolyl, especially thiazol-4-yl such as isothiazol-3-yl;
1H-imidazolyl, especially 1H-imidazol-2-yl, Cl-6alkyl substituted imidazolyl,
especially 1-methyl-1H-imidazol-2y1;
triazolyl, especially 3H-[1,2,3]triazolyl, more especially 3H-[1,2,3]triazol-4-
yl,
especially Cl_6alkyl substituted 3H-[1,2,3]triazolyl, more especially 3-phenyl-
3H-
[1,2,3]triazolyl -4-yl;
quinolinyl, especially quinolin-2-yl, quinolin-2-yl;
furanyl, especially furan-2-yl, especially substituted furanyl, such as 5-
ethyl-furan-
2-yl;
thieno[3,2-b]thiophene, especially thieno[3,2-b]thiophene-2-yl, C1_6alkyl
substituted thieno[3,2-b]thiophene-2-yl, especially 3,4-dimethyl-thieno[3,2-
b]thiophene-2-yl.
The compounds of embodiment IA have the same uses described throughout this
specification for compounds of Formula I. The compounds of embodiment IA may
be
formulated into pharmaceutical compositions and used in methods of treatment
as
described for compounds of Formula I throughout this specification.
26
CA 02412353 2002-12-13
WO 01/95911 PCT/USO1/19062
Compounds of Formula I selected from the following group are particularly
preferred embodiments of the present invention:
Example Chemical Name
No.
1 { (S)-1-[ 1-((S)-2-Benzyloxycarbonylamino-4-methyl-pentanoyl)-3-
oxo-azepan-4-ylcarbamoyl}carbamic acid benzyl ester;
2 Naphthylene-2-carboxylic acid[(S)-1-(1-benzyl-3-oxo-azepan-4-
ylcarbamoyl)-3-methyl-butyl] amide;
3 Benzo[1,3]dioxole-5-carboxylic acid [(S)-1-(1-benzyl-3-oxo-
azepan-4-ylcarbamoyl)-3-methyl-butyl] amide;
4 Benzofuran-2-carboxylic acid [(S)-1-(1-benzyl-3-oxo-azepan-4-
ylcarbamoyl)-3-methyl-butyl] amide;
Benzo[b]thiophene-2-carboxylic acid [(S)-1-(1-benzyl-3-oxo-
azepan-4-ylcarbamoyl)-3-methyl-butyl]amide;
6 Naphthylene-2-sulphonyl [(S)-1-(1-benzyl-3-oxo-azepan-4-
ylcarbamoyl)-3-methyl-butyl]-amide;
7 Quinoline-2-carboxylic acid [(S)-1-(1-benzyl-3-oxo-azepan-4-
ylcarbamoyl)-3-methyl-butyl] amide;
8 3,4-dichlorobenzoic acid [(S)-1-(1-benzyl-3-oxo-azepan-4-
ylcarbamoyl)-3-methyl-butyl] amide;
9 4-{ (S)-Methyl-2-[(quinoline-2-carbonyl)-amino]pentanoylamino
}-
3-oxo-1-[2-(3-pyridin-2-yl-phenyl)-acetyl]azepanium;
1-((S)-2-Benzyloxycarbonylamino-4-methyl-pentyl)-4-{
(S)-4-
methyl-2-[(2-quinoiline-2-carbonyl)-amino]-pentanoylamino)-3-
oxo-azepanium;
11 1-Benzoyl-4-((S)-2-(benzo[1,3]dioxole-carbonylamino)-4-methyl-
pentanoylamino)-3-oxo-azepanium;
12 1-Benzoyl-4-((S)-2-(4-fluoro-benzoylamino)-4-methyl-
pentanoylamino)-3-oxo-azepanium;
13 3-Oxo-4-((S)-4-methyl-2-{ [5-(2-morpholino-4-yl-ethoxy)-
benzofuran-2-carbonyl]amino }-pentanoylamino)-1-(4-methyl-
pentanoyl)-azepanium;
27
CA 02412353 2002-12-13
WO 01/95911 PCT/USO1/19062
14 5-(2-Morpholin-4-yl-ethoxy)-benzofuran-2-carboxylic acid [(S)-1-
( 1-benzenesulfonyl-3-oxo-azepan-4-ylcarbamoyl)-3-methyl-
butyl]amide;
15 - 4-((S)-4-Methyl-2-{ [5-(2-morpholino-4-yl-ethoxy)-benzofuran-2-
carbonyl]amino }-pentanoylamino)-3-oxo-azepane-1-carboxylic
acid phenylamide;
16 5-(2-Morpholino-4-yl-ethoxy)-benzofuran-2-carboxylic acid ((S)-
3-methyl-1-{ 3-oxo-1-[2-(3-pyridin-2-yl-phenyl)acetyl]-azepan-4-
ylcarbamoyl }-butyl)amide;
17 5-(2-Morpholino-4-yl-ethoxy)-benzofuran-2-carboxylic acid [(S)-
1-(benzoyl-3-oxo-azepan-4-ylcarbamoyl)-3-methyl-butyl] amide;
18 5-(2-Pyrrolidin-1-yl-ethoxy)-benzofuran-2-carboxylic acid [(S)-1-
( 1-benzenesulfonyl-3-oxo-azepan-4-ylcarbamoyl)-3-methyl-
butyl]amide;
19 5-(2-Piperidin-1-yl-ethoxy)-benzofuran-2-carboxylic acid [(S)-1-
( 1-benzenesulfonyl-3-oxo-azepan-4-ylcarbamoyl)-3-methyl-
butyl] amide;
20 5-(2-Morpholino-4-yl-ethoxy)-benzofuran-2-carboxylic acid ((S)-
3-methyl-1-{ 3-oxo-1-[2-(3-pyridin-2-yl-phenyl)ethyl]-azepan-4-
ylcarbamoyl }-butyl)amide;
21 Naphthlene-2-carboxylic acid ((S)-3-methyl-1-{3-oxo-1-[2-(3-
pyridin-2-yl-phenyl)ethyl]-azepan-4-ylcarbamoyl }-butyl)amide;
22 1H_Indole-2-carboxylic acid ((S)-3-methyl-1-{3-oxo-1-[2-(3-
pyridin-2-yl-phenyl)ethyl]-azepan-4-ylcarbamoyl }-butyl)amide;
23 1H-Indole-2-carboxylic acid [(S)-1-(1-benzenesulfonyl-3-oxo-
azepan-4-ylcarbamoyl)-3-methyl-butyl]amide;
24 Benzofuran-2-carboxylic acid [(S)-1-(1-benzenesulfonyl-3-oxo-
azepan-4-ylcarbamoyl)-3-methyl-butyl] amide;
25 Benzofuran-2-carboxylic acid [(S)-3-methyl-1-{3-oxo-1-[2-(3-
pyridin-2-yl-phenyl)ethyl]-azepan-4-ylcarbamoyl }-butyl)amide;
26 5-(2-Morpholino-4-yl-ethoxy)-benzofuran-2-carboxylic acid [(S)-
3-methyl-1-(3-oxo-1-phenethyl-azepan-4-ylc arbamoyl]-
butyl } amide;
28
CA 02412353 2002-12-13
WO 01/95911 PCT/USO1/19062
27 Naphthylene-2-carboxylic acid [(S)-3-methyl-1-(3-oxo-1-
phenethyl-azepan-4-ylcarbamoyl]-butyl } amide;
28 Benzofuran-2-carboxylic acid {(S)-3-methyl-1-[3-oxo-1-(pyridine-
2-sulfonyl)-azepan-4-ylcarbamoyl]-butyl }-amide;
29 Naphthylene-2-carboxylic acid {(S)-3-methyl-1-[3-oxo-1-
(pyridine-2-sulfonyl)-azepan-4-ylcarbamoyl]-butyl
}-amide;
30 5-(2-Morpholino-4-yl-ethoxy)-benzofuran-2-carboxylic
acid { (S)-
3-methyl-1-[3-oxo-1-(pyridine-2-sulfonyl)-azepan-4-ylcarbamoyl]-
butyl }-amide;
31 4-((S)-4-Methyl-2-{ [(5-(2-morpholino-4-yl-ethoxy)-benzofuran-2-
carbonyl]-amino }-pentanoylamino)-3-oxo-azepane-1-carboxylic
acid tert-butyl ester;
32 4-((S)-4-Methyl-2-{ [(5-(2-morpholino-4-yl-ethoxy)-benzofuran-2-
carboxylic acid [(S)-3-methyl-1-(3-oxo-azepan-4-ylcarbamoyl]-
butyl } amide;
33 4-Methyl-pentanoic acid {3-oxo-1-[2-(3-pyridin-2-yl-phenyl-
acetyl]-azepan-4-yl }-amide;
34 ((S)-3-Methyl-1-{ 3-oxo-1-[2-(3-pyridin-2-yl-phenyl)-acetyl]-
azepan-4-ylcarbamoyl }-butyl)-naphthylene-2-methyl-carbamic
acid tert-butyl ester;
35 (S)-4-Methyl-2-[(naphthylen-2-ylmethyl)-amino]-pentenoic
acid
[3-oxo-1-[2-(3-pyridin-2-yl-phenyl)-acetyl]-azepan-4-yl
}-amide;
36 4-[2-(2-{ (S)-3-Methyl-1-[3-oxo-1-(pyidine-2-sulfonyl)-azepan-4-
ylcarbamoyl]-butylcarbamoyl }-benzofuran-5-yloxy)-ethyl]-
piperazine-1-carboxylic acid tert-butyl ester;
37 5-(2-Piperizin-1-yl-ethoxy)-benzofuran-2-carboxylic
acid {(S)-3-
methyl-1-[3-oxo-1-(pyridine-2-sulfonyl)-azepan-4-ylcarbamoyl]-3-
butyl }-amide;
38 5-(2-Cyclohexyl-ethoxy)-benzofuran-2-carboxylic
acid { (S)-3-
methyl-1-[3-oxo-1-(pyridine-2-sulfonyl)-azepan-4-ylcarbamoyl]-
butyl } amide;
29
CA 02412353 2002-12-13
WO 01/95911 PCT/USO1/19062
39 5-(2-Cyclohexyl-ethoxy)-benzofuran-2-carboxylic acid ((S)-3-
methyl-1-{ 3-oxo-1-[2-(3-pyridin-2-yl-phenyl)ethyl]-azepan-4-
ylcarbamoyl }-butyl)amide;
40 4- [2-(2-{ (S)-3-Methyl-1-[3-oxo-1-(3-pyridin-2-yl-phenyl)-ethyl
[azepan-4-ylcarbamoyl]-butylcarbamoyl }-benzofuran-5-yloxy)-
ethyl]-piperazine-1-carboxylic acid test-butyl ester;
41 5-(2-piperizin-1-yl-ethoxy)-benzofuran-2-carboxylic acid ((S)-3-
methyl-1-{ 3-oxo-1-[2-(3-pyridin-2-yl-phenyl)ethyl]-azepan-4-
ylcarbamoyl }-butyl)amide;
42 (S)-4-Methyl-2-(methyl-naphthalen-2-ylmethyl-amino)pentanoic
acid [3-oxo-1-(pyridine-2-sulphonyl)-azepan-4-yl]-amide;
43 (S)-4-Methyl-2-(methyl-naphthalen-2-ylmethyl-amino)pentanoic
acid {3-oxo-1-[2-(3-pyridin-2-yl-phenyl)-acetyl]-azepan-4-yl}-
amide;
44 5-(2-Morpholino-4-yl-ethoxy)-benzofuran-2-carboxylic acid
methyl ((S)-3-methyl-1-{3-oxo-1-[2-(3-pyridin-2-yl-
phenyl)acetyl]-azepan-4-ylcarbamoyl }-butyl)amide;
45 Benzofuran-2-carboxylic acid methyl { (S)-3-methyl-1-[3-oxo-1-
(pyridine-2-sulfonyl)-azepan-4-ylcarbamoyl)-3-methyl-butyl]-
amide;
46 2,2,2-Trifluoro-N-((S)-3-methyl-1-{ 3-oxo-1-[2-(3-pyridin-2-yl-
phenyl)-acetyl]-azepan-4-ylcarbamoyl }-butyl)-N-naphthylen-2-
ylmethyl-acetamide;
47 4-[(S)-(Methanesulphonyl-naphthylen-2-ylmethyl-amino)-4-
methyl-pentanoylamino]-3-oxo-azepane-1-carboxylic acid benzyl
ester;
48 Quinoline-2-carboxylic acid {(S)-3-methyl-1-[3-oxo-1-(pyridine-
2-sulfonyl)-azepan-4-ylcarbamoyl]-butyl } amide;
49 Quinoline-8-carboxylic acid {(S)-3-methyl-1-[3-oxo-1-(pyridine-
2-sulfonyl)-azepan-4-ylcarbamoyl]-butyl } amide;
50 Quinoline-6-carboxylic acid {(S)-3-methyl-1-[3-oxo-1-(pyridine-
2-sulfonyl)-azepan-4-ylcarbamoyl]-butyl}amide;
CA 02412353 2002-12-13
WO 01/95911 PCT/USO1/19062
51 Quinoline-4-carboxylic acid {(S)-3-methyl-1-[3-oxo-1-(pyridine-
2-sulfonyl)-azepan-4-ylcarbamoyl]-butyl } amide;
52 Quinoline-3-carboxylic acid {(S)-3-methyl-I-[3-oxo-1-(pyridine-
2-sulfonyl)-azepan-4-ylcarbamoyl]-butyl } amide;
53 Isoquinoline-3-carboxylic acid {(S)-3-methyl-1-[3-oxo-1-
(pyridine-2-sulfonyl)-azepan-4-ylcarbamoyl]-butyl } annide;
54 Isoquinoline-1-carboxylic acid {(S)-3-methyl-1-[3-oxo-1-
(pyridine-2-sulfonyl)-azepan-4-ylcarbamoyl]-butyl } annide;
55 Quinoxaline-2-carboxylic acid {(S)-3-methyl-1-[3-oxo-1-
(pyridine-2-sulfonyl)-azepan-4-ylcarbamoyl]-butyl } amide;
56 Benzo[b]thiophene-2-carboxylic acid {(S)-3-methyl-1-[3-oxo-1-
(pyridine-2-sulfonyl)-azepan-4-ylcarbamoyl]-butyl } amide;
57 1,8-Naphthyridine-2-carboxylic acid {(S)-3-methyl-1-[3-oxo-1-
(pyridine-2-sulfonyl)-azepan-4-ylcarbamoyl]-butyl } amide;
58 1H-Indole-2-carboxylic acid {(S)-3-methyl-1-[3-oxo-1-(pyridine-
2-sulfonyl)-azepan-4-ylcarbamoyl]-butyl } amide;
59 5-Methoxy-benzofuran-2-carboxylic acid { (S)-3-methyl-1-[3-oxo-
1-(pyridine-2-sulfonyl)-azepan-4-ylcarbamoyl]-butyl } amide;
60 5-Bromo-furan-2-carboxylic acid { (S)-3-methyl-1-[3-oxo-1-
(pyridine-2-sulfonyl)-azepan-4-ylcarbamoyl]-butyl } amide;
61 Furan-2-carboxylic acid {(S)-3-methyl-1-[3-oxo-1-(pyridine-2-
sulfonyl)-azepan-4-ylcarbamoyl]-butyl } amide;
62 5-Nitro-furan-2-carboxylic acid {(S)-3-methyl-1-[3-oxo-1-
(pyridine-2-sulfonyl)-azepan-4-ylcarbamoyl]-butyl } amide;
63 5-(4-Nitro-phenyl)-furan-2-carboxylic acid {(S)-3-methyl-1-[3-
oxo-1-(pyridine-2-sulfonyl)-azepan-4-ylcarbamoyl]-butyl } amide;
64 5-(3-Trifluoromethyl-phenyl)-furan-2-carboxylic acid { (S)-3-
methyl-1-[3-oxo-1-(pyridine-2-sulfonyl)-azepan-4-ylcarbamoyl]-
butyl } amide;
65 Tetrahydro-furan-2-carboxylic acid {(S)-3-methyl-1-[3-oxo-1-
(pyridine-2-sulfonyl)-azepan-4-ylcarbamoyl]-butyl } amide;
66 (S)-4-Methyl-2-(2-phenoxy-acetylamino)-pentanoic acid [3-oxo-
(pyridine-2-sulfonyl)-azepan-4-yl]-amide;
31
CA 02412353 2002-12-13
WO 01/95911 PCT/USO1/19062
67 (S)-2-[2-(4-Fluoro-phenoxy)-acetylamino]-4-methyl-pentanoic
acid [3-oxo-(pyridine-2-sulfonyl)-azepan-4-yl]-amide;
68 Benzofuran-2-carboxylic acid {(S)-3-methyl-1-[3-oxo-1-(pyridine-
2-carbonyl)-azepan-4-ylcarbamoyl)-3- butyl]-amide;
69 Benzofuran-2-carboxylic acid {(S)-3-methyl-1-[3-oxo-1-(1-oxy-
pyridine-2-carbonyl)-azepan-4-ylcarbamoyl]-butyl } amide;
70 4-((S)-2-tert-Butylcarbonylamino-4-methyl-pentanoylamino)-3-
oxo-azepane-1-carboxylic acid benzyl ester;
71 5,6-Dimethoxy-benzofuran-2-carboxylic acid {(S)-3-methyl-1-[3-
oxo-1-( 1-methyl-1 H-imidazole-4-sulfonyl)-azepan-4-
ylcarbamoyl]-butyl }amide;
72 Benzofuran-2-carboxylic acid {(S)-3-methyl-1-[1-(5-methyl-1H-
[ 1,2,4]triazole-3-sulfonyl)-3-oxo-azepan-4-ylcarbamoyl]-
butyl } amide;
73 Benzofuran-2-carboxylic acid {(S)-3-methyl-1-[1-(1-methyl-1H-
imidazole-3-sulfonyl)-3-oxo-azepan-4-ylcarbamoyl]-butyl } amide;
74 Benzofuran-2-carboxylic acid {(S)-3-methyl-1-[1-(1H-imidazole-
2-sulfonyl)-3-oxo-azepan-4-ylcarbamoyl]-butyl } amide;
75 Benzofuran-2-carboxylic acid { (S)-3-methyl-1-[3-oxo-1-(thiazole-
2-sulfonyl)-azepan-4-ylcarbamoyl]-butyl } amide;
76 Benzofuran-2-carboxylic acid {(S)-3-methyl-1-[1-(1-methyl-1H-
imidazole-4-sulfonyl)-3-oxo-azepan-4-ylcarbamoyl]-butyl } amide;
77 5-(4-Oxy-morpholino-4-yl-ethoxy)-benzofuran-2-carboxylic acid
{ (S )-3-methyl-1- [3-oxo-1-(pyr idine-2-sulfonyl)-azepan-4-
ylcarbamoyl]-butyl } amide;
78 Benzofuran-2-carboxylic acid {(S)-3-methyl-1-[3-oxo-1-(pyridine-
3-sulfonyl)-azepan-4-ylcarbamoyl]-butyl } amide;
79 Benzofuran-2-carboxylic acid {(S)-3-methyl-1-[3-oxo-1-(I-oxy-
pyridine-3-sulfonyl)-azepan-4-ylcarbamoyl]-butyl } amide;
80 Quinoline-3-carboxylic acid {(S)-1-(3,4-dichloro-benzene-
sulfonyl)-3-oxo-azepan-4-ylcarbamoyl)]-3-methyl-butyl }-amide;
32
CA 02412353 2002-12-13
WO 01/95911 PCT/USO1/19062
81 5-Hydroxy-benzofuran-2-carboxylic acid {(S)-3-methyl-1-[1-(1-
methyl-1H-imidazole-4-sulfonyl)-3-oxo-azepan-4-ylcarbamoyl]-
butyl } amide;
82 Benzofuran-2-carboxylic acid {(S)-3-methyl-1-[3-oxo-1-(1-oxy-
pyridine-2-sulfonyl)-azepan-4-ylcarbamoyl)]-3-methyl-butyl
}-
amide;
83 2-(4-{ (S)-2-{ (Benzofuran-2-carbonyl)-amino
}-4-methyl-
pentanoylamino}-3-oxo-azepane-1-sulfonyl)-benzoic
acid;
84 3-(4-{ (S)-2-{ (Benzofuran-2-carbonyl)-amino]-4-methyl-
pentanoylamino}-3-oxo-azepane-1-sulfonyl)-benzoic
acid;
85 Benzo[b]thiophene-2-carboxylic acid {(S)-3-methyl-1-[3-oxo-1-
(1-oxy-pyridine-2-sulfonyl)-azepan-4-ylcarbamoyl]-butyl
} amide;
86 5-Bromo-furan-2-carboxylic acid {(S)-3-methyl-1-[3-oxo-1-(1-
oxy-pyridine-2-sulfonyl)-azepan-4-ylcarbamoyl]-butyl}amide;
87 5,6-Dimethoxy-benzofuran-2-carboxylic acid {(S)-3-methyl-1-[3-
oxo-1-( 1-oxy-pyridine-2-sulfonyl)-azepan-4-ylcarbamoyl]-
butyl } amide;
88 1-Oxy-pyridine-2-carboxylic acid {(S)-3-methyl-1-[3-oxo-1-
(pyridine-2-sulfonyl)-azepan-4-ylcarbamoyl]-butyl
} amide;
89 (S)-4-Methyl-2-(pyridine-2-sulfonylamino)-pentanoic
acid [3-oxo-
1-(pyridine-2-sulfonyl)-azepan-4-yl]-amide;
90 (S)-2-(3-Benzyl-ureido)-4-methyl-pentanoic acid
[3-oxo-1-
(pyridine-2-sulfonyl)-azepan-4-yl]-amide;
91 (S)-4-Methyl-2-(3-phenyl-uriedo)-pentanoic acid
[3-oxo-1-
(pyridine-2-sulfonyl)-azepan-4-yl]-amide;
92 Benzofuran-2-carboxylic acid {(S)-1-[6,6-dimethyl-3-oxo-
1 (pyridine-sulphonyl)-azepan-4-ylcarbamoyl]-3-methyl-butyl
}-
amide;
93 5-Methoxy-benzofuran-2-carboxylic acid {(S)-3-methyl-1-[3-oxo-
1-( 1-oxy-pyridine-2-sulfonyl)-azepan-4-ylcarbamoyl]-
butyl } amide;
33
CA 02412353 2002-12-13
WO 01/95911 PCT/USO1/19062
94 Thieno[3,2-b]thiophene-2-carboxylic acid {(S)-3-methyl-1-[3-oxo-
1-( 1-oxy-pyridine-2-sulfonyl)-azepan-4-ylcarbamoyl]-
butyl } amide;
95 , Quinoxaline-2-carboxylic acid {(S)-3-methyl-1-[3-oxo-1-(1-oxy-
pyridine-2-sulfonyl)-azepan-4-ylcarbamoyl]-butyl } amide;
96 Quinoline-2-carboxylic acid {(S)-3-methyl-1-[3-oxo-1-(1-oxy-
pyridine-2-sulfonyl)-azepan-4-ylcarbamoyl]-butyl } amide;
97 Thiophene-3-carboxylic acid {(S)-3-methyl-1-[3-oxo-1-(1-oxy-
pyridine-2-sulfonyl)-azepan-4-ylcarbamoyl]-butyl } amide;
98 1H-Indole-5-carboxylic acid {(S)-3-methyl-1-[3-oxo-1-(1-oxy-
pyridine-2-sulfonyl)-azepan-4-ylcarbamoyl]-butyl } amide;
99 Benzo[1,3]dioxole-5-carboxylic acid {(S)-3-methyl-1-[3-oxo-1-(1-
oxy-pyridine-2-sulfonyl)-azepan-4-ylcarbamoyl]-butyl } amide;
100 Furan-2-carboxylic acid {(S)-3-methyl-1-[3-oxo-1-(1-oxy-
pyridine-2-sulfonyl)-azepan-4-ylcarbamoyl]-butyl } amide;
101 (S)-4-Methyl-2-(2-thiophen-2-yl-acetylamino)-pentanoic acid [3-
oxo-1-( 1-oxy-pyridine-2-sulfonyl)-azepan-4-yl]-amide;
102 1H-Indole-2-carboxylic acid {(S)-3-methyl-1-[3-oxo-1-(1-oxy-
pyridine-2-sulfonyl)-azepan-4-ylcarbamoyl]-butyl } amide;
103 4-Fluoro- { (S)-3-methyl-1-[3-oxo-1-( 1-oxy-pyridine-2-sulphonyl)-
azepan-4-carbamoyl]-butyl }-benzamide;
104 5-(2-Morpholin-4-yl-ethoxy)-benzofuran-2-carboxylic acid { (S)-3-
methyl-1-[3-oxo-( 1-oxy-pyridine2-sulphonyl)-azepan-4-
ylcarbamoyl]- -buty }-amide;
105 Thiophene-2-carboxylic acid {(S)-3-methyl-1-[3-oxo-1-(1-oxy-
pyridine-2-sulfonyl)-azepan-4-ylcarbamoyl]-butyl } amide;
106 3-Methyl-benzofuran-2-carboxylic acid {(S)-3-methyl-1-[3-oxo-1-
( 1-oxy-pyridine-2-sulfonyl)-azepan-4-ylcarbamoyl]-butyl } amide;
107 6-Methyl-N-{ (S)-3-methyl-1-[3-oxo-1-(1-oxy-pyridine-2-
sulfonyl)-azepan-4-ylcarbamoyl]-butyl }-nicotinamide;
108 (S)-4-Methyl-2-(2-thiophen-yl-acetylamino)-pentanoic acid-[3-
oxo-1-(pyridine-2-sulfonyl)-azepan-4-yl]-butyl}amide;
34
CA 02412353 2002-12-13
WO 01/95911 PCT/USO1/19062
109 1H-Indole-6-carboxylic acid {(S)-3-methyl-1-[3-oxo-1-(pyridine-
2-sulfonyl)-azepan-4-ylcarbamoyl]-butyl } amide;
1I0 Benzo[1,3]dioxole-5-carboxylic acid {(S)-3-methyl-1-[3-oxo-1-
(pyridine-2-sulfonyl)-azepan-4-ylcarbamoyl]-butyl
} amide;
111 3,4-Dihydro-2H-benzo[b][1,4]dioxepine-7-carboxylic
acid {(S)-3-
methyl-1-[3-oxo-1-(1-oxy-pyridine-2-sulfonyl)-azepan-4-
ylcarbamoyl] butyl}amide;
112 , 5-Methyl-thiophene-2-carboxylic acid {(S)-3-methyl-1-[3-oxo-1-
( 1-oxy-pyridine-2-sulfonyl)-azepan-4-ylcarbamoyl]-butyl
} amide;
113 4,5-Dibromo-thiophene-2-carboxylic acid { (S)-3-methyl-1-[3-oxo-
1-( 1-oxy-pyridine-2-sulfonyl)-azepan-4-ylcarbamoyl]-
butyl } amide;
114 3,5-Dimethyl-isoxazole-4-carboxylic acid { (S)-3-methyl-1-[3-oxo-
1-(1-oxy-pyridine-2-sulfonyl)-azepan-4-ylcarbamoyl]-
butyl } amide;
115 (S)-2-(2-Benzyloxy-acetylamino)-4-methyl-pentanoic
acid[1-(4-
methoxy-benzenesulfonyl)-3-oxo-azepan-4-yl]-amide;
116 5-(3-Trifluoromethyl-phenyl)-furan-2-carboxylic
acid {(S)-3-
methyl-1-[3-oxo-1-(1-oxy-pyridine-2-sulfonyl)-azepan-4-
ylcarbamoyl]-butyl } amide;
117 5-Methyl-2 -phenyl-oxazole-4-carboxylic acid
{ (S)-3-methyl-1-[3-
oxo-1-(1-oxy-pyridine-2-sulfonyl)-azepan-4-ylcarbamoyl]-
butyl } amide;
118 Benzofuran-2-carboxylic acid {(S)-1-[ 1-(3,4-dimethoxy-
benzenesulfonyl)-3-oxo-azepan-4-ylcarbamoyl]-butyl
}-amide;
119 Benzofuran-2-carboxylic acid {(S)-1-[1-(4-bromo-
benzenesulfonyl)-3-oxo-azepan-4-ylcarbamoyl]-3-methyl-butyl }-
amide;
120 Benzofuran-2-carboxylic acid {(S)-1-[1-(benzo[1,2,5]oxadiazole-
4-sulfonyl)-3-oxo-azepan-4-ylcarbamoyl]-3-methyl-butyl }-amide;
121 Benzofuran-2-carboxylic acid {(S)-1-[1-(3,5-dimethyl-oxazole-4-
sulfonyl)-3-oxo-azepan-4-ylcarbamoyl]-3-methyl-butyl }-amide;
CA 02412353 2002-12-13
WO 01/95911 PCT/USO1/19062
122 3-Methyl-benzofuran-2-carboxylic acid {(S)-3-methyl-1-[3-oxo-1-
(pyridine-2-sulfonyl)-azepan-4-ylcarbamoyl]-butyl } amide;
123 Thieno[3,2-b]thiophene-2-carboxylic acid {(S)-3-methyl-1-[3-oxo-
1-(pyridine-2-sulfonyl)-azepan-4-ylcarbamoyl]-butyl } amide;
124 5-tert-Butyl-3-methyl-thieno[3,2-b]thiophene-2-carboxylic acid
{ (S)-3-methyl-1- [3-oxo-1-(pyridine-2-sulfonyl)-azepan-4-
ylcarbamoyl]-butyl } amide;
125 5-Methyl-2-phenyl-oxazole-4-carboxylic acid {(S)-3-methyl-1-[3-
oxo-1-(pyridine-2-sulfonyl)-azepan-4-ylcarbamoyl]-butyl } amide;
126 2-Phenyl-5-trifluoromethyl-oxazole-4-carboxylic acid { (S)-3-
methyl-1-[3-oxo-1-(pyridine-2-sulfonyl)-azepan-4-ylcarbamoyl]-
butyl } amide;
127 Quinoline-2-carboxylic acid [(S)-1-(1-methanesulfonyl-3-oxo-
azepan-4-ylcarbamoyl)-3-methyl-butyl]-amide;
128 1-Methyl-1H-indole-2-carboxylic acid [(S)-1-(1-methanesulfonyl-
3-oxo-azepan-4-ylcarbamoyl)-3-methyl-butyl]-amide;
129 Furan-2-carboxylic acid { [(S)-1-(1-methanesulfonyl-3-oxo-
azepan-4-ylcarbamoyl)-3-methyl-butylcarbamoyl]-methyl }-amide;
130 , 5-Methoxy-benzofuran-2-carboxylic acid [(S)-1-(1-
methanesulfonyl-3-oxo-azepan-4-ylcarbamoyl)-3-methyl-butyl]-
amide;
131 Quinoxaline-2-carboxylic acid [(S)-1-(1-methanesulfonyl-3-oxo-
azepan-4-ylcarbamoyl)-3-methyl-butyl]-amide;
132 5-(4-Chloro-phenyl)-furan-2-carboxylic acid {(S)-3-methyl-1-[3-
oxo-1-(pyridine-2-sulfonyl)-azepan-4-ylcarbamoyl]-butyl } amide;
133 (S)-2-[2-(4-Methoxy-phenyl)-acetylamino)-4-methyl-pentanoic
acid (1-methanesulfonyl-3-oxo-azepan-4-yl)-amide;
134 Quinoline-2-carboxylic acid {[(S)-1-[1-(2-cyano-
benzenesulfonyl)-3-oxo-azepan-4-ylcarbamoyl]-3-methyl-butyl }-
amide;
135 1-Methyl-1H-indole -2-carboxylic acid { [(S)-1-[ 1-(2-cyano-
benzenesulfonyl)-3-oxo-azepan-4-ylcarbamoyl]-3-methyl-butyl }-
amide;
36
CA 02412353 2002-12-13
WO 01/95911 PCT/USO1/19062
136 Furan-2-carboxylic acid ({(S)-1-[1-(2-cyano-benzenesulfonyl)-3-
oxo-azepan-4-ylcarbamoyl]-3-methyl-butylcarbamoyl }-methyl)-
amide;
137 5-Methoxy-benzofuran-2-carboxylic acid {(S)-1-[1-(2-cyano-
benzenesulfonyl)-3-oxo-azepan-4-ylcarbamoyl]-3-methyl-butyl }-
amide;
138 Quinoxaline-2-carboxylic acid {(S)-1-[1-(2-cyano-
benzenesulfonyl)-3-oxo-azepan-4-ylcarbamoyl]-3-methyl-butyl }-
amide;
139 (S)-2-[2-(4-Methoxy-phenyl)-acetylamino)-4-methyl-pentanoic
acid [1-(2-cyano-benzenesulfonyl)-3-oxo-azepan-4-yl]-amide;
140 Quinoline-2-carboxylic acid {[(S)-1-[1-(4-methoxy-
benzenesulfonyl)-3-oxo-azepan-4-ylcarbamoyl]-3-methyl-butyl } L
amide;
141 1-Methyl-1H-indole-2-carboxylic acid {[(S)-1-[1-(4-methoxy-
benzenesulfonyl)-3-oxo-azepan-4-ylcarbamoyl]-3-methyl-butyl }-
amide;
142 Furan-2-carboxylic acid ({(S)-1-[1-(4-methoxy-benzenesulfonyl)-
3-oxo-azepan-4-ylcarbamoyl]-3-methyl-butylcarbamoyl }-methyl)-
amide;
143 5-Methoxy-benzofuran-2-carboxylic acid {[(S)-1-[1-(4-methoxy-
benzenesulfonyl)-3-oxo-azepan-4-ylcarbamoyl]-3-methyl-butyl }-
amide;
144 Quinoxaline-2-carboxylic acid {[(S)-1-[1-(4-methoxy-
benzenesulfonyl)-3-oxo-azepan-4-ylcarbamoyl]-3-methyl-butyl }-
amide;
145 (S)-2-[2-(4-Methoxy-phenyl)-acetylamino)-4-methyl-pentanoic
acid [ 1-(4-methoxy-benzenesulfonyl)-3-oxo-azepan-4-yl]-amide;
146 1-Methyl-1H-indole-2-carboxylic acid {[(S)-1-[1-(4-fluoro-
benzenesulfonyl)-3-oxo-azepan-4-ylcarbamoyl]-3-methyl-butyl}-
amide;
37
CA 02412353 2002-12-13
WO 01/95911 . PCT/USO1/19062
147 Furan-2-carboxylic acid ({(S)-1-[1-(4-fluoro-benzenesulfonyl)-3-
oxo-azepan-4-ylcarbamoyl]-3-methyl-butylcarbamoyl }-methyl)-
amide;
148 5-Methoxy-benzofuran-2-carboxylic acid {[(S)-1-(1-(4-fluoro-
benzenesulfonyl)-3-oxo-azepan-4-ylcarbamoyl]-3-methyl-butyl }-
amide;
149 Quinoxaline-2-carboxylic acid { [(S)-1-(1-(4-fluoro-
benzenesulfonyl)-3-oxo-azepan-4-ylcarbamoyl]-3-methyl-butyl
}-
amide;
150 (S)-2-[2-(4-Methoxy-phenyl)-acetylamino)-4-methyl-pentanoic
acid [1-(4-fluoro-benzenesulfonyl)-3-oxo-azepan-4-yl]-amide;
151 Benzofuran-2-carboxylic acid-{(S)-1-[1-(3-chloro-
benzenesulphonyl)-3-oxo-azepan-4-ylcarbamoyl]-3-methyl-butyl
}-
amide;
152 5-Methoxy-benzofuran-2-carboxylic acid-{(S)-1-[1-(3-chloro-
benzenesulphonyl)-3-oxo-azepan-4-ylcarbamoyl]-3-methyl-butyl
}-
amide;
153 7-Methoxy-benzofuran-2-carboxylic acid-{(S)-1-[1-(3-chloro-
benzenesulphonyl)-3-oxo-azepan-4-ylcarbamoyl]-3-methyl-butyl
}-
amide;
154 5,6-Dimethoxy-benzofuran-2-carboxylic acid-{(S)-1-[1-(3-chloro-
benzenesulphonyl)-3-oxo-azepan-4-ylcarbamoyl]-3-methyl-butyl
}-
amide;
155 3-Methyl-benzofuran-2-carboxylic acid-{(S)-1-[1-(3-chloro-
benzenesulphonyl)-3-oxo-azepan-4-ylcarbamoyl]-3-methyl-butyl
}-
amide;
156 Benzo[b]thiophene-2-carboxylic acid-{(S)-1-[1-(3-chloro-
benzenesulphonyl)-3-oxo-azepan-4-ylcarbamoyl]-3-methyl-butyl
}-
amide;
157 1-Methyl-1H-indole-2-carboxylic acid-{(S)-1-[1-(3-chloro-
benzenesulphonyl)-3-oxo-azepan-4-ylcarbamoyl]-3-methyl-butyl
}-
amide;
38
CA 02412353 2002-12-13
WO 01/95911 PCT/USO1/19062
158 Quinoxaline-2-carboxylic acid-{(S)-1-[1-(3-chloro-
benzenesulphonyl)-3-oxo-azepan-4-ylcarbamoyl]-3-methyl-butyl }-
amide;
159 Benzofuran-2-carboxylic acid-{(S)-1-[1-(2-fluoro-
benzenesulphonyl)-3-oxo-azepan-4-ylcarbamoyl]-3-methyl-butyl
}-
amide;
160 5-Methoxy-benzofuran-2-carboxylic acid-{(S)-1-[1-(2-fluoro-
benzenesulphonyl)-3-oxo-azepan-4-ylcarbamoyl]-3-methyl-butyl
}-
amide;
161 7-Methoxy-benzofuran-2-carboxylic acid-{(S)-1-[1-(2-fluoro-
benzenesulphonyl)-3-oxo-azepan-4-ylcarbamoyl]-3-methyl-butyl
}-
amide;
162 5,6-Dimethoxy-benzofuran-2-carboxylic acid-{(S)-1-[1-(2-fluoro-
benzenesulphonyl)-3-oxo-azepan-4-ylcarbamoyl]-3-methyl-butyl
}-
amide;
163 5-Methyl-benzofuran-2-carboxylic acid-{(S)-1-[1-(2-fluoro-
benzenesulphonyl)-3-oxo-azepan-4-ylcarbamoyl]-3-methyl-butyl
}-
amide;
164 Benzo[b]thiophene-2-carboxylic acid-{(S)-1-[1-(2-fluoro-
benzenesulphonyl)-3-oxo-azepan-4-ylcarbamoyl]-3-methyl-butyl
}-
amide;
165 1-Methyl-1H-indole-2-carboxylic acid-{(S)-1-[1-(2-fluoro-
benzenesulphonyl)-3-oxo-azepan-4-ylcarbamoyl]-3-methyl-butyl
}-
amide;
166 (S)-4-Methyl-2-(1-oxy-pyridine-2-sulfonylamino)-pentanoic
acid
[3-oxo-1-(pyridine-2-sulfonyl)-azepan-4-yl]-amide;
167 Quinoxaline-2-carboxylic acid-{(S)-1-[1-(2-fluoro-
benzenesulphonyl)-3-oxo-azepan-4-ylcarbamoyl]-3-methyl-butyl
}-
amide;
168 5-Methoxy-benzofuran-2-carboxylic acid-{(S)-3-methyl-1-[3-oxo-
1-(thiophene-2-sulfonyl)-azepan-4-ylcarbamoyl]-butyl
}-amide;
169 7-Methoxy-benzofuran-2-carboxylic acid-{(S)-3-methyl-1-[3-oxo-
1-(thiophene-2-sulfonyl)-azepan-4-ylcarbamoyl]-butyl
}-amide;
39
CA 02412353 2002-12-13
WO 01/95911 PCT/USO1/19062
170 5,6-Dimethoxy-benzofuran-2-carboxylic acid-{
(S)-3-methyl-1-[3-
oxo-1-(thiophene-2-sulfonyl)-azepan-4-ylcarbamoyl]-butyl
}-
amide;
171 3-Methyl-benzofuran-2-carboxylic acid-{ (S)-3-methyl-1-[3-oxo-1-
(thiophene-2-sulfonyl)-azepan-4-ylcarbamoyl]-butyl
}-amide;
172 Benzo[b]thiophene-2-carboxylic acid-{(S)-3-methyl-1-[3-oxo-1-
(thiophene-2-sulfonyl)-azepan-4-ylcarbamoyl]-butyl
}-amide;
173 I-Methyl-1-H-indole-2-carboxylic acid-{(S)-3-methyl-1-[3-oxo-1-
(thiophene-2-sulfonyl)-azepan-4-ylcarbamoyl]-butyl
}-amide;
174 Quinoxaline-2-carboxylic acid-{(S)-3-methyl-1-[3-oxo-1-
(thiophene-2-sulfonyl)-azepan-4-ylcarbamoyl]-butyl
}-amide;
175 Benzofuran-2-carboxylic acid-{(S)-1-[1-(4-chloro-
benzenesulphonyl)-3-oxo-azepan-4-ylcarbamoyl]-3-methyl-butyl
}-
amide;
176 5-Methoxy-benzofuran-2-carboxylic acid-{(S)-1-[1-(4-chloro-
benzenesulphonyl)-3-oxo-azepan-4-ylcarbamoyl]-3-methyl-butyl
}-
amide;
177 '7-Methoxy-benzofuran-2-carboxylic acid-{(S)-1-[1-(4-chloro-
benzenesulphonyl)-3-oxo-azepan-4-ylcarbamoyl]-3-methyl-butyl
}-
amide;
178 5,6-Dimethoxy-benzofuran-2-carboxylic acid-{(S)-1-[1-(4-chloro-
benzenesulphonyl)-3-oxo-azepan-4-ylcarbamoyl]-3-methyl-butyl }-
amide;
179 3-Methyl-benzofuran-2-carboxylic acid-{(S)-1-[1-(4-chloro-
benzenesulphonyl)-3-oxo-azepan-4-ylcarbamoyl]-3-methyl-butyl }-
amide;
180 Benzo[b]thiophene-2-carboxylic acid-{(S)-1-[1-(4-chloro-
benzenesulphonyl)-3-oxo-azepan-4-ylcarbamoyl]-3-methyl-butyl }-
amide;
181 1-Methyl-IH-indole-2-carboxylic acid-{(S)-1-[1-(4-chloro-
benzenesulphonyl)-3-oxo-azepan-4-ylcarbamoyl]-3-methyl-butyl }-
amide;
CA 02412353 2002-12-13
WO 01/95911 PCT/USO1/19062
182 Quinoxaline-2-carboxylic acid-{(S)-1-[1-(4-chloro-
benzenesulphonyl)-3-oxo-azepan-4-ylcarbamoyl]-3-methyl-butyl }-
amide;
183 Benzofuran-2-carboxylic acid-{(S)-1-[1-(3-methoxy-
benzenesulphonyl)-3-oxo-azepan-4-ylcarbamoyl]-3-methyl-butyl }-
amide;
184 5-Methoxy-benzofuran-2-carboxylic acid-{(S)-1-[1-(3-methoxy-
benzenesulphonyl)-3-oxo-azepan-4-ylcarbamoyl]-3-methyl-butyl }-
amide;
185 7-Methoxy-benzofuran-2-carboxylic acid-{(S)-1-[1-(3-methoxy-
benzenesulphonyl)-3-oxo-azepan-4-ylcarbamoyl]-3-methyl-butyl}-
amide;
186 5,6-Dimethoxy-benzofuran-2-carboxylic acid-{(S)-1-[1-(3-
methoxy-benzenesulphonyl)-3-oxo-azepan-4-ylcarbamoyl]-3-
methyl-butyl }-amide;
187 3-Methyl-benzofuran-2-carboxylic acid-{(S)-1-[.l-(3-methoxy-
benzenesulphonyl)-3-oxo-azepan-4-ylcarbamoyl]-3-methyl-butyl }-
amide;
188 Benzo[b]thiophene-2-carboxylic acid-{(S)-1-[1-(3-methoxy-
benzenesulphonyl)-3-oxo-azepan-4-ylcarbamoyl]-3-methyl-butyl }-
amide;
189 1-Methyl-1H-indole-2-carboxylic acid-{(S)-1-[1-(3-methoxy-
benzenesulphonyl)-3-oxo-azepan-4-ylcarbamoyl]-3-methyl-butyl }-
amide;
190 Quinoxaline-2-carboxylic acid-{(S)-1-[1-(3-methoxy-
benzenesulphonyl)-3-oxo-azepan-4-ylcarbamoyl]-3-methyl-butyl }-
amide;
191 Benzofuran-2-carboxylic acid-{(S)-3-methyl-1-[3-oxo-1-
(thiophene-2-sulfonyl)-azepan-4-ylcarbamoyl]-butyl }-amide;
192 Benzofuran-2-carboxylic acid {(S)-3-methyl-1-[(2,2',4-
tridueterio)-3-oxo-1-(pyridine-2-sulfonyl)-azepan-4-ylcarbamoyl]-
butyl } amide;
41
CA 02412353 2002-12-13
WO 01/95911 PCT/USO1/19062
193 Benzofuran-2-carboxylic acid {(S)-2-methyl-1-[3-oxo-1-(pyridine-
2-sulfonyl)-azepan-4-ylcarbamoyl]-butyl }-amide;
194 Benzofuran-2-carboxylic acid {(S)-1-[3-oxo-1-(pyridine-2-
sulfonyl)-azepan-4-ylcarbamoyl]-propy1 }-amide;
195 Benzofuran-2-carboxylic acid {(S)-2-cyclohexyl-1-[3-oxo-1-
(pyridine-2-sulfonyl)-azepan-4-ylcarbamoyl]-ethyl
}-amide;
196 Benzofuran-2-carboxylic acid {(S)-1-[3-oxo-1-(pyridine-2-
sulfonyl)-azepan-4-ylcarbamoyl]-ethyl }-amide;
197 Benzofuran-2-carboxylic acid {(S)-3-methanesulfinyl-1-[3-oxo-1-
(pyridine-2-sulfonyl)-azepan-4-ylcarbamoyl]-propyl
}-amide;
198 Benzofuran-2-carboxylic acid { [3-oxo-1-(pyridine-2-sulfonyl)-
azepan-4-ylcarbamoyl]-methyl }-amide;
199 Benzofuran-2-carboxylic acid {(S)-1-[3-oxo-1-(pyridine-2-
sulfonyl)-azepan-4-ylcarbamoyl]-penty1 }-amide;
200 Benzofuran-2-carboxylic acid {(S)-1-[3-oxo-1-(pyridine-2-
sulfonyl)-azepan-4-ylcarbamoyl]-butyl }-amide;
201 Benzofuran-2-carboxylic acid {(S)-2-methyl-1-[3-oxo-1-(pyridine-
2-sulfonyl)-azepan-4-ylcarbamoyl]-propyl }-amide;
202 Benzofuran-2-carboxylic acid {(S)-2-hydroxy-1-[3-oxo-1-
(pyridine-2-sulfonyl)-azepan-4-ylcarbamoyl]-propyl
}-amide;
203 Benzofuran-2-carboxylic acid {(S)-1-[3-oxo-1-(pyridine-2-
sulfonyl)-azepan-4-ylcarbamoyl]-2-phenyl-ethyl
}-amide;
204 1-(Benzofuran-2-carbonyl)-pyrrolidine-2-carboxylic
acid [3-oxo-1-
(pyridine-2-sulfonyl)-azepan-4-yl]-amide;
205 3,4-Dimethoxy-N-{(S)-1-[ 1-(4-methoxy-benzenesulfonyl)-3-oxo-
azepan-4-ylcarbamoyl]-3-methyl-butyl }-benzamide;
206 Benzo[b]thiophene-2-carboxylic acid-{(S)-1-[
1-(4-imethoxy-
benzenesulfonyl)-3-oxo-azepan-4-ylcarbamoyl]-3-methyl-butyl
}-
amide;
207 Benzo[1,3]dioxole-5-carboxylic acid {(S)-1-[1-(4-fluoro-
benzenesulfonyl)-3-oxo-azepan-4-ylcarbamoyl]-3methyl-butyl }-
amide;
42
CA 02412353 2002-12-13
WO 01/95911 PCT/USO1/19062
208 (S)-2-(2-Benzyloxy-acetylamino)-4-methyl-pentanoic acid[1-(4-
fluoro-benzenesulfonyl)-3-oxo-azepan-4-yl]-amide;
209 Benzo[b]thiophene-2-carboxylic acid-{(S)-1-[ 1-(4-fluoro-
benzenesulfonyl)-3-oxo-azepan-4-yl carbamoyl]-3-methyl-butyl}-
amide;
210 Benzofuran-2-carboxylic acid {(S)-1-[1-benzoyl-3-oxo-azepan-4-
ylcarbamoyl]-3-methyl-butyl }-amide;
211 (S)-4-Methyl-2-(quinoline-8-sulfonylamino)-pentanoic acid [3-
oxo-1-(pyridine-2-sulfonyl)-azepan-4-yl]-amide;
212 (S)-4-Methyl-2-(naphthylene-2-sulfonylamino)-pentanoic acid [3-
oxo-1-(pyridine-2-sulfonyl)-azepan-4-yl]-amide;
213 Benzofuran-2-carboxylic acid-{(S)-1-[ 1-(4-fluoro-
benzenesulfonyl)-3-oxo-azepan-4-yl carbamoyl]-3-methyl-butyl}-
amide;
214 N-{(S)-1-[1-(4-Fluoro-benzenesulfonyl)-3-oxo-azepan-4-
ylcarbamoyl }-3-methyl-butyl }-3,4-dimethoxy-benzamide;
215 Cyclohexanecarboxylic acid {(S)-1-[1-(4-fluoro-benzenesulfonyl)-
3-oxo-azepan-4-ylcarbamoyl }-3-methyl-butyl
}-amide;
216 (S)-2-(2-Benzyloxy-acetylamino)-4-methyl-pentanoic
acid[1-
(methanesulfonyl)-3-oxo-azepan-4-yl]-amide;
217 Benzo[b]thiophene-2-carboxylic acid-{(S)-1-(1-methanesulfonyl-
3-oxo-azepan-4-yl carbamoyl)-3-methyl-butyl]-amide;
218 Benzo[1,3]dioxole-5-carboxylic acid-{(S)-1-(1-methanesulfonyl-3-
oxo-azepan-4-yl carbamoyl)-3-methyl-butyl]-amide;
219 Benzofuran-2-carboxylic acid-{(S)-1-(1-methanesulfonyl-3-oxo-
azepan-4-yl carbamoyl)-3-methyl-butyl]-amide;
220 N-[(S)-1-( 1-Methanesulfonyl)-3-oxo-azepan-4-ylcarbamoyl
}-3-
methyl-butyl }-3,4-dimethoxy-benzamide;
221 (S)-2-(2-Benzyloxy-acetylamino)-4-methyl-pentanoic
acid[1-(2-
cyano-benzensulfonyl)-3-oxo-azepan-4-yl]-amide;
222 N-{ (S)-1-[1-(2-Cyano-benzenesulfonyl)-3-oxo-azepan-4-
ylcarbamoyl }-3-methyl-butyl }-4-methanesulfonyl-1-benzamide;
43
CA 02412353 2002-12-13
WO 01/95911 PCT/USO1/19062
223 Benzo[b]thiophene-2-carboxylic acid-{(S)-1-[1-(2-cyano-
benzenesulfonyl)-3-oxo-azepan-4-yl carbamoyl)-3-methyl-butyl]-
amide;
224 Benzo[1,3]dioxole-5-carboxylic acid-{(S)-1-[1-(2-cyano-
benzenesulfonyl)-3-oxo-azepan-4-ylcarbamoyl)-3-methyl-butyl]-
amide;
225 (S)-4-Methyl-2-[4-oxo-4-((4-phenoxy-phenyl)-butyrylamino }-
pentanoic acid [3-oxo-1-(pyridine-2-sulfonyl)-azepan-4-yl]-amide;
226 N-{(S)-1-[(1-(2-cyano-benzenesulfonyl)-3-oxo-azepan-4-
ylcarbamoyl }-3-methyl-butyl }-3,4-dimethoxy-benzamide;
227 Cyclohexanecarboxylic acid {(S)-1-[1-(4-methoxy-
benzenesulfonyl)-3-oxo-azepan-4-ylcarbamoyl }-3-methyl-butyl }-
amide;
228 4-Methansulfonyl-N-{(S)-1-[4-methoxy-benzenesulfonyl)-3-oxo-
azepan-4-carbamoyl]-3-methyl-butyl-benzamide;
229 4-Methansulfonyl-N-{ (S)-1-[4-fluoro-benzenesulfonyl)-3-oxo-
azepan-4-carbamoyl]-3-methyl-butyl-benzamide;
230 ( { (S)-3-Methyl-1-[3-oxo-1-(pyridine-2-sulfonyl)-azepan-4-
ylcarbamoyl]-butylcarbamoyl}-carbamic acid benzyl
ester;
231 (S)-2-[5-(4-Methoxy-phenyl)-pentanoylamnio]-4-methyl-pentanoic
acid [3-oxo-1-(pyridine-2-sulfonyl)-azepan-4-yl]-amide;
232 (S)-2-[2-(3-Benzyloxy-4-methoxy-phenyl)-acetylamnio]-4-
methylpentanoic acid [3-oxo-1-(pyridine-2-sulfonyl)-azepan-4-yl]-
amide;
233 5,6-Difluoro-benzofuran-2-carboxylic acid {(S)-3-methyl-1-[1-
(pyridine-2-sulfonyl)-3-oxo-azepan-4-ylcarbamoyl]-butyl } amide;
234 (S)-4-Methyl-2-(5-oxo-hexanoylamino)-pentanoic acid [3-oxo-1-
(pyridine-2-sulfonyl)-azepan-4-yl]-amide;
235 Benzofuran-2-carboxylic acid {(S)-3-methyl-1-[1-(6-methyl-
pyridine-2-sulfonyl)-3-oxo-azepan-4-ylcarbamoyl]-butyl } amide;
236 5-Methoxy-benzofuran-2-carboxylic acid {(S)-3-methyl-1-[1-(6-
methyl-pyridine-2-sulfonyl)-3-oxo-azepan-4-ylcarbamoyl]-
butyl } amide;
44
CA 02412353 2002-12-13
WO 01/95911 PCT/USO1/19062
237 3-Methyl-benzofuran-2-carboxylic acid {(S)-3-methyl-1-[1-(6-
methyl-pyridine-2-sulfonyl)-3-oxo-azepan-4-ylcarbamoyl]-
butyl } amide;
238 7-Methoxy-benzofuran-2-carboxylic acid ~{(S)-3-methyl-1-[1-
(pyridine-2-sulfonyl)-3-oxo-azepan-4-ylcarbamoylJ-butyl
} amide;
239 5,6-Dimethoxy-benzo[b]thiophene-2-carboxylic
acid {(S)-3-
methyl-1-[ 1-(pyridine-2-sulfonyl)-3-oxo-azepan-4-ylcarbamoyl]-
butyl } amide;
240 (R)-1-Benzyl-5-oxo-pyrrolidine-2-carboxylic
acid {(S)-3-methyl-
1-{3-oxo-(pyridine-2-sulfonyl)-azepan-4-ylcarbamoyl]-
butyl } amide;
241 (S)-1-Benzyl-5-oxo-pyrrolidine-2-carboxylic
acid {(S)-3-methyl-
1-{ 3-oxo-(pyridine-2-sulfonyl)-azepan-4-ylcarbamoyl]-
butyl } amide;
242 Benzofuran-2-carboxylic acid {(S)-2-cyclopropyl-1-[3-oxo-1-
(pyridine-2-sulfonyl)-azepan-4-ylcarbamoyl)-ethyl]-amide;
243 Benzofuran-2-carboxylic acid {(S)-3-methylsulfanyl-1-[3-oxo-1-
(pyridine-2-sulfonyl)-azepan-4-ylcarbamoyl)-propyl]-amide;
244 Benzofuran-2-carboxylic acid {(S)-2-naphthylen-2-yl-1-[3-oxo-1-
(pyridine-2-sulfonyl)-azepan-4-ylcarbamoyl)-ethyl]-amide;
245 Thieno[3,2-b]thiophene-2-carboxylic acid {(S)-3-methyl-1-[1-(6-
methyl-pyridine-2-sulfonyl)-3-oxo-azepan-4-ylcarbamoylJ-
butyl } amide;
246 Thieno[3,2-b]thiophene-2-carboxylic acid {(S)-3-methyl-1-[1-(3-
methyl-pyridine-2-sulfonyl)-3-oxo-azepan-4-ylcarbamoylJ-
butyl } amide;
247 3-Methyl-benzofuran-2-carboxylic acid {(S)-3-methyl-1-[1-(3-
methyl-pyridine-2-sulfonyl)-3-oxo-azepan-4-ylcarbamoylJ-
butyl } amide;
248 5-Methoxy-benzofuran-2-carboxylic acid {(S)-3-methyl-1-[1-(3-
methyl-pyridine-2-sulfonyl)-3-oxo-azepan-4-ylcarbamoyl]-
butyl } amide;
CA 02412353 2002-12-13
WO 01/95911 PCT/USO1/19062
249 5,6-Difluoro-benzofuran-2-carboxylic acid {(S)-3-methyl-1-[3-
oxo-1-( 1-oxy-pyridine-2-sulfonyl)-azepan-4-ylcarbamoyl]-
butyl } amide;
250 5-(3-Trifluoromethyl-phenyl)-furan-2-carboxylic acid{(S)-2-
cyclohexyl-1-{3-oxo-1-(pyridine-2-sulfonyl)-azepan-4-
ylcarbamoyl]-ethyl }-amide;
251 5-(4-Chloro-phenyl)-furan-2-carboxylic acid{(S)-2-cyclohexyl-1-
{ 3-oxo-1-(pyridine-2-sulfonyl)-azepan-4-ylcarbamoyl]-ethyl }-
amide;
252 Benzofuran-2-carboxylic acid {(S)-3-methyl-1-[6-methyl-3-oxo-1-
(pyridine-sulphonyl)-azepan-4-ylcarbamoyl]-butyl
}-amide;
253 5-(4-Chloro-phenyl)-furan-2-carboxylic acid{(S)-2-cyclohexyl-1-
[3-oxo-1-( 1-oxy-pyridine-2-sulfonyl)-azepan-4-ylcarbamoyl]-
ethyl }-amide;
254 5-(3-Trifluoromethyl-phenyl)-furan-2-carboxylic
acid{(S)-2-
cyclohexyl-f=[3-oxo-1-(1-oxy-pyridine-2-sulfonyl)-azepan-4-
ylcarbamoyl]-ethyl}-amide;
255 5-Fluoro-benzofuran-2-carboxylic acid {(S)-3-methyl-1-[3-oxo-1-
(pyridine-2-sulfonyl)-azepan-4-ylcarbamoyl]-butyl
}-amide;
256 5,6-Dimethoxy-benzofuran-2-carboxylic acid{(S)-2-cyclohexyl-1-
[3-oxo-1-(1-oxy-pyridine-2-sulfonyl)-azepan-4-ylcarbamoyl]-
ethyl }-amide;
257 5,5-Bis-(4-methoxy-phenyl)-pent-4-enoic acid {(S)-3-methyl-1-
[3-oxo-1-(pyridine-2-sulfonyl)-azepan-4-ylcarbamoyl] }-butyl }-
amide;
258 Quinoline-8-carboxylic acid {(S)-2-naphthylen-2-yl-1-[3-oxo-1-
(pyridine-2-sulfonyl)-azepan-4-ylcarbamoyl)-ethyl]-amide;
259 Naphthylene-1-carboxylic acid {(S)-2-naphthylen-2-yl-1-[3-oxo-1-
(pyridine-2-sulfonyl)-azepan-4-ylcarbamoyl)-ethyl]-amide;
260 Quinoline-8-carboxylic acid {(S)-1-(3-oxo-1-(pyridine-2
-sulfonyl)-azepan-4-ylcarbamoyl]-2-phenyl-ethyl }-amide;
261 Naphthyridine-2-carboxylic acid {(S)-3-methyl-I-[3-oxo-1-
(pyridine-2-sulfonyl)-azepan-4-ylcarbamoyl)-butyl }-amide;
46
CA 02412353 2002-12-13
WO 01/95911 PCT/USO1/19062
262 Naphthylene-1-carboxylic acid {(S)-1-[3-oxo-1-(pyridine-2
-sulfonyl)-azepan-4-ylcarbamoyl]-2-phenyl-ethyl }-amide;
263 3-Methylbenzofuran-2-carboxylic acid { (S)-3-methyl-1-[3-oxo-
1-(cyclohexyl-proprionyl)-azepan-4-ylcarbamoyl]-butyl }-amide;
264 3-Methylbenzofuran-2-carboxylic acid { (S)-3-methyl-1-
[3-oxo-1-(4-methyl-pentanoyl)-azepan-4-ylcarbamoyl]-butyl }-
amide;
265 3-Methylbenzofuran-2-carboxylic acid {(S)-3-methyl-1-[3-oxo-1-
(1-oxy-pyridine-2-carbonyl)-azepan-4-ylcarbamoyl]-butyl }-amide;
266 (S)-Acetylamino-4-methyl-pentanoic acid [3-oxo-1-(pyridine-2-
sulfonyl)-azepan-4-yl]-amide;
267 Quinoline-2-carboxylic acid { 1-[3-oxo-1-(pyridine-2-sulfonyl)-
azepan-4-ylcarbamoyl]-pentyl }-amide;
268 Benzofuran-2-carboxylic acid {(S)-3-methyl-1-[3-oxo
-1-(cyclohexyl-proprionyl)-azepan-4-ylcarbamoyl]-butyl }-amide;
269 Benzofuran-2-carboxylic acid {(S)-3-methyl-1-[3-oxo-1-(4-
methyl-pentanoyl)-azepan-4-ylcaxbamoyl]-butyl }-amide;
270 Quinoline-2-carboxylic acid {(S)-1-[3-oxo-1-(pyridine-2
-sulfonyl)-azepan-4-ylcarbamoyl]-2-phenyl-ethyl }-amide;
271 Benzofuran-2-carboxylic acid{(S)-2-benzyloxy-1-[3-oxo-1-
(pyridine-2-sulfonyl)-azepane-4-ylcarbamoyl]-ethyl }-amide;
272 Benzofuran-2-carboxylic acid{(S)-2-hydroxy-1-[3-oxo-1-
(pyridine-2-sulfonyl)-azepane-4-ylcarbamoyl]-ethyl }-amide;
273 5-Methoxybenzofuran-2-carboxylic acid {(S)-3-methyl-1-[3-oxo-
1-(thiazole-2-sulfonyl)-azepan-4-ylcaxbamoyl]-butyl } amide;
274 7-Methoxybenzofuran-2-carboxylic acid {(S)-3-methyl-1-[3-oxo-
1-(thiazole-2-sulfonyl)-azepan-4-ylcaxbamoyl]-butyl } amide;
275 3-Methylbenzofuran-2-carboxylic acid {(S)-3-methyl-1-[3-oxo-1-
(thiazole-2-sulfonyl)-azepan-4-ylcarbamoyl]-butyl } amide;
276 Benzo[b]thiophene-2-carboxylic acid {(S)-3-methyl-1-[3-oxo-1-
(thiazole-2-sulfonyl)-azepan-4-ylcaxbamoyl]-butyl } amide;
277 1-Methyl-1H-indole-2-carboxylic acid {(S)-3-methyl-1-[3-oxo-1-
(thiazole-2-sulfonyl)-azepan-4-ylcarbamoyl]-butyl } amide;
47
CA 02412353 2002-12-13
WO 01/95911 PCT/USO1/19062
278 Quinoxaline-2-carboxylic acid {(S)-3-methyl-1-[3-oxo-1-(thiazole-
2-sulfonyl)-azepan-4-ylcarbamoyl]-butyl } amide;
279 Quinoline-2-carboxylic acid {[(S)-1-[1-(4-fluoro-benzenesulfonyl)-
3-oxo-azepan-4-ylcarbamoyl]-3-methyl-butyl }-amide;
The following compounds are also particularly preferred
embodiments of the present invention:
280 Benzofuran-2-carboxylic acid {(S)-1-[-(3-fluoro-benzensulfonyl)-
3-oxo-azepan-4-ylcarbamoyl]-3-methyl-1-butyl}- amide;
281 , (S)-4-methyl-2-(3-piperidin-1-yl-propanoylamino)-pentanoic acid
[3-oxo-1-(pyridine-2-sulfonyl)-azepan-4-yl]-amide;
282 Benzofuran-2-carboxylic acid {(S)-1-[-(4-ethyl-benzensulfonyl)-3-
oxo-azepan-4-ylcarbamoyl]-3-methyl-1-butyl}- amide;
283 5-(3-Trifluoromethyl-phenyl)-furan-2-carboxylic acid ((S)-3-
methyl-1-{3-oxo-1-[1-(1-oxy-pyridin-2-yl)-methanoyl]-azepan-4-
ylcaxbamoyl }-butyl)-amide;
284 Benzo[1,3]-dioxole-5-carboxylic acid ((S)-3-methyl-1-{3-oxo-1-
[ 1-oxy-pyridin-2-yl)-methanoyl]-azepan-4-ylcarbamoyl }-butyl)-
amide;
285 5-(3-Trifluoromethyl-phenyl)-furan-2-carboxylic acid {(S)-1-[1-(3-
cyclohexyl-propanoyl)-3-oxo-azepan-4-ylcarbamoyl]-3-methyl-
butyl }-amide;
286 Benzo[1,3]-dioxole-5-carboxylic acid {(S)-1-[1-(3-cyclohexyl-
propanoyl)-3-oxo-azepan-4-ylcarbamoyl]-3-methyl-butyl }-amide;
287 5-(3-Trifluoromethyl-phenyl)-furan-2-carboxylic acid {(S)-1-[1-(4-
methyl-pentanoyl)-3-oxo-azepan-4-ylcarbamoyl]-3-methyl-butyl }-
amide;
288 Benzo[1,3]-dioxole-5-carboxylic acid {(S)-1-[1-(4-methyl-
pentanoyl)-3-oxo-azepan-4-ylcarbamoyl]-3-methyl-butyl }-amide;
289 Benzofuran-2-carboxylic acid {(S)1-[3-oxo-1-(propane-1-
sulfonyl)-azepan-4-ylcaxbamoyl]-3-methyl-1-butyl}- amide
290 Benzofuran-2-carboxylic acid [(S)-1-[3-oxo-1-(ethanesulfonyl-
azepan-4-ylcarbamoyl)-3-methyl-1-butyl]- amide;
48
CA 02412353 2002-12-13
WO 01/95911 PCT/USO1/19062
291 5-Fluoro-benzofuran-2-carboxylic acid {(S)-3-methyl-1-[3-oxo-1-
( 1-oxy-pyridine-2-sulfonyl)-azepan-4-ylcarbamoyl]-butyl
}-amide;
292 5-Fluoro-3-methyl-benzofuran-2-carboxylic acid
{(S)-3-methyl-1-
[3-oxo-1-(1-oxy-pyridine-2-sulfonyl)-azepan-4-ylcarbamoyl]-
butyl}-amide;
293 6-Fluoro-3-methyl-benzofuran-2-carboxylic acid
{(S)-3-methyl-1-
[3-oxo-1-(1-oxy-pyridine-2-sulfonyl)-azepan-4-ylcarbamoyl]-
butyl }-amide;
294 3-Methyl-benzofuran-2-carboxylic acid {(R)-3-methyl-1-[3-oxo-1-
( 1-oxy-pyridine-2-sulfonyl)-azepan-4-ylcarbamoyl]-butyl
}-amide;
295 3-Methyl-furo[3,2-b]-pyridine-2-carboxylic
acid {(S)-3-methyl-1-
[-3-oxo-1-( 1-oxy-pyridine-2-sulfonyl)-azepan-4-ylcarbamoyl]-
butyl }-amide;
296 5-Methoxy-benzofuran-2-carboxylic acid {(S)-1-[1-(3-fluoro-
benzenesulfonyl)-3-oxo-azepan-4-ylcarbamoyl]-3-methyl-butyl
}-
amide;
297 , 3-Methyl-benzofuran-2-carboxylic acid {(S)-1-[1-(3-fluoro-
benzenesulfonyl)-3-oxo-azepan-4-ylcarbamoyl]-3-methyl-butyl }-
amide;
298 Benzo[b]thiophene-2-carboxylic acid {(S)-1-[1-(3-fluoro-
benzenesulfonyl)-3-oxo-azepan-4-ylcarbamoyl]-3-methyl-butyl }-
amide;
299 3-methyl-furan-2-carboxylic acid {(S)-1-[1-(3-fluoro-
benzenesulfonyl)-3-oxo-azepan-4-ylcarbamoyl]-3-methyl-butyl }-
amide;
300 Quinoline-2-carboxylic acid {(S)-1-[1-(3-fluoro-benzenesulfonyl)-
3-oxo-azepan-4-ylcarbamoyl]-3-methyl-butyl }-amide;
301 Thieno[3,2-b]thiophene-2-carboxylic acid {(S)-1-[1-(3-fluoro-
benzenesulfonyl)-3-oxo-azepan-4-ylcarbamoyl]-3-methyl-butyl }-
amide;
302 Quinoxaline-2-carboxylic acid {(S)-1-[1-(3-fluoro-
benzenesulfonyl)-3-oxo-azepan-4-ylcarbamoyl]-3-methyl-butyl }-
amide;
49
CA 02412353 2002-12-13
WO 01/95911 PCT/USO1/19062
303 Thiophene-2-carboxylic acid {(S)-1-[1-(3-fluoro-benzenesulfonyl)-
3-oxo-azepan-4-ylcarbamoyl]-3-methyl-butyl }-amide;
304 5-Methyl-thiophene-2-carboxylic acid {(S)-1-[1-(3-fluoro-
benzenesulfonyl)-3-oxo-azepan-4-ylcarbamoyl]-3-methyl-butyl }-
amide;
305 5-Methoxy-benzofuran-2-carboxylic acid [(S)-1-(1-ethanesulfonyl-
3-oxo-azepan-4-ylcarbamoyl)-3-methyl-butyl]-amide;
306 3-Methyl-benzofuran-2-carboxylic acid [(S)-1-(1-ethanesulfonyl-3-
oxo-azepan-4-ylcarbamoyl)-3-methyl-butyl]-amide;
307 Benzo[b]thiophene-2-carboxylic acid [(S)-1-(1-ethanesulfonyl-3-
oxo-azepan-4-ylcarbamoyl)-3-methyl-butyl]-amide;
308 3-Methyl-furan-2-carboxylic acid [(S)-1-(1-ethanesulfonyl-3-oxo-
azepan-4-ylcarbamoyl)-3-methyl-butyl]-amide;
309 Quinoline-2-carboxylic acid [(S)-1-(1-ethanesulfonyl-3-oxo-
azepan-4-ylcarbamoyl)-3-methyl-butyl]-amide;
310 Thieno[3,2-b]thiophene-2-carboxylic acid [(S)-1-(1-
ethanesulfonyl-3-oxo-azepan-4-ylcarbamoyl)-3-methyl-butyl]-
amide;
311 Quinoxaline-2-carboxylic acid [(S)-1-(1-ethanesulfonyl-3-oxo-
azepan-4-ylcarbamoyl)-3-methyl-butyl]-amide;
312 Thiophene-2-carboxylic acid [(S)-1-(1-ethanesulfonyl-3-oxo-
azepan-4-ylcarbamoyl)-3-methyl-butyl]-amide;
313 5-Methyl-thiophene-2-carboxylic acid [(S)-1-(1-ethanesulfonyl-3-
oxo-azepan-4-ylcarbamoyl)-3-methyl-butyl]-amide;
314 5-Methoxy-benzofuran-2-carboxylic acid {(S)-1-[3-oxo-1-
(propane-1-sulfonyl)-azepan-4-ylcarbamoyl]-3-methyl-1-butyl
}-
amide;
315 3-Methyl-benzofuran-2-carboxylic acid {(S)-1-[3-oxo-1-(propane-
1-sulfonyl)-azepan-4-ylcarbamoyl]-3-methyl-1-butyl
}-amide;
316 Benzo[b]thiophene-2-carboxylic acid {(S)-1-[3-oxo-1-(propane-1-
sulfonyl)-azepan-4-ylcarbamoyl]-3-methyl-1-butyl
}-amide;
317 3-Methyl-furan-2-carboxylic acid {(S)-1-[3-oxo-1-(propane-1-
sulfonyl)-azepan-4-ylcarbamoyl]-3-methyl-1-butyl
}-amide;
CA 02412353 2002-12-13
WO 01/95911 PCT/USO1/19062
318 2,5-Dimethyl-furan-2-carboxylic acid {(S)-1-[3-oxo-1-(propane-1-
sulfonyl)-azepan-4-ylcarbamoyl]-3-methyl-1-butyl}-amide;
319 Quinoline-2-carboxylic acid {(S)-1-[3-oxo-1-(propane-1-sulfonyl)-
azepan-4-ylcarbamoyl]-3-methyl-1-butyl }-amide;
320 Thieno[3,2-b]thiophene-2-carboxylic acid {(S)-1-[3-oxo-1-
(propane-1-sulfonyl)-azepan-4-ylcarbamoyl]-3-methyl-1-butyl }-
amide;
321 Quinoxaline-2-carboxylic acid { (S)-1-[3-oxo-1-(propane-1-
sulfonyl)-azepan-4-ylcarbamoyl]-3-methyl-1-butyl }-amide;
322 Thiophene-2-carboxylic acid {(S)-1-[3-oxo-1-(propane-1-
sulfonyl)-azepan-4-ylcarbamoyl]-3-methyl-1-butyl}-amide;
323 5-Methyl-thiophene-2-carboxylic acid {(S)-1-[3-oxo-1-(propane-1-
sulfonyl)-azepan-4-ylcarbamoyl]-3-methyl-1-butyl }-amide;
324 5-Methoxy-3-methyl-benzofuran-2-carboxylic acid { (S)-3-methyl-
1-[3-oxo-1-(1-oxy-pyridine-2-sulfonyl)-azepan-4-ylcarbamoyl]-
butyl }-amide;
325 3,5-Dimethyl-benzofuran-2-carboxylic acid {(S)-3-methyl-1-[3-
oxo-1-( 1-oxy-pyridine-2-sulfonyl)-azepan-4-ylcarbamoyl]-butyl }-
amide;
326 3-Ethyl-benzofuran-2-carboxylic acid {(S)-3-methyl-1-[3-oxo-1-
( 1-oxy-pyridine-2-sulfonyl)-azepan-4-ylcarbamoyl]-butyl }-amide;
327 4-Methoxy-3-methyl-benzofuran-2-carboxylic acid { (S)-3-methyl-
1-[3-oxo-1-(1-oxy-pyridine-2-sulfonyl)-azepan-4-ylcarbamoyl]-
butyl }-amide; .
328 1-methyl-naphtho[2,1-b]-furan-2-carboxylic acid {(S)-3-methyl-1-
[3-oxo-1-(1-oxy-pyridine-2-sulfonyl)-azepan-4-ylcarbamoyl]-
butyl }-amide;
329 6-Methoxy-3-methyl-benzofuran-2-carboxylic acid {(S)-3-methyl-
1-[3-oxo-1-(1-oxy-pyridine-2-sulfonyl)-azepan-4-ylcarbamoyl]-
butyl }-amide;
330 3-Methyl-benzofuran-2-carboxylic acid { 1,3-dimethyl-1-[3-oxo-1-
( 1-oxy-pyridine-2-sulfonyl)-azepan-4-ylcarbamoyl]-butyl }-amide;
51
CA 02412353 2002-12-13
WO 01/95911 PCT/USO1/19062
331 Benzofuran-2-carboxylic acid [(S)-3-methyl-1-[3-oxo-1-quinolin-
2-ylmethyl-azepan-4-ylcarbamoyl]-butyl}-amide;
332 3-Methyl-benzofuran-2-carboxylic acid [(S)-3-methyl-1-[3-oxo-1-
quinolin-2-ylmethyl-azepan-4-ylcarbamoyl]-butyl
}-amide;
333 Benzo[b]thiophene-2-carboxylic acid [(S)-3-methyl-1-[3-oxo-1-
quinolin-2-ylmethyl-azepan-4-ylcarbamoyl]-butyl
}-amide;
334 Benzofuran-2-carboxylic acid ((S)-3-methyl-1-{3-oxo-1-[1-
toluene-2-sulfonylamino)-methanoyl]-azepan-4-ylcarbamoyl
}-
butyl)-amide;
335 3-Methyl-benzofuran-2-carboxylic acid ((S)-3-methyl-1-{3-oxo-1-
[ 1-toluene-2-sulfonylamino)-methanoyl]-azepan-4-ylcarbamoyl
}-
butyl)-amide;
336 Benzo[b]thiophene-2-carboxylic acid ((S)-3-methyl-1-{3-oxo-1-[1-
toluene-2-sulfonylamino)-methanoyl]-azepan-4-ylcarbamoyl
}-
butyl)-amide;
337 Benzofuran-2-carboxylic acid ((S)-3-methyl-1-{3-oxo-1-[2-chloro-
benzenesulfonylamino)-methanoyl]-azepan-4-ylcarbamoyl}-butyl)-
amide;
338 3-Methyl-benzofuran-2-carboxylic acid ((S)-3-methyl-1-{3-oxo-1-
[2-chloro-benzenesulfonylamino)-methanoyl]-azepan-4-
ylcarbamoyl }-butyl)-amide;
339 Benzo[b]thiophene-2-carboxylic acid ((S)-3-methyl-1-{3-oxo-1-[2-
chloro-benzenesulfonylamino)-methanoyl]-azepan-4-
ylcarbamoyl}-butyl)-amide;
340 Benzofuran-2-carboxylic acid ((S)-3-methyl-1-{3-oxo-1-[4-fluoro-
benzenesulfonylamino)-methanoyl]-azepan-4-ylcarbamoyl }-butyl)-
amide;
341 3-Methyl-benzofuran-2-carboxylic acid ((S)-3-methyl-1-{3-oxo-1-
[4-fluoro-benzenesulfonylamino)-methanoyl]-azepan-4-
ylcarbamoyl }-butyl)-amide;
342 Benzo[b]thiophene-2-carboxylic acid ((S)-3-methyl-1-{3-oxo-1-[4-
fluoro-benzenesulfonylamino)-methanoyl]-azepan-4-
ylcarbamoyl }-butyl)-amide;
52
CA 02412353 2002-12-13
WO 01/95911 PCT/USO1/19062
343 Benzofuran-2-carboxylic acid ((S)-3-methyl-1-{3-oxo-1-[1-
toluene-4-sulfonylamino)-methanoyl]-azepan-4-ylcarbamoyl }-
butyl)-amide;
344 3-Methyl-benzofuran-2-carboxylic acid ((S)-3-methyl-1-{3-oxo-1-
[ 1-toluene-4-sulfonylamino)-methanoyl]-azepan-4-ylcarbamoyI }-
butyl)-amide;
345 Benzo[b]thiophene-2-carboxylic acid ((S)-3-methyl-1-{3-oxo-1-[1-
toluene-4-sulfonylamino)-methanoyl]-azepan-4-ylcarbamoyl }-
butyl)-amide;
346 Benzofuran-2-carboxylic acid {(S)-3-methyl-1-[1-(6-methyl-
pyridin-2-ylmethyl)-3-oxo-azepan-4-ylcarbamoyl]-butyl }-amide;
347 3-Methyl-benzofuran-2-carboxylic acid {(S)-3-methyl-1-[1-(6-
methyl-pyridin-2-ylmethyl)-3-oxo-azepan-4-ylcarbamoyl]-butyl
}-
amide;
348 Benzo[b]thiophene-2-carboxylic acid {(S)-3-methyl-1-[1-(6-
methyl-pyridin-2-ylmethyl)-3-oxo-azepan-4-ylcarbamoyl]-butyl
}-
amide; ',.
349 Benzo[b]thiophene-2-carboxylic acid {(S)-1-[1-(2-fluoro-
phenylcarbamoyl)-3-oxo-azepan-4-ylcarbamoyl]-3-methyl-butyl
}-
amide;
350 3-Methyl-benzofuran-2-carboxylic acid {(S)-1-[1-(2-fluoro-
phenylcarbamoyl)-3-oxo-azepan-4-ylcarbamoyl]-3-methyl-butyl
}-
amide;
351 2,4-Dimethylfuran-3-carboxylic acid {(S)-1-[1-(2-fluoro-
phenylcarbamoyl)-3-oxo-azepan-4-ylcarbamoyl]-3-methyl-butyl
}-
amide;
352 Quinoxaline-2-carboxylic acid {(S)-1-[1-(2-fluoro-
phenylcarbamoyl)-3-oxo-azepan-4-ylcarbamoyl]-3-methyl-butyl
}-
amide;
353 Thieno[3,2-b]thiophene-2-carboxylic acid {(S)-1-[1-(2-fluoro-
phenylcarbamoyl)-3-oxo-azepan-4-ylcarbamoyl]-3-methyl-butyl
}-
amide;
53
CA 02412353 2002-12-13
WO 01/95911 PCT/USO1/19062
354 Quinoline-2-carboxylic acid {(S)-1-[1-(2-fluoro-
phenylcarbamoyl)-3-oxo-azepan-4-ylcarbamoyl]-3-methyl-butyl }-
amide;
355 4-Methyl-thiophene-2-carboxylic acid { (S)-1-[ 1-(2-fluoro-
phenylcarbamoyl)-3-oxo-azepan-4-ylcarbamoyl]-3-methyl-butyl }-
amide;
356 5-Methoxy-benzofuran-2-carboxylic acid {(S)-1-[1-(2-fluoro-
phenylcarbamoyl)-3-oxo-azepan-4-ylcarbamoyl]-3-methyl-butyl }-
amide;
357 4-Methyl-furan-2-carboxylic acid {(S)-1-[1-(2-fluoro-
phenylcarbamoyl)-3-oxo-azepan-4-ylcarbamoyl]-3-methyl-butyl }-
amide;
358 Benzofuran-2-carboxylic acid [(S)-1-(1-butyl-3-oxo-azepan-4-
ylcarbamoyl)-3-methyl-butyl]-amide;
359 Benzofuran-2-carboxylic acid [(S)-1-(1-propyl-3-oxo-azepan-4-
ylcarbamoyl)-3-methyl-butyl]-amide;
360 Benzofuran-2-carboxylic acid {(S)-1-[1-(2-fluoro-benzyl)-3-oxo
azepan-4-ylcarbamoyl]-3-methyl-butyl }-amide;
361 Benzofuran-2-carboxylic acid {(S)-3-methyl-1-[1-(2-morpholin-4-
yl-thiazol-4-ylmethyl)-3-oxo-azepan-4-ylcarbamoyl]-butyl }-
amide;
362 Benzofuran-2-carboxylic acid {(S)-1-[1-(5-ethyl-furan-2-
ylmethyl)-3-oxo-azepan-4-ylcarbamoyl]-3-methyl-butyl }-amide;
363 Benzofuran-2-carboxylic acid {(S)-1-[1-(3,4-dimethyl-thieno[3,2-
b]thiophene-2-ylmethyl)-3-oxo-azepan-4-ylcarbamoyl]-3-methyl-
butyl }-amide;
364 Benzofuran-2-carboxylic acid { (S)-3-methyl-1-[3-oxo-1-(3-phenyl-
3H-[ 1,2,3]triazol-4-ylmethyl)-azepan-4-ylcarbamoyl]-butyl }-
amide;
365 Benzofuran-2-carboxylic acid [(S)-1-[1-(isothiazol-3-ylmethyl-3-
oxo-azepan-4-ylcarbamoyl)-3-methyl-butyl }-amide;
366 Benzofuran-2-carboxylic acid [(S)-3-methyl-1-(3-oxo-1-thiophen-
2-ylmethyl-azepan-4-ylcarbamoyl)-butyl]-amide;
54
CA 02412353 2002-12-13
WO 01/95911 PCT/USO1/19062
367 Benzofuran-2-carboxylic acid [(S)-1-(1-benzo[b]thiophen-2-
ylmethyl-3-oxo-azepan-4-ylcarbamoyl]-3-methyl-butyl]-amide;
368 Benzofuran-2-carboxylic acid [(S)-3-methyl-1-(3-oxo-1-pentyl-
azepan-4-ylcarbamoyl)-butyl]-amide;
369 Benzofuran-2-carboxylic acid {(S)-3-methyl-1-[1-(1-methyl-1H-
imidazol-2-ylmethyl)-3-oxo-azepan-4-ylcarbamoyl]-buty }-amide;
370 1-Oxy-pyridine-2-carboxylic acid {(S)-3-methyl-1-[3-oxo-1-
(pyridine-2-sulfonyl)-azepan-4-ylcarbamoyl ]-butyl}-amide;
371 2-Oxy-pyridine-3-carboxylic acid {(S)-3-methyl-1-[3-oxo-1-
(pyridine-2-sulfonyl)-azepan-4-ylcarbamoyl ]-butyl}-amide;
372 1H-Benzoimidazole-5-carboxylic acid {(S)-3-methyl-1-[3-oxo-1-
(pyridine-2-sulfonyl)-azepan-4-ylcarbamoyl]-butyl }-amide;
373 4-{ (S)-2-[( 1-Benzofuran-2-yl-methanoyl)-amino]-4-methyl-
pentanoylamino }-1-methyl-3-oxo-1-pentyl-azepanium;
374 Benzofuran-2- carboxylic acid {(S)-1-[1-(1,2-dimethyl-1 H -
imidazole-4-sulfonyl)-3-oxo-azepan-4-ylcarbamoyl]-3-methyl-
butyl }-amide;
375 Benzofuran-2- carboxylic acid {(S)-1-[1-(1-methyl-1 H -
imidazole-4-sulfonyl)-3-oxo-azepan-4-ylcarbamoyl]-3-methyl-
butyl }-amide;
376 Benzofuran-2-carboxylic acid {(S)-1-[1-(4-methanesulfonyl-
benzenesulfonyl)-3-oxo-azepan-4-ylcarbamoyl]-3-methyl-butyl }-
amide;
377 Benzofuran-2-carboxylic acid {(S)-1-[1-(2-methanesulfonyl-
benzenesulfonyl)-3-oxo-azepan-4-ylcarbamoyl]-3-methyl-butyl }-
amide;
378 Benzofuran-2-carboxylic acid {(S)-1-[1-(3,5-dimethyl-isoxazole-4-
sulfonyl)-3-oxo-azepan-4-ylcarbamoy 1]-3-methyl-butyl }-amide;
379 3-Methyl-benzofuran-2-carboxylic acid {(1S,2R)-2-methyl-1-[3-
oxo-1-(pyridine-2-sulfonyl)-azepan-4-ylcarbamoyl]-butyl }-amide;
380 3-Methyl-benzofuran-2-carboxylic acid { 1-[3-oxo-1-(pyridine-2-
sulfonyl)-azepan-4-ylcarbamoyl]-cyclopentyl }-amide; and
CA 02412353 2002-12-13
WO 01/95911 PCT/USO1/19062
381 Furo[3,2-b]-pyridine-2-carboxylic acid {(S)-3-methyl-1-[-3-oxo-1-
(1-oxy-pyridine-2-sulfonyl)-azepan-4-ylcarbamoyl]-butyl}-amide.
Particularly preferred compounds of embodiment IA are Example Nos. 280 to 381
in the list herein above.
Specific representative compounds of the present invention are set forth in
Examples 1-381.
Compared to the corresponding 5 and 6 membered ring compounds, the 7
membered ring compounds of the present invention are configurationally more
stable at the
carbon center alpha to the ketone.
The present invention includes deuterated analogs of the inventive compounds.
A
representative example of such a deuterated compound is set forth in Example
192. A
representative synthetic route fox the deuterated compounds of the present
invention is set
forth in Scheme 4, below. The deuterated compounds of the present invention
exhibit
superior chiral stability compared to the protonated isomer.
Where possible the present invention includes quaternary salts of the
inventive
compounds. A representative example of such a quaternary salt is set forth in
Example
373. A representative synthetic route for the quaternary salts of the present
invention is set
forth in Scheme 6, below.
Definitions
The present invention includes all hydrates, solvates, complexes and prodrugs
of
the compounds of this invention. Prodrugs are any covalently bonded compounds
which
release the active parent drug according to Formula I in vivo. If a chiral
center or another
form of an isomeric center is present in a compound of the present invention,
all forms of
such isomer or isomers, including enantiomers and diastereomers, are intended
to be
covered herein. Inventive compounds containing a chiral center may be used as
a racemic
mixture, an enantiomerically enriched mixture, or the racemic mixture may be
separated
using well-known techniques and an individual enantiomer may be used alone. In
cases in
which compounds have unsaturated carbon-carbon double bonds, both the cis (Z)
and traps
(E) isomers are within the scope of this invention. In cases wherein compounds
may exist
in tautomeric forms, such as keto-enol tautomers, each tautomeric form is
contemplated as
56
CA 02412353 2002-12-13
WO 01/95911 PCT/USO1/19062
being included within this invention whether existing in equilibrium or
predominantly in
one form.
The meaning of any substituent at any one occurrence in Formula I or any
subformula thereof is independent of its meaning, or any other substituent's
meaning, at any
other occurrence, unless specified otherwise.
Abbreviations and symbols commonly used in the peptide and chemical arts are
used herein to describe the compounds of the present invention. In general,
the amino acid
abbreviations follow the IUPAC-IUB Joint Commission on Biochemical
Nomenclature as
described in Eur. J. BiochenZ., 158, 9 (1984).
"Proteases" are enzymes that catalyze the cleavage of amide bonds of peptides
and
proteins by nucleophilic substitution at the amide bond, ultimately resulting
in hydrolysis.
Such proteases include: cysteine proteases, serine proteases, aspartic
proteases, and
metalloproteases. The compounds of the present invention are capable of
binding more
strongly to the enzyme than the substrate and in general are not subject to
cleavage after
enzyme catalyzed attack by the nucleophile. They therefore competitively
prevent
proteases from recognizing and hydrolyzing natural substrates and thereby act
as inhibitors.
The term "amino acid" as used herein refers to the D- or L- isomers of
alanine,
arginine, asparagine, aspartic acid, cysteine, glutamine, glutamic acid,
glycine, histidine,
isoleucine, leucine, lysine, methionine, phenylalanine, proline, serine,
threonine,
tryptophan, tyrosine and valine.
"C1_6alkyl" as applied herein is meant to include substituted and
unsubstituted
methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl and t-butyl, pentyl, n-
pentyl, isopentyl,
neopentyl and hexyl and the simple aliphatic isomers thereof. C1_6alkyl may be
optionally
substituted by a moiety selected from the group consisting of: OR14, C(O)R14,
SR14,
S(O)R14, NR142, R14NC(O)ORS, C02R14, C02NR142, N(C=NH)NH2, Het, C3_
6cycloalkyl, and Ar; where R5 is selected from the group consisting of: H,
C1_6alkyl,
C2_galkenyl, C2_6alkynyl, C3_6cycloalkyl-CO_6alkyl, Ar-CO_6alkyl and Het-
CO_galkyl;
and R14 is selected from the group consisting of: H, C1_6alkyl, Ar-CO_6alkyl,
and Het-
CO_6alkyl;
"C3_gcycloalkyl" as applied herein is meant to include substituted and
unsubstituted cyclopropane, cyclobutane, cyclopentane and cyclohexane.
"C2_6 alkenyl" as applied herein means an alkyl group of 2 to 6 carbons
wherein a
carbon-carbon single bond is replaced by a carbon-carbon double bond.
C2_6alkenyl
57
CA 02412353 2002-12-13
WO 01/95911 PCT/USO1/19062
includes ethylene, 1-propene, 2-propene, 1-butene, 2-butene, isobutene and the
several
isomeric pentenes and hexenes. Both cis and trans isomers are included.
"C2_(alkynyl" means an alkyl group of 2 to 6 carbons wherein one carbon-carbon
single bond is replaced by a carbon-carbon triple bond. C2_( alkynyl includes
acetylene, 1-
propyne, 2-propyne, 1-butyne, 2-butyne, 3-butyne and the simple isomers of
pentyne and
. hexyne.
"Halogen" means F, Cl, Br, and I.
"Ar" or "aryl" means phenyl or naphthyl, optionally substituted by one or more
of
Ph-CO_6alkyl; Het-CO-6alkyl; C1_6alkoxy; Ph-CO_6alkoxy; Het-CO_6alkoxy; OH,
(CH2)1
6NR15R16; O(CH2)1_6NR15R16; C1-6alkyl, OR1~, N(Rl~)2, SRl~, CF3, N02, CN,
C02R1~, CON(R1~), F, Cl, Br or I; where R15 and R16 are H, C1_6alkyl, Ph-CO-
6alkyl,
naphthyl-CO_galkyl or Het-CO-6alkyl; and R1~ is phenyl, naphthyl, or
C1_6alkyl.
As used herein "Het" or "heterocyclic" represents a stable 5- to 7-membered
monocyclic, a stable 7- to 10-membered bicyclic, or a stable 11- to 18-
membered tricyclic
heterocyclic ring which is either saturated or unsaturated, and which consists
of carbon
atoms and from one to three heteroatoms selected from the group consisting of
N, O and 5,
and wherein the nitrogen and sulfur heteroatoms may optionally be oxidized,
and the
nitrogen heteroatom may optionally be quaternized, and including any bicyclic
group in
which any of the above-defined heterocyclic rings is fused to a benzene ring.
The
heterocyclic ring may be attached at any heteroatam or carbon atom which
results in the
creation of a stable structure, and may optionally be substituted with one or
two moieties
selected from CO_gAr, C1_6alkyl, OR1~, N(Rl~)2, SR1~, CF3, N02, CN, C02R1~,
CON(R1~), F, Cl, Br and I, where R1~ is phenyl, naphthyl, or C1_6alkyl.
Examples of such
heterocycles include piperidinyl, piperazinyl, 2-oxopiperazinyl, 2-
oxopiperidinyl, 2-
oxopyrrolodinyl, 2-oxaazepinyl, azepinyl, pyrrolyl, 4-piperidonyl,
pyrrolidinyl, pyrazolyl,
pyrazolidinyl, imidazolyl, pyridinyl, 1-oxo-pyridinyl, pyrazinyl,
oxazolidinyl, oxazolinyl,
oxazolyl, isoxazolyl, morpholinyl, thiazolidinyl, thiazolinyl, thiazolyl,
quinuclidinyl,
indolyl, quinolinyl, quinoxalinyl, isoquinolinyl, benzimidazolyl,
benzopyranyl,
benzoxazolyl, furanyl, benzofuranyl, thiophenyl, benzo[b]thiophenyl,
thieno[3,2-
b]thiophenyl, benzo[1,3]dioxolyl, 1,8 naphthyridinyl, pyranyl,
tetrahydrofuranyl,
tetrahydropyranyl, thienyl, benzoxazolyl, thiamorpholinyl sulfoxide,
thiamorpholinyl
sulfone, and oxadiazolyl, as well as triazolyl, thiadiazolyl, oxadiazolyl,
isothiazolyl,
imidazolyl, pyridazinyl, pyrimidinyl, triazinyl and tetrazinyl which are
available by routine
58
CA 02412353 2002-12-13
WO 01/95911 PCT/USO1/19062
chemical synthesis and are stable. The term heteroatom as applied herein
refers to oxygen,
nitrogen and sulfur.
Here and throughout this application the term CO denotes the absence of the
substituent group immediately following; for instance, in the moiety
ArCO_6alkyl, when C
is 0, the substituent is Ar, e.g., phenyl. Conversely, when the moiety
ArCO_6alkyl is
identified as a specific aromatic group, e.g., phenyl, it is understood that
the value of C is 0.
Certain radical groups are abbreviated herein. t-Bu refers to the tertiary
butyl
radical, Boc refers to the t-butyloxycarbonyl radical, Fmoc refers to the
fluorenylmethoxycarbonyl radical, Ph refers to the phenyl radical, Cbz refers
to the
benzyloxycarbonyl radical.
Certain reagents are abbreviated herein. m-CPBA refers to 3-
chloroperoxybenzoic
acid, EDC refers to N-ethyl-N'(dimethylaminopropyl)-carbodiimide, DMF refers
to
dimethyl formamide, DMSO refers to dimethyl sulfoxide, TEA refers to
triethylamine,
TFA refers to trifluoroacetic acid, and THF refers to tetrahydrofuran.
Methods of Preparation
Compounds of the general formula I may be prepared in a fashion analogous to
that
outlined in Schemes 1. 2 and 3. Alkylation of tert-butyl N-allylcarbamate (1)
with a base
such as sodium hydride and 5-bromo-1-pentene provides the dime 2. Treatment of
2 with
either 2,6-diisopropylphenylimido neophylidene molybenum bis(tert-butoxide) or
bis(tricyclohexylphosphine)benzylidine ruthenium (IV) dichloride olefin
metathesis
catalysts developed by Grubbs provides the azepine 3. Epoxidation of 3 with
standard
oxidizing agents common to the art such as na-CPBA provide the epoxide 4.
Nucleophilic
epoxide ring opening may be effected with a reagent such as sodium azide to
provide the
azido alcohol (not shown) which may be reduced to the amino alcohol 5 under
conditions
common to the art such as 1,3-propanedithiol and triethylamine in methanol or
with
hydrogen gas in the presence of a catalyst such as palladium on carbon.
Acylation of 5
with an acid such as Cbz-leucine in the presence of a coupling agent such as
EDC followed
by removal of the BOC protecting group under acidic conditions provides the
amine salt 6.
Coupling of 6 with Cbz-leucine may be effected with a coupling agent such as
EDC to
provide the intermediate alcohol (not shown) which was oxidized with an
oxidant such as
pyridine sulfur trioxide complex in DMSO and triethylamine to provide the
ketone 7.
59
CA 02412353 2002-12-13
WO 01/95911 PCT/USO1/19062
Scheme 1
0
0 ~
/ -O N~ b w
O~N~% --~ ~ O~N
H
O
'I 2 3
O OH
NH2 f, 9
O N ~ O N '
O ~ O
4 5
O H
OH N _ ~ h, i OII N~N~O
+ II H O W ~ W O~N N~ O H I i
H-N O I i I H
H ~ O
CI-
6
7
Reagents and conditions: a.) NaH, 5-bromo-1-pentene, DMF; b.) 2,6-
diisopropylphenylimido
neophylidene molybenum bis(tert-butoxide) or
bis(tricyclohexylphosphine)benzylidine ruthenium
(IV) dichloride catalyst, toluene c.) m-CPBA, CHZC12; d.) NaN3, CH30H, H20,
NHQCI; e.) 10%
Pd/C, H2, f.) Cbz-leucine, EDC, CIizClz; g.) HCI, EtOAc; h.) Cbz-leucine, EDC,
CH2Cl2; i.)
pyridine sulfur trioxide complex, DMSO, TEA.
Compounds of the general formula I wherein R' and RZ are amides may be
prepared in
the general fashion outlined in Scheme 2. Alkylation of N-Cbz allyl amine (8)
with a base
such as sodium hydride and 5-bromo-1-pentene provides the dime 9. Treatment of
9 with
bis(tricyclohexylphosphine)benzylidine ruthenium(IV)dichloride olefin
metathesis catalyst
developed by Grubbs provides the azepine 10. Epoxidation of 10 with standard
oxidizing
agents common to the art such as nz-CPBA provide the epoxide 11. Nucleophilic
epoxide
ring opening may be effected with a reagent such as sodium azide to provide
the azido
alcohol (not shown) which may be reduced to the amino alcohol 12 with a
reducing agent
such as propanedithiol in the presence of triethylamine. Acylation of 12 with
N-Boc-
CA 02412353 2002-12-13
WO 01/95911 PCT/USO1/19062
leucine and a coupling agent such as EDC followed by removal of the Cbz
protecting group
under hydrogenolysis conditions provides the amine 13. Coupling of 13 with a
carboxylic
acid was effected with a coupling agent such as EDC followed by removal of the
acid labile
N-Boc protecting group with an acid such as HCl or TFA provides intermediate
14.
Acylation of 14 may be effected with a carboxylic acid in the presence of a
coupling agent
common to the art such as EDC to give the intermediate alcohol (not shown)
which is
oxidized with an oxidant such as pyridine sulfur trioxide complex in DMSO and
triethylamine to provide the ketone 15.
Scheme 2
0
O a y O.~N~ b ~ w
OJLH~/ ~ ~ / ~ ~ O I~N
O
8 9 10
OH
O
/~ ~ I NHz f.9
--~ w I O NI 1 ~ ~O~N~
O ~J O
11 12
OH ~ \ OH ~ ~ O H
N~O~ h, i ~NH3+CI- J. k N~N~R2
N O H ' R N~ O ~Ri N~ O H
H ~ p
13 14 15
Reagents and conditions: a.) NaH, 5-bromo-1-pentene, DMF; b.)
bis(tricyclohexylphosphine)benzylidine ruthenium (IV) dichloride catalyst,
CHZCI=; c.) rn-CPBA,
CHzCl2; d.) NaN3, CH30H, H20, NH4Cl; e.) propanedithiol, CH30H, TEA; f.) Boc-
leucine, EDC,
CH2Clz; g.) 10% Pd/C, H2; h.) R,C02H, EDC, CH2Clz or R,COCI, CHZCIz; i.) HCl/
EtOAc; j.)
RzC02H, EDC, CHZC12; k.) pyridine sulfur trioxide complex, DMSO, TEA.
61
CA 02412353 2002-12-13
WO 01/95911 PCT/USO1/19062
Compounds of the general formula I wherein RZ is an alkyl, urea or
sulphonamide
group and R~ is an amide may be prepared in the general fashion outlined in
Scheme 3.
Reductive amination of 13 may be effected by treatment with an aldehyde
followed by a
reducing agent such as sodium triacetoxyborohydride. Subsequent deprotection
of the N-
Boc group under acidic conditions provides the amine salt 16. Coupling of 16
with an acid
chloride or with a carboxylic acid in the presence of a coupling agent common
to the art
such as EDC followed by oxidation of the intermediate alcohol (not shown) with
an oxidant
such as pyridine sulfur trioxide complex provides the ketone 17.
Alternatively, treatment
of amine 13 with an isocyanate followed by deprotection of the N-Boc group
provides the
amine salt 18. Acylation and oxidation provides the ketone 19. Further
derivatization of
amine 13 may be effected by treatment with a sulphonyl chloride followed by
deprotection
of the N-Boc group to provide the amine salt 20. Acylation and oxidation
provides the
ketone 21.
Scheme 3
OH ~ OH HI~
a,b ~NH3+CI- c.d ~~~~R2
~H O ' R~N~ O ~ R1~N~ I1O
H.N~ O
13 16 17
OH ~_ O H
c'd ~~~~~R2
~NH3+CI- ' Ri ~ N O
f b Ri, uN O
IOI O
18 i9
OH
~NH3+CI- c,d 'S ~H R2
n N O ~ ~i N O
Rp RO
21
Reagents and conditions: a.) R,CHO, NaBH(OAc)3; b.) HC1; c.) RzCO2H, EDC,
CHZCIz; d.)
pyridine sulfur trioxide complex, DMSO, TEA; e.) R,NCO, base; f.) R,S02C1,
TEA, CHZCIz.
62
CA 02412353 2002-12-13
WO 01/95911 PCT/USO1/19062
The deuterated compound of the Example 192 may be conveniently prepared
according to Scheme 4. The skilled artisan will understand from Example 192
and Scheme
4 how to make any of the the deuterated compounds of the present invention.
The individual diastereomers of benzofuran-2-carboxylic acid {(S)-3-methyl-1-
[(2,2',4-trideuterio)-3-oxo-1-(pyridine-2-sulfonyl)-azepan-4-ylcarbamoyl]-
butyl}amide 31
and 32 may be prepared as outlined in Scheme 4. Alkylation of allyl-carbamic
acid benzyl
ester 22 with 5-bromo-1-pentene in the presence of a base such as sodium
hydride provides
the dime 23. Treatment of dime 23 with bis(tricyclohexylphosphine)benzylidine
ruthenium (IV) dichloride developed by Grubbs provides the 2,3,4,7-tetrahydro-
azepine-1-
carboxylic acid benzyl ester 24. Epoxidation of azepine 24 may be effected
with standard
oxidizing agents common to the art such as nz-CPBA to provide epoxide 25.
Nucleophilic
epoxide ring opening of 25 may be effected with a reagent such as sodium azide
to provide
the azido alcohol (not shown).
63
CA 02412353 2002-12-13
WO 01/95911 PCT/USO1/19062
Scheme 4
a ~ b
I i OON~ ~ I ~ OON~ \ I O~N
22 23 24
OH
O
c i d. a NHz f. 9
\ I O Nr~ \ I O N
O O
25 26
OH H ~ OH
N~ - ~ ~ h' ~ ~NH
II H O --~ O ,N O Z
H N O I \ 6
N~O
27 28
OH H ~ O
O N II H / I \ k N IOI N O I \
.. ,N O O ~ O ~ H
g ~ N
I ,N O I N O
29 30
O D N ~ p O p
pm II N / I \ O II N / I \
-~ O ,N~ O H O , + O N O H O i
\ O I \ SO
iN iN
3't 32
Reagents and Conditions: a.) NaH, 5-bromo-1-pentene, DMF; b.)
bis(tricyclohexylphosphine)benzylidine ruthenium (IV) dichloride, CHZC12; c.)
rn-CPBA, CHZCIz; d.)
NaN3, CH30H, HZO, NHQCl; e.) 1,3-propanedithiol, TEA, methanol; f.) N-Boc-
leucine, EDC,
CHzCl2; g.) 10% Pd/C, HZ; h.) 2-pyridinesulphonyl chloride, TEA, CHZCl2; i.) 4
N HCl/dioxane,
methanol; j.) benzofuran-2-carboxylic acid, EDC, CHZCIZ; k.) pyridine sulfur
trioxide complex,
DMSO, TEA; 1.) CD30D;D20 (10:1), TEA; m.) HPLC separation.
64
CA 02412353 2002-12-13
WO 01/95911 PCT/USO1/19062
The intermediate azido alcohol may be reduced to the amino alcohol 26 under
conditions
common to the art such as 1,3-propanedithiol and triethylamine in methanol or
with
triphenylphosphine in tetrahydrofuran and water. Acylation of 26 may be
effected with an
acid such as N-Boc-leucine in the presence of a coupling agent such as EDC.
Removal of
the benzyloxycarbonyl protecting group with hydrogen gas in the presence of
IO%o PdIC
provides the amine 27. Treatment of the amine 27 with 2-pyridinesulphonyl
chloride in the
presence of triethylamine or saturated sodium bicarbonate and CHZC12 followed
by removal
of the tent-butoxycarbonyl protecting group under acidic conditions provides
28. Coupling
of 28 with benzofuran-2-carboxylic acid may be effected with a coupling agent
such as
EDC to provide intermediate alcohol 29. Alcohol 29 may be oxidized with an
oxidant such
as sulfur trioxide pyridine complex in DMSO and triethylamine to provide the
ketone 30 as
a mixture of diastereomers. Treatment of ketone 30 with triethylamine in
CD30D:D20 at
reflux provides the deuterated analog as a mixture of diastereomers which are
separated by
HPLC to provide the deuterated compounds 31 and 32.
Compounds of the general formula I may also be prepared as outlined in Scheme
5.
The amine of compound 12 may be protected with with di-tart-butyldicarbonate
to provide
the N-Boc derivative 33 (Scheme 2). Removal of the benzyloxycarbonyl
protecting group
may be effected by treatment of 33 with hydrogen gas in the presence of a
catalyst such as
10% Pd/C to provide the amine 34. Treatment of amine 34 with a sulfonyl
chloride such as
2-pyridinesulfonyl chloride in the presence of a base such as N-
methylmorpholine or
triethylamine provides the sulfonamide derivative 3S. Removal of the tart-
butoxycarbonyl
protecting group may be effected with an acid such as hydrochloric acid to
provide
intermediate 36. Coupling of 36 with an acid such as N-Boc-cyclohexylalanine
in the
presence of a coupling agent common to the art such as HBTU or polymer
supported EDC
provides the alcohol intermediate 37. Removal of the tart-butoxycarbonyl
protecting group
under acidic conditions provides amine 38. Coupling of 38 with an acid such as
benzofuran-2-carboxylic acid in the presence of a coupling agent such as HBTU
or polymer
supported EDC provides alcohol 39. Alcohol 39 may be oxidized with an oxidant
common
to the art such as pyridine sulfur trioxide complex in DMSO and triethylamine
or the Dess-
Martin periodinane to provide the ketone 40.
CA 02412353 2002-12-13
WO 01/95911 PCT/USO1/19062
Scheme 5
OH H OH H OH
HZN~ ~ a O N- ~ b O N
)~~,,1N~O w I ~O ~1N~O W I ~ ~ p ~NH
IOI O
12 33 34
OH O_H
BocNH - ~ d H2N i I a
I ~ ~N,
N~g' N ~ \~ N
O O O O
35 36
OH l H OH
BocNH ~ I f ~N ~ g ,
HzN II I
O ~N,S, ~N O ~N~g\ ~N
O O O~ O
37 38
O O H O
H OH N ~I~I
~~////''~~~~ i
O H O N~N, ~ I h / ~ O H O ~N_S~
,S~ N
O O O O
39 40
Reagents and Conditions: (a) Di-tert-butyldicarbonate, THF; (b) HZ, 10% Pd/C,
EtOAc; (c) 2-
pyridylsulfonyl chloride, TEA ; (d) HCI, EtOAc; (e) N-Boc-cylohexylalanine, P-
EDC, CHzCIz; (f)
HCl, CHzCIz; (g) benzofuran-2-carboxylic acid, P-EDC, CH_Cl=; (h) Dess-Martin
periodinane,
methylene chloride.
The quaternized, 4-amino-azepan-3-one compounds of the present invention may
be conveniently prepared according to Scheme 6. The skilled artisan will
understand from
Scheme 6 how to make any of the quaternized, 4-amino-azepan-3-one compounds of
the
present invention. Reductive amination of 13 may be effected by treatment with
an
aldehyde followed by a reducing agent such as sodium triacetoxyborohydride.
Subsequent
deprotection of the N-Boc group under acidic conditions provides the amine
salt 16.
Treatment of 16 with an acid chloride or with a carboxylic acid in the
presence of a
coupling agent common to the art such as EDC followed by oxidation of the
intermediate
66
CA 02412353 2002-12-13
WO 01/95911 PCT/USO1/19062
alcohol (not shown) with an oxidant such as pyridine sulfur trioxide complex
provides the
ketone 17. Quaternization of the amine of 17 may be effected by treatment with
an
alkylating agent such as iodomethane to provide the quaternary amine salt 41.
Scheme 6
OH H ~ a, b OH H ~ c, d O H
N~N O' \ ~ N~NHZ H ~ N~N~R2
HN~ O H ~N~ O rN J O H
R1 R ~/1
16 1~
13
a
O H
N+ N~H~R2
Ri~ ~
41
Reagents and conditions: a.) R,CHO, NaBH(OAc)3; b.) HC1; c.) RZCOZH, EDC,
CH2Clz; d.)
pyridine sulfur trioxide complex, DMSO, TEA; e.) iodomethane
The starting materials used herein are commercially available amino acids or
are
prepared by routine methods well known to those of ordinary skill in the art
and can be
found in standard reference books, such as the COMPENDIUM OF ORGANIC
SYNTHETIC METHODS, Vol. I-VI (published by Wiley-Interscience).
Coupling methods to form amide bonds herein are generally well known to the
art.
The methods of peptide synthesis generally set forth by Bodansky et al., THE
PRACTICE
OF PEPTIDE SYNTHESIS, Springer-Verlag, Berlin, 1984; E. Gross and J.
Meienhofer,
THE PEPTIDES, Vol. 1, 1-284 (1979); and J.M. Stewart and J.D. Young, SOLID
PHASE
PEPTIDE SYNTHESIS, 2d Ed., Pierce Chemical Co., Rockford, Ill., 1984. are
generally
illustrative of the technique and are incorporated herein by reference.
Synthetic methods to prepare the compounds of this invention frequently employ
protective groups to mask a reactive functionality or minimize unwanted side
reactions.
Such protective groups are described generally in Green, T.W, PROTECTIVE
GROUPS IN
ORGANIC SYNTHESIS, John Wiley & Sons, New York (1981). The term "amino
protecting groups" generally refers to the Boc, acetyl, benzoyl, Fmoc and Cbz
groups and
67
CA 02412353 2002-12-13
WO 01/95911 PCT/USO1/19062
derivatives thereof as known to the art. Methods for protection and
deprotection, and
replacement of an amino protecting group with another moiety are well known.
Acid addition salts of the compounds of Formula I are prepared in a standard
manner in a suitable solvent from the parent compound and an excess of an
acid, such as
hydrochloric, hydrobromic, hydrofluoric, sulfuric, phosphoric, acetic,
trifluoroacetic,
malefic, succinic or methanesulfonic. Certain of the compounds form inner
salts or
zwitterions which may be acceptable. Cationic salts are prepared by treating
the parent
compound with an excess of an alkaline reagent, such as a hydroxide, carbonate
or
alkoxide, containing the appropriate cation; or with an appropriate organic
amine. Cations
such as Li+, Na+, K+, Ca++, Mg++ and NH4+ are specific examples of cations
present in
pharmaceutically acceptable salts. Halides, sulfate, phosphate, alkanoates
(such as acetate
and trifluoroacetate), benzoates, and sulfonates (such as mesylate) are
examples of anions
present in pharmaceutically acceptable salts. Quaternary ammonium salts are
prepared by
treating a parent amine compound with an excess of alkyl halide, such as
methyl iodide.
This invention also provides a pharmaceutical composition which comprises a
compound according to Formula I and a pharmaceutically acceptable carrier,
diluent or
excipient. Accordingly, the compounds of Formula I may be used in the
manufacture of a
medicament. Pharmaceutical compositions of the compounds of Formula I prepared
as
hereinbefore described may be formulated as solutions or lyophilized powders
for
parenteral administration. Powders may be reconstituted by addition of a
suitable diluent
or other pharmaceutically acceptable carrier prior to use. The liquid
formulation may be a
buffered, isotonic, aqueous solution. Examples of suitable diluents are normal
isotonic
saline solution, standard 5% dextrose in water or buffered sodium or ammonium
acetate
solution. Such formulation is especially suitable for parenteral
administration, but may also
be used for oral administration or contained in a metered dose inhaler or
nebulizer for
insufflation. It may be desirable to add excipients such as
polyvinylpyrrolidone, gelatin,
hydroxy cellulose, acacia, polyethylene glycol, mannitol, sodium chloride or
sodium
citrate.
Alternately, these compounds may be encapsulated, tableted or prepared in an
emulsion or syrup for oral administration. Pharmaceutically acceptable solid
or liquid
carriers may be added to enhance or stabilize the composition, or to
facilitate preparation of
the composition. Solid carriers include starch, lactose, calcium sulfate
dihydrate, terra alba,
magnesium stearate or stearic acid, talc, pectin, acacia, agar or gelatin.
Liquid carriers
68
CA 02412353 2002-12-13
WO 01/95911 PCT/USO1/19062
include syrup, peanut oil, olive oil, saline and water. The carrier may also
include a
sustained release material such as glyceryl monostearate or glyceryl
distearate, alone or
with a wax. The amount of solid carrier varies but, preferably, will be
between about 20
mg to about 1 g per dosage unit. The pharmaceutical preparations are made
following the
conventional techniques of pharmacy involving milling, mixing, granulating,
and
compressing, when necessary, for tablet forms; or milling, mixing and filling
for hard
gelatin capsule forms. When a liquid carrier is used, the preparation will be
in the form of
a syrup, elixir, emulsion or an aqueous or non-aqueous suspension. Such a
liquid
formulation may be administered directly p.o. or filled into a soft gelatin
capsule.
For rectal administration, the compounds of this invention may also be
combined
with excipients such as cocoa butter, glycerin, gelatin or polyethylene
glycols and molded
into a suppository.
Novel Intermediates
Referring to the methods of preparing the compounds of Formula I set forth in
Schemes 1-4 above, the skilled artisan will appreciate that the present
invention includes all
novel intermediates required to make the compounds of Formula I. In
particular, the
present invention provides the compounds of Formula II:
1
R~N~R
OH
r
Rs»
z
R
II
wherein:
R1 is selected from the group consisting of:
O O O
R'
X
R4/ N Rsi
g R3 R3
R
69
CA 02412353 2002-12-13
WO 01/95911 PCT/USO1/19062
I, O I, O
a/N
w
R4 R"" R
R3 ; and
R2 is selected from the group consisting of: H, C1_6alkyl, Cg_6cycloalkyl-
CO_6alkyl, Ar-
CO_6alkyl, Het-CO_6alkyl, R9C(O)-, R9C(S)-, R9S02-, R90C(O)-,
N C(O) N~ CH2
R9R11NC(O)_, R9R11NC(S)_~ R9(R11)NS02- I ~
,
R6
R~iN~ZW
IRa
and R9S02R11NC(O)- ;
R3 is selected from the group consisting of: H, C1_6alkyl, C3_6cycloalkyl-
Cp_6alkyl, C2_galkenyl, C2_6alkynyl, HetCO_6alkyl and ArCO_6alkyl;
R3 and R' may be connected to form a pyrrolidine, piperidine or morpholine
ring;
R4 is selected from the group consisting of: H, C1_6alkyl, C3_gcycloalkyl-
CO_6alkyl, Ar-CO_6alkyl, Het-CO_6alkyl, RSC(O)-, RSC(S)-, R5S02-, RSOC(O)-,
R5R12NC(O)-, and RSR12NC(S)-;
RS is selected from the group consisting of: H, C1_6alkyl, C2_6alkenyl,
C2_6alkynyl, C3_6cycloalkyl-CO_6alkyl, Ar-CO_6alkyl and Het-CO_6alkyl;
R6 is selected from the group consisting of: H, C1_6alkyl, Ar-CO_galkyl, or
Het-
CO_6alkyl;
R7 is selected from the group consisting of: H, C1_6alkyl, C3_6cycloalkyl-
CO_6alkyl, Ar-CO_6alkyl, Het-CO_6alkyl, R10C(O)-, R10C(S)-, R10S02-, R100C(O)-
,
RlORI3NC(O)_~ and R10R13NC(S)_~
Rg is selected from the group consisting of: H, C1_6alkyl, C2_6alkenyl,
C2_6alkynyl, HetCO_6alkyl and ArCp_6alkyl;
R9 is selected from the group consisting of: C1_6alkyl, C3_6cycloalkyl-
CO_6alkyl,
Ar-CO_6alkyl and Het-CO_6alkyl;
R10 is independently selected from the group consisting of: C1_6alkyl,
CA 02412353 2002-12-13
WO 01/95911 PCT/USO1/19062
C3_6cycloalkyl-Cp_galkyl, Ar-Cp_6alkyl and Het-Cp_6alkyl;
R11 is selected from the group consisting of: H, C1_6alkyl, Ar-Cp_6alkyl, and
Het-
Cp_6alkyl;
R12 is selected from the group consisting of: H, Cl_6alkyl, Ar-Cp_6alkyl, and
Het-
Cp_6alkyl;
R13 is selected from the group consisting of: H, C1_galkyl, Ar-Cp_6alkyl, and
Het-
Cp_6alkyl;
R' is selected from the group consisting of: H, C1_6alkyl, Ar-Cp_6alkyl, and
Het-
Cp_6alkyl;
R" is selected from the group consisting of: H, C1-6alkyl, Ar-Cp_6alkyl, or
Het-
Cp_6alkyl;
R"' is selected from the group consisting of: H, C1_6alkyl, Cg-6cycloalkyl-
Cp_6alkyl, Ar-Cp_6alkyl, and Het-Cp_6alkyl;
R"" is selected from the group consisting of: C1_6alkyl, C3_6cycloalkyl-
Cp_6alkyl
C2_6alkenyl, C2_6alkynyl, HetCp_6alkyl and ArCp_6alkyl;
n is an integer of from 1 to 5;
and salts, hydrates and solvates thereof
With reference to embodiment IA, the present invention includes the novel
intermediates of Formula IIA:
R\N~R
OH
R»> ~N
~R2
IIA
wherein:
R1 is selected from the group consisting of:
O N' O N' O
R'
N 4/ ~ 4/
R4/ R R»» R
3 3
R , R ,and ~~ ;
71
CA 02412353 2002-12-13
WO 01/95911 PCT/USO1/19062
R2 is selected from the group consisting of: Cl_6alkyl, Ar-CO_6alkyl, Het-
CO_6alkyl, R9C(O)-, R9S02-, R9R11NC(O)-, and R9S02R11NC(O)-;
R3 is selected from the group consisting of: C1_6alkyl, C3_6cycloalkyl-
CO_6alkyl,
C2_6alkenyl, C2_6alkynyl, Het-Cp_6alkyl and Ar-CO_6alkyl, preferably
C1_6alkyl;
R3 and R' may be connected to form a pyrrolidine, piperidine or morpholine
ring;
R4 is R5C(O)-;
RS is selected from the group consisting of : Cl_6alkyl and Het-CO_6alkyl,
preferably Het-CO_6alkyl;
R9 is selected from the group consisting of: Cl_6alkyl, Cg_6cycloalkyl-
CO_6alkyl,
Ar-CO_6alkyl and Het-CO_6alkyl;
R11 is selected from the group consisting of: H, Cl_6alkyl, Ar-CO_galkyl and
Het-
CO_6alkyl, preferably H;
R' is H;
R" is H;
R"' is selected from the group consisting of: H and C1_6alkyl, preferably H;
R"" is selected from the group consisting of; Cl_6alkyl, C3_6cycloalkyl-
CO_6alkyl,
C2_6alkenyl, C2_6alkynyl, HetCO_6alkyl and ArCO_6alkyl, preferably C1_6alkyl;
and
n is an integer from 1 to 5, preferably n is 3;
and pharmaceutically acceptable salts, hydrates and solvates thereof.
The following compounds are preferred novel intermediates:
[(S)-1(3-Hydroxy-azepan-4-ylcarbamoyl)-3-methyl-butyl]-carbamic acid benzyl
ester;
(S)-2-Amino-4-methyl-pentanoic acid (1-benzyl-3-hydroxy-azepan-4-yl)-amide;
(S)-2-Amino-4-methyl-pentanoic acid{3-hydroxy-1-[2-(3-pyridin-2-yl-phenyl)-
acetyl]-azepan-4-yl }-amide;
{(S)-1-[4-((S)-2-Amino-4-methyl-pentanoylamino)-3-hydroxy-azepan-1-
ylmethyl]-3-methyl-butyl}-carbamic acid benzyl ester;
(S)-2-Amino-4-methyl-pentanoic acid-(1-benzoyl-3-hydroxy-azepan-4-yl)-amide;
72
CA 02412353 2002-12-13
WO 01/95911 PCT/USO1/19062
(S)-2-Anuno-4-methyl-pentanoic acid [3-hydroxy-1-(4-methyl-pentanoyl)-azepan-
4-yl]-amide;
(S)-2-Amino-4-methyl-pentanoic acid (1-benzenesulfonyl-3-hydroxy-azepan-4-yl)-
amide;
thieno[3,2-b]thiophene-2-carboxylic acid {(S)-3-methyl-1-[3-hydroxy-1-(1-oxy-
pyridine-2-sulfonyl)-azepan-4-ylcarbamoyl]-butyl } amide;
5-methoxybenzofuran-2-carboxylic acid {(S)-3-methyl-1-[3-hydroxy-1-(1-oxy-
pyridine-2-sulfonyl)-azepan-4-ylcarbamoyl]-butyl } amide;
thieno[3,2-b]thiophene-2-carboxylic acid {(S)-3-methyl-1-[3-hydroxy-1-
(pyridine-
2-sulfonyl)-azepan-4-ylcarbamoyl]-butyl}amide;
3-methylbenzofuran-2-carboxylic acid {(S)-3-methyl-1-[3-hydroxy-1-(1-oxy-
pyridine-2-sulfonyl)-azepan-4-ylcarbamoyl]-butyl } amide;
quinoline-2-carboxylic acid {(S)-3-methyl-1-j3-hydroxy-1-(1-oxy-pyridine-2-
sulfonyl)-azepan-4-ylcarbamoyl]-butyl}amide; and
quinoxaline-2-carboxylic acid {(S)-3-methyl-1-[3-hydroxy-1-(1-oxy-pyridine-2-
sulfonyl)-azepan-4-ylcarbamoyl]-butyl } amide.
Process for Synthesis of Inventive Compounds
Referring to Schemes 1-6 herein above, the present invention provides a
process for
the synthesis of compounds of Formula (I) comprising the step of oxidizing the
appropriate
compound of Formula (II) with an oxidant to provide the compound of Formula
(I) as a
mixture of diastereomers. Preferably the oxidant is sulfur trioxide pyridine
complex in
DMSO and triethylamine.
Refernng to Scheme 4, the present invention also provides a process for the
synthesis of deuterated compounds of Formula (I). Specifically, when a
deuterated isomer
is desired, an additional step, following the oxidation step, of deuterating
the protonated
isomer with a deuterating agent to provide the deuterated compound of Formula
(I) as a
mixture of diastereomers is added to the synthesis. Preferably, the
deuterating agent is
CD30D:Dz0 (10:1) in triethylamine.
The process further comprises the step of separating the diasteromers of
Formula
(I) by separating means, preferably by high presssure liquid chromatography
(HPLC).
Referring to Scheme 6, the present invention also provides a process for the
synthesis of quaternary salts of the 4-amino-azepan-3-one compounds of Fornula
(I).
73
CA 02412353 2002-12-13
WO 01/95911 PCT/USO1/19062
Utility of the Present Invention
The compounds of Formula I are useful as protease inhibitors, particularly as
inhibitors of cysteine and serine proteases, more particularly as inhibitors
of cysteine
proteases, even more particularly as inhibitors of cysteine proteases of the
papain
superfamily, yet more particularly as inhibitors of cysteine proteases of the
cathepsin
family, most particularly as inhibitors of cathepsin K. The present invention
also provides
useful compositions and formulations of said compounds, including
pharmaceutical
compositions and formulations of said compounds.
The present compounds are useful for treating diseases in which cysteine
proteases
are implicated, including infections by pneumocystis carinii, trypsanoma
cruzi, trypsanoma
brucei, and Crithidia fusiculata; as well as in schistosomiasis, malaria,
tumor metastasis,
metachromatic leukodystrophy, muscular dystrophy, amytrophy; and especially
diseases in
which cathepsin K is implicated, most particularly diseases of excessive bone
or cartilage
loss, including osteoporosis, gingival disease including gingivitis and
periodontitis,
arthritis, more specifically, osteoarthritis and rheumatoid arthritis, Paget's
disease;
hypercalcemia of malignancy, and metabolic bone disease.
Metastatic neoplastic cells also typically express high levels of proteolytic
enzymes
that degrade the surrounding matrix, and certain tumors and metastatic
neoplasias may be
effectively treated with the compounds of this invention.
The present invention also provides methods of treatment of diseases caused by
pathological levels of proteases, particularly cysteine and serine proteases,
more
particularly cysteine proteases, even more particularly cysteine proteases of
the papain
superfamily, yet more particularly cysteine proteases of the cathepsin family,
which
methods comprise administering to an animal, particularly a mammal, most
particularly a
human in need thereof a compound of the present invention. The present
invention
especially provides methods of treatment of diseases caused by pathological
levels of
cathepsin K, which methods comprise administering to an animal, particularly a
mammal,
most particularly a human in need thereof an inhibitor of cathepsin K,
including a
compound of the present invention. The present invention particularly provides
methods
for treating diseases in which cysteine proteases are implicated, including
infections by
pneumocystis carinii, trypsanoma cruzi, trypsanoma brucei, and Crithidia
fusiculata; as
well as in schistosomiasis, malaria, tumor metastasis, metachromatic
leukodystrophy,
74
CA 02412353 2002-12-13
WO 01/95911 PCT/USO1/19062
muscular dystrophy, amytrophy, and especially diseases in which cathepsin K is
implicated,
most particularly diseases of excessive bone or cartilage loss, including
osteoporosis,
gingival disease including gingivitis and periodontitis, arthritis, more
specifically,
osteoarthritis and rheumatoid arthritis, Paget's disease, hypercalcemia of
malignancy, and
metabolic bone disease.
This invention further provides a method for treating osteoporosis or
inhibiting
bone loss which comprises internal administration to a patient of an effective
amount of a
compound of Formula I, alone or in combination with other inhibitors of bone
resorption,
such as bisphosphonates (i.e., allendronate), hormone replacement therapy,
anti-estrogens,
or calcitonin. In addition, treatment with a compound of this invention and an
anabolic
agent, such as bone morphogenic protein, iproflavone, may be used to prevent
bone loss or
to increase bone mass.
For acute therapy, parenteral administration of a compound of Formula I is
preferred. An intravenous infusion of the compound in 5% dextrose in water or
normal
saline, or a similar formulation with suitable excipients, is most effective,
although an
intramuscular bolus injection is also useful. Typically, the parenteral dose
will be about
0.01 to about 100 mg/kg; preferably between 0.1 and 20 mg/kg, in a manner to
maintain the
concentration of drug in the plasma at a concentration effective to inhibit
cathepsin K. The
compounds are administered one to four times daily at a level to achieve a
total daily dose
of about 0.4 to about 400 mg/kg/day. The precise amount of an inventive
compound which
is therapeutically effective, and the route by which such compound is best
administered, is
readily determined by one of ordinary skill in the art by comparing the blood
level of the
agent to the concentration required to have a therapeutic effect.
The compounds of this invention may also be administered orally to the
patient, in
a manner such that the concentration of drug is sufficient to inhibit bone
resorption or to
achieve any other therapeutic indication as disclosed herein. Typically, a
pharmaceutical
composition containing the compound is administered at an oral dose of between
about 0.1
to about 50 mg/kg in a manner consistent with the condition of the patient.
Preferably the
oral dose would be about 0.5 to about 20 mg/kg.
No unacceptable toxicological effects are expected when compounds of the
present
invention are administered in accordance with the present invention.
CA 02412353 2002-12-13
WO 01/95911 PCT/USO1/19062
Biological Assays
The compounds of this invention may be tested in one of several biological
assays
to determine the concentration of compound which is required to have a given
pharmacological effect.
Determination of cathepsin K proteolytic catalytic activity
All assays for cathepsin I~ were carried out with human recombinant enzyme.
Standard assay conditions for the determination of kinetic constants used a
fluorogenic
peptide substrate, typically Cbz-Phe-Arg-AMC, and were determined in 100 mM Na
acetate at pH 5.5 containing 20 mM cysteine and 5 mM EDTA. Stock substrate
solutions
were prepared at concentrations of 10 or 20 mM in DMSO with 20 uM final
substrate
concentration in the assays. All assays contained 10% DMSO. Independent
experiments
found that this level of DMSO had no effect on enzyme activity or kinetic
constants. All
assays were conducted at ambient temperature. Product fluorescence (excitation
at 360
nM; emission at 460 nM) was monitored with a Perceptive Biosystems Cytofluor
II
fluorescent plate reader. Product progress curves were generated over 20 to 30
minutes
following formation of AMC product.
Inhibition studies
Potential inhibitors were evaluated using the progress curve method. Assays
were
carried out in the presence of variable concentrations of test compound.
Reactions were
initiated by addition of enzyme to buffered solutions of inhibitor and
substrate. Data
analysis was conducted according to one of two procedures depending on the
appearance of
the progress curves in the presence of inhibitors. For those compounds whose
progress
curves were linear, apparent inhibition constants (Ki,app) were calculated
according to
equation 1 (Brandt et al., Bzochemitsry, 1989, 2~, 140):
v = V»aA l IKa(1 + IIKI aPP~ +Aj
where v is the velocity of the reaction with maximal velocity Vj~t , A is the
concentration of
substrate with Michaelis constant of Ka, and 1 is the concentration of
inhibitor.
76
CA 02412353 2002-12-13
WO 01/95911 PCT/USO1/19062
For those compounds whose progress curves showed downward curvature
characteristic of time-dependent inhibition, the data from individual sets was
analyzed to
give kobs according to equation 2:
[AMC] = vss t + w0 - vss~ ~l - exP ~-kobst)~ ~ kobs (2)
where [AMC] is the concentration of product formed over time t, vp is the
initial reaction
velocity and vss is the final steady state rate. Values for kobs were then
analyzed as a
linear function of inhibitor concentration to generate an apparent second
order rate
constant (kobs / inhibitor concentration or kobs l [I]) describing the time-
dependent
inhibition. A complete discussion of this kinetic treatment has been fully
described
(Morrison et al., Adv. Enzymol. Relat. Areas Mol. Baol., 1988, 61, 201).
Human Osteoclast Resorption Assay
Aliquots of osteoclastoma-derived cell suspensions were removed from liquid
nitrogen storage, warmed rapidly at 37°C and washed x1 in RPMI-1640
medium by
centrifugation (1000 rpm, 5 min at 4°C). The medium was aspirated and
replaced with
murine anti-HLA-DR antibody, diluted 1:3 in RPMI-1640 medium, and incubated
for 30
min on ice The cell suspension was mixed frequently.
The cells were washed x2 with cold RPMI-1640 by centrifugation (1000 rpm, 5
min at 4°C) and then transferred to a sterile 15 mL centrifuge tube.
The number of
mononuclear cells were enumerated in an improved Neubauer counting chamber.
Sufficient magnetic beads (5 / mononuclear cell), coated with goat anti-mouse
IgG,
were removed from their stock bottle and placed into 5 mL of fresh medium
(this washes
away the toxic azide preservative). The medium was removed by immobilizing the
beads
on a magnet and is replaced with fresh medium.
The beads were mixed with the cells and the suspension was incubated for 30
min
on ice. The suspension was mixed frequently. The bead-coated cells were
immobilized on
a magnet and the remaining cells (osteoclast-rich fraction) were decanted into
a sterile 50
mL centrifuge tube. Fresh medium was added to the bead-coated cells to
dislodge any
trapped osteoclasts. This wash process was repeated x10. The bead-coated cells
were
discarded.
77
CA 02412353 2002-12-13
WO 01/95911 PCT/USO1/19062
The osteoclasts were enumerated in a counting chamber, using a large-bore
disposable plastic pasteur pipette to charge the chamber with the sample. The
cells were
pelleted by centrifugation and the density of osteoclasts adjusted to
1.5x104/mL in EMEM
medium, supplemented with 10% fetal calf serum and 1.7g/litre of sodium
bicarbonate. 3
mL aliquots of the cell suspension ( per treatment) were decanted into 15 mL
centrifuge
tubes. These cells were pelleted by centrifugation. To each tube 3 mL of the
appropriate
treatment was added (diluted to 50 uM in the EMEM medium). Also included were
appropriate vehicle controls, a positive control (87MEM1 diluted to 100 ug/mL)
and an
isotype control (IgG2a diluted to 100 ug/mL). The tubes were incubate at
37°C for 30 min.
0.5 mL aliquots of the cells were seeded onto sterile dentine slices in a 48-
well
plate and incubated at 37°C for 2 h. Each treatment was screened in
quadruplicate. The
slices were washed in six changes of warm PBS (10 mL / well in a 6-well plate)
and then
placed into fresh treatment or control and incubated at 37°C for 48 h.
The slices were then
washed in phosphate buffered saline and fixed in 2% glutaraldehyde (in
0.2M.sodium
cacodylate) for 5 min., following which they were washed in water and
incubated in buffer
for 5 min at 37°C. The slices were then washed in cold water and
incubated in cold acetate
buffer / fast red garnet for 5 min at 4°C. Excess buffer was aspirated,
and the slices were
air dried following a wash in water.
The TRAP positive osteoclasts were enumerated by bright-field microscopy and
were then removed from the surface of the dentine by sonication. Pit volumes
were
determined using the Nikon/Lasertec ILM21W confocal microscope.
General
Nuclear magnetic resonance spectra were recorded at either 250 or 400 MHz
using,
respectively, a Broker AM 250 or Broker AC 400 spectrometer. CDC13 is
deuteriochloroform, DMSO-d6 is hexadeuteriodimethylsulfoxide, and CD30D is
tetradeuteriomethanol. Chemical shifts are reported in parts per million (d)
downfield from
the internal standard tetramethylsilane. Abbreviations for NMR data are as
follows: s =
singlet, d = doublet, t = triplet, q = quartet, m = multiplet, dd = doublet of
doublets, dt =
doublet of triplets, app = apparent, br = broad. J indicates the NMR coupling
constant
measured in Hertz. Continuous wave infrared (IR) spectra were recorded on a
Perkin-
Elmer 683 infrared spectrometer, and Fourier transform infrared (FTIR) spectra
were
recorded on a Nicolet Impact 400 D infrared spectrometer. IR and FTIR spectra
were
78
CA 02412353 2002-12-13
WO 01/95911 PCT/USO1/19062
recorded in transmission mode, and band positions are reported in inverse
wavenumbers
(cm 1). Mass spectra were taken on either VG 70 FE, PE Syx API III, or VG ZAB
HF
instruments, using fast atom bombardment (FAB) or electrospray (ES) ionization
techniques. Elemental analyses were obtained using a Perkin-Elmer 240C
elemental
analyzer. Melting points were taken on a Thomas-Hoover melting point apparatus
and are
uncorrected. All temperatures are reported in degrees Celsius.
Analtech Silica Gel GF and E. Merck Silica Gel 60 F-254 thin layer plates were
used for thin layer chromatography. Both flash and gravity chromatography were
carried
out on E. Merck Kieselgel 60 (230-400 mesh) silica gel.
Where indicated, certain of the materials were purchased from the Aldrich
Chemical Co., Milwaukee, Wisconsin, Chemical Dynamics Corp., South Plainfield,
New
Jersey, and Advanced Chemtech, Louisville, Kentucky.
Examples
In the followingsynthetic examples, temperature is in degrees Centigrade
(°C).
Unless otherwise indicated, all of the starting materials were obtained from
commercial
sources. Without further elaboration, it is believed that one skilled in the
art can, using the
preceding description, utilize the present invention to its fullest extent.
These Examples are
given to illustrate the invention, not to limit its scope. Reference is made
to the claims for
what is reserved to the inventors hereunder.
79
CA 02412353 2002-12-13
WO 01/95911 PCT/USO1/19062
Example 1
Preparation of 1 (S)-1-f 1-((S)-2-Benzyloxycarbonylamino-4-methyl-pentanoyl)-3-
oxo-
azepan-4-ylcarbamo~~carbamic acid benz, l ester
a.) Allyl-pent-4-enyl-carbamic acid tert-butyl ester
To a suspension of NaH (3.05 g, 76.33 mmol of 60% NaH in oil; washed with
hexanes) in DMF (30 mL) was added tert-butyl N-allylcarbamate (6.0 g, 38.2
mmol) in a
dropwise fashion. The mixture was stirred at room temperature for
approximately 10
minutes whereupon 5-bromo-1-pentene (6.78 mL, 57.24 mmol) was added in a
dropwise
fashion. The reaction was heated to 40°C for approximately 2 hours
whereupon the
reaction was partitioned between ethyl acetate and water. The organic layer
was washed
with water (2 x's), brine, dried (MgS04), filtered and concentrated to give 10
grams of the
title compound as an oil: MS(EI) 226 (M+H+).
b.) 2,3,4,7-Tetrahydro-azepine-1-carboxylic acid tent-butyl ester
To a solution of compound of Example la (4.5 g) in benzene was added the 2,6-
diisopropylphenylimidoneophylidene molybdenum bis(t-butoxide) (600 mg). The
reaction
was heated to reflux for 1.5 hours whereupon the reaction was concentrated in
vacuo.
Chromatography (50% CHZCI2:hexanes) of the residue gave 3.92 g of the product:
c.) 8-Oxa-3-aza-bicyclo[5.1.0]octane-3-carboxylic acid tert-butyl ester
To a solution of the compound of Example 1b (3.0 g, 15.2 mmol) in CH2Cl2 was
added m-CPBA (7.8 g, 45.6 mmol). The mixture was stirred overnight at room
temperature
whereupon it was partitioned between CHZClz and staurated I~C03. The organic
layer was
washed with sat. NaHC03, water, brine, dried (MgS04), filtered and
concentrated to give
3.11 g of the title compound as an oil: MS(EI) 214 (M+H+).
d.) 4-Azido-3-hydroxy-azepane-1-carboxylic acid tert-butyl ester
To a solution of the epoxide from Example lc ( 3.92 g, 20 mmol) in
methanol:water (180 mL of an 8:1 solution) was added NH4C1 (3.18 g, 60 mmol)
and
sodium azide (3.9 g, 60 mmol). The reaction was heated to 40°C until
complete
consumption of the starting epoxide was observed by TLC analysis. The majority
of the
CA 02412353 2002-12-13
WO 01/95911 PCT/USO1/19062
solvent was removed i~2 vacuo and the remaining solution was diluted with
ethyl acetate
and washed with water, brine dried (Na2S04), filtered and concentrated. Column
chromatography (40% ethyl acetate:hexanes) of the residue provided 3.43 g of
the title
compound.
e.) 4-Amino-3-hydroxy-azepane-1-carboxylic acid tart-butyl ester
To a solution of the azido alcohol of Example 1d (3.4 g) and 10% Pd/C
(catalytic)
in ethyl acetate:methanol (2:1 solution) was affixed a balloon of hydrogen.
The reaction
was stirred until complete consumption of the starting material was observed
by TLC
analysis. The reaction was filtered to remove the catalyst and the filtrate
was concentrated
in vacuo. Column chromatography of the residue (25% methanol:dichloromethane)
provided 2.57 g of the title compound: MS(EI) 231 (M+H+)
f.) 4-((S)-2-benzyloxycarbonylamino-4-methyl-pentanoylamino)-3-hydroxy-azepane-
1-carboxylic acid tart butyl ester
To a solution of the amino alcohol of Example 1e (160 mg, 0.70 mmol) in CH2C12
Was added EDC (134 mg), HOBt (94 mg) and Cbz-leucine (185 mg). The reaction
was
maintained at room temperature until complete consumption of the starting
material was
observed by TLC analysis. The reaction was diluted with ethyl acetate and
washed with
1N HCI, sat. K2C03, water, brine, dried (MgS04), filtered and concentrated.
Column
chromatography of the residue (3% methanol:dichloromethane) gave 200 mg of the
title
compound: MS(EI) 478 (M+H+), 500 (M+Na+).
g.) [(S)-1-(3-hydroxy-azepan-4-ylcarbamoyl)-3-methyl-butyl]-carbamic acid
benzyl
ester
A solution of the compound of Example if (200 mg, 0.42 mmol) in methanol (5
mL) was added 4M HCl in dioxane (5 mL). The reaction was stirred at room
temperature
for approximately 2 hours whereupon the solvent was removed in vacLCO to
provide 168 mg
of the title compound: MS(EI) 378 (M+H+)
81
CA 02412353 2002-12-13
WO 01/95911 PCT/USO1/19062
h.) {(S)-1-[4-((S)-2-Benzyloxycarbonylamino-4-methyl-pentanoylamino)-3-hydroxy-
azepane-1-carbonyl]-3-methyl-butyl}carbamic acid benzyl ester
To a solution of the amine salt of Example 1g (168 mg, 0.42 mmol) in CH2Cl2
was added EDC (81 mg), HOBt (57 mg), triethylamine (0.09 mL) and Cbz-leucine
(111
mg). The reaction was stirred until complete by TLC analaysis. Workup followed
by
column chromatography (5% CH30H:CH2C12) provided 159 mg of the title compound:
MS(EI) 625 (M+H+).
i.) {(S)-1-[4-((S)-2-Benzyloxycarbonylamino-4-methyl-pentanoylamino)-3-oxo-
azepane-1-carbonyl]-3-methyl-butyl}carbamic acid benzyl ester
To a solution of the alcohol of Example 1h (130 mg, 0.21 mmol) in DMSO was
added TEA (0.17 mL) and pyridine sulfur trioxide complex (97 mg, 0.62 mmol).
The
reaction was stirred at room temperature for approximately 2 hours whereupon
it was
partitioned between ethyl acetate and water. The organic layer was washed with
brine,
dried (MgS04), filtered and concentrated. Column chromatography of the residue
(5%
CH30H:CH2C12) provided 100 mg of the title compound as a mixture of
diastereorriers: 'H
NMR (CDC13): 8 1.0 ( m, 12H), 1.5-2.1 ( m, 8H), 2.2 ( m, 4H), 3.0 (m, IH), 3.5
(d, 1H). 3.6
(d, 1H), 4.01 (m, 1H), 4.5 ( m, 2H), 4.7 (m, 1H), 5.0 ( m, 5H), 7.3 (m, 10H):
MS (EI)
623(M+H+), 645 (M+Na+). Separation of the diastereomers by HPLC provided
diastereomer 1:MS (EI) 623 (M+H+), 645 (M+Na+) and diastereomer 2: MS (ES) 623
(M+H+), 645 (M+Na+).
82
CA 02412353 2002-12-13
WO 01/95911 PCT/USO1/19062
Example 2
Preparation of Naphthylene-2-carboxylic acids(S)-1~1-benzyl-3-oxo-azepan-4-
ylcarbamoyl)-3-meth ~~1-butyllamide
a.) Allyl-pent-4-enyl-carbamic acid benzyl ester
To a suspension of NaH (1.83 g, 76.33 mmol of 90% NaH) in DMF was added
benzyl allyl-carbamic acid benzyl ester (7.3 g, 38.2 mmol) in a dropwise
fashion. The
mixture was stirred at room temperature for approximately 10 minutes whereupon
5-
bromo-1-pentene (6.78 mL, 57.24 mmol) was added in a dropwise fashion. The
reaction
was heated to 40°C for approximately 4 hours whereupon the reaction was
partitioned
between dichloromethane and water. The organic layer was washed with water
(2x's),
brine, dried (MgS04), filtered and concentrated. Column chromatography of the
residue
(10% ethyl acetate:hexanes) provided 10.3 grams of the title compound as an
oil: MS(EI)
-: 260 (M+H+)
b.) 2,3,4,7-Tetrahydro-azepine-1-carboxylic acid benzyl ester
To a solution of compound of Example 2a (50 g) in dichloromethane was added
bis(tricyclohexylphosphine)benzylidine ruthenium (TV) dichloride (5.0 g). The
reaction
was heated to reflux until complete as determined by TLC analysis. The
reaction was
concentrated i~z vacuo. Column chromatography of the residue (50%
dichloromethane:hexanes) gave 35 g of the title compound: MS(EI) 232 (M+H+)
c.) 8-Oxa-3-aza-bicyclo[5.1.0]octane-3-carboxylic acid benzyl ester
Following the general procedure of Example lc except substituting the compound
of Example 2b the title compound was prepared: MS(EI) 248 (M+H+), 270 (M+Na+)
d.) 4-azido-3-hydroxy-azepane-1-carboxylic acid benzyl ester
To a solution of the epoxide from Example 2c (2.0 g, 8.1 mmol) in
methanol:water
(8:1 solution) was added NHøCl (1.29 g, 24.3 mmol) and sodium azide (1.58 g,
24.30
mmol). The reaction was heated to 40°C until complete consumption of
the starting
epoxide was observed by TLC analysis. The majority of the solvent was removed
irz vaczzo
and the remaining solution was partitioned between ethyl acetate and pH 4
buffer. The
83
CA 02412353 2002-12-13
WO 01/95911 PCT/USO1/19062
organic layer was washed with sat. NaHC03, water, brine dried (MgS04),
filtered and
concentrated. Column chromatography (20% ethyl acetate:hexanes) of the residue
provided 1.3 g of the title compound: MS(EI) 291 (M+H+) plus 0.14 g of traps-4-
hydroxy-3-azido-hexahydro-1H-azepine
e.) 4-amino-3-hydroxy-azepane-1-carboxylic acid benzyl ester
To a solution of the azido alcohol of Example 2d (1.1 g, 3.79 mmol) in
methanol
was added triethylamine (1.5 mL, 11.37 mmol) and 1,3-propanedithiol (1.1 mL,
11.37 mL).
The reaction was stirred until complete consumption of the starting material
was observed
by TLC analysis whereupon the reaction was concentrated ifa vacuo. Column
chromatography of the residue (20% methanol:dichloromethane) provided 0.72 g
of the
title compound: MS(EI) 265 (M+H+)
f.) 4-((S)-2-tert-Butoxycarbonylamino-4-methyl-pentanoylamino)-3-hydroxy-
azepan-
1-carboxylic acid benzyl ester
To a solution of the amino alcohol of Example 2e (720 mg, 2.72 mmol) in CH2Cl2
was added EDC (521 mg), HOBt (368 mg) and N-Boc-leucine (630 mg). The reaction
was
maintained at room temperature until complete consumption of the starting
material was
observed by TLC analysis. The reaction was diluted with ethyl acetate and
washed with
1N HCl, sat. K2C03, water, brine, dried (MgS04), filtered and concentrated.
Column
chromatography of the residue (3% methanol:dichloromethane) gave 1.0 g of the
title
compound: MS(EI) 478 (M+H+)
g.) [(S)-1-(3-Hydroxy-azepan-4-ylcarbamoyl)-3-methyl-butyl]-carbamic acid tent
butyl ester
To a solution of the compound of Example 2f (1.0 g) and 10% Pd/C (catalytic)
in
ethyl acetate:methanol (2:1 solution) was affixed a balloon of hydrogen. The
reaction was
stirred until complete consumption of the starting material was observed by
TLC analysis.
The reaction was filtered to remove the catalyst and the filtrate was
concentrated in vacuo
to provide 0.82 g of the title compound: MS(EI) 344 (M+H+)
84
CA 02412353 2002-12-13
WO 01/95911 PCT/USO1/19062
h.) [(S)-1-(1-Benzyl-3-Hydroxy-azepan-4-ylcarbamoyl)-3-methyl-butyl]-carbamic
acid
tert butyl ester
To a solution of the compound of Example 2g (0.69 g, 2.01 mmol) in CH2C12 was
added benzaldehyde (0.32 mL, 3.01 mmol) followed by sodium
triacetoxyborohydride
(0.85 g, 4.02 mmol). The reaction was stirred until complete as determined by
TLC
analysis whereupon several drops of water were added to the reaction to
destroy the excess
sodium triacetoxyborohydride. The mixture was diluted with ethyl acetate
washed with sat.
NaHC03, water, brine, dried (Na2S04), filtered and concentrated. Column
chromatography of the residue (5% methanol:dichloromethane) gave 800 mg of the
title
compound: MS(ES) 434 (M+H+).
i.) (S)-2-Amino-4-methyl-pentanoic acid (1-benzyl-3-hydroxy-azepan-4-yl)-amide
To a solution of the compound of Example 2h (800 mg) in methanol (15 mL) was
added 4M HCl in dioxane ( 15 mL). The reaction was stirred at room temperature
overnight
whereupon it was concentrated in vacuo to give 800 mg of the title compound:
MS(ES)
334 (M+H+).
j.) Naphthylene-2-carboxylic acid [(S)-1-(1-benzyl-3-hydroxy-azepan-4-
ylcarbamoyl)-3-
methyl-butyl]-amide
To a solution of the amine salt of Example 2i (200 mg, 0.49 mmol) in CH2Cl2
was
added triethylamine (0.17 mL, 1.22 mmol), EDC (103.5 mg, 0.54 mmol), HOBt (73
mg,
0.54 mmol) and 2-naphthoic acid (93 mg, 0.54 mmol). The reaction was stirred
until
complete by TLC analysis. The reaction was diluted with ethyl acetate and
washed with
sat. NaHC03, water, brine, dried (Na2S04), filtered and concentrated. Column
chromatography of the residue (5% methanol:dichloromethane) gave 0.14 g of the
title
compound: MS(EI) 488 (M+H+).
k.) Naphthylene-2-carboxylic acid[(S)-1-(1-benzyl-3-oxo-azepan-4-ylcarbamoyl)-
3-
methyl-butyl]-amide
Following the general procedure of Example 1i except substituting the compound
of Example 2j for the compound of Example 1i the title compound was prepared:
'H NMR
(CDCl3): 8 1.0 ( m, 6H), 1.5-2.1 ( m, 5H), 2.2 ( m, 2H), 2.9 (m, 1H), 3.2 (dd,
1H). 3.4 (m,
1H), 3.7 (m, 2H), 4.7 ( m, 1H), 5.2 ( m, 1H), 7.2-8.4 (m, 12H); MS(EI): 486
CA 02412353 2002-12-13
WO 01/95911 PCT/USO1/19062
(M+H+,100%). Separation of the diastereomers by HPLC provided diastereomer l:
MS
(EI) 486.3 (M+H+), and diastereomer 2: MS (ES) 486.3 (M+H+).
Example 3
Preparation of Benzof 1,31dioxole-5-carboxylic acid f(S)-1-(1-benzyl-3-oxo-
azepan-4-
ylcarbamo~)-3-methyl-butyll amide
a.) Benzo[1,3]dioxole-5-carboxylic acid [(S)-1-(1-benzyl-3-hydroxy-azepan-4-
ylcarbamoyl)-3-methyl-butyl]amide
Following the general procedure of Example 2j except substituting piperonylic
acid
for 2-naphthoic acid the title compound was prepared: MS(ES) 482 (M+H+).
b.) Benzo[1,3]dioxole-5-carboxylic acid [(S)-1-(1-benzyl-3-oxo-azepan-4-
' ylcarbamoyl)-3-methyl-butyl]amide
Following the general procedure of Example 1i except substituting the compound
of Example 3a the title compound was prepared: 'H NMR (CDC13): 8 1.0 ( m, 6H),
1.5-2.1
m, 5H), 2.2 ( m, 2H),.2.9 (m, 1H), 3.0 ( m, 1H). 3.2 (d, 1H), 3.5 (q, 1H), 3.7
(m, 2H), 4.7
m, 1H), 5.2 ( m, 1H), 6.0 (s, 2H), 6.8 (m, 2H).7.2 (m, 6H); MS(EI): 480
(M+H+,100%).
The diastereomers were separated by preparative scale HPLC. Lyophilisation of
the eluents
provided diastereomer l: MS (EI) 480.3 (M+H+), 959.6 2M+H+) and diastereomer
2: MS
(EI) 480.3 (M+H+), 959.6 2M+H+).
86
CA 02412353 2002-12-13
WO 01/95911 PCT/USO1/19062
Example 4
Preparation of Benzofuran-2-carboxylic acid f(S)-1-(1-benzyl-3-oxo-azepan-4- ,
ylcarbamoyl)-3-meth~yll amide
a.) Benzofuran-2-carboxylic acid [(S)-1-(1-benzyl-3-hydroxy-azepan-4-
ylcarbamoyl)-
3-methyl-butyl]amide
Following the general procedure of Example 2j except substituting benzofuran-2-
carboxylic acid for 2-naphthoic acid the title compound was prepared: MS(ES)
478
(M+H+).
b.) Benzofuran-2-carboxylic acid [(S)-1-(1-benzyl-3-oxo-azepan-4-ylcarbamoyl)-
3-
methyl-butyl]amide
Following the general procedure of Example 1i except substituting the compound
of Example 4a the title compound was prepared: 476 MS(EI): 492 (M+H+,100%).
The
diastereomers were separated by preparative scalevHPLC. Lyophilisation of the
eluents
provided diastereomer 1: MS (EI) 476.4 (M+H+), 951.6 (M+H+) and diastereomer
2: .
MS (EI) 476.4 (M+H+), 951.6 2M+H+).
Example 5
Preparation of Benzofblthiophene-2-carboxylic acid [(S)-1-(1-benzyl-3-oxo-aze
ap n-4-
ylcarbamoyl -3-methyl-butyllamide
a.) Benzo[b]thiophene-2-carboxylic acid [(S)-1-(1-benzyl-3-hydroxy-azepan-4-
ylcarbamoyl)-3-methyl-butyl] amide
Following the general procedure of Example 2j except substituting
benzothiophene-2-carboxylic acid for 2-naphthoic acid the title compound was
prepared:
MS(ES) 494 (M+H+).
87
CA 02412353 2002-12-13
WO 01/95911 PCT/USO1/19062
b.) Benzo[b]thiophene-2-carboxylic acid [(S)-1-(I-benzyl-3-oxo-azepan-4-
ylcarbamoyl)-3-
methyl-butyl]amide
Following the general procedure of Example 1i except substituting the compound
of Example 5a the title compound was prepared: 'H NMR (CDCl3): 8 1.0 ( m, 6H),
1.5-2.1
m, 5H), 2.2 ( m, 2H), 2.9 (m, 1H), 3.2 (dd, 1H). 3.4 (m, 1H), 3.7 (m, 2H), 4.7
(m, 1H),
5.2 ( m, 1H), 7.2-8.4 (m, 10H): MS(EI): 492 (M+H+,100%)
The diastereomers were separated by preparative scale HPLC. Lyophilisation of
the eluents provided diastereomer l: MS (EI) 492.4 (M+H+), 983.7 2M+H+) and
diastereomer 2: MS (EI) 492.4 (M+H+), 983.7 2M+H+)
Example 6
Preparation of Naphthylene-2-sulphonyl f(S)-1-(1-benzyl-3-oxo-azepan-4-
ylcarbamoyl)-3-
meth~yll-amide
a.) Naphthylene-2-sulphonyl [(S)-1-(1-benzyl-3-hydroxy-azepan-4-ylearbamoyl)-3-
methyl-butyl]-amide
To a solution of the amine salt of Example 2i (200 mg, 0.49 mmol) in CH2Cl2
was
added triethylamine (0.24 mL, 1.72 mmol) and 2-naphthalenesulphonyl chloride
(122 mg,
0.54 mmol). The reaction was stirred at room temperature until complete as
determined by
TLC analysis. The reaction was worked-up, dried (Na2S04), filtered and
concentrated.
Column chromatography of the residue (10% methanol:dichloromethane) provided
52 mg
of the title compound: MS(EI) 524 (M+H+).
b.) Naphthylene-2-sulphonyl [(S)-1-(1-benzyl-3-oxo-azepan-4-ylcarbamoyl)-3-
methyl-
butyl]-amide
Following the general procedure of Example 1i except substituting the compound
of Example 6a the title compound was prepared: : 'H NMR (CDCl3): 8 1.0 ( m,
6H), 1.5-2.1
( m, 5H), 2.2 ( m, 2H), 2.7 (m, 1H), 3.0 (dd, 1H). 3.3 (m, 1H), 3.6 (m, 2H),
3.7 ( m, 1H),
4.7 (m, 1H), 5.3 ( m, 1H), 7.2-8.4 (m, 12H): MS(EI): 522 (M+H+,100%)
88
CA 02412353 2002-12-13
WO 01/95911 PCT/USO1/19062
Example 7
Preparation of Quinoline-2-carboxylic acid f(S)-1-(1-benzyl-3-oxo-azepan-4-
ylcarbamoyl)-
3-methyl-butyllamide
a.) Quinoline-2-carboxylic acid [(S)-1-(1-benzyl-3-hydroxy-azepan-4-
ylcarbamoyl)-3-
methyl-butyl]amide
Following the general procedure of Example 2j except substituting 2-
quinolinecarboxylic acid for 2-naphthoic acid the title compound was prepared:
MS(ES)
489 (M+H+)
b.) Quinoline-2-carboxylic acid [(S)-1-(1-benzyl-3-oxo-azepan-4-ylcarbamoyl)-3-
methyl-
butyl]amide
Following the general procedure of Example 1i except substituting the compound
of Example 7a the title compound was prepared: 'H NMR (CDC13): 8 1.0 ( m, 6H),
1.5-2.1
m, 5H), 2.2 ( m, 2H), 2.9 (m, 1H), 3.2 (dd, 1H). 3.4 (m, 1H), 3.7 (m, 2H), 4.7
( m, 1H),
5.2 ( m, 1H), 7.2-8.4 (m, 11H); MS(EI): 487 (M+H+,100%). The diastereomers
were
separated by preparative scale HPLC. Lyophilisation of the eluents provided
diastereomer
l: MS (EI) 492.4 (M+H+), 983.7 2M+H+) and diastereomer 2: MS (EI) 492.4
(M+H+),
983.7 2M+H+).
Example 8
Preparation of 3,4-dichlorobenzoic acid f(S)-1-(1-benzyl-3-oxo-azepan-4-
ylcarbamoyl)-3-
methyl-butyllamide
a.) 3,4-dichlorobenzoic acid [(S)-1-(1-benzyl-3-hydroxy-azepan-4-ylcarbamoyl)-
3-
methyl-butyl]amide
Following the general procedure of Example 2j except substituting 3,4-
dichlorbenzoic acid for 2-naphthoic acid the title compound was prepared:
MS(ES) 506
(M+H+).
89
CA 02412353 2002-12-13
WO 01/95911 PCT/USO1/19062
b.) 3,4-dichlorobenzoic acid [(S)-1-(1-benzyl-3-oxo-azepan-4-ylcarbamoyl)-3-
methyl-
butyl]amide
Following the general procedure of Example 1i except substituting the compound
of Example 8a the title compound was prepared: 'H NMR (CDC13): b 1.0 ( m, 6H),
1.5-2.1
m, 5H), 2.2 ( m, 2H), 2.9 (m, 1H), 3.2 (dd, 1H). 3.4 (m, 1H), 3.7 (m, 2H), 4.7
( m, 2H), 5.2
m, 1H), 7.2-8.4 (m, 8H); MS(EI): 504 (M+,100%) .
Example 9
Preparation of 4-1 (S)-Methyl-2-f (quinoline-2-carbon)-aminolpentanoylamino i-
3-oxo-1-
(3-pyridin-2-yl-phenyl)-acetyll azepanium
a.) 4-((S)-2-tert-Butoxycarbonylamino-4-methyl-pentanoylamino)-3-hydroxy-1-[2-
(3-
pyridin-2-yl-phenyl)-acetyl]-azepanium
To a solution of the compound of Example 2g (0.5g, 1.46 mmol) in CH2C12 was
added EDC (307 mg, 1.60 mmol), HOBt (216 mg, 1.60 mmol) and 3-(2-
pyridyl)phenyl
acetic acid (341 mg, 1.60 mmol). The reaction was stirred at room temperature
until
complete as determined by TLC analysis. Workup and column chromatography (2%
methanol:dichloromethane) provided the title compound: MS(ES) 539 (M+H+).
b.) 4-((S)-Amino-4-methyl-pentanoylamino)-3-hydroxy-1-[2-(3-pyridin-2-yl-
phenyl)-
acetyl]-azepanium
To a solution of the compound of Example 9a (1.3 g) dissolved in methanol (20
mL
was added 4M HCl in dixoane (20 mL). The reaction was stirred until complete
by TLC
analysis whereupon it was concentrated in vacuo to give 1.1 g of the title
compound:
MS(EI) 439 (M+H+).
c.) 4-{(S)-Methyl-2-[(quinoline-2-carbonyl)-amino]pentanoylamino}-3-hydroxy-1-
[2-
(3-pyridin-2-yl-phenyl)-acetyl] azepanium
Following the procedure of Example 7a except substituting the compound of
Example 9b the title compound was prepared: MS(EI) 594 (M+H+)
CA 02412353 2002-12-13
WO 01/95911 PCT/USO1/19062
d.) 4-{(S)-Methyl-2-[(quinoline-2-carbonyl)-amino]pentanoylamino}-3-oxo-1-[2-
(3-
pyridin-2-yl-phenyl)-acetyl] azepanium
Following the procedure of Example 1i except substituting the compound of
Example 9c the title compound was prepared: 'H NMR (CDC13): 8 1.0 ( m, 6H),
1.5-2.1
m, 5H), 2.2 ( m, 2H), 2.9 (m, 1H), 3.4 (dd, 1H). 3.8 (m, 3H), 4.1 (m, 2H), 4.7
( m, 3H),
5.4 ( m, 1H), 7.2-8.4 (m, 14H); MS(EI): 592 (M+H+,100°Io) .
Example 10
IO Preparation of 1-((S)-2-Benz~ycarbonylamino-4-meth~pentyl)-4-~(S)-4-methyl-
2-((2-
quinoiline-2-carbonyl)-aminol-pentanoylamino)-3-oxo-azepanium
a.) 1-((S)-2-Benzyloxycarbonylamino-4-methyl-pentyl)-4-((S)-2-tert-
butoxycarbonylamino-4-methyl-pentanoylamino)-3-hydroxy-azepanium
Following the procedure of Example 2h except substituting Cbz-leucinal for
benzaldehyde the title compound was prepared: MS(EI) 577 (M+H+)
b.) 4-((S)-2-Amino-4-methy-pentanoylamino)-1-((S)-2-tert-benzylxycarbonylamino-
4-
methyl-pentyl)-3-hydroxy-azepanium
Following the procedure of Example 2i except substituting the compound of
Example IOa the title compound was prepared: MS(El] 477 (M+H+)
c.) 1-((S)-2-Benzyloxycarbonylamino-4-methyl-pentyl)-4-{(S)-4-methyl-2-[(2-
quinoiline-2-carbonyl)-amino]-pentanoylamino)-3-hydroxy-azepanium
Following the procedure of Example 7a except substituting the compound of
Example 10b the title compound was prepared: MS(El] 632 (M+H+).
d.) 1-((S)-2-Benzyloxycarbonylamino-4-methyl-pentyl)-4-{(S)-4-methyl-2-[(2-
quinoiline-2-carbonyl)-amino]-pentanoylamino)-3-oxo-azepanium
Following the procedure of Example 1i except substituting the compound of
Example lOc the title compound was prepared: 'H NMR (CDC13): 8 1.0 ( m, 12H),
1.5-2.1
(m, 10H),
91
CA 02412353 2002-12-13
WO 01/95911 PCT/USO1/19062
2.2 ( m, 4H), 2.9 (m, 1H), 3.4 ( M, 2H). 3.7 (m, 1H), 4.7 ( m, 2H), 5.2 ( m,
3H), 7.2 (m,
4H), 7.5 (m, 1H), 7.6 (m, 1H), 7.7 (m, 1H), 8.1 (m, 1H), 8.2 (m, 2H), 8.5 (m,
1H); MS(EI):
630 (M+H+,100%) .
Example 11
Preparation of 1-Benzoyl-4-((S)-2-(benzof 1 3ldioxole-carbonylamino)-4-meth
~~1-
pentanoylamino)-3-oxo-azepanium
a.) 1-Benzoyl-4-((S)-2-tent-butoxycarbonylamino-4-methyl-pentanoylamino)-3-
hydroxy-azepanium
Following the procedure of Example 9a except substituting benzoic acid for 3-
(2-
pyridyl)phenyl acetic acid the title compound was prepared: MS(EI) 448(M+H+)
b.) 4-((S)-2-Amino-4-methyl-pentanoylamino)-1-benzoyl-3-hydroxy-azepanium
Following the procedure of Example 2i except substituting the compound of
Example l la the title compound was prepared: MS(EI) 348 (M+H+)
c.) 1-Benzoyl-4-((S)-2-(benzo[1,3]dioxole-carbonylamino)-4-methyl-
pentanoylamino)-
3-hydroxy-azepanium
Following the procedure of Example 2j except substituting the compound of
Example 1 1b for the compound of Example 2j and piperonylic acid for 2-
naphthoic acid the
title compound was prepared: MS(EI) 496 (M+H+).
d.) 1-Benzoyl-4-((S)-2-(benzo[1,3]dioxole-carbonylamino)-4-methyl-
pentanoylamino)-3-
oxo-azepamum
Following the procedure of Example 1i except substituting the compound of
Example l lc the title compound was prepared: 'H NMR (CDCl3): 8 1.0 ( m, 6H),
1.5-2.1
(m, 5H), 2.2 (m, 2H), 2.9 (m, 1H), 3.2 (dd, 1H). 3.4 (m, 1H), 3.7 (m, 2H), 4.7
( m, 1H),
5.2 ( m, 1H), 6.0 (s, 2H), 7.2-8.4 (m, 8H); MS(EI): 494 (M+H+, 70%).
92
CA 02412353 2002-12-13
WO 01/95911 PCT/USO1/19062
Example 12
Preparation of 1-Benzoyl-4-((S)-2-(4-fluoro-benzoylamino)-4-methyl-
~entanoylamino)-3-
oxo-azepamum
a.) 1-Benzoyl-4-((S)-2-(4-fluoro-benzoylamino)-4-methyl-pentanoylamino)-3-
hydroxy-
azepanium
Following the procedure of Example l lc except substituting 4-fluorobenzoic
acid
for piperonylic acid the title compound was prepared: MS(En 470 (M+H+).
b.) 1-Benzoyl-4-((S)-2-(4-fluoro-benzoylamino)-4-methyl-pentanoylamino)-3-oxo-
azepamum
Following the procedure of Example 1i except substituting the compound of
Example 12a the title compound was prepared: 'H NMR (CDC13): 8 1.0 ( m, 6H),
1.5-2.1
(m, 5H), 2.2 (m, 2H), 2.7 (m, 1H), 3.0 (dd, 1H). 3.6 (m, 1H), 4.0 (m, 2H), 4.7
( m, 1H),
5.2 ( m, 1H), 7.2-8.4 (m, 9H); MS(EI): 468 (M+H+, 10%).
Example 13
Preparation of 3-Oxo-4-((S)-4-methyl-2-4' f5-(2-morpholino-4-yl-ethoxy)-
benzofuran-2-
carbonyllamino 1-pentanoylamino)-1-(4-methyl-pentano~)-azepanium
a.) 4-((S)-2-tart-butoxycarbonylamino-4-methyl-pentanoylamino)-3-hydroxy-1-(4-
methyl-pentanoyl)-azepanium
Following the procedure of Example 9a except substituting iso-caproic acid for
3-
(2-pyridyl)phenyl acetic acid the title compound was prepared: MS(EI) 442
(M+H+)
b.) 4-((S)-2-Amino-4-methyl-pentanoylamino)-3-hydroxy-1-(4-methyl-pentanoyl)-
azepanium
Following the procedure of Example 2i except substituting the compound of
Example 13a the title compound was prepared: MS(EI) 342 (M+H+)
93
CA 02412353 2002-12-13
WO 01/95911 PCT/USO1/19062
c.) 3-~iydroxy-4-((S)-4-methyl-2-{ [5-(2-morpholino-4-yl-ethoxy)-benzofuran-2-
carbonyl] amino }-pentanoylamino)-1-(4-methyl-pentanoyl)-azepanium
To a solution of the compound of Example 13b (200 mg, 0.53 mmol) in
dichloromethane was added EDC (111 mg, 0.58 mmol), HOBt (78 mg, 0.58 mmol),
TEA
(0.11 mL, 0.79 mmol) and 5-(2-morpholin-4-yl-ethyloxy)benzofuran-2-carboxylic
acid.
The reaction was stirred at room temperature until complete as indicated by
TLC analysis.
Workup and column chromatography (5% methanol:dichloromethane) provided 160 mg
of
the title compound: MS(EI) 615 (M+H+).
d.) 3-Oxo-4-((S)-4-methyl-2-{ [5-(2-morpholino-4-yl-ethoxy)-benzofuran-2-
carbonyl]amino}-pentanoylamino)-1-(4-methyl-pentanoyl)-azepanium
Following the procedure of Example 1i except substituting the compound of
Example 13d the title compound was prepared: 'H NMR (CDC13): 8 1.0 ( m, 12H),
1.5-2.1
(m, 8H), 2.2 (m, 2H), 2.3 (m, 1H), 2.4-2.5 (m, 2H), 2.6 (m 5H), 2.7 (m, 2H),
2.9 (m, 1H),
3.4 (m, 1H), 3.7 (m, 4H), 4.1 (m, 2H), 4.5-4.6 (m, 2H), 5.2 ( m, 1H), 7.2-8.4
(m, 4H):
MS(EI): 613 (M+H+,100%). The diastereomers were separated by preparative scale
HPLC.
Lyophilisation of the eluents provided diastereomer 1 and diastereomer 2
Example 14
Preparation of 3-Oxo-4-((S)-4-methyl-2-i f 5-(2-morpholino-4-yl-ethoxy)-
benzofuran-2-
carbonyllamino i-pentanoylamino)-1-benzenesulphon~panium
a.) 1-Benzenesulphonyl-4-((S)-2-tent-butoxycarbonylamino-methyl-
pentanoylamino)-
3-hydroxy-azepanium
To a solution of the amine of Example 2g (0.5 g, 1.4.6 mmol) in
dichloromethane
was added triethylamine (0.4 mL, 2.92 mmol) followed by benzenesulphonyl
chloride (0.28
mL, 2.18 mmol). The reaction was stirred at room temperature until complete as
determined by TLC analysis. Workup and column chromatography (10%
methanol:dichloromethane) provided 450 mg of the title compound: MS(EI) 484
(M+H+)
94
CA 02412353 2002-12-13
WO 01/95911 PCT/USO1/19062
b.) 4-((S)-2-Amino-methyl-pentanoylamino) 1-benzenesulphonyl-3-hydroxy-
azepanium
Following the procedure of Example Zi except substituting the compound of
Example 14a the title compound was prepared: MS(EI) 384 (M+H+).
c.) 3-Hydroxy-4-((S)-4-methyl-2-{ [5-(2-morpholino-4-yl-ethoxy)-benzofuran-2-
carbonyl]amino}-pentanoylamino)-1-benzenesulphonyl-azepanium
Following the procedure of Example 13c except substituting the compound of
Example 14b the title compound was prepared: MS(EI) 657 (M+H+).
d.) 3-Oxo-4-((S)-4-methyl-2-{ [5-(2-morpholino-4-yl-ethoxy)-benzofuran-2-
carbonyl]amino }-pentanoylamino)-1-benzenesulphonyl-azepanium
Following the procedure of Example 1i except substituting the compound of
Example 14c the title compound was prepared: 'H NMR (CDC13): 8 1.0 ( m, 6H),
1.5-2.1
(m; 5H), 2.2 (m, 2H), 2.4 (m, 1H), 2.7 (m, 4H), 2.8 (m, 2H), 3.5 (m, 1H), 3.8
(m, 4H),
4.0 (m, 1 H), 4.1 (m, 2H), 4.4 (m, 1 H), 4.5 (m, 1 H), 4.7 (m, 1 H), 5.1 ( m,
1 H), 7.0 (m,
3H), 7.3 (m, 2H), 7.5 (m, 3H), 7.7 (m, 2H): MS(EI): 655 (M+H+,100°l0) .
Analysis of the diastereomeric mixture by analytical HPLC (40:60 to 45:55
CH3CN:20 mm KHP04 (pH 7 buffer) 60 min. gradient 1 mL/min.; inertsil ODS-3
column
4.6 x 250 mm; LTV detection at 215 nM) showed two peaks (Rt = 44.6 rains. and
45.9
rains). The diastereomers were separated by preparative scale HPLC (40:60 to
50:50
CH3CN: mm KIIP04 (pH 7 buffer)gradient, 12 mL/min., 60 rains; inertsil ODS-3
column
250 x 20 mm; LTV detection at 215 nM). Lyophilisation of the eluents provided
diastereomer 1 (anal. Rt = 44.6 rains.) and diastereomer 2 (anal. Rt = 45.9
rains).
CA 02412353 2002-12-13
WO 01/95911 PCT/USO1/19062
Example 15
Preparation of 4-((S)-4-Methyl-2-~ f 5-(2-morpholino-4 yl-ethoxy)-benzofuran-2-
carbonyllamino~-pentanoylamino)-3-oxo-azepane-1-carboxylic acid phenylamide
a.) [(S)-1-(3-Hydroxy-I-phenylcarbamoyl-azepan-4-ylcarbamoyl)-3-methyl-butyl]-
carbamic acid tert-butyl ester
To a solution of the amine of Example 2g (0.5 g, 1.46 mmol) in dichloromethane
(20 mL) was added phenyl isocyanate (0.24 mL, 2.18 mmol). The reaction was
stirred at
room temperature until complete as determined by TLC analysis. Workup and
column
chromatography (5% methanol:dichloromethane) provided 578 mg of the title
compound:
MS(EI) 463 (M+H+).
b.) 4-((S)-2-Amino-methyl-pentanoylamino)-3-hydroxy-azepane-1-carboxylic acid
phenyl amide
Following the procedure of Example 2i except substituting the compound of
Example 15a the title compound was prepared: MS(EI) 363 (M+H+).
c.) 3-Hydroxy-4-((S)-4-Methyl-2-{ [5-(2-morpholino-4-yl-ethoxy)-benzofuran-2-
carbonyl]amino}-pentanoylamino)-azepane-1-carboxylic acid phenylamide
Following the procedure of Example 13c except substituting the compound of
Example 15b the title compound was prepared: MS(EI) 636 (M+H+).
d.) 4-((S)-4-Methyl-2-{[5-(2-morpholino-4-yl-ethoxy)-benzofuran-2-
carbonyl]amino}-
pentanoylamino)-3-oxo-azepane-1-carboxylic acid phenylamide
Following the procedure of Example 1i except substituting the compound of
Example 15c the title compound was prepared: 'H NMR (CDCl3): ): ~ I.0 ( m,
6H), 1.5-2.1
( m, 5H), 2.2 (m, 2H), 2.7 (m, 4H), 3.0 (m, 2H), 3.1 (m, 1H), 3.8 (m, 1H), 3.9
(m, 4H),
4.2 (m, 1H), 4.3 (m, 2H), 4.9 (m, 2H), 5.2 ( m, 1H), 7.2-8.4 (m, 9H): MS(EI):
634
(M+H+,100%)
Analysis of the diastereomeric mixture by analytical HPLC (40:60 CH3CN:20 mM
KHP04 (pH 7 buffer) isocratic, 1 mL/min.; inertsil ODS-3 column 4.6 x 250 mm;
UV
96
CA 02412353 2002-12-13
WO 01/95911 PCT/USO1/19062
detection at 215 nM) showed two peaks (Rt = 27.3 mins. and 30.1 mins). The
diastereomers were separated by preparative scale HPLC (40:60 to 50:50 CH3CN:
20 mM
KIIP04 (pH 7 buffer) gradient, 12 mL/min., 60 rains; inertsil ODS-3 column 250
x 20 mm;
LTV detection at 215 nM). Lyophilisation and desalting of the eluents by
NaHC03:ethyl
acetate extraction provided diastereomer 1 (anal. Rt = 27.3 rains.) and
diastereomer 2
(anal. Rt = 30.1 rains).
Example 16
Preparation of 5-(2-Morpholino-4-yl-ethoxy)-benzofuran-2-carboxylic acid ((S)-
3-methyl-1-
~3-oxo-1-f2-(3-pyridin-2- ~~1-phenyl)ace~ll-azepan-4-ylcarbamoyl~-butyl)amide
a.) 5-(2-Morpholino-4-yl-ethoxy)-benzofuran-2-carboxylic acid ((S)-3-methyl-1-
{3-
hydroxy-1-[2-(3-pyridin-2-yl-phenyl)acetyl]-azepan-4-ylcarbamoyl }-butyl)amide
Following the procedure of Example 13c except substituting the compound of
Example 9b the title compound was prepared: MS(EI) 712 (M+H+).
b.) 5-(2-Morpholino-4-yl-ethoxy)-benzofuran-2-carboxylic acid ((S)-3-methyl-1-
{3-
oxo-1-[2-(3-pyridin-2-yl-phenyl)acetyl]-azepan-4-ylcarbamoyl }-butyl)amide
Following the procedure of Example 1i except substituting the compound of
Example 16c the title compound was prepared: 'H NMR (CDCl3): ): ~ 1.0 ( m,
6H), 1.5-2.1
( m, 5H), 2.2 ( m, 2H), 2.7 (m, 4H), 2.8 (m, 2H), 2.9 (m, 1H), 3.5 (m, 1H),
3.7 (m, 4H),
3.9 (m, 3H), 4.3 (m, 2H), 4.7 (m, 2H), 5.4 ( m, 1H), 7.2-8.0 (m, 13H), 8.5 (m,
1H);
MS(EI): 710 (M+H+,100%) MS(EI).
Analysis of the diastereomeric mixture by analytical HPLC (40:60 CH3CN:20 mM
KHP04 (pH 7 buffer) isocratic, 1 mL/min.; inertsil ODS-3 column 4.6 x 250 mm;
UV
detection at 215 nM) showed two peaks (Rt = 33.9 rains. and 37.9 rains). The
diastereomers were separated by preparative scale HPLC (40:60 to 45:55 CH3CN:
20 mM
KHP04 (pH 7 buffer) gradient, 12 mL/min., 60 rains; inertsil ODS-3 column 250
x 20 mm;
LTV detection at 215 nM). Lyophilisation and desalting of the eluents by
NaHC03:ethyl
acetate extraction provided diastereomer l: MS(EI) 710.3 (M+H+) (anal. Rt =
33.9 rains.)
and diastereomer 2: MS(EI) 710.3 (M+H+) (anal. Rt = 37.9 rains).
97
CA 02412353 2002-12-13
WO 01/95911 PCT/USO1/19062
Example 17
Preparation of 5-(2-Morpholino-4-yl-ethoxy)-benzofuran-2-carboxylic acid f(S)-
1-(benzoyl-
3-oxo-azepan-4-ylcarbamoyl)-3-meth~yllamide
a.) 5-(2-Morpholino-4-yl-ethoxy)-benzofuran-2-carboxylic acid [(S)-1-(benzoyl-
3-
hydroxy-azepan-4-ylcarbamoyl)-3-methyl-butyl] amide
Following the procedure of Example 13c except substituting the compound of
Example l 1b the title compound was prepared: MS(EI) 621 (M+H+)
b.) 5-(2-Morpholino-4-yl-ethoxy)-benzofuran-2-carboxylic acid [(S)-1-(benzoyl-
3-
oxo-azepan-4-ylcarbamoyl)-3-methyl-butyl] amide
Following the procedure of Example 1i except substituting the compound of
Example 17a the title compound was prepared: 'H NMR (CDCl3): 8 1.0 ( m, 6H),
1.5-2.1
m, SH), 2.2 (m, 2H), 2.7 (m, 4H), 2.9 (m, 2H), 3.0 (m, 1H), 3.7 (m, 5H), 4.0
(m, 1H), 4.1
(m, 2H), 4.7 (m, 2H), 5.4 ( m, 1H), 7.2-8.4 (m, 11H): MS(EI): 619 (M+H+,100%).
Analysis of the diastereomeric mixture by analytical HPLC (40:60 to 55:45
CH3CN:20 mM KHP04 (pH 7 buffer) 30 min. gradient, 1 mL/min.; inertsil ODS-3
column
4.6 x 250 mm; UV detection at 215 nM) showed two peaks (Rt = mins. 13.5 and
17.6
mins). The diastereomers were separated by preparative scale HPLC (40:60 to
45:55
CH3CN: mM KHPO4 (pH 7 buffer) 60 min. gradient, 15 mL/min., 60 mins; inertsil
ODS-3
column 250 x 20 mm; UV detection at 215 nM). Lyophilisation and desalting of
the
eluents by NaHC03:ethyl acetate extraction provided diastereomer 1 (anal. Rt =
13.5
mins.) and diastereomer 2 (anal. Rt = 17.6 mins).
98
CA 02412353 2002-12-13
WO 01/95911 PCT/USO1/19062
Exam 1p a 18
Preparation of 5-(2-Pyrrolidin-1 yl-ethoxy)-benzofuran-2-carboxylic acid f(S)-
1-(1-
benzenesulfonyl-3-oxo-azepan-4-ylcarbamoyl)-3-methyl-but~ll amide
a.) 5-(2-Pyrrolidin-1-yl-ethoxy)-benzofuran-2-carboxylic acid [(S)-1-(1-
benzenesulfonyl-
3-hydroxy-azepan-4-ylcarbamoyl)-3-methyl-butyl] amide
Following the procedure of Example 14c except substituting 5-(2-pyrrolidin-1-
yl-
ethyloxy)-benzofuran-2-carboxylic acid for 5-(2-morpholin-4-yl-
ethyloxy)benzofuran-2-
carboxylic acid the title compound was prepared: MS(EI) 641 (M+H+).
b.) 5-(2-Morpholino-4-yl-ethoxy)-benzofuran-2-carboxylic acid [(S)-1-(benzoyl-
3-
oxo-azepan-4-ylcarbamoyl)-3-methyl-butyl] amide
Following the procedure of Example 1i except substituting the compound of
Example 18a the title compound was prepared: 'H NMR (CDC13): ~ 1.0 ( m, 6H),
1.5-2.1
(m, 9H), 2.2 ( m, 2H), 2.5 (m, 1H), 2.7 (m, 4H), 3.0 (m, 2H), 3.4 (m, 1H), 4.0
(m, 1H),
4.1 (m, 2H), 4.5 (m, 1H), 4.6 (m, 1H), 5.0 ( m, 1H), 7.2-8.4 (m, 11H): MS(EI):
639
(M+H+,100%) .
Example 19
Preparation of 5-(2-Piperidin-1-yl-ethoxy)-benzofuran-2-carboxylic acid ~(S)-1-
(1-
benzenesulfonyl-3-oxo-azepan-4~lcarbamoyl)-3-methyl-butyll amide
a.) 5-(2-Piperidin-1-yl-ethoxy)-benzofuran-2-carboxylic acid [(S)-1-(1-
benzenesulfonyl-3-
oxo-azepan-4-ylcarbamoyl)-3-methyl-butyl] amide
Following the procedure of Example 14c except substituting 5-(2-piperidin-1-yl-
ethyloxy)-benzofuran-2-carboxylic acid for 5-(2-morpholin-4-yl-
ethyloxy)benzofuran-2-
carboxylic acid the title compound was prepared: MS(EI) 655 (M+H+)
99
CA 02412353 2002-12-13
WO 01/95911 PCT/USO1/19062
b.) 5-(2-Piperidin-1-yl-ethoxy)-benzofuran-2-carboxylic acid [(S)-1-(1-
benzenesulfonyl-3-
hydroxy-azepan-4-ylcarbamoyl)-3-methyl-butyl] amide
Following the procedure of Example 1i except substituting the compound of
Example 18a the title compound was prepared: 'H NMR (CDC13): 8 1.0 ( m, 6H),
1.5-2.1
(m, 11H), 2.2 (m, 2H), 2.5 (m, 5H), 2.7 (m, 2H), 3.5 (m, 1H), 4.0 (m, 1H), 4.1
(m, 2H),
4.5 (m, 1H), 4.6 (m, 1H), 5.0 (m, 1H), 7.2-8.4 (m, 11H): MS(EI): 653
(M+H+,100%) .
Example 20
Preparation of 5-(2-Morpholino-4-yl-ethoxy)-benzofuran-2-carboxylic acid ((S)-
3-meth ~~l-
1-~ 3-oxo-1-f 2-(3-pyridin-2-yl-phenyl)ethyll-azepan-4-ylcarbamoyl ~-
butyl)amide
a.) 5-(2-morpholin-4-yl-ethyloxy)benzofuran-2-carboxylic acid methoxy methyl
amide
To a solution of 3-(2-pyridyl)phenyl acetic acid (1g) in dichloromethane was
added
N, O-dimethylhydroxylamine hydrochloride (0.92 g), triethylamine (1.3 mL),
HOBt (0.96
g) and EDC (1.1 g). The reaction was stirred until complete. Workup and column
chromatography (40% .ethyl acetate:hexanes provided 1.1 g of the title
compound: MS(EI)
257 (M+H+).
b.) 5-(2-morpholin-4-yl-ethyloxy)benzofuran-2-carbaldehyde
To a solution of 5-(2-morpholin-4-yl-ethyloxy)benzofuran-2-carboxylic acid
methoxy methyl amide (0.2 g) of Example 20a in THF was added LAH (2.0 mL of a
1 M
solution in THF). The reaction was stirred until complete consumption of the
starting
material. Workup gave 160 mg of the title compound.
c.) ((S)-{3-hydroxy-1-[2-(3-pyridin-2-yl-phenyl)-ethyl]-azepan-4-ylcarbamoyl}-
3-methyl-
butyl)-carbamic acid ter-t butyl ester
Following the general procedure of Example 2g except substituting 5-(2-
morpholin-4-yl-ethyloxy)benzofuran-2-carbaldehyde for benzaldehyde the title
compound
was prepared: MS(EI) 525 (M+H+)
100
CA 02412353 2002-12-13
WO 01/95911 PCT/USO1/19062
d.) (S)-2-Amino-4-methyl-pentanoic acid-{3-hydroxy-1-[2-(3-pyridin-2-yl-
phenyl)-ethyl]-
azepan-4-yl}-amide
Following the procedure of Example 2i except substituting the compound of
Example 20c the title compound was prepared.
e.) 5-(2-Morpholino-4-yl-ethoxy)-benzofuran-2-carboxylic acid ((S)-3-methyl-1-
{ 3hydroxy--I-[2-(3-pyridin-2-yl-phenyl)ethyl]-azepan-4-ylcarbamoyl }-
butyl)amide
Following the procedure of Example 13c except substituting the compound of
Example 20d the title compound was prepared.
f.) 5-(2-Morpholino-4-yl-ethoxy)-benzofuran-2-carboxylic acid ((S)-3-methyl-1-
{3-oxy-
1-[2-(3-pyridin-2-yl-phenyl)ethyl]-azepan-4-ylcarbamoyl }-butyl)amide
Following the procedure of Example Ii except substituting the compound of
Example 20e the title compound was prepared: 'H NMR (CDC13): 8 1.0 ( m, 6H),
1.5-2.1
(m, 5H), 2.2 (m, 2H), 2.7 (m, 4H), 2.8 (m, 6H), 3.1 (m, 1H), 3.3 (m, 1H), 3.5
(m, 1H),
3.7 (m, 4H), 4.2 (m, 3H), 4.6 (m, 1H), 5.2 ( m, 1H), 7.2-8.4 (m, 13H), 8.6 (m,
1H);
MS(EI): 696 (M+H+, 80°Io).
The diastereomeric mixture was separated by HPLC to provide the faster eluting
diastereoemer; MS(EI): 696 (M+H+, 100%), and the slower eluting diastereomer;
MS(EI):
696 (M+H+, 100%).
Example 21
Preparation of Naphthlene-2-carboxylic acid ((S)-3-methyl-1- 3-oxo-1-f2-(3-
pyridin-2-yl-
hen l~yll-azepan-4-ylcarbamoyl?-but~)amide
a.) Naphthlene-2-carboxylic acid ((S)-3-methyl-I-{3-hydroxy-1-[2-(3-pyridin-2-
yI-
phenyl)ethyl]-azepan-4-ylcarbamoyl }-butyl)amide
Following the procedure of Example 20f except substituting 2-naphthoic acid
for 5-
(2-morpholin-4-yl-ethyloxy)benzofuran-2-carboxylic acid the title compound was
prepared:
MS(EI) 579 (M+H+)
101
CA 02412353 2002-12-13
WO 01/95911 PCT/USO1/19062
b.) Naphthlene-2-carboxylic acid ((S)-3-methyl-1-{3-oxo-1-[2-(3-pyridin-2-yl-
phenyl)ethyl]-azepan-4-ylcarbamoyl }-butyl)amide
Following the procedure of Example 1i except substituting the compound of
Example 21b the title compound was prepared: 'H NMR (CDCl3): 8 1.0 ( m, 6H),
1.5-2.1
(m, 6H), 2.2 (m, 2H), 2.9 (m, 4H), 3.0 (m, 1H), 3.4 (d, 1H). 3.5 (m, 1H), 4.7
( m, 1H),
5.0 ( m, 1H), 6.8-7.2 (m, 6H), 7.3 (m, 1H), 7.5 (m, 2H), 7.9 ( m, 6H), 8.2 (M,
1H), 8.7
(m, 1H): MS(EI):577 (M+H+,100°Io) .
Example 22
Preparation of 1H-Indole-2-carboxylic acid ((S)-3-meth-1-{3-oxo-1-f2~3-pyridin-
2-yl-
phenyl)ethyll-azepan-4-ylcarbamoyll-butyl)amide
a.) ((S)-3-methyl-1-{3-hydroxy-1-[2-(3-pyridin-2-yl-phenyl)ethyl]-azepan-4-
ylcarbamoyl}-butyl)amide
Following the procedure of Example 20f except substituting 1H-indole-2-
carboxylic acid for 5-(2-morpholin-4-yl-ethyloxy)benzofuran-2-carboxylic acid
the title
compound was prepared: MS(EI) 568 (M+H+)
b.) ((S)-3-methyl-1-{3-oxo-1-[2-(3-pyridin-2-yl-phenyl)ethyl]-azepan-4-
ylcarbamoyl }-butyl)amide
Following the procedure of Example 1i except substituting the compound of
Example 22b the title compound was prepared: : 'H NMR (CDC13): ): 8 1.0 ( m,
6H), 1.5-
2.1 ( m, 5H), 2.2 (m, 2H), 2.9 (m, 4H), 3.0 (m; 1H), 3.4 (d, 1H). 3.5 (m, 1H),
4.7 ( m,
1H), 5.0 ( m, 1H), 6.8-7.2 (m, 6H), 7.0-7.9 (m, 12H), 8.7 (m, 1H), 9.5 (m,
1H): MS(EI):
566 (M+H+,100010)
102
CA 02412353 2002-12-13
WO 01/95911 PCT/USO1/19062
Example 23
Preparation of 1H-Indole-2-carboxylic acid f(S)-1~1-benzenesulfonyl-3-oxo-
azepan-4-
ylcarbamo~)-3-methyl-but ~~llamide
a.) 1H-Indole-2-carboxylic acid [(S)-1-(1-benzenesulfonyl-3-hydroxy-azepan-4-
ylcarbamoyl)-3-methyl-butyl] amide
Following the procedure of Example 2j except substituting the compound of
Example 14b and substituting 1H-indole-2-carboxylic acid for naphthoic acid
the title
compound was prepared: MS(EI) 527 (M+H+).
b.) 1H-Indole-2-carboxylic acid [(S)-1-(1-benzenesulfonyl-3-oxo-azepan-4-
ylcarbamoyl)-3-
methyl-butyl]annide
Following the procedure of Example 1i except substituting the compound of
Example 23b the title compound was prepared: 'H NMR (CDC13): 8 1.0 ( m, 6H),
1.5-2.1
(m, 5H), 2.2 (m, 2H), 2.5 (m, 1H), 3.5 (dd, 1H). 3.9 (m, 1H), 4.5 (dd, 2H),
4.7 (m, 1H),
5.0 ( m, 1H), 7.2 -7.6 (m, 10H). 9.5 (b, 1H); MS(EI): 525 (M+H+, 10%).
Example 24
Preparation of Benzofuran-2-carboxylic acid f(S)-1-(1-benzenesulfonyl-3-oxo-
azepan-4-
ylcarbamoyl)-3-methyl-butyl amide
a.) Benzofuran-2-carboxylic acid [(S)-1-(1-benzenesulfonyl-3-hydroxy-azepan-4-
ylcarbamoyl)-3-methyl-butyl]amide
Following the procedure of Example 23a except substituting benzofuran-2-
carboxylic acid for 1H-indole 2-carboxylic acid the title compound was
prepared: MS(EI)
528 (M+H+).
b.) Benzofuran-2-carboxylic acid [(S)-1-(1-benzenesulfonyl-3-oxo-azepan-4-
ylcarbamoyl)-3-methyl-butyl] amide
Following the procedure of Example 1i except substituting the compound of
Example 24b the title compound was prepared: 'H NMR (CDC13): 8 1.0 ( m, 6H),
1.5-2.1
103
CA 02412353 2002-12-13
WO 01/95911 PCT/USO1/19062
(m, 5H), 2.2 (m, 2H), 2.6 (m, 1H), 3.5 (d, 1H). 4.1 (m, 1H), 4.7 ( m, 2H), 5.0
( m, 1H),
7.2-7.2 (m, 10H).
Example 25
Preparation of Benzofuran-2-carboxylic acid f(S)-3-methyl-1-(3-oxo-1-f2-(3-
pyridin-2-yl-
phenyl)ethyll-azepan-4-ylcarbam~ll-butyl)amide
a.) Benzofuran-2-carboxylic acid [(S)-3-methyl-1-{3-hydroxy-1-[2-(3-pyridin-2-
yl-
phenyl)ethyl]-azepan-4-ylcarbamoyl }-butyl)amide
Following the procedure of Example 20e except substituting benzofuran-2-
carboxylic acid for 5-(2-morpholin-4-yl-ethyloxy)benzofuran-2-carboxylic the
title
compound was prepared: MS(EI) 569 (M+H+).
b.) Benzofuran-2-carboxylic acid [(S)-3-methyl-1-{ 3-oxo-1-[2-(3-pyridin-2-yl-
phenyl)ethyl]-azepan-4-ylcarbamoyl }-butyl)amide
Following the procedure of Example 1i except substituting the compound of
Example 25b the title compound was prepared: 'H NMR (CDC13): 8 1.0 (m, 6H),
1.5-2.1
(m, 5H), 2.2 (m, 2H), 2.7 (m, 5H), 3.0 (m, 1H). 3.3 (m, 1H), 3.5 (m, 1H), 4.7
(m, 1H), 5.2
(m, 1H), 7.2-7.7 (m, 14H), 8.7 (m, 1H); MS(EI): 567 (M+H+,100%)
The diastereomeric mixture was separated by HPLC to provide the faster eluting
diastereoemer; MS(EI): 656 (M+H+,100%), and the slower eluting diastereomer;
MS(EI):
656 (M+H+,100%).
Example 26
Preparation of 5-(2-Morpholino-4-yl-ethoxy)-benzofuran-2-carboxylic acid f(S)-
3-methyl-1-
~3-oxo-1- henethyl-azepan-4-ylcarbamo 1~-butyllamide
Following the procedures of Examples 20c-f except substituting
phenylacetaldehyde for 5-(2-morpholin-4-yl-ethyloxy)benzofuran-2-carbaldehyde
of
Example 20c the title compound was prepared: 'H NMR (CDC13): 8 1.0 ( m, 6H),
1.5-2.1
(m, 5H), 2.2 ( m, 2H), 2.4 (m, 1H), 2.6 (m,4H), 2.7 (m, 6H), 3.0 (m, 1H), 3.3
(dd, 1H), 3.5
104
CA 02412353 2002-12-13
WO 01/95911 PCT/USO1/19062
(q, 1H), 3.7 ( m, 4H). 4.2 (m, 2H), 4.7 (m,lH), 5.0 ( m, 1H), 7.2-7.2 (m,
11H); MS(EI):
619 (M+H+, 80%)
The diastereomeric mixture was separated by HPLC to provide the faster eluting
diastereoemer; MS(EI): 619 (M+H+,100%), and the slower eluting diastereomer;
MS(EI):
619 (M+H+,100%).
Example 27
Preparation of Naphthylene-2-carboxylic acid f(S)-3-methyl-1-(3-oxo-1-
phenethyl-azepan-
4-ylcarbamoyll-butyllamide
Following the procedures of Examples 2h-k except substituting
phenylacetaldehyde
for benzaldehyde of Example 2h the title compound was prepared: 'H NMR
(CDC13): 8 1.0
( m, 6H), 1.5-2.1 ( m, 5H), 2.2 ( m, 2H), 2.4 (m, 1H), 2.7 (m, 4H), 3.0 (m,
1H), 3.7 (d, 1H),
~ 3.5 (q, 1H), 4.7 ( m, 1H), 5.1 ( m, 1H), 6.9 -7.2 (m, 7H), 7.5 (m, 2H), 7.9
( m, 4H) 8.4
(m, 1H); MS(EI): 500 (M+H+,100%) .
Example 28
Preparation of Benzofuran-2-caxbox lic acid (S)-3-methyl-1-f3-oxo-l~pyridine-2-
sulfonxl)-azepan-4-ylcarbamoyll-butyl 1 amide
a.) (S)-2-Amino-4-methyl-pentanoic acid [3-hydroxy-1-(pyridine-2-sulfonyl)-
azepan-4-yl]-
amide
Following the procedure of Examples 14a-b except substituting 2-
pyridinesulfonyl
chloride for benzenesulfonyl chloride of Example 14a the title compound was
prepared:
MS(EI) 385 (M+H+).
b.) Benzofuran-2-carboxylic acid {(S)-3-methyl-1-[3-hydroxy-1-(pyridine-2-
sulfonyl)-
azepan-4-ylcarbamoyl]-butyl}amide
To a solution of (S)-2-amino-4-methyl-pentanoic acid [3-hydroxy-1-(pyridine-2-
sulfonyl)-azepan-4-yl]-amide of Example 28a (0.15 g) in dichloromethane was
added TEA
(0.11 mL), HOBt (49 mg), EDC (69 mg) and benzofuran-2-carboxylic acid (58 mg).
The
105
CA 02412353 2002-12-13
WO 01/95911 PCT/USO1/19062
reaction was stirred until complete. Workup and column chromatography (5%
methanol:ethyl acetate) provided the title compound: MS(EI) 529 (M+H+).
c.) Benzofuran-2-carboxylic acid {(S)-3-methyl-1-[3-oxo-1-(pyridine-2-
sulfonyl)-azepan-4-
ylcarbamoyl]-butyl}amide
Following the procedure of Example 1i except substituting the compound of
Example 28b the title compound was prepared: 'H NMR (CDC13): 8 1.0 ( m, 6H),
1.5-2.1
(m, 5H), 2.2 (m, 2H), 2.7 (m, 1H), 3.7 (dd, 1H). 4.0 (m, 1H), 4.7 (m, 2H), 5.0
(m, 1H),
7.2-7.3 (m, 3H), 7.4 (m, 4H), 7.6 (m, 1H), 8.0 ( m, 2H), 8.7 (m, 1H); MS(EI):
527
(M+H'~, 40%).
The diastereomeric mixture was separated by HPLC to provide the faster eluting
diastereoemer; 'HNMR: 8 1.0 (m, 6H), 1.5-2.1 (m, 5H), 2.2 (m, 2H), 2.7 (t,
IH), 3.7 (d,
1H); 4.0 (d, 1H), 4.7 (m, 2H), 5.0 (m, 1H), 7.2-7.3 (m, 3H), 7.4 (m, 4H), 7.6
(m, 1H), 8.0
(m, 2H), 8.7 (m, 1H); MS(EI): 527 (M+H+, 100%), and the slower eluting
diastereomer;
I5 'HNMR: 8 1.0 (m, 6H), 1.5-2.1 (m, 5H), 2.2 (m, 2H), 2.7 (t, 1H), 3.7 (d,
1H); 4.0 (d, 1H),
4.7 (m, 2H), 5.0 (m, 1H), 7.2-7.3 (m, 3H), 7.4 (m, 4H), 7.6 (m, 1H), 8.0 (m,
2H), 8.7 (m,
1H); MS(EI): 527 (M+H+, 100%).
Example 29
Preparation of Naphthylene-2-carboxylic acid 1 (S)-3-methyl-1-f 3-oxo-1-
(pyridine-2-
sulfonyl)-azepan-4-ylcarbamoyll-butyl amide
a.) Naphthylene-2-carboxylic acid { (S)-3-methyl-1-[3-hydroxy-1-(pyridine-2-
sulfonyl)-
azepan-4-ylcarbamoyl]-butyl}amide
Following the procedure of Example 28b except substituting 2-naphthoic acid
for
benzofuran-2-carboxylic acid the title compound was prepared: MS(EI) 539
(M+H+)
b.) Naphthylene-2-carboxylic acid { (S)-3-methyl-1-[3-oxo-1-(pyridine-2-
sulfonyl)-
azepan-4-ylcarbamoyl]-butyl}amide
Following the procedure of Example 1i except substituting the compound of
Example 29a the title compound was prepared: 'H NMR (CDCl3): b 1.0 ( m, 6H),
1.5-2.1
(m, 5H), 2.2 ( m, 2H), 2.7 (m, 1H), 3.7 (dd, 1H). 4.0 (m, 1H), 4.7 ( m, 2H),
5.0 ( m, 1H),
106
CA 02412353 2002-12-13
WO 01/95911 PCT/USO1/19062
7.2-7.3 (m, 2H), 7.5 (m, 3H), 7.9 (m, 6H), 8.3 ( m, 1H), 8.4 (m, 1H); MS(EI):
537
(M+H+, 50%).
The diastereomeric mixture was separated by HPLC to provide the faster eluting
diastereoemer; MS(EI): 537 (M+H+, 100%), and the slower eluting diastereomer;
MS(EI):
537 (M+H+, 100%).
Example 30
Preparation of 5-(2-Morpholino-4-yl-ethoxy)-benzofuran-2-carboxylic acid ( S)-
3-methyl-
1-f3-oxo-1-(pyridine-2-sulfonyl)-azepan-4-ylcarbamo 1~~1)amide
a.) 5-(2-Morpholino-4-yl-ethoxy)-benzofuran-2-carboxylic acid { (S)-3-methyl-1-
[3-
hydroxy-1-(pyridine-2-sulfonyl)-azepan-4-ylcarbamoyl]-butyl } amide
Following the procedure of Example 13c except substituting the compound of
Example 28a the title compound was prepared: MS(EI) 658 (M+H+)
b.) 5-(2-Morpholino-4-yl-ethoxy)-benzofuran-2-carboxylic acid { (S)-3-methyl-1-
[3-oxo-1-
(pyridine-2-sulfonyl)-azepan-4-ylcarbamoyl]-butyl } amide
Following the procedure of Example 1i except substituting the compound of
Example 29a the title compound was prepared: 'H NMR (CDCl3): ~ 1.0 (m, 6H),
1.5-2.1 m,
5H), 2.2 (m, 2H), 2.7 (m, 1H), 3.5 ( m, 4H). 3.7 (m, 6H), 4.1 (m, 1H), 4.5 (m,
2H), 4.7 (m,
2H), 5.0 (m, 1H), 7.2-7.3 (m, 4H), 7.4 (m, 2H), 8.0 (m, 2H), 8.7 (m, 1H), 8.7
(m, 1H);
MS(EI): 656 (M+H+,100%) .
The diastereomeric mixture was separated by HPLC to provide the faster eluting
diastereoemer; MS(EI): 656 (M+H+, 100%), and the slower eluting diastereomer;
MS(EI):
656 (M+H+, 100%).
107
CA 02412353 2002-12-13
WO 01/95911 PCT/USO1/19062
Example 31
Preparation of 4-((S)-4-Methyl-2-j f (5-(2-morpholino-4 yl-ethoxy)-benzofuran-
2-carbonyll-
aminol-pentanoylamino)-3-oxo-azepane-1-carboxylic acid tart-butyl ester
a.) 4-((S)-2-Amino-4-methyl-pentanoylamino)-3-hydroxy-azepane-1-carboxylic
acid
tart-butyl ester
To a solution of the compound of Example if (0.89 g) in ethyl acetate:methanol
(30
mL of a 2:1 mixture ) was added 10 % Pd/C and a balloon of hydrogen gas was
attached.
The reaction was stirred until complete by TLC analysis whereupon it was
filtered and
concentrated to provide the title compound (0.57 g).
b.) 4-((S)-4-Methyl-2-{ [(5-(2-morpholino-4-yl-ethoxy)-benzofuran-2-carbonyl]-
amino }-pentanoylamino)-3-hydroxy-azepane-1-carboxylic acid tart-butyl ester
Following the procedure of Example 13c except substituting the compound of
Example 3Ia the title compound was prepared.
c.) 4-((S)-4-Methyl-2-{ [(5-(2-morpholino-4-yl-ethoxy)-benzofuran-2-carbonyl]-
amino}-pentanoylamino)-3-oxo-azepane-1-carboxylic acid tart-butyl ester
Following the procedure of Example 1i except substituting the compound of
Example 31b the title compound was prepared: 'H NMR (CDC13): ~ 1.0 (m, 6H),
1.5 (m,
9H), 1.7 (m, 5H), 2.2 (m, 2H), 2.5 (m, 5H), 2.7 (m, 2H), 3.5 (m , 1H). 3.8 (m,
4H), 4.1 (m,
3H), 4.2 (m, 1H), 4.7 (m, 2H), 5.0 (m, 1H), 7.2-7.3 (m, 5H); MS(EI): 615
(M+H+,100°Io) .
Example 32
Preparation of 4-((S)-4-Methyl-2~ f (5-(2-morpholino-4-yl-ethoxv)-benzofuran-2-
carboxylic
acid f(S)-3-methyl-1-(3-oxo-azepan-4-ylcarbamoyll-butyl~amide
To a solution of the compound of Example 31c in THF (5 mL) was added 1M HCl
in ether (5 mL). Th reaction was stirred overnight whereupon it was
concentrated to
provide the title compound: 'H NMR (CDC13): ~ 1.0 (m, 6H), 1.5-2.1 (m, 5H),
2.2 (m, 2H),
108
CA 02412353 2002-12-13
WO 01/95911 . PCT/USO1/19062
2.7 (m, 4H), 3.2 (dd, 3H). 3.7 (m, 6H), 4.0 (m, 3H), 4.5 (m, 2H), 5.0 (m, 1H),
7.2-7.3 (m,
6H); MS(EI): 515 (M+H+,100%) .
Example 33
Preparation of 4-Methyl-pentanoic acid ~3-oxo-1-f2-(3-pyridin-2-yl-phenyl-
acetyll-azepan-
4-yl l-amide
a.) 3-Hydroxy-4-(4-methyl-pentanoylamino)-azepane-1-carboxylic acid tert-butyl
ester
Following the procedure of Example if except substituting 4-methylpentanoic
acid
for Cbz-leucine the title compound was prepared: MS(EI) 329 (M+H+)
b.) 4-Methyl pentanoic acid (3-hydroxy-azepan-4-yl)-amide
To a solution of the compound of Example 33a (200 mg) in methanol (5 mL) was
added 4M HCl dioxane (5 mL). The reaction was stirred until complete whereupon
it was
concentrated to provide the title compound (132 mg): MS(EI) 229 (M+H+).
c.) 4-Methyl-pentanoic acid {3-hydroxy-1-[2-(3-pyridin-2-yl-phenyl-acetyl]-
azepan-4-yl}
amide
Following the procedure of Example 9a except substituting the compound of
Example 33b the title compound was prepared: MS(En 424 (M+H+).
d.) 4-Methyl-pentanoic acid {3-oxo-1-[2-(3-pyridin-2-yl-phenyl-acetyl]-azepan-
4-yl}-
amide
Following the procedure of Example 1i except substituting the compound of
Example 33c the title compound was prepared: 'H NMR (CDC13 ) ~ 1.0 (m, 6H),
1.5-2.1
(m, 5H), 2.2 (m, 2H), 2.7 (m, 1H), 2.9 (m, 1H), 3.5 (m, 1H), 3.7 (m, 2H), 4.1
(m, 3H),
4.6 (m, 1H), 5.3 (m, 1H), 7.2-8.0 (m, 7H), 8.7 (m, 1H); MS(EI): 422
(M+H+,100%) .
109
CA 02412353 2002-12-13
WO 01/95911 PCT/USO1/19062
Exam 1p a 34
Preparation of ((S)-3-Methyl-1-d3-oxo-1-f2-(3-pyridin-2-yl-phen l~yll-azepan-4-
ylcaxbamo 1~1-butyl)-naphthylene-2-methyl-carbamic acid tert-but 1
a.) (S)-4-Methyl-2-[naphthalene-2-ylmethyl)-amino]-pentanoic acid methyl ester
To a solution of leucine methyl ester hydrochloride (0.5 g) in dichlormethane
was
added triethylamine (0.9 mL), 2-naphthaldehyde (0.43 g) and sodium
triacetoxyborohydride
(0.87 g). The mixture was stirred until complete. Workup and column
chromatography
(5% ethyl acetate:dichloromethane) provided 0.4 g of the title compound:
MS(EI) 286
(M+H+)
b.) (S)-2-(tert-Butoxycaxbonyl-naphthlen-2-ylmethyl-amino)-4-metyhyl pentanoic
acid
methyl ester
To a solution of the compound of Example 34a (0.35 g) in dichloromethane was
added di-tert-butyldicarbonate (0.29 g). After 2 hours at room temperature
triethylamine
was added and the reaction heated to reflux. Upon completion, the reaction was
concentrated and the residue was purified by column chromatography (50%
hexane:dichloromethane) to provide 0.17 g of the title compound: MS(EI) 386
(M+H+).
c.) (S)-2-(tert-Butoxycarbonyl-naphthlen-2-ylmethyl-amino)-4-methyl pentanoic
acid
To a solution of the compound of Example 34b (0.17 g) in THF:methanol (15 mL
of a 2:1 solution) was added LiOH (0.019 g). The reaction was stirred
overnight
whereupon it was concentrated to provide the title compound .
d.) 4-[(S)-tert-butoxycarbonyl-naphthylen-2-ylmethyl-amino)-4-methyl-
pentanoylamino]-3-hydroxy-azepane-1-carboxylic acid benzyl ester
To a sloution of the compound of Example 2e (0.11 g) in dichloromethane was
added EDC (0.08 g), HOBt (0.06 g) and the acid of Example 34c. Upon completion
the
reaction was worked up and chromatographed (5% methanol:dichloromethane) to
provide
the title compound (0.18 g): MS(EI) 618 (M+H+).
110
CA 02412353 2002-12-13
WO 01/95911 PCT/USO1/19062
e.) [(S)-1-(3-Hydroxy-azepan-4-ylcarbamoyl)-3-methyl-butyl]-naphthylen-2-
ylmethyl
carbamic acid tart-butyl ester
To a solution of the compound of Example 34d (0.17 g) in ethyl
acetate:methanol
(20:10 mL) was added 10% PdIC. A balloon of hydrogen was attached and the
reaction
was stirred until complete consumption of the starting material. The reaction
was filtered
and concentrated to provide the title compound (0.10g): MS(En 484 (M+H+).
f.) ((S)-3-Methyl-1-{3-hydroxy-1-[2-(3-pyridin-2-yl-phenyl)-acetyl]-azepan-4-
ylcarbamoyl}-butyl)-naphthylene-2-methyl-carbamic acid tart-butyl ester
Following the procedure of Example 9a except substituting the compound of
Example 34e the title compound was prepared: MS(EI) 679 (M+H+).
g.) ((S)-3-Methyl-1-{3-oxo-1-[2-(3-pyridin-2-yl-phenyl)-acetyl]-azepan-4-
ylcarbamoyl}-butyl)-naphthylene-2-methyl-carbamic acid tart-butyl ester
Following the procedure of Example 1i except substituting the compound of
Example 34f the title compound was prepared: : 'H NMR (CDC13): 8 1.0 (m, 6H),
1.5-2.2
(m, 16H), 2.7 (m, 1H), 3.2 (m, 1H). 3.7 (m, 3H), 4.0 (m, 1H), 4.7 (m, 2H), S.2
(m, 1H),
7.2-7.3 (m, 16H), 8.6 (m, 1H); MS(EI): 677 (M+H+,100%) .
Example 35
Preparation of (S)-4-Methyl-2-f(nanhthylen-2-ylmeth~)-aminol=pentenoic acid f3-
oxo-1-f2-
(3-pyridin-2-yI-phen 1)-acetyll-azepan-4-yIl-amide
To a solution of the compound of Example 34g (20 mg) in THF was added 1M HCl
in ether. The reaction Was stirred until complete consumption of the starting
material
whereupon it was concentrated to provide the title compound: 'H NMR (CDC13): 8
1.0 (m,
6H), 1.5-2.1 (m, 5H), 2.2 (m, 2H), 2.5 (m, 1H), 3.5 (m, 5H), 4.0 (m, 1H), 4.7
(m, 2H), 4.4
(m, 1H), 7.2-8.0 (m, 16H), 8.7 (m, 1H); MS(EI): 577 (M+H+,100%) .
111
CA 02412353 2002-12-13
WO 01/95911 PCT/USO1/19062
Example 36
Preparation of 4-f 2-(2-{ (S)-3-Methyl-1-f 3-oxo-1-(pyidine-2-sulfonyl)-azepan-
4-
ylcarbamoyll-butylcarbamo~~-benzofuran-5-yloxy)-eth~pi~perazine-1-carboxylic
acid
tart-but, luster
a.) 4-[2-(2-{ (S)-3-Methyl-1-[3-hydroxy-1-(pyidine-2-sulfonyl)-azepan-4-
ylcarbamoyl]-
butylcarbamoyl}-benzofuran-5-yloxy)-ethyl]-piperazine-1-carboxylic acid ter-t-
butyl ester
To a solution of the compound of Example 28a (0.15 g) in dichloromethane was
added EDC (0.07 g), HOBt (0.05 g), triethylamine (0.11 mL) and 4-[2-(2-carboxy-
benzofuran-5-yloxy)-ethyl]-piperazine-1-carboxylic acid tent-butyl ester. The
reaction was
stirred until complete. Work up and column chromatography (10 % methanol:
ethyl
acetate) provided the title compound (0.10 g): MS(EI) 757 (M+H+)
b.) 4-[2-(2-{ (S)-3-Methyl-1-[3-oxo-1-(pyidine-2-sulfonyl)-azepan-4-
ylcarbamoyl]-
butylcarbamoyl}-benzofuran-5-yloxy)-ethyl]-piperazine-1-carboxylic acid tart-
butyl ester
Following the procedure of Example 1i except substituting the compound of
Example 36a the title compound was prepared: 'H NMR (CDC13): 8 1.0 (m, 6H),
1.5-2.1
(m, 14H), 2.2 (m, 2H), 2.7 (m, 1H), 3.0 (m, 2H), 3.5 (m, 4H). 3.7 (m, 6H), 4.1
(m, 1H), 4.5
(m, 2H), 4.7 (m, 2H), 5.0 (m, 1H), 7.0-7.6 (m, 6H), 8.0 (m, 2H), 8.7 (m, 1H);
MS(EI):
755 (M+H+,100%) .
Exam lie 37
Preparation of 5-(2-Piperizin-1-yl-ethoxy)-benzofuran-2-carboxylic acid i (S)-
3-methyl-1-
f 3-oxo-1-(pyridine-2-sulfonyl)-azepan-4-ylcarbam~l)-3-butyl-amide
The compound of Example 36b (0.02 g) was dissolved in 4M HCl in dioxane. The
reaction was stirred until complete whereupon it was concentrated to provide
the title
compound: 'H NMR (CDC13): 8 1.0 (m, 6H), 1.5- 1.7 (m, 7H), 2.7 (m, 2H), 3.3
(M, 2H), 3.5
(m , 1H). 3.8 (m, 5H), 4.1 (m, 3H), 4.7 (m, 4H), 5.0 (m, 1H), 7.0-7.3 (m, 2H),
7.4 (m,
6H), 8.0 (m, 2H), 8.7 (m, 1H): MS(EI): 655 (M+H+,100%) .
112
CA 02412353 2002-12-13
WO 01/95911 PCT/USO1/19062
Example 38
Preparation of 5-(2-C clohexyl-ethoxy)-benzofuran-2-carboxylic acid ~ (S)-3-
methyl-1-f 3-
oxo-1-(pyridine-2-sulfonyl)-azepan-4-ylcarbamoyll-butyl amide
a.) 5-(2-Cyclohexyl-ethoxy)-benzofuran-2-carboxylic acid { (S)-3-methyl-1-[3-
hydroxy-1-(pyridine-2-sulfonyl)-azepan-4-ylcarbamoyl]-butyl } amide
To a solution of the compound of Example 28a (0.15 g) in dichloromethane was
added EDC (0.07 g), HOBt (0.05 g), triethylamine (0.11 mL) and 5-(2-cyclohexyl-
ethoxy)-
benzofuran carboxylic acid (0.01 g). The reaction was stirred until complete
by TLC
analysis. Workup and column chromatography (100% ethyl acetate) provided the
title
compound (0.15 g): MS(EI) 655 (M+H+).
b.) 5-(2-Cyclohexyl-ethoxy)-benzofuran-2-carboxylic acid { (S)-3-methyl-1-[3-
oxo-1-
(pyridine-2-sulfonyl)-azepan-4-ylcarbamoyl]-butyl}amide
Following the procedure of Example 1i except substituting the compound of
Example 38a the title compound was prepared: MS(ET) 653 (M+H+).
Example 39
Preparation of 5-(2-Cyclohexyl-ethoxy)-benzofuran-2-carboxylic acid ((S)-3-
meth 1-1- 3-
oxo-1-f 2-(3-pyridin-2-yl-phenyl)ethyll-azepan-4-ylcarbamoyl l-but,~l)amide
a.) 5-(2-Cyclohexyl-ethoxy)-benzofuran-2-carboxylic acid ((S)-3-methyl-1-{3-
hydroxy-1-[2-(3-pyridin-2-yl-phenyl)ethyl]-azepan-4-ylcarbamoyl}-butyl)amide
To a solution of the compound of Example 20d (0.15 g) in dichloromethane was
added EDC (0.06 g), HOBt (0.04 g), triethylamine (0.14 mL) and 5-(2-cyclohexyl-
ethoxy)-
benzofuran carboxylic acid (0.09 g). The reaction was stirred until complete
by TLC
analysis. Workup and column chromatography (100% ethyl acetate) provided the
title
compound (0.10 g): MS(EI) 695 (M+H+)
113
CA 02412353 2002-12-13
WO 01/95911 PCT/USO1/19062
b.) 5-(2-Cyclohexyl-ethoxy)-benzofuran-2-carboxylic acid ((S)-3-methyl-1-{ 3-
oxo-1-
[2-(3-pyridin-2-yl-phenyl)ethyl]-azepan-4-ylcarbamoyl }-butyl)amide
Following the procedure of Example 1i except substituting the compound of
Example 39a the title compound was prepared: 'H NMR (CDC13): 8 1.0 (m, 6H),
1.5-2.1
(m, 18H), 2.2 (m, 2H), 2.7 (m, 3H), 3.2 (m, 1H), 3.5 (m, 1H). 3.9 (m, 4H), 4.7
(m, 2H), 5.0
(m, 1H), 7.2-7.3 (m, 13H), 8.7 (m, 1H): MS(EI): 693 (M+H+,100%)
Example 40
Preparation of 4-f2-(2-((S)-3-Methyl-1-f3-oxo-1-(3-pyridin-2-yl-phenyl)-ethyl
faze$an-4-
ylcarbamoyll-butylcarbamoyll-benzofuran-5-yloxy)-ethyll-piperazine-1-
carboxylic acid
tent but 1 ester
a.) 4-[2-(2-{(S)-3-Methyl-1-[3-hydroxy-1-(3-pyridin-2-y1-phenyl)-ethyl [azepan-
4-
ylcarbamoyl]-butylcarbamoyl}-benzofuran-5-yloxy)-ethyl]-piperazine-1-
carboxylic acid
tart-butyl ester
To a solution of the compound of Example 20d (0.15 g) in dichloromethane was
added EDC (0.06 g), HOBt (0.04 g), triethylamine (0.14 mL) and 4-[2-(2-carboxy-
benzofuran-5-yloxy)-ethyl]-piperazine-1-carboxylic acid tart-butyl ester (0.12
g). The
reaction was stirred until complete by TLC analysis. Workup and column
chromatography
(10% methanol:ethyl acetate) provided the title compound (0.09 g): MS(EI) 797
(M+H+).
b.) 4-[2-(2-{ (S)-3-Methyl-1-j3-oxo-1-(3-pyridin-2-yl-phenyl)-ethyl [azepan-4-
ylcarbamoyl]-butylcarbamoyl}-benzofuran-5-yloxy)-ethyl]-piperazine-1-
carboxylic acid
ter-t-butyl ester
Following the procedure of Example 1i except substituting the compound of
Example 40a the title compound was prepared: MS(EI) 795.9 (M+H+)
114
CA 02412353 2002-12-13
WO 01/95911 PCT/USO1/19062
Example 41
Preparation of 5-(2-piperizin-1-yl-ethoxy)-benzofuran-2-carboxylic acid ((S)-3-
methyl-1-
j 3-oxo-1-f 2-(3-pyridin-2-yl-phenyl)ethyll-azepan-4-ylcarbamoyll-butyl)amide
Following the procedure of Example 37 except substituting the compound of
Example 40b the title compound was prepared: 'H NMR (CDC13): b 1.0 (m, 6H),
1.5-2.1
(m, 5H), 2.2 (m, 2H), 3.4-3.6 (m, 19H), 4.5 (m, 1H), 4.7 (m, 2H), 5.0 (m, 1H),
7.2 (m,
1H), 7.4 (m, 1H), 7.5 (m, 2H), 7.7 (m, 2H), 7.8 (m, 1H), 8.1 (m, 2H), 8.4 (m,
1H), 8.7 (m,
1H); MS(EI): 695 (M+H+, 70%).
Example 42
Prepaxation of (S)-4-Methyl-2-(meth~phthalen-2-ylmethyl-amino)pentanoic acid f
3-
oxo-1-(pyridine-2-sulphon ly_)-azepan-4-yll-amide
a.) 4-[(S)-2-(tert-Butoxycarbonyl-methyl-amino)-4-methyl-pentanoylamino]-3-
hydroxy-azepane-1-carboxylic acid benzyl ester
To a solution of the compound of Example 2e (0.35 g)in dichloromethane was
added N-methyl-N-Boc-leucine (0.36 g), HOBt (0.2 g) and EDC (0.28 g). The
reaction was
stirred until complete. Worlcup and column chromatography (5%
methanol:dichloromethane) provided 0.6 g of the title compound: MS(EI) 492
(M+H+)
b.) [(S)-1-(3-Hydroxy-azepan-4-ylcarbamoyl)-3-methyl-butyl]-methyl-carbamic
acid
tert-butyl ester
To a solution of the compound of Example 42a (0.6 g) in methanol:ethyl acetate
(10:20 mL) was added 10% Pd/C and a balloon of hydrogen was attached. The
reaction
was stirred overnight whereupon it was filtered and concentrated to provide
0.50 g of the
title: MS(EI) 358 (M+H+).
c.) {(S)-1-[3-Hydroxy-1-(pyridine-2-sulfonyl)-azepan-4-ylcarbamoyl]-3-methyl-
butyl}-
methyl-carbamic acid tert-butyl ester
To a solution of the compound of Example 42b (0.2 g) in dichloromethane was
added triethylamine (0.16 mL) and 2-pyridinesulfonyl chloride (0.15 g). The
reaction was
115
CA 02412353 2002-12-13
WO 01/95911 PCT/USO1/19062
stirred until complete. Workup and column chromatography (5% methanol:ethyl
acetate)
provided the title compound (0.23 g): MS(EI) 499 (M+H+)
d.) (S)-4-Methyl-2-methylamino-pentanoic acid [3-hydroxy-1-(2-pyridine-2-
sulfonyl)-
azepan-4-yl]-amide
To a solution of the compound of Example 42c (0.23 g) in methanol (3.0 mL) was
added 4M HCl in dioxane (3.0 mL). The reaction was stirred until complete.
Concentration provided the title compound: MS(EI) 399 (M+H+).
e.) (S)-4-Methyl-2-(methyl-naphthalen-2-ylmethyl-amino)pentanoic acid [3-
hydroxy-1-
(pyridine-2-sulphonyl)-azepan-4-yl]-amide
To a solution of the compound of Example 42d (0.05 g) in dichloromethane was
added triethylamine (0.07 mL), 2-naphthaldehyde (0.05 g) and sodium
triacetoxyborohydride (0.11 g). The reaction was stirred until complete.
Workup and
column; chromatography (5% methanol ethyl acetate) provided the title compound
(0.03 g):
MS(EI) 539 (M+H+)
f.) (S)-4-Methyl-2-(methyl-naphthalen-2-ylmethyl-amino)pentanoic acid [3-oxo-1-
(pyridine-2-sulphonyl)-azepan-4-yl]-amide
Following the procedure of Example 1i except substituting the compound of
Example 42e the title compound was prepared: 'H NMR (CDC13): 8 1.0 (m, 6H),
1.5-2.1
(m, 5H), 2.2 (m, 5H), 2.6 (m, 1H), 3.3 (m, 1H), 3.7 (m, ZH), 4.1 (m, 1H), 4.7
(m, 1H), 5.2
(m, 1H), 7.2-8.0 (m, 10H), 8.7 (m, 1H); MS(EI): 537 (M+H+,100°Io) .
Example 43
Preparation of (S)-4-Methyl-2-(methyl-naphthalen-2- l~yl-amino)pentanoic acid
~ 3-
oxo-1-f 2-(3-pyridin-2-yl-phenxl)-acetyll-azepan-4-~)-amide
a.) ((S)-1-{3-Hydroxy-1-[2-(3-pyridin-2-yl-phenyl)-acetyl]-azepan-4-
ylcarbamoyl}-3-
methyl-butyl)-methyl-carbamic acid tert-butyl ester
To a solution of the compound of Example 42b (0.25 g) was added 3-(2-
pyridyl)phenyl acetic acid (0.16 g), HOBt (0.12 g) and EDC (0.15 g). The
reaction was
116
CA 02412353 2002-12-13
WO 01/95911 PCT/USO1/19062
stirred until complete. Workup and column chromatography (5% methanol:ethyl
acetate)
provided the title compound (0.24 g): MS(EI) 553 (M+H+).
b.) (S)-4-Methyl-2-methylamino-pentanoic acid { 3-hydroxy-1-[2-(3-pyridin-2-yl-
phenyl)-acetyl]-azepan-4-yl }-amide
Following the procedure of Example 42d except substituting the compound of
Example 43a the title compound was produced: MS(E)] 453 (M+H+)
c.) (S)-4-Methyl-2-(methyl-naphthalen-2-ylmethyl-amino)pentanoic acid {3-oxo-1-
[2-
(3-pyridin-2-yl-phenyl)-acetyl]-azepan-4-yl}-amide
Following the procedures of Examples 42e-f except substituting the compound of
Example 43b the title compound was produced: 'H NMR (CDC13): 8 1.0 (m, 6H),
1.5-2.1
(m, SH), 2.2 (m, SH), 3.0 (m, 1H), 3.5 (m, 1H), 3.7 (m, 4H), 4.1 (m, 1H), 4.7
(m, 2H), 5.2
(m, 1H), 7.2-8.0 (m, 15H), 8.7 (m, 1H); MS(EI): 591 (M+H+,100%) .
IS
Example 44
Preparation of 5-(2-Morpholino-4-yl-ethoxy)-benzofuran-2-carboxylic acid
methyl ((S)-3-
methyl-1- 3-oxo-1-f2-(3-pyridin-2-yl-phenyl)acetyll-azepan-4-ylcarbam~l~-
butyl)amide
a.) 5-(2-Morpholino-4-yl-ethoxy)-benzofuran-2-carboxylic acid methyl ((S)-3-
methyl-
1-{ 3-hydroxy-1-[2-(3-pyridin-2-yl-phenyl)acetyl]-azepan-4-ylcarbamoy1 }-
butyl)amide
To a solution of the compound of Example 43b (0.1 g) in dichloromethane was
added 5-(2-morpholin-4-yl-ethyloxy)benzofuran-2-carboxylic acid (0.06 g), HOBt
(0.026
g), TEA (0.07 mL) and EDC (0.04 g). The reaction was stirred until complete.
Workup
and chromatography (20% methanol:ethyl acetate) provided the title compound
(0.07 g):
MS(EI) 726 (M+H+).
b.) 5-(2-Morpholino-4-yl-ethoxy)-benzofuran-2-carboxylic acid methyl ((S)-3-
methyl-
1-{ 3-oxo-1-[2-(3-pyridin-2-yl-phenyl)acetyl]-azepan-4-ylcarbamoyl }-
butyl)amide
Following the procedure of Example 1i except substituting the compound of
Example 44a the title compound was prepared: 'H NMR (CDC13): ): 8 1.0 (m, 6H),
1.5-2.1
(m, SH), 2.2 (m, SH), 2.7 (m, 4H), 2.8 (m, 2H), 2.9 (m, 1H), 3.5 (m, 1H), 3.7
(m, 4H),
117
CA 02412353 2002-12-13
WO 01/95911 PCT/USO1/19062
3.9 (m, 3H), 4.3 (m, 2H), 4.7 (m, 2H), 5.4 (m, 1H), 7.2-8.0 (m, 12H), 8.5 (m,
1H);
MS(EI): 724 (M+H+,100%) .
Example 45
Preparation of Benzofuran-2-carboxylic acid methyl(S)-3-methyl-1-f3-oxo-
l~pyridine-2-
sulfon l~pan-4-ylcarbamo~)-3-metal-butyl]-amide
a.) Benzofuran-2-carboxylic acid methyl {(S)-3-methyl-1-[3-hydroxy-1-(pyridine-
2-
sulfonyl)-azepan-4-ylcarbamoyl)-3-methyl-butyl]-amide
To a solution of the compound of Example 42d (0.1 g) in dichloromethane was
added benzofuran-2-carboxylic acid (0.04 g), TEA (excess), HOBt (0.03 g), and
EDC (0.04
g). The reaction was stirred until complete. Workup and column chromatography
(5%
methanol:dichloromethane) provided the title compound (0.04 g): MS(EI) 542.9
(M+H+)
b.) Benzofuran-2-carboxylic acid methyl {(S)-3-methyl-1-[3-oxo-1-(pyridine-2-
sulfonyl)-azepan-4-ylcarbamoyl)-3-methyl-butyl]-amide
Following the procedure of Example 1i except substituting the compound of
Example 45a the title compound was prepared: 'H NMR (CDC13): 8 1.0 (m, 6H),
1.5-2.1
(m, 8H), 2.2 (m, 2H), 2.7 (m, 1H), 3.0 (m, 1H), 3.7 (m, 2H), 4.1 (m, 1H), 4.7
(m, 1H), 5.2
(m, 1H), 7.2-8.0 (m, 8H), 8.7 (m, 1H); MS(EI): 541 (M+H+, 10%).
Exam 1u a 46
Preparation of 2,2,2-Trifluoro-N-((S)-3-methyl-1 j3-oxo-1-f2-(3-pyridin-2-~-
~hen~)-
acetyll-azepan-4-ylcarbamoy~-butyl)-N-naphthylen-2-ylmethyl-acetamide
a.) (S)-4-Methyl-2-[naphthylen-2-ylmethyl-(2,2,2-trifluoro-acetyl)-amino]-
pentanoic
acid methyl ester
To a solution of the compound of Example 34a (0.5 g) in dichloromethane was
added potassium carbonate (catalytic amount), and trifluoroacetic acid (0.44
g). The
reaction was stirred at room temperature for 1 hour whereupon it was
concentrated and
chromatographed (20% ethyl acetate:hexane) to provide the title compound.
118
CA 02412353 2002-12-13
WO 01/95911 PCT/USO1/19062
b.) (S)-4-Methyl-2-[naphthylen-2-ylmethyl-(2,2,2-trifluoro-acetyl)-amino]-
pentanoic
acid lithium salt
To a solution of the compound of Example 46a (0.49 g) in THF:water (3 mL of a
2:1 solution) was added lithium hydroxide monohydrate (0.06 g). The reaction
was stirred
overnight whereupon it was concentrated to provide the title compound (0.46
g): MS(En
366 (M+H+).
c.) 3-Hydroxy-4-{ (S)-4-methyl-2-[naphthylen-2-ylmethyl-(2,2,2-trifluoro-
acetyl)-
amino]-pentanoylamino}-azepane-1-carboxylic acid benzyl ester
To a solution of the compound of Example 2e (0.29 g) in dichloromethane was
added EDC (0.24 g), HOBt (0.16 g) and the compound of Example 46b (0.46 g).
The
reaction was stirred until complete. Workup and column chromatography
(5°Io
methanol:ethyl acetate) provided the title compound (0.25 g): MS(EI) 614
(M+H+).
d.) 2,2,2-Trifluoro-N-[(S)-1-(3-hydroxy-azepan-ylcarbamoyl)-3-methyl-butyl]-N-
naphthlen-2-ylmethyl-acetamide
Following the procedure of Example 42b except substituting the compound of
Example 46c the title compound was produced: MS(EI) 480 (M+H+).
e.) 2,2,2-Trifluoro-N-((S)-3-methyl-1-{3-hydroxy-1-[2-(3-pyridin-2-yl-phenyl)-
acetyl]-
azepan-4-ylcarbamoyl }-butyl)-N-naphthylen-2-ylmethyl-acetamide
Following the procedure of Example 43a except substituting the compound of
Example 46d the title compound was produced: MS(EI) 675 (M+H+)
f.) 2,2,2-Trifluoro-N-((S)-3-methyl-1-{3-oxo-1-[2-(3-pyridin-2-yl-phenyl)-
acetyl]-
azepan-4-ylcarbamoyl }-butyl)-N-naphthylen-2-ylmethyl-acetarriide
Following the procedure of Example 1i except substituting the compound of
Example 46e the title compound was prepared: 'H NMR (CDC13): 8 1.0 (m, 6H),
1.5-2.1
(m, 5H), 2.2 (m, 2H), 2.7 (m, 1H), 3.2 (m, 1H), 3.7 (m, 3H), 4.1 (m, 1H), 4.5
(m, 2H), 4.7
(m, 2H), 5.2 (m, 1H), 7.2-8.0 (m, 14H), 8.7 (m, 1H): MS(EI): 673
(M+H+,100°Io) .
119
CA 02412353 2002-12-13
WO 01/95911 PCT/USO1/19062
Example 47
Preparation of 4-[(S)-(Methanesulphonyl-naphthylen-2-ylmethyl-amino)-4-meth~-
pentanoylaminol-3-oxo-azepane-1-carbolic acid benzyl ester
a.) (S)-2-(Methanesulfonyl-naphthylen-2-ylmethyl-amino)-4-methyl-pentanoic
acid methyl
ester
To a solution of the compound of Example 34a (0.5 g) in dichloromethane was
added triethylamine (0.36 mL) and methansulfonyl chloride (0.16 mL). The
reaction was
stirred at room temperature until complete. Workup and chromatography (20%
ethyl
acetate:hexanes) provided the title compound (0.24 g).
b.) (S)-2-(Methanesulfonyl-naphthylen-2-ylmethyl-amino)-4-methyl-pentanoic
acid
lithium salt
Following the procedure of Example 46b except substituting the compound of
Example 47a the title compound was prepared: MS(EI) 348 (M+H+).
c.) 4-[(S)-(Methanesulphonyl-naphthylen-2-ylmethyl-amino)-4-methyl-
pentanoylamino]-3-hydroxy-azepane-1-carboxylic acid benzyl ester
Following the procedure of Example 46c except substituting the compound of
Example 47b the title compound was prepared: MS(EI) 596 (M+H+)
d.) 4-[(S)-(Methanesulphonyl-naphthylen-2-ylmethyl-amino)-4-methyl-
pentanoylamino]-3-oxo-azepane-1-carboxylic acid benzyl ester
Following the procedure of Example 1i except substituting the compound of
Example 47c the title compound was prepared: 'H NMR (CDCl3): 8 1.0 (m, 6H),
1.5-2.1
(m, 5H), 2.2 (m, 5H), 3.0 (m, 1H), 3.5 (m, 1H), 4.1 (m, 1H), 4.5 (m, 3H), 4.7
(m, 1H), 5.2
(m, 3H), 7.2-8.0 (m, 13H); MS(EI): 596 (M+3H+,100%) .
120
CA 02412353 2002-12-13
WO 01/95911 PCT/USO1/19062
Example 48
Preparation of Ouinoline-2-carboxylic acid 1(S)-3-methyl-1-f3-oxo-1-(pyridine-
2-sulfon,~l)-
az~an-4-Xlcarbamoyll-butyl } amide
a.) Quinoline-2-carboxylic acid { (S)-3-methyl-1-[3-hydroxy-1-(pyridine-2-
sulfonyl)-
azepan-4-ylcarbamoyl]-butyl } amide
Following the procedure of Example 28b except substituting quinoline-2-
carboxylic
acid for benzofuran-2-carboxylic acid the title compound was prepared: MS(EI)
540
(M+H+)
b.) Quinoline-2-carboxylic acid {(S)-3-methyl-1-[3-oxo-1-(pyridine-2-sulfonyl)-
azepan-4-ylcarbamoyl]-butyl } amide
Following the procedure of Example 1i except substituting the compound of
Example 48a the title compound was prepared: 'H NMR (CDC13): 8 1.0 (m, 6H),
1.5-2.1
(m, 5H), 2.2 (m, 2H), 2.7 (m, 1H), 3.7 (d, 1H). 4.1 (m, 1H), 4.7 (m, 2H), 5.0
(m, 1H),
7.0-7.2 (m, 1H), 7.3 (m, 1H), 7.5 (m, 1H), 7.7 (m, 1H), 7.8 (m, 3H), 8.1 (m,
1H), 8.3 (m,
2H), 8.7 (m, 2H); MS(EI): 538 (M+H+,100%) .
The diastereomeric mixture was separated by HPLC to provide the faster eluting
diastereoemer; MS(EI): 538 (M+H+,100%), and the slower eluting diastereomer;
MS(EI):
538 (M+H+,100%).
Example 49
Preparation of Ouinoline-8-carbox lic acid (S)-3-methyl-1-f3-oxo-1-(pyridine-2-
sulfonyl)-
azepan-4-ylcarbamo l~yllamide
a.) Quinoline-8-carboxylic acid { (S)-3-methyl-1-[3-hydroxy-1-(pyridine-2-
sulfonyl)-
azepan-4-ylcarbamoyl]-butyl } amide
Following the procedure of Example 28b except substituting quinoline-8-
carboxylic
acid for benzofuran-2-carboxylic acid the title compound was prepared: MS(EI)
540
(M+H+)
121
CA 02412353 2002-12-13
WO 01/95911 PCT/USO1/19062
b.) Quinoline-8-carboxylic acid { (S)-3-methyl-1-[3-oxo-1-(pyridine-2-
sulfonyl)-
azepan-4-ylcarbamoyl]-butyl } amide
Following the procedure of Example 1i except substituting the compound of
Example 49a the title compound was prepared: 'H NMR (CDC13): 8 1.0 (m, 6H),
1.5-2.1
(m, 5H), 2.2 (m, 2H), 2.7 (m, 1H),a3.7 (d, 1H). 4.0 (m, 1H), 4.7 (m, 2H), 5.0
(m, 1H), 7.5
(m, 4H), 7.6 (m, 1H), 7.7 (m, 3H), 8.2 (m, 1H), 8.6 (m, 1H), 8.7 (m, 1H), 8.9
(m, 1H);
MS(EI): 538 (M+H+,100%) .
Example 50
Preparation of Quinoline-6-carboxylic acid 1 (S)-3-methyl-1-(3-oxo-1-(pyridine-
2-sulfonyl)-
azepan-4-ylcarbamoyll-butyl amide
a.) Quinoline-6-carboxylic acid { (S)-3-methyl-1-[3-hydroxy-1-(pyridine-2-
sulfonyl)-
azepan-4-ylcarbamoyl]-butyl}amide
Following the procedure of Example 28b except substituting quinoline-6-
carboxylic
acid for benzofuran-2-carboxylic acid the title compound was prepared: MS(En
540
(M+H+).
b.) Quinoline-6-carboxylic acid {(S)-3-methyl-1-[3-oxo-1-(pyridine-2-sulfonyl)-
azepan-4-ylcarbamoyl]-butyl } amide
Following the procedure of Example 1i except substituting the compound of
Example 50a the title compound was prepared: 'H NMR (CDC13): 8 1.0 (m, 6H),
1.5-2.1
(m, 5H), 2.2 (m, 2H), 2.7 (m, 1H), 3.7 (d, 1H). 4.0 (m, 1H), 4.7 (m, 2H), 5.0
(m, 1H), 7.0
(m, 2H), 7.5 (m, 2H), 7.9 (m, 2H), 8.0 (m, 3H), 8.2 (m, 1H), 8.7 (m, 1H), 8.9
(m, 1H);
MS(EI): 538 (M+H+,100%) .
The diastereomeric mixture was separated by HPLC to provide the faster eluting
diastereoemer; MS(EI): 538 (M+H+,100%), and the slower eluting diastereomer;
MS(EI):
538 (M+H+,100%).
122
CA 02412353 2002-12-13
WO 01/95911 PCT/USO1/19062
Example 51
Preparation of Ouinoline-4-carboxylic acid (S)-3-methyl-1-f3-oxo-1-(pyridine-2-
sulfonxlZ
azepan-4-ylcarbamoyll-butyl l amide
a.) Quinoline-4-carboxylic acid { (S)-3-methyl-1-[3-hydroxy-1-(pyridine-2-
sulfonyl)-
azepan-4-ylcarbamoyl]-butyl } amide
Following the procedure of Example 28b except substituting quinoline-4-
carboxylic
acid for benzofuran-2-carboxylic acid the title compound was prepared: MS(EI)
540
(M+H+).
b.) Quinoline-4-carboxylic acid {(S)-3-methyl-1-[3-oxo-1-(pyridine-2-sulfonyl)-
azepan-4-ylcarbamoyl]-butyl } amide
Following the procedure of Example 1i except substituting the compound of
Example Sla the title compound was prepared: 'H NMR (CDC13): 8 1.0 (m, 6H),
1.5-2.1
(m, 5H), 2.2 (m, 2H), 2.7 (m, 1H), 3.7 (d, 1H). 4.0 (m, 1H), 4.7 (m, 2H), 5.0
(m, 1H), 6.5-
7.2 (m, 2H), 7.4 (m, 2H), 7.5 (m, 1H), 7.7 (m, 1H), 7.9 (m, 2H), 8.0 (m, 1H),
8.2 (m, 1H),
8.7 (m, 1H), 8.9 (m, 1H); MS(EI): 538 (M+H+,100%)
The diastereomeric mixture was separated by HPLC to provide the faster eluting
diastereoemer; MS(EI): 538 (M+H+,100%), and the slower eluting diastereomer;
MS(EI):
538 (M+H+,100%).
Example 52
Preparation of Ouinoline-3-carbolic acid ((S)-3-methyl-1-f3-oxo-1-(pyridine-2-
sulfon~)-
azepan-4-ylcarbamo l~yl~amide
a.) Quinoline-3-carboxylic acid { (S)-3-methyl-1-[3-hydroxy-1-(pyridine-2-
sulfonyl)-
azepan-4-ylcarbamoyl]-butyl } amide
Following the procedure of Example 28b except substituting quinoline-3-
carboxylic
acid for benzofuran-2-carboxylic acid the title compound was prepared: MS(EI)
540
(M+H+).
123
CA 02412353 2002-12-13
WO 01/95911 PCT/USO1/19062
b.) Quinoline-3-carboxylic acid {(S)-3-methyl-1-[3-oxo-1-(pyridine-2-sulfonyl)-
azepan-4-ylcarbamoyl]-butyl } amide
Following the procedure of Example 1i except substituting the compound of
Example 52a the title compound was prepared: 'H NMR (CDC13): 8 1.0 (m, 6H),
1.5-2.1
(m, 5H), 2.2 (m, 2H), 2.7 (m, 1H), 3.7 (d, 1H). 4.0 (m, 1H), 4.7 (m, 2H), 5.0
(m, 1H), 7.2
(m 2H), 7.5 (m, 1H), 7.6 (m, 1H), 7.7-7.9 (m, 4H), 8.1 (m, 1H), 8.5 (m, 1H),
8.6 (m,
1H), 9.3 (m, 1H); MS(EI): 538 (M+H~,100%) .
The diastereomeric mixture was separated by HPLC to provide the faster eluting
diastereoemer; MS(EI): 538 (M+H+,100%), and the slower eluting diastereomer;
MS(EI):
538 (M+H+,100%).
Example 53
Preparation of Isoquinoline-3-carboxylic acid ~(S)-3-methyl-1-f3-oxo-1-
(pyridine-2-
sulfonyl)-azepan-4-ylcarbamo l~~) amide
a.) Isoquinoline-3-carboxylic acid {(S)-3-methyl-1-[3-hydroxy-1-(pyridine-2-
sulfonyl)-
azepan-4-ylcarbamoyl]-butyl } amide
Following the procedure of Example 28b except substituting isoquinoline-3-
carboxylic acid for benzofuran-2-carboxylic acid the title compound was
prepared: MS(E))
540 (M+H+)
b.) Isoquinoline-3-carboxylic acid {(S)-3-methyl-1-[3-oxo-1-(pyridine-2-
sulfonyl)-
azepan-4-ylcarbamoyl]-butyl } amide
Following the procedure of Example 1i except substituting the compound of
Example 53a the title compound was prepared: 'H NMR (CDC13): b 1.0 (m, 6H),
1.5-2.1
(m, 5H), 2.2 (m, 2H), 2.7 (m, 1H), 3.7 (d, 1H). 4.0 (m, 1H), 4.7 (m, 2H), 5.0
(m, 1H), 7.0
(m, 1H). 7.5 (m, 1H), 7.7 (m, 2H), 7.9 (m, 4H), 8.7 (m, 3H), 9.2 (m, 1H);
MS(EI): 538
(M+H+,100%) .
124
CA 02412353 2002-12-13
WO 01/95911 PCT/USO1/19062
Example 54
Preparation of Isoquinoline-1-carboxylic acid (S)-3-methyl-1-f3-oxo-1-
(pyridine-2-
sulfonyl)-azepan-4-ylcarbamo 1~-b_utyl~amide
a.) Isoquinoline-1-carboxylic acid {(S)-3-methyl-1-[3-hydroxy-1-(pyridine-2-
sulfonyl)-
azepan-4-ylcarbamoyl]-butyl } amide
Following the procedure of Example 28b except substituting isoquinoline-1-
carboxylic acid for benzofuran-2-carboxylic acid the title compound was
prepared: MS(EI)
540 (M+H+)
b.) Isoquinoline-1-carboxylic acid { (S)-3-methyl-1-[3-oxo-1-(pyridine-2-
sulfonyl)-
azepan-4-ylcarbamoyl]-butyl } amide
Following the procedure of Example 1i except substituting the compound of
Example 54a the title compound was prepared: 'H NMR (CDC13): 8 1.0 (m, 6H),
1.5-2.1
(m, 5H), 2.2 (m, 2H), 2.7 (m, 1H), 3.7 (d, 1H). 4.0 (m, 1H), 4.7 (m, 2H), 5.0
(m, 1H), 7.3
(m, 1H), 7.5 (m, 1H), 7.7-8.0 (m, 6H), 8.7 (m, 3H), 9.5 (m, 1H); MS(EI): 538
(M+H+,100%) .
The diastereomeric mixture was separated by HPLC to provide the faster eluting
diastereoemer; MS(EI): 537 (M+,100%), and the slower eluting diastereomer;
MS(EI): 537
(M+,100%).
Example 55
Preparation of Quinoxaline-2-carboxylic acid ( (S)-3-meth-1-f 3-oxo-1-
(pyridine-2-
sulfon 1~)-azepan-4-ylcarbamoyll-butyl~amide
a.) Quinoxaline-2-carboxylic acid {(S)-3-methyl-1-[3-hydroxy-1-(pyridine-2-
sulfonyl)-
azepan-4-ylcarbamoyl]-butyl } amide
Following the procedure of Example 28b except substituting quinoxaline-2-
carboxylic acid for benzofuran-2-carboxylic acid the title compound was
prepared: MS(EI)
541 (M+H+)
125
CA 02412353 2002-12-13
WO 01/95911 PCT/USO1/19062
b.) Quinoxaline-2-carboxylic acid { (S)-3-methyl-1-[3-oxo-1-(pyridine-2-
sulfonyl)-
azepan-4-ylcarbamoyl]-butyl } amide
Following the procedure of Example 1i except substituting the compound of
Example 55a the title compound was prepared: 'H NMR (CDCl3): cS 1.0 (m, 6H),
1.5-2.1
(m, 5H), 2.2 (m, 2H), 2.7 (m, 1H), 3.7 (d, 1H). 4.0 (m, 1H), 4.7 (m, 2H), 5.0
(m, 1H), 7..0-
7.2 (m, 2H), 7.5 (m, 1H), 7.7 (m, 3H), 8.2 (m, 2H), 8.3 (m, 1H), 8.7 (m, 1H),
9.5 (m,
1H); MS(EI): 539 (M+H+, 30%).
Exam, 1p a 56
Preparation of Benzofblthiophene-2-carboxylic acid ~(S)-3-methyl-1-f3-oxo-1-
(pyridine-2-
sulfon 1)-azepan-4-ylcarbamoyll-butyllamide
a.) Benzo[b]thiophene-2-carboxylic acid {(S)-3-methyl-1-[3-hydroxy-1-(pyridine-
2-
sulfonyl)-azepan-4-ylcarbamoyl]-butyl}amide
Following the procedure of Example 28b except substituting benzo[b]thiophene-2-
carboxylic acid for benzofuran-2-carboxylic acid the title compound was
prepared: MS(EI)
545 (M+H+).
b.) Benzo[b]thiophene-2-carboxylic acid {(S)-3-methyl-1-[3-oxo-1-(pyridine-2-
sulfonyl)-azepan-4-ylcarbamoyl]-butyl } amide
Following the procedure of Example 1i except substituting the compound of
Example 56a the title compound was prepared: 'H NMR (CDCl3): 81.0 (m, 6H), 1.5-
2.1
(m, 5H), 2.2 (m, 2H), 2.7 (m, 1H), 3.7 (d, 1H). 4.0 (m, 1H), 4.7 (rn, 2H), 5.0
(m, 1H), 6.8-
7.2 (m, 1H), 7.5 (m, 3H), 8.0 (m, 6H), 8.7 (m, 1H); MS(EI): 543 (M+H+, 60%).
The diastereomeric mixture was separated by HPLC to provide the faster eluting
diastereoemer;'HNMR (CDCI~): 8 1.0 (m, 6H), 1.5-2.2 (m, 6H), 2.7 (m, 1H), 3.8
(m,lH),
4.1 (m, 1H), 4.7 (m, 2H), 5.1 (m, 1H), 7.4-8.0 (m, 8H), 8.7 (m, 1H); MS(EI):
543
(M+H+,100%), and the slower eluting diastereomer; 1.0 (m, 6H), 1.5-2.2 (m,
6H), 2.7 (m,
1H), 3.8 (m,lH), 4.1 (m, 1H), 4.7 (m, 2H), 5.1 (m, 1H), 7.4-8.0 (m, 8H), 8.7
(m, 1H);
MS(EI): 543 (M+H~,100%).
126
CA 02412353 2002-12-13
WO 01/95911 PCT/USO1/19062
Example 57
Preparation of 1,8-Naphthyridine-2-carboxylic acid ((S)-3-methyl-1-f3-oxo-1-
(pyridine-2-
sulfonyl)-azepan-4-ylcarbamoyll-butyl 1 amide
a.) 1,8-Naphthyridine-2-carboxylic acid {(S)-3-methyl-1-[3-hydroxy-1-(pyridine-
2-
sulfonyl)-azepan-4-ylcarbamoyl]-butyl } amide
Following the procedure of Example 28b except substituting 1,8-naphthyridine-2-
carboxylic acid for benzofuran-2-carboxylic acid the title compound was
prepared: MS(EI)
IO 541 (M+H+)
b.) 1,8-Naphthyridine-2-carboxylic acid { (S)-3-methyl-1-[3-oxo-1-(pyridine-2-
sulfonyl)-azepan-4-ylcarbamoyl]-butyl } amide
Following the procedure of Example 1i except substituting the compound of
Example 57a the title compound was prepared: 'H NMR (CDC13): S 1.0 (m, 6H),
1.5-2.1
(m, 5H), 2.2 (m, 2H), 2.7 (m, 1H), 3.7 (d, 1H). 4.0 (m, 1H), 4.7 (m, 2H), 5.0
(m, 1H), 7.2
(m, 1H), 7.6 (m, 2H), 7.9 (m, 2H), 8.3 (m, 1H), 8.4 (m, 2H), 8.5 (m, 2H), 9.2
(m, 1H);
MS(EI): 539 (M+H+,100%)
Example 58
Preparation of 1H-Indole-2-carboxylic acid ~(S)-3-methyl-1-f3-oxo-1-(pyridine-
2-sulfonyl)-
azepan-4-ylcarbamoyll-butyl ~ amide
a.) 1H-Indole-2-carboxylic acid {(S)-3-methyl-1-[3-hydroxy-1-(pyridine-2-
sulfonyl)-
azepan-4-ylcarbamoyl]-butyl } amide
Following the procedure of Example 28b except substituting 1H-indole-2-
carboxylic acid for benzofuran-2-carboxylic acid the title compound was
prepared: MS(EI)
528 (M+H+).
b.) 1H-Indole-2-carboxylic acid {(S)-3-methyl-1-[3-oxo-1-(pyridine-2-sulfonyl)-
azepan-4-ylcarbamoyl]-butyl } amide
Following the procedure of Example 1i except substituting the compound of
Example 58a the title compound was prepared: 'H NMR (CDC13): 8 1.0 (m, 6H),
1.5-2.1
127
CA 02412353 2002-12-13
WO 01/95911 PCT/USO1/19062
(m, 5H), 2.2 (m, 2H), 2.7 (m, 1H), 3.7 (d, 1H). 4.0 (m, 1H), 4.7 (m, 2H), 5.0
(m, 1H), 6.8
(m, 1H), 7.1 (m, 1H), 7.3 (m, 3H), 7.4 (m, 1H), 7.5 (m, 1H), 7.6 (m, 1H), 8.0
(m, 2H),
8.7 (m, 1H), 9.4 (b, 1H); MS(EI): 526 (M+H+, 80%).
Example 59
Preparation of 5-Methoxybenzofuran-2-carboxylic acid 1 (S)-3-methyl-1-f 3-oxo-
1-(pyridine-
2-sulfon~)-azepan-4-ylcarbamo l~yl~amide
a.) 5-Methoxybenzofuran-2-carboxylic acid { (S)-3-methyl-1-[3-hydroxy-1-
(pyridine-2-
sulfonyl)-azepan-4-ylcarbamoyl]-butyl } amide
Following the procedure of Example 28b except substituting 5-methoxybenzofuran-
2-carboxylic acid for benzofuran-2-carboxylic acid the title compound was
prepared:
MS(EI) 559 (M+H+)
b.) 5-Methoxybenzofuran-2-carboxylic acid {(S)-3-methyl-1-[3-oxo-1-(pyridine-2-
sulfonyl)-azepan-4-ylcarbamoyl]-butyl } amide
Following the procedure of Example 1i except substituting the compound of
Example 59a the title compound was prepared: 'H NMR (CDCl3): ~ 1.0 (m, 6H),
1.5-2.1
(m, 5H), 2.2 (m, 2H), 2.7 (m, 1H), 3.7 (d, 4H). 4.0 (m, 1H), 4.7 (m, 2H), 5.0
(m, 1H), 7.0
(m, 4H), 7.6 (m, 3H), 8.0 (m, 2H), 8.7 (m, 1H); MS(EI): 557 (M+H+, 70%).
The diastereomeric mixture was separated by HPLC to provide the faster eluting
diastereoemer; 'HNMR (CDCl3): b 1.0 (m, 6H), 1.5-2.1 (m, 5H), 2.2 (m, 2H), 2.7
(t, 1H),
3.7 (m, 4H). 4.0 (d, 1H), 4.7 (m, 2H), 5.0 (d, 1H), 7.0 (m, 4H), 7.6 (m, 3H),
8.0 (m, 2H),
8.7 (d, 1H); MS(EI): 557 (M+H+,100%), and the slower eluting diastereomer;
MS(EI): 557
(M+H+,100%).
128
CA 02412353 2002-12-13
WO 01/95911 PCT/USO1/19062
Example 60
Preparation of 5-Bromo-furan-2-carboxylic acid 1 (S)-3-methyl-1-f 3-oxo-1-
(pyridine-2-
sulfonyl)-azepan-4-ylcarbamoyll-butyl amide
a.) 5-Bromo-furan-2-carboxylic acid { (S)-3-methyl-1-[3-hydroxy-1-(pyridine-2-
sulfonyl)-azepan-4-ylcarbamoyl]-butyl}amide
Following the procedure of Example 28b except substituting 5-bromo-2-furoic
acid
for benzofuran-2-carboxylic acid the title compound was prepared: MS(EI) 558
(M+H+).
b.) 5-Bromo-furan-2-carboxylic acid { (S)-3-methyl-1-[3-oxo-1-(pyridine-2-
sulfonyl)-
azepan-4-ylcarbamoyl]-butyl } amide
Following the procedure of Example 1i except substituting the compound of
Example 60a the title compound was prepared: 'H NMR (CDC13): S 1.0 (m, 6H),
1.5-2.1
(m, 5H), 2.2 (m, 2H), 2.7 (m, 1H), 3.7 (d, 1H). 4.0 (m, 1H), 4.7 (m, 2H), 5.0
(m, 1H),~6.5
(m, 1H), 6.7 (m, 1H), 7.1 (m, 2H), 7.5 (m, 1H), 8.0 (m, 2H), 8.7 (m, 1H);
MS(EI): 555
(M+H+, 60%).
The diastereomeric mixture was separated by HPLC to provide the faster eluting
diastereoemer; MS(EI): 555 (M+H~,100%), and the slower eluting diastereomer;
MS(EI):
555 (M+H+,100%).
Example 61
Preparation of Furan-2-carboxylic acid ~(S)-3-methyl-1-f3-oxo-1-(pyridine-2-
sulfonyl)-
azepan-4-ylcaxbamoyll-but~lamide
a.) Furan-2-carboxylic acid { (S)-3-methyl-1-[3-hydroxy-1-(pyridine-2-
sulfonyl)-
azepan-4-ylcarbamoyl]-butyl } amide
Following the procedure of Example 28b except substituting 2-furoic acid for
benzofuran-2-carboxylic acid the title compound was prepared: MS(EZ) 479
(M+H+).
129
CA 02412353 2002-12-13
WO 01/95911 PCT/USO1/19062
b.) Furan-2-carboxylic acid {(S)-3-methyl-1-[3-oxo-1-(pyridine-2-sulfonyl)-
azepan-4-
ylcarbamoyl]-butyl } amide
Following the procedure of Example 1i except substituting the compound of
Example 61a the title compound was prepared: 'H NMR (CDCl3): S 1.0 (m, 6H),
1.5-2.1
(m, 5H), 2.2 (m, 2H), 2.7 (m, 1H), 3.7 (d, 1H). 4.0 (m, 1H), 4.7 (m, 2H), 5.0
(m, 1H), 6.5
(m, 1H), 7.2 (m, 3H), 7.5 (m, 2H), 8.0 (m, 2H), 8.7 (m, 1H); MS(EI): 477
(M+H+, 50%).
Example 62
Preparation of 5-Nitro-furan-2-carboxylic acid ~~S)-3-methyl-1-f3-oxo-1-
(pyridine-2-
sulfonyl)-azepan-4-ylcarbamo l~yl)amide
a.) 5-Nitro-furan-2-carboxylic acid { (S)-3-methyl-1-[3-hydroxy-1-(pyridine-2-
sulfonyl)-azepan-4-ylcarbamoyl]-butyl } amide
Following the procedure of Example 28b except substituting 5-nitro-2-furoic
acid
for benzofuran-2-carboxylic acid the title compound was prepared: MS(EI) 524
(M+H+).
b.) 5-Nitro-furan-2-carboxylic acid { (S)-3-methyl-1-[3-oxo-1-(pyridine-2-
sulfonyl)-
azepan-4-ylcarbamoyl]-butyl } amide
Following the procedure of Example 1i except substituting the compound of
Example 62a the title compound was prepared: 'H NMR (CDCl3): 8 1.0 (m, 6H),
1.5-2.1
(m, 5H), 2.2 (m, 2H), 2.7 (m, 1H), 3.7 (d, 1H). 4.0 (m, 1H), 4.7 (m, 2H), 5.0
(m, 1H), 7.2
(m, 1H), 7.3 (m, 1H), 7.5 (m, 1H), 7.9 (m, 2H), 8.7 (m, 1H); MS(EI): 522
(M+H~,
80%).
130
CA 02412353 2002-12-13
WO 01/95911 PCT/USO1/19062
Example 63
Preparation of 5-(4-Nitro-phenyl)-furan-2-carboxylic acid (S)-3-methyl-1-f3-
oxo-1-
pyridine-2-sulfonyl)-azepan-4-Ylcarbamoyll-butt) amide
a.) 5-(4-Nitro-phenyl)-furan-2-carboxylic acid {(S)-3-methyl-1-[3-hydroxy-1-
(pyridine-2-sulfonyl)-azepan-4-ylcarbamoyl]-butyl } amide
Following the procedure of Example 28b except substituting 5-(4-nitrophenyl)-2-
furoic acid for benzofuxan-2-carboxylic acid the title compound was prepared:
MS(EI) 600
(M+H+)
b.) 5-(4-Nitro-phenyl)-furan-2-carboxylic acid { (S)-3-methyl-1-[3-oxo-1-
(pyridine-2-
sulfonyl)-azepan-4-ylcarbamoyl]-butyl } amide
Following the procedure of Example 1i except substituting the compound of
15.. Example 63a the title compound was prepared: 'H NMR (CDC13): 8 1.0 (m,
6H), 1.5-2.1
(m, SH), 2.2 (m, 2H), 2.7 (m, 1H), 3.7 (d, 1H). 4.0 (m, 1H), 4.7 (m, 2H), 5.0
(m, 1H), 6.9
(m, 1H), 7.2 (m, 1H), 7.5 (m, 2H), 7.9-8.0 (m, 4H), 8.5 (m, 1H), 8.6 (m, 1H);
MS(EI):
598 (M+H+, 80°Io).
Example 64
Preparation of 5-(3-Trifluoromethyl-phen~)-furan-2-carboxylic acid ~(S)-3-
methyl-1-f3-
oxo-l~pyridine-2-sulfonXl)-azepan-4-ylcarbamo l~utyl?amide
a.) 5-(3-Trifluoromethyl-phenyl)-furan-2-carboxylic acid {(S)-3-methyl-1-[3-
hydroxy-
1-(pyridine-2-sulfonyl)-azepan-4-ylcarbamoyl]-butyl } amide
Following the procedure of Example 28b except substituting 5-[3-
(trifluoromethyl)phenyl]-2-furoic acid for benzofuran-2-carboxylic acid the
title compound
was prepared: MS(EI) 623 (M+H+).
b.) 5-(3-Trifluoromethyl-phenyl)-furan-2-carboxylic acid { (S)-3-methyl-1-[3-
oxo-1-
(pyridine-2-sulfonyl)-azepan-4-ylcarbamoyl]-butyl } amide
Following the procedure of Example 1i except substituting the compound of
Example 64a the title compound was prepared: 'H NMR (CDCl3): 8 1.0 (m, 6H),
1.5-2.1
131
CA 02412353 2002-12-13
WO 01/95911 PCT/USO1/19062
(m, 5H), 2.2 (m, 2H), 2.7 (m, 1H), 3.7 (d, 1H). 4.0 (m, 1H), 4.7 (m, 2H), 5.0
(m, 1H), 7.1
(m, 1H), 7.5 (m, 3H), 8.0 (m, 4H) 8.7 (m, 1H); MS(EI): 621 (M+H+, 80%).
The diastereomeric mixture was separated by HPLC to provide the faster eluting
diastereoemer; MS(EI): 621 (M+H+,100%), and the slower eluting diastereomer;
MS(EI):
621 (M+H+,100%).
Example 65
Preparation of Tetrahydro-furan-2-carboxylic acid ~ (S)-3-metal-1-f 3-oxo-1-
(pyridine-2-
sulfon 1~)-azepan-4-ylcarbamo l~yl~amide
a.) Tetrahydro-furan-2-carboxylic acid {(S)-3-methyl-1-[3-hydroxy-1-
(pyridine~2-
sulfonyl)-azepan-4-ylcarbamoyl]-butyl } amide
Following the procedure of Example 28b except substituting tetrahydrofuran-2-
carboxylic acid for benzofuran-2-carboxylic acid the title compound was
prepared: MS(EI)
483 (M+H+).
b.) Tetrahydro-furan-2-carboxylic acid {(S)-3-methyl-1-[3-oxo-1-(pyridine-2-
sulfonyl)-
azepan-4-ylcarbamoyl]-butyl } amide
Following the procedure of Example 1i except substituting the compound of
Example 65a the title compound was prepared: 'H NMR (CDC13): S 1.0 (m, 6H),
1.5-2.2
(m, 12H), 2.7 (m, 1H), 3.8 (m, 3H). 4.0 (m, 1H), 4.5 (m, 2H), 4.8 (m, 1H), 5.0
(m, 1H), 7.0
(m, 1H), 7.5 (m, 1H), 7.9 (m, 2H), 8.7 (m, 1H). MS(EI): 481 (M+H+, 80%).
Example 66
Preparation of (S)-4-Meth 1-~2-(2-phenoxy-acetylamino)-pentanoic acid f 3-oxo-
(pyridine-2-
sulfonyl -azepan-4-yll-amide
a.) (S)-4-Methyl-2-(2-phenoxy-acetylamino)-pentanoic acid [3-hydroxy-(pyridine-
2-
sulfonyl)-azepan-4-yl]-amide
Following the procedure of Example 28b except substituting phenoxyacetic acid
for
benzofuran-2-carboxylic acid the title compound was prepared: MS(EI) 519
(M+H+)
132
CA 02412353 2002-12-13
WO 01/95911 PCT/USO1/19062
b.) (S)-4-Methyl-2-(2-phenoxy-acetylamino)-pentanoic acid [3-oxo-(pyridine-2-
sulfonyl)-azepan-4-yl]-amide
Following the procedure of Example 1i except substituting the compound of
Example 66a the title compound was prepared: 'H NMR (CDC13): 8 1.0 (m, 6H),
1.5-2.1
(m, 5H), 2.2 (m, 2H), 2.7 (m, 1H), 3.7 (d, 1H). 4.0 (m, 1H), 4.5 (m, 3H), 4.7
(m, 1H), 5.1
(m, 1H), 7.0 (m, 3H), 7.3 (m, 2H), 7.5 (m, 1H), 7.9 (m, 2H), 8.6 (m, 1H);
MS(EI): 517
(M+H+, 60%).
Example 67
Preparation of (S)-2-f 2-(4-Fluoro-phenoxx)-acetylaminol-4-meth ~~1-pentanoic
acid~3-oxo-
(pyridine-2-sulfonyl)-azepan-4 yll-amide
a.) (S)-2-[2-(4-Fluoro-phenoxy)-acetylamino]-4-methyl-pentanoic acid [3-
hydroxy-
(pyridine-2-sulfonyl)-azepan-4-yl]-amide
Following the procedure of Example 28b except substituting 4-
fluorophenoxyacetic
acid for benzofuran-2-carboxylic acid the title compound was prepared: MS(EI)
537
(M+H+).
b.) (S)-2-[2-(4-Fluoro-phenoxy)-acetylamino]-4-methyl-pentanoic acid [3-oxo-
(pyridine-2-sulfonyl)-azepan-4-yl]-amide
Following the procedure of Example 1i except substituting the compound of
Example 67a the title compound was prepared: 'H NMR (CDC13): 8 1.0 (m, 6H),
1.5-2.1
(m, 5H), 2.2 (m, 2H), 2.7 (m, 1H), 3.6 (d, 1H). 4.0 (m, 1H), 4.5 (, 3H), 4.8
(m, 1H), 5.1
(m, 1H), 7.0 (m, 4H), 7.5 (m, 1H), 7.9 (m, 2H), 8.6 (m, 1H); MS(EI): 535
(M+H+, 50%).
133
CA 02412353 2002-12-13
WO 01/95911 PCT/USO1/19062
Example 68
Preparation of Benzofuran-2-carboxylic acid ((S)-3-methyl-1-f3-oxo-1-(pyridine-
2-
carbon -azepan-4-ylcarbamoyl)-3- butyll-amide
a.) {(S)-1-[3-Hydroxy-1-(pyridine-2-carbonyl)-azepan-4-ylcarbamoyl]-3-methyl-
butyl}-
carbamic acid tert-butyl ester
To a solution of the compound of Example 2g (0.25 g) in dichloromethane was
added picolinic acid (0.09g), EDC (0.14 g) and HOBt (0.10 g). The reaction was
stirred
until complete. Workup and column chromatography (5% methanol:ethyl acetate)
provided
the title compound (0.35 g).
b.) (S)-2-Amino-4-methylpentanoic acid [3-hydroxy-1-(pyridine-2-carbonyl)-
azepan-4-
yl]-amide
To a solution of the compound of Example 68a (0.34 g) in methanol (6 mL) was
added 4M HCl in dioxane (6 mL). The reaction was stirred until complete
whereupon it
was concentrated to provide the title compound (0.34 g): MS(EI) 349 (M+H+). '
c.) Benzofuran-2-carboxylic acid {(S)-3-methyl-1-[3-hydroxy-1-(pyridine-2-
carbonyl)-
azepan-4-ylcarbamoyl)-3- butyl]-amide
Following the procedure of Example 28b except substituting the compound of
Example 68b the title compound was prepared: MS(EI) 493 (M+H+).
d.) Benzofuran-2-carboxylic acid { (S)-3-methyl-1-[3-oxo-1-(pyridine-2-
carbonyl)-
azepan-4-ylcarbamoyl)-3- butyl]-amide
Following the procedure of Example 1i except substituting the compound of
Example 68c the title compound was prepared: 'H NMR (CDC13): 8 1.0 (m, 6H),
1.5-2.1
(m, 5H), 2.2 (m, 2H), 2.5 (m, 1H), 3.7 (m, 1H), 4.7 (m, 4H), 5.0 (m, 1H), 7.0-
7.5 (m,
8H), 8.2 (m, 1H); MS(EI): 491 (M+,100%).
134
CA 02412353 2002-12-13
WO 01/95911 PCT/USO1/19062
Example 69
Preparation of Benzofuran-2-carboxylic acid d(S)-3-methyl-1-f3-oxo-1-(1-oxy-
pyridine-2-
carbon~)-azepan-4-ylcarbamo l~-butyl~amide
Following the procedures of Examples 68a-d except substituting picolinic acid
N-
oxide for picolinic acid of Example 68c the title compound was prepared: 'H
NMR
(CDC13): b 1.0 (m, 6H), 1.5-2.1 (m, 5H), 2.2 (m, 2H), 2.5 (m, 1H), 3.5 (d,
1H). 4.0 (m, IH),
4.7 (m, 3H), 5.5 (m, 1H), 7.0 (m, 2H), 7.2-7.5 (m, 7H), 8.1 (m, 2H); MS(EI):
507 (M+,
20%).
Example 70
Preparation of 4-((S)-2-ter-t-Butylcarbonylamino-4-methyl-pentanoylamino)-3-
oxo-azepane-
I-carboxylic acid Benz 1y ester
Following the procedure of Example 92j, except substituting 4-((S)-2-tert-
Butoxycarbonylamino-4-methyl-pentanoylamino)-3-hydroxy-azepane-1-carboxylic
acid
benzyl ester for benzofuran-2-carboxylic acid { (S)-1-[3-hydroxy-6,6-dimethyl-
1-(pyridine-
2-sulfonyl)-azepan-4-ylcarbamoyl]-3-methyl-butyl}-amide, the title compound
was
prepared. The residue was purified by HPLC. First eluting diastereomer; MS
(M+H+):
476.2; IH-NMR (400 MHz, CDCl3): ~ 7.40-6.95(m, 7H), 5.25-4.60(m, 4H), 4.40-
4.06(m,
2H), 3.70-3.58(t, 1H), 2.70-2.50(m, 1H), 2.25-1.30(m, 1 6H); and the second
eluting
diastereomer:, 1.00-0.85(d, 6H); and the second eluting diastereomer: MS
(M+H+) 476.2.
Example 71
Preparation of 5,6-Dimethoxybenzofuran-2-carboxylic acids(S)-3-methyl-1-f3-oxo-
1-(1-
methyl-I H-imidazole-4-sulfonyl)-azepan-4-ylcarbam~ll-bull i amide
a.) {(S)-1-[3-Hydroxy-1-(1-methyl-1H-imidazole-2-sulfonyl)-azepan-4-
ylcarbamoyl}-
3-methyl-butyl}-carbamic acid tert-butyl ester
To a solution of the amine of Example 2g in methylene chloride (5m1) was added
pyridine (92p,L, 1.14mmol) followed by 1-methylimidazole-4-sulfonylchloride
(0.112g,
I35
CA 02412353 2002-12-13
WO 01/95911 PCT/USO1/19062
0.623mmo1). The reaction was allowed to stir for I6h at room temperature. The
solution
was then washed with saturated aqueous NaHC03, water and brine. The product
was
purified by column chromatography (silica gel: methanol/ methylenechloride) to
yield the
title compound as a white solid (0.172g, 68%): 'HNMR (400MHz, CDCl3) 8 7.6 (d,
1H),
7.5 (d, 1H), 6.6 (d, 1H), 3.8 (s, 3H), 1.5 (s, 9H), 1 (d, 6H); MS(ESI): 488.2
(M+H)+
b.) (S)-2-Amino-4-methyl-pentanoic acid [3-hydroxy-1-(1-methyl-1H-imidazole-2-
sulfonyl)-azepan-4-yl]-amide
To a solution of the compound of Example 71a (0.172g, 0.353mmo1) in minimal
MeOH was added 4M HCl in dioxane (lOmL) and stirred for 4h at room
temperature. The
reaction mixture was concentrated and azeotroped with toulene (2x's) to yield
the title
compound as an off white solid: MS(ESI): 388.2 (M+H)+
c.) 5,6-Dimethoxybenzofuran-2-carboxylic acid {(S)-3-methyl-1-[3-hydroxy-1-(1-
methyl-1H-imidazole-4-sulfonyl)-azepan-4-ylcarbamoyl]-butyl } amide
To a stirring solution of the compound of Example 71b (0.137g, 0.353 mmol),
5,6-
dimethoxybenzofuran-2-carboxylic acid (0.86g, 0.388mmol), triethylamine (246
mL, 1.77
mmol) and 1-hydroxybenzotriazole (O.OIg, 0.070mmo1) in DMF (5mL) was added 1-
(3-
dimethylaminopropyl)3-ethylcarbodimide hydrochloride (0.074g, 0.388mmo1).
After
stirring at room temperature for 16h, the solution was diluted with EtOAc and
washed
successively with saturated aqueous sodium bicarbonate, water (2x's), and
saturated brine.
The organic layer was dried over NaZSO~, filtered and concentrated. The
product was
purified by column chromatography ( silica gel; methanol/dichloromethane) to
yield the
title compound as a white solid (0.088g, 42%): MS(ESI): 592.1 (M+H)+
d.) 5,6-Dimethoxybenzofuran-2-carboxylic acid {(S)-3-methyl-1-[3-oxo-1-(1-
methyl-
1H-imidazole-4-sulfonyl)-azepan-4-ylcarbamoyl]-butyl } amide
Oxalyl chloride (52~,L, 0.596mmo1) chloride was cooled to -78°. To this
was added
dimethyl sulfoxide (206~.L, 1.49mmo1) in methylene chloride dropwise. After
stirring for
l5min at -78°, the alcohol in methylene chloride was added slowly and
allowed to stir for
1h when Et3N (416p.L,2.98mmo1) was added. The solution was then brought to
room
temperature and quenched with water and extracted into methylene chloride. The
organic
layer was separated and washed with brine, dried over MgS04, filtered and
concentrated.
The product was purified by column chromatography (silica gel:
methanol/methylene
136
CA 02412353 2002-12-13
WO 01/95911 PCT/USO1/19062
chloride) to yield the title compound as white solid (0.068g, 78%): 'H NMR
(400MHz,
CDC13) b 6.8-7.6 (m, 14H), 4 (d, 12H), 1 (d, 12H); MS(ESI): 590.1 (M+H)+
Example 72
Preparation of Benzofuran-2-carbox lic acid (S)-3-methyl-1-f 1-(5-methyl-1H-
f 1,2,4~triazole-3-sulfonyl)-3-oxo-azepan-4-ylcarbamoyll-butyllamide
a.) 4-((S)-2-Amino-4-methyl-pentanoylamino)-3-hydroxy-azepane-1-carboxylic
acid
benzyl ester
To a stirring solution of the compound of Example 2f (3.5 g, 7.33 mmol) in
EtOAc
(0.5 mL) was added 4M HCl in dioxane (12.8 mL). The mixture was stirred for 1h
at room
temperature. The reaction mixture was then concentrated and azeotroped with
toluene
(2x20 mL) to yield the title compound as a pale yellow oil (3.138, 100%):
MS(ESI) 378.4
(M+H)+
b.) 4-{(S)-2-[(Benzofuran-2-carbonyl)-amino]-4-methyl-pentanoylamino}-3-
hydroxy-
azepane-1-carboxylic acid benzyl ester
To a stirring solution of the compound of Example 72a (3.13g, 7.57mmo1),
benzofuran-2-carboxylic acid (1.35g, 8.32mmo1), triethylamine (1.17m1,
8.25mmo1) and 1-
hydroxybenzotriazole (0.2g, 1.48mmol) in DMF (30mL) was added 1-(3-
dimethylaminopropyl)3-ethylcarbodimide hydrochloride (1.6g, 8.33mmo1). After
stirring at
room temperature for 16h, the solution was diluted with EtOAc and washed
successively
with saturated aqueous sodium bicarbonate, water (2X), and brine. The organic
layer was
dried over Na2S04, filtered and concentrated. The product was purified by
column
chromatography (silica gel; ethylacetate/dichloromethane) to yield the title
compound
(3.7g, 93%). 'HNMR (400MHz, CDC13) 8 6.8-7.7 (m, 12H), 5.35 (s, 2H), 1.0 (d,
6H):
MS(ESI): 522 (M+H)+
c.) Benzofuran-2-carboxylic acid [(S)-1-(3-hydroxy-azepan-4-ylcaxbamoyl)-3-
methyl-
butyl]-amide
To a solution the compound of Example 72b (2.6 g, 4.9 mmol) in EtOAc (150 mL)
was added 10% palladium on carbon (1.3 g) and stirred at room temperature for
64 h under
137
CA 02412353 2002-12-13
WO 01/95911 PCT/USO1/19062
a hydrogen atmosphere. The mixture was then filtered through celite and the
filtrate
concentrated to yield the title compound as a white solid (1.92 g, 100%): 'H
NMR
(400MHz, CDC13) ~ 6.8-7.7(m, 7H), I.02 (d, 6H); MS(ESI) 388 (M+H)~
d.) Benzofuran-2-carboxylic acid {(S)-3-methyl-1-[1-(5-methyl-1H-
[1,2,4]triazole-3-
sulfonyl)-3-hydroxy-azepan-4-ylcarbamoyl]-butyl } amide
To a stirring solution of the compound of Example 72c (0.100g, 0.25mmo1) and
triethylamine (35~.L, 0.25mmo1) in methylene chloride (2mL) was added 5-methyl-
1H-
1,2,4-triazolesulfonylchloride (0.043g, 0.25mmol). The reaction was allowed to
stir for 10
min and washed with saturated aqueous NaHC03, water and saturated brine. The
organic
layer was dried over Na2S0ø, filtered and concentrated. The compound was
purified by
column chromatography (silica gel; ethylacetate/ hexane) to yield the title
compound as a
pale yellow oil (0.111, 84%): MS(ESI) 532.73 (M+H)+
e.) Benzofuran-2-carboxylic acid {(S)-3-methyl-1-[1-(5-methyl-1H-
[1,2,4]triazole-3-
sulfonyl)-3-oxo-azepan-4-ylcarbamoyl]-butyl } amide
To a stirring solution of the compound of Example 72d (0.108g, , 0.206mmo1) in
dimethylsulfoxide (2mL) was added triethylamine (172~,L, 1.23mmo1) followed by
sulfur
trioxide pyridine (0.116g, 0.718mmo1) and stirred for 16h at room temperature.
The
reaction mixture was diluted with EtOAc and washed with water (X2). The
organic layer
was dried over Na2S04, filtered and conentrated. The crude product was
purified by column
chromatography (silica gel; methanollmethylenechloride) to yield the title
compound as a
white solid (0.08g, '81 %): 'HNMR (400MHz, CDC13) b 7.1-7.7 (m, 7H), 2.65 (s,
3H), 1.0 (d,
6H); .MS(ESI): 552.71 (M+Na)+
138
CA 02412353 2002-12-13
WO 01/95911 PCT/USO1/19062
Example 73
Preparation of Benzofuran-2-carboxylic acid ~(S)-3-methyl-1-f 1-(1-methyl-1H-
imidazole-3-
sulfonyl)-3-oxo-azepan-4-ylcarbamoyll-butyl ~ amide
a.) Benzofuran-2-carboxylic acid {(S)-3-methyl-I-[1-(I-methyl-1H-imidazole-3-
sulfonyl)-3-hydroxy-azepan-4-ylcarbamoyl]-butyl } amide
To a stirring solution of the compound of Example 72c (0.100g, 0.25mmol) and
triethylamine (35~.L, 0.25mmol) was added 1-methylimidazole sulfonyl chloride
(0.046g,
0.255mmo1). The reaction was allowed to stir for IOmin and washed with
saturated aqueous
NaHC03, water and saturated brine. The organic layer was dried over NaZSOA,
filtered and
concentrated. The compound was purified by column chromatography (silica gel;
ethylacetate /hexane) to yield the title compound as a pale yellow oil
(0.113g, 82%):
'HNMR (400 MHz, CDC13) 8 6.9-7.7 (m, 9H), 3.9 (2s, 3H), 1.0 (d, 6H); MS(ESI):
531.8
(M+H)~
b.) Benzofuran-2-carboxylic acid {(S)-3-methyl-1-[1-(1-methyl-1H-imidazole-3-
sulfonyl)-3-oxo-azepan-4-ylcarbamoyl]-butyl } amide
To a stirring solution of the compound of Example 73a (0.085g, 0.159mmo1) in
dimethylsulfoxide was added triethylamine (133~.L, 0.95mmo1) followed by
sulfurtrioxide
pyridine (0.08g, 0.5mmol) and stirred for 16h at room temperature. The
reaction mixture
was diluted with EtOAc and washed with water (X2). The organic layer was dried
over
NaZSO~, filtexed and conentrated. The crude product was purified by column
chromatography (silica gel; methanol/methylenechloride) to yield the title
compound as a
white solid (0.072g, 83%). MS(ESI): 529.76 (M+H)+
139
CA 02412353 2002-12-13
WO 01/95911 PCT/USO1/19062
Example 74
Preparation of Benzofuran-2-carboxylic acid (S)-3-meth-1-f 1-(1H-imidazole-2-
sulfonXl)-
3-oxo-azepan-4-ylcarbam~ll-butyl ~ amide
a.) Benzofuran-2-carboxylic acid {(S)-3-methyl-1-[1-(1H-imidazole-2-sulfonyl)-
3-oxo-
azepan-4-ylcarbamoyl]-butyl } amide
To a stirring solution of the compound of Example 72c (0.100g, 0.25mmo1) and
triethylamine (35pL, 0.25mmo1) was added 2-imidazolesulfonyl chloride (0.046g,
0.255mmol). The reaction was allowed to stir for lOmin and washed with
saturated aqueous
NaHC03, water and saturated brine. The organic layer was dried over NaZS04,
filtered and
concentrated. The compound was purified by column chromatography (silica gel;
ethylacetate/hexane) to yield the title compound as a pale yellow oil (0.113g,
82%):
'HNMR (400MHz, CDCl3) ~ 7.1-7.7 (m, 9H), 4.8 (s, 1H), d, 6H); MS(ESI): 517.76
(M+H)+
b.) Benzofuran-2-carboxylic acid {(S)-3-methyl-1-[1-(1H-imidazole-2-sulfonyl)-
3-oxo-
azepan-4-ylcarbamoyl]-butyl } amide
To a stirring solution of the compound of Example 74a (0.107g, 0.206mmo1) in
dimethylsulfoxide (2mL) was added triethylamine (172~,L, 1.23mmo1) followed by
sulfurtrioxide pyridine (0.115g, 0.718mmo1) and stirred for 16h at room
temperature. The
reaction mixture was diluted with EtOAc and washed with water (X2). The
organic layer
was dried over Na2S0~, filtered and conentrated. The crude product was
purified by column
chromatography (silica gel; methanol/methylenechloride) to yield the title
compound as a
white solid (0.098, 85%); MS(ESI): 515.84 (M+H)+
140
CA 02412353 2002-12-13
WO 01/95911 PCT/USO1/19062
Exam In a 75
Preparation of Benzofuran-2-carboxylic acid ~(S)-3-methyl-1-f3-oxo-1-(thiazole-
2-
sulfonxl)-azepan-4-ylcarbamoyll-but~~ amide
a.) {(S)-1-[3-Hydroxy-1-(thiazole-2-sulfonyl)-azepan-4-ylcarbamoyl}-3-methyl-
butyl }-carbamic acid tert-butyl ester
To a solution of the compound of Example 2g (2.50g, 7.29mmo1) in DCE (100 mL)
was added P-NMM (4.0 g) and thioazole-2-sulphonyl chloride (1.6 g, 8.75 mmol).
After
shaking at room temperature overnight, the solution was filtered. The filtrate
was
concentrated to yield the title compound as white solid (2.50 g, 5.10 mmol,
70%); MS:
490.91 (M+H)+.
b.) Benzofuran-2-carboxylic acid {(S)-3-methyl-1-[3-hyroxy-1-(thiazole-2-
sulfonyl)-
azepan-4-ylcarbamoyl]-butyl }-amide .
To a solution of the compound of Example 75b (0.15 g, 0.45 mmol) in CHZCIz (20
mL) was added benzofuran-2-carboxylic acid (0.109 g, 0.172 mmol), 1-
hydroxybenzotriazole (0.106 g, 0.762mmo1), and P-EDC (0.85g, lmmollg) in
CHzCl2 (10
mL) . After shaking at room temperature overnight, the solution was treated
with tisamine
(0.589g, 3.75mmollg). After shaking for another 2hr, the solution was filtered
and
concentrated to yield the title compound as a white solid (166.7 mg, 70%); MS
(ESI):
535.3 (M+H)+.
c.) Benzofuran-2-carboxylic acid{S}-3-methyl-1-[3-oxo-1-(thiazole-2-sulfonyl)-
azepan-4-ylcarbamoyl]-butyl }-amide
To a stirring solution of the compound of Example 75c (166.7 mg, 0.313 mmol)
in
dichloromethane (4 mL) was added Dess-Martin reagent (265.5 mg, 0.626 mmol).
After
stirring at room temperature for 2 h, solutions of sodium thiosulfate (2 mL of
10% in
water) and saturated aqueous sodium bicarbonate (2 mL) were added
simultaneously to the
solution. The aqueous was extracted with dichloromethane (2x). The organic
phases were
combined, washed with saturated brine, dried (MgS04), filtered and
concentrated. The
residue was purified by HPLC (50:50 ethanol: hexane, 20mLlmin, 25min, WhelkO-
1(R,R)
21x250mm column, I1V detection at 280 nm and 305 nm) to yield the first
elution as a
141
CA 02412353 2002-12-13
WO 01/95911 PCT/USO1/19062
white solid (84.8mg, 50.8 %). MS (ESI): 533.2 (M+H)+ and the second elution as
a white
solid (50.1mg, 30.0%) MS: 533.2 (M+H+).
Example 76
Preparation of Benzofuran-2-carboxylic acid ( S)-3-methyl-1-f 1-(1-methyl-1H-
imidazole-4-
sulfonXl)-3-oxo-azepan-4-~carbamoyll-butt amide
a.) {(S)-1-[3-Hydroxy-1-(1-methyl-1H-imidazole-2-sulfonyl)-azepan-4-
ylcarbamoyl}-
3-methyl-butyl}-carbamic acid tert-butyl ester
To a solution of the amine of Example 2g in methylenechloride (5m1) was added
pyridine (92~.L, 1.14mmo1) followed by 1-methylimidazole-4-sulfonylchloride
(0.112g,
0.623mmo1). The reaction was allowed to stir for 16h at room temperature. The
solution
was then washed with saturated aqueous NaHC03, water and brine. The product
was
purified by column chromatography (silica gel: methanol/ methylenechloride) to
yield the
title compound as a white solid (0.172g, 68%): 'HNMR (400MHz, CDC13) 8 7.6 (d,
1H),~
7.5 (d, 1H), 6.6 (d, 1H), 3.8 (s, 3H), 1.5 (s, 9H), 1 (d, 6H); MS(ESI): 488.2
(M+H)+
b.) (S)-2-Amino-4-methyl-pentanoic acid [3-hydroxy-1-(1-methyl-1H-imidazole-2-
sulfonyl)-azepan-4-yl]-amide
To a solution of the compound of Example 76a (O.I72g, 0.353mmol) in minimal
MeOH was added 4M HCl in dioxane (lOmL) and stirred for 4h at room
temperature. The
reaction mixture was concentrated and azeotroped with toulene (2x's) to yield
the title
compound as an off white solid. MS(ESI): 388.2 (M+H)+
c.) Benzofuran-2-carboxylic acid {(S)-3-methyl-1-[1-(1-methyl-1H-imidazole-4-
sulfonyl)-3-hydroxy-azepan-4-ylcarbamoyl]-butyl } amide
To a stirring solution of the compound of Example 72c (0.2g, 0.471mmol),
benzofuran-2-carboxylic acid (0.084 g, 0.388 mmol), triethylamine (72~,L,
0.517mmo1) and
1-hydroxybenzotriazole (0.012 g, 0.088 mmol) in DMF (5 mL) was added 1-(3-
dimethylaminopropyl)3-ethylcarbodimide hydrochloride (0.099g, 0.515mmo1).
After
stirring at room temperature for 16h, the solution was diluted with EtOAc and
washed
successively with saturated aqueous sodium bicarbonate, water (2x's), and
saturated brine.
The organic layer was dried over NazSO~, filtered and concentrated. The
product was
142
CA 02412353 2002-12-13
WO 01/95911 PCT/USO1/19062
purified by column chromatography (silica gel; methanol/dichloromethane) to
yield the title
compound as a white solid (0.2268, 90%): 'HNMR (400MHz, CDC13) 8 6.9-8.1 (m,
18H),
3.75 (2s, 6H), 1 (d, 12H); MS(ESI): 531.80(M+H)+'
d.) Benzofuran-2-carboxylic acid {(S)-3-methyl-1-[1-(1-methyl-1H-imidazole-4-
sulfonyl)-3-oxo-azepan-4-ylcarbamoyl]-butyl}amide
To a stirring solution of the compound of Example 76a (0.226 g, 0.426mmol) in
dimethylsulfoxide (2rnL) was added triethylamine (355~L, 2.55mmo1) followed by
sulfur
trioxide pyridine (0.2388, 1.48mmol) and stirred for 16h at room temperature.
The reaction
mixture was diluted with EtOAc and washed with water (X2). The organic layer
was dried
over NazS04, filtered and conentrated. The crude product was purified by
column
chromatography (silica gel; methanol/methylenechloride) to yield the title
compound as a
white solid (0.1688, 76%): 'HNMR (400MHz, CDC13) 8 7.1-7.7 9m, 18H), 3.7 (2s,
6H), 0.9
(d, 12H); MS(ESI): 529.80 (M+H)+
EXample 77
Preuaration of 5-(4-Ox~morpholino-4-yl-ethox~)-benzofuran-2-carboxylic acid
(S)-3-
methyl-1-f3-oxo-1-(pyridine-2-sulfonyl)-azepan-4 ylcarbamoyll-butyl lamide
To a solution of the compound of Example 30b (0.01 g) in dichloromethane (2
mL)
was added m-CPBA (0.008 g). The reaction was stirred overnight. Workup and
column
chromatography (30% methanol:dichloromethane) provided the title compound: 'H
NMR
(CDC13): ~ 1.0 (m, 6H), 1.5-2.1 (m, 5H), 2.2 (m, 2H), 2.5 (m, 4H), 2.7 (m,
1H), 2.8 (m 2H),
3.7 (m, 4H), 3.8 (q, 1H). 4.0 (m, 3H), 4.7 (m, 1H), 4.8 (m, 1H), 5.0 (m, 1H),
7.0 (m, 3H),
7.4 (m, 2H), 7.5 (m, 1H), 7.9 (m, 2H), 8.6 (m, 1H); MS(EI): 671 (M~',100%) .
143
CA 02412353 2002-12-13
WO 01/95911 PCT/USO1/19062
Example 78
Preparation of Benzofuran-2-carboxylic acid ~(S~ 3-methyl-1-f3-oxo-1-(pyridine-
3-
sulfonyl -azepan-4-ylcarbamoyll-butyl~amide
a.) 4-((S)-2-Amino-4-methyl-pentanoylamino)-3-hydroxy-azepane-1-carboxylic
acid benzyl
ester
To a solution of 4-((S)-2-tert-butoxycarbonylamino-4-methyl-pentanoylamino)-3-
hydroxy-azepan-1-carboxylic acid benzyl ester of Example 2f (4.0 g) in
methanol (20 mL)
was added 4M HCl in dioxane (20 mL). The reaction was stirred at room
temperature for 2
hours whereupon it was concentrated to provide the title compound (3.8 g):
MS(EI) 378
(M+H+).
b.) 4-{(S)-2-[(Benzofuran-2-carbonyl)-amino]-4-methyl-pentanoylamino}-3-
hydroxy-
azepane-1-carboxylic acid benzyl ester
To a solution of 4-((S)-2-amino-4-methyl-pentanoylamino)-3-hydroxy-azepane-1-
carboxylic acid benzyl ester of Example 78a (3.2 g) in dichloromethane (200
mL) was
added EDC (1.48 g), HOBt (1.05 g), TEA (1.29 mL) and benzofuran-2-carboxylic
acid.
The reaction was stirred until complete. Workup and column chromatography
(2°Io
methanol:dichloromethane) provided the title compound (3.78 g): MS(EI) 521
(M+H+).
c.) Benzofuran-2-carboxylic acid [(S)-1-(3-hydroxy-azepan-4-ylcarbamoyl)-3-
methyl-
butyl]-amide
To a solution of 4-{ (S)-2-[(benzofuran-2-carbonyl)-amino]-4-methyl-
pentanoylamino}-3-hydroxy-azepane-1-carboxylic acid benzyl ester of Example
78b (1.6 g)
in methanol:ethyl acetate (50 mL:100 mL) was added 10% Pd/C. The reaction was
stirred
under a balloon of hydrogen for 2 hours whereupon it was filtered and
concentrated to
provide the title compound (1.16 g): MS(EI) 387 (M+H+)
d.) Benzofuran-2-carboxylic acid {(S)-3-methyl-1-[3-hydroxy-1-(pyridine-3-
sulfonyl)-
azepan-4-ylcarbamoyl]-butyl } amide
To a solution of benzofuran-2-carboxylic acid [(S)-1-(3-hydroxy-azepan-4-
ylcarbamoyl)-3-methyl-butyl]-amide of Example 78c (0.3 g) in dichloromethane
was added
triethylamine (0.17 mL) followed by 3-pyridinesulfonyl chloride (0.25 g). The
reaction was
144
CA 02412353 2002-12-13
WO 01/95911 PCT/USO1/19062
stirred at room temperature until complete as determined by TLC analysis.
Workup and
column chromatography (5% methanol:ethyl acetate) provided 0.32 g of the title
compound: MS(En 528 (M+H+).
e.) Benzofuran-2-carboxylic acid { (S)-3-methyl-1-[3-oxo-1-(pyridine-3-
sulfonyl)-
azepan-4-ylcarbamoyl]-butyl } amide
Following the procedure of Example 1i except substituting benzofuran-2-
carboxylic
acid { (S)-3-methyl-1-[3-hydroxy-1-(pyridine-3-sulfonyl)-azepan-4-ylcarbamoyl]-
butyl}amide of Example 78d the title compound was prepared: 1H NMR (CDC13): 8
1.0 (m,
6H), 1.5-2.1 (m, SH), 2.2 (m, 2H), 2.5 (m, 1H), 3.5 (d, 1H). 4.0 (m, 1H), 4.7
(m, IH), 4.8
(m, 1H), 5.0 (m, 1H), 7.0 (m, 2H), 7.2-7.5 (m, 6H), 8.1 (m, 1H), 8.9-9.0 (m,
2H); MS(El):
526 (M+,100%) .
Example 79
Preparation of Benzofuran-2-carboxylic acid 1(S)-3-methyl-1-f3-oxo-1-(1-oxy-
pyridine-3-
sulfon 1~-azepan-4-ylcarbamoyll-butyl amide
a.) Benzofuran-2-carboxylic acid {(S)-3-methyl-1-[3-hydroxy-1-(1-oxy-pyridine-
3-
sulfonyl)-azepan-4-ylcarbamoyl]-butyl}amide
To a solution of benzofuran-2-carboxylic acid { (S)-3-methyl-1-[3-hydroxy-1-
(pyridine-3-sulfonyl)-azepan-4-ylcarbamoyl]-butyl}amide of Example 78d (0.05g)
in
dichloromethane was added m-CPBA (0.05 g). The reacrton was stirred overnight.
Workup and column chromatography (10% methanol:dichloromethane) provided the
title
compound (0.03 g): MS(EI] 544 (M+H+)
b.) Benzofuran-2-carboxylic acid {(S)-3-methyl-1-[3-oxo-1-(1-oxy-pyridine-3-
sulfonyl)-azepan-4-ylcarbamoyl]-butyl } amide
Following the procedure of Example 1i except substituting benzofuran-2-
carboxylic
acid {(S)-3-methyl-1-[3-hydroxy-1-(1-oxy-pyridine-3-sulfonyl)-azepan-4-
ylcarbamoyl]-
butyl}amide of Example 79a the title compound was prepared:'H NMR (CDC13): 8
1.0 (m,
6H), 1.5-2.1 (m, 5H), 2.2 (m, 2H), 2.5 (m, 1H), 3.5 (d, 1H). 4.0 (m, 1H), 4.5
(m, 1H), 4.7
(m, 1H), 5.0 (m, 1H), 7.2-7.5 (m, 7H), 8.1-8.2 (m, 2H). MS(E)): 542 (M+, 50%).
145
CA 02412353 2002-12-13
WO 01/95911 PCT/USO1/19062
Example 80
Preparation of Quinoline-3-carbox lic acid (S)-1-(3 4-dichloro-benzene-
sulfon~)-3-oxo-
azepan-4-ylcarbamoyl)1-3-methyl-bull -} amide
Following the procedures of Example 75a-d except substituting 3,4-
dichlorosulfonyl chloride for thioazole-2-sulphonyl chloride of Example 75a
and quinoline-
3-carboxylic acid fox benzofura-2-carboxylic acid the title compound was
prepared: 'H
NMR(CDCI3, 400 MHz) 8 9.34 (s, 1H), 8.61 (s, 1H), 8.14 (m, 1H), 7.81 (m, 3H),
7.60 (m,
3H), 7.19 m, 2H), 5.09 (m, 1H), 4.88 (m, 1H), 4.50 (m, 1H), 3.92 (m, 1H), 3.51
(m, 1H),
2.57 (m, 1H), 2.23 (m, 2H), 1.60 (m, SH), 1.01 (m, 6H).
Example 81
Prepeparation of 5-Hydroxy-benzofuran-2-carboxylic acid ~(S)-3-methyl-1-f 1-(1-
methyl-
1H-imidazole-4-sulfony 1)-3-oxo-azepan-4-ylcarbamo~ll-butyl~amide
a.) 5-Hydroxy-benzofuran-2-carboxylic acid {(S)-3-methyl-1-[1-(1-methyl-1H-
imidazole-4-sulfonyl)-3-hydroxy-azepan-4-ylcarbamoyl]-butyl}amide
To a stirring solution of the compound of Example 76b (0.1 g, 0.235 mmol), 5-
hydroxybenzofuran-2-carboxylic acid(0.046g, 0.256mmo1), triethylamine (36 ~.L,
0.258
mmol) and 1-hydroxybenzotriazole (0.006g, 0.044mmo1) in DMF (5mL) was added 1-
(3-
dimethylaminopropyl)3-ethylcarbodimide hydrochloride (0.05g, 0.26mmo1). After
stirring
at room temperature for 16h, the solution was diluted with EtOAc and washed
successively
with saturated aqueous sodium bicarbonate, water (2X), and saturated brine.
The organic
layer was dried over Na2S04, filtered and concentrated. The product was
purified by column
chromatography ( silica gel; methanol/dichloromethane) to yield the title
compound as a
white solid (0.129g, 100%). 'HNMR (400MHz, CDC13) b 6.8-8 (m, 16H), 3.6 (2s,
6H), 0.85
(d, 12H).
MS(ESI):547.88(M+H)+'
146
CA 02412353 2002-12-13
WO 01/95911 PCT/USO1/19062
b.) 5-Hydroxy-benzofuran-2-carboxylic acid {(S)-3-methyl-1-[I-(1-methyl-1H-
imidazole-4-sulfonyl)-3-oxo-azepan-4-ylcarbamoyl]-butyl } amide
Oxalyl chloride (13 ~.L, 0.149 mmol) chloride was taken to-78°. To this
was added
dimethyl sulfoxide (28 ~.L, 0.394mmol) in methylene chloride dropwise. After
stirring for
l5min at-78 °, the alcohol of Example 81a in methylene chloride was
added slowly and
allowed to stir for 1h when Et3N (7 ~L, 0.05 mmol) was added. The solution was
then
brought to room temperature and quenched with water and extracted into
methylene
chloride. The organic layer was separated and washed with brine, dried over
MgSOd,
filtered and concentrated. The product was purified by column chromatography
(silica gel:
methanol/methylene chloride) to yield the title compound as white solid
(0.021g, 78%):
MS(ESI) 545.9(M+H)+'
Example 82
Preparation of Benzofuran-2-carboxylic acid (S)-3-methyl-1-f3-oxo-1-(1-oxy-
pyridine-2-
sulfon~)-azepan-4-ylcarbamoXl)1-3-methyl-butyl )-amide
a.) Benzofuran-2-carboxylic acid {(S)-3-methyl-1-j3-hydroxy-1-(1-oxy-pyridine-
2-
sulfonyl)-azepan-4-ylcarbamoyl)]-3-methyl-butyl }-amide
To a solution of benzofuran-2-carboxylic acid [(S)-1-(3-hydroxy-azepan-4-
ylcarbamoyl)-3-methyl-butyl]-amide of Example 78c (0.10 g) in dichloromethane
was
added triethylamine (0.07 mL) followed by 2-pyidinesulphonylchloride N-oxide.
The
reaction was stirred at room temperature overnight. Workup and chromatography
(10%
methanol:dichloromethane) provided the title compound (0.01 g): MS(En 544
(M+H+).
147
CA 02412353 2002-12-13
WO 01/95911 PCT/USO1/19062
b.) {(S)-3-methyl-1-[3-oxo-1-(1-oxy-pyridine-2-sulfonyl)-azepan-4-
ylcarbamoyl)]-3-
methyl-butyl }-amide
Following the procedure of Example 1i except substituting benzofuran-2-
carboxylic acid {(S)-3-methyl-1-[3-hydroxy-1-(1-oxy-pyridine-2-sulfonyl)-
azepan-4-
ylcarbamoyl)]-3-methyl-butyl}-amide of Example 82a the title compound was
prepared:
'H NMR (CDC13): 8 1.0 (m, 6H), 1.5-2.1 (m, 5H), 2.2 (m, 2H), 2.7 (m, 1H), 3.8
(q, 1H). 4.0
(m, 1H), 4.7 (m, 1H), 4.8 (m, 1H), 5.0 (m, 1H), 7.0 -7.5 (m, 9H), 8.1-8.2 (m,
2H). MS(EI):
542 (M+, 20%).
The diastereomeric mixture was separated by HPLC to provide the faster eluting
diastereoemer; 'HNMR (CDC13): 8 1.0 (m, 6H), 1.5-2.1 (m, 5H), 2.2 (m, 2H), 2.7
(t, 1H),
3.8 (d, 1H). 4.0 (d, 1H), 4.7 (m, 1H), 4.8 (d, 1H), 5.0 (m, 1H), 7.0 -7.5 (m,
9H), 8.1-8.2 (m,
2H); MS(EI): 542 (M+,100%), and the slower eluting diastereomer; MS(EI): 542
(M+H+,100%).
Example 83
Preparation of 2-(4-~ (S)-2-1 (Benzofuran-2-carbonyl)-amino -4-methyl-
pentanoylamino }-3-
oxo-azepane-1-sulfonyl)-benzoic acid
a.) 2-(4-{(S)-2-[(Benzofuran-2-carbonyl)-amino]-4-methyl-pentanoylamino}-3-
hydroxy-azepane-1-sulfonyl)-benzoic acid methyl ester
Following the procedure of Example 75a-c, except substituting 2-
carboxymethylsulphonyl chloride for 2-thiazolesulfonyl chloride, the title
compound was
prepared: MS (M+H* ) = 585.56, M+Na+ = 607.76, 2M+H+ = 1170.48.
b.) 2-(4-{(S)-2-[(Benzofuran-2-carbonyl)-amino]-4-methyl-pentanoylamino}-3-
hydroxy-azepane-1-sulfonyl)-benzoic acid
2-(4-{ (S)-2-[(benzofuran-2-carbonyl)-amino]-4-methyl-pentanoylamino }-3-
hydroxy-azepane-1-sulfonyl)-benzoic acid methyl ester (compound 83a, 180 mg,
0.309
mmol) was dissolved in 5:1 MeOH/water (6 ml) LiOH (14 mg, 0.34 mmol) was added
and
the reaction mixture was stirred and refluxed for 6 h. The reaction mixture
was then
quenched with water and 6 N HCl (adjusted to pH=2), extracted with EtOAc (3 x
10 ml),
dried with MgSOd, filtered, concentrated, and chromatographed (silica gel, 1%
acetic acid/
148
CA 02412353 2002-12-13
WO 01/95911 PCT/USO1/19062
4% MeOH/ CHzCl2) to yield the title compound as a white solid (48 mg, 27%):
M+H+=
572.2
c.) 2-(4-{(S)-2-[(Benzofuran-2-carbonyl)-amino]-4-methyl-pentanoylamino}-3-oxo-
azepane-1-sulfonyl)-benzoic acid
Following the procedure of Example 75d, except substituting 2-(4-{ (S)-2-
[(benzofuran-2-carbonyl)-amino]-4-methyl-pentanoylamino }-3-hydroxy-azepane-1-
sulfonyl)-benzoic acid for benzofuran-2-carboxylic acid { (S)-3-methyl-1-[3-
hydroxy-1-
(thiazole-2-sulfonyl)-azepan-4-ylcarbamoyl]-butyl}amide, the title compound
was prepared:
MS (M+H+): 570.2 (M+H+). 1H NMR(400Hz,CDCl3-CD30D): 8 8.05-7.95 (m, 1H), 7.70-
7.15 (m, 8H), 5.15-5.00 (m,lH), 4.95-4.75 (m, 2H), 4.15-4.00 (m, 1H), 3.65 (d,
IH), 2.85-
2.70 (m, 1H), 2.25-2.05 (m, 2H), 1.90-1.70 (m, 4H), I.60-1.45 (m, 1H), 0.95
(d, 6H).
Example 84
Preparation of 3-(4-~ (S)-2-~ (Benzofuran-2-carbonyl)-aminol-4-meth-
pentano~%lamino ~-3-
oxo-azepane-1-sulfonyl)-benzoic acid
Following the procedure of Example 83, except substituting 3-
carboxymethylbenzenesulphonyl chloride for 2-carboxymethylbenzenesulfonyl
chloride,
the title compound was prepared: MS 570.2 (M+H+); 1H NMR (400Hz,CDCl3
CD30D): 8 8.46 (d,lH), 8.31-8.25 (m,lH), 8.00-7.97 (m,lH), 7.70-7.62 (m, 2H),
7.55-7.46
(m, 1H), 7.45-7.35 (m,lH), 7.30-7.25 (m, 1H), 5.10-S.OS (m,lH), 4.95-4.78
(m,lH), 4.75-
4.55 (q,lH), 4.00 (d,lH), 3.S (d, 1H), 2.60-2.40 (m, 2H), 2.25-2.15 (m,lH),
1.95-1.70 (m,
2S 4H), 1.55-1.40 (m,lH), 0.98 (t, 6H).
149
CA 02412353 2002-12-13
WO 01/95911 PCT/USO1/19062
Example 85
Pr~aration of Benzofblthiophene-2-carboxylic acid 1(S)-3-methyl-1-f3-oxo-1. (1-
oxy-
pyridine-2-sulfon~)-azepan-4-ylcarbamoyll-butyl ~ amide
a.) {(S)-1-[3-Hydroxy-1-(1-oxy-pyridine-sulfonyl)-azepan-4-ylcarbamoyl]-3-
methyl-
butyl-carbamic acid tart-butyl ester
To a solution of [(S)-1-(3-hydroxy-azepan-4-ylcarbamoyl)-3-methyl-butyl]-
carbamic acid tart butyl ester of Example 2g (2.5 g) in dichloromethane (100
mL) and
saturated sodium bicarbonate was added freshly prepared 2-pyidinesulphonyl
chloride N-
oxide (prepared by bubbling chlorine gas through a solution of 2-
mercaptopyridine-N-
oxidein 9M HCl for approximately 90 minutes. Removal of excess chlorine under
vacuum
provided the 2-pyridinesulfonyl chloride-N-oxide). The reaction was stirred at
room
temperature for 1 hour. Workup and column chromatography (10%
methanol:dichloromethane) provided the title compound (2.0 g): MS(EI) 500
(M+H+).
b.) (S)-2-Amino-4-methyl-pentanoic acid [3-hydroxy-1-(1-oxy-pyyridine-
sulfonyl)-
azepan-4-yl]-amide
To a solution of {(S)-I-[3-hydroxy-1-(1-oxy-pyridine-sulfonyl)-azepan-4-
ylcarbamoyl]-3-methyl-butyl-carbamic acid tart-butyl ester of Example 8Sa (2.0
g) in
methanol (20 xnL) was added 4M HCl in dioxane (20 mL). The reaction was
stirred at
room temperature for 1.5 hours whereupon it was concentrated to provide the
title
compound (1.8 g): MS(EI) 400 (M+H+).
c.) Benzo[b]thiophene-2-carboxylic acid {(S)-3-methyl-1-[3-hydroxy-1-(1-oxy-
pyridine-2-sulfonyl)-azepan-4-ylcarbamoyl]-butyl } amide
To a solution of (S)-2-amino-4-methyl-pentanoic acid [3-hydroxy-1-(1-oxy-
pyyridine-sulfonyl)-azepan-4-yl]-amide of Example 85b (0.25 g) in
dichloromethane (12
mL) was added triethylamine (0.12 mL), EDC (0.11 g), HOBt (0.077 g) and
benzo[b]thiophene-2-carboxylic acid. The reaction was stirred until complete.
Workup and
column chromatography (10% methanol: dichloromethane) provided the title
compound
(0.26 g): MS(EI) 560 (M+H+).
150
CA 02412353 2002-12-13
WO 01/95911 PCT/USO1/19062
d.) Benzo[b]thiophene-2-carboxylic acid {(S)-3-methyl-1-[3-oxo-1-(1-oxy-
pyridine-2-
sulfonyl)-azepan-4-ylcarbamoyl]-butyl } amide
Following the procedure of Example 1i except substituting benzo[b]thiophene-2-
carboxylic acid {(S)-3-methyl-1-[3-hydroxy-1-(1-oxy-pyridine-2-sulfonyl)-
azepan-4-
ylcarbamoyl]-butyl}amide of Example 85c the title compound was prepared:'H NMR
(CDC13): ~ 1.0 (m, 6H), 1.5-2.1 (m, 5H), 2.2 (m, 2H), 2.7 (m, IH), 3.8 (q,
1H). 4.0 (m, 1H),
4.7 (m, 1H), 4.8 (m, 1H), 5.0 (m, 1H), 7.5 (m, 4H), 7.8 (m, 3H), 8.1-8.2 (m,
2H). MS(EI):
558 (M+,100%) .
The diastereomeric mixture was separated by HPLC to provide the faster eluting
diastereoemer; MS(EI): 558 (M+,100%), and the slower eluting diastereomer;
MS(EI): 558
(M+,100%).
Exam 1p a 86
Preparation of 5-Bromo-furan-2-carboxylic acid ~ S)-3-methyl-1-f3-oxo-1-(1-ox~
yridine-
2-sulfonyl)-azepan-4-ylcarbam~ll-butyl ~ amide
a. 5-Bromo-furan-2-carboxylic acid {(S)-3-methyl-1-[3-hydroxy-1-(1-oxy-
pyridine-2-
sulfonyl)-azepan-4-ylcarbamoyl]-butyl } annide
Following the procedure of Example 85c except substituting 5-bromo-2-furoic
acid
for benzo[b]thiophene-2-carboxylic acid the title compound was prepared:
MS(EI) 574
(M+H+).
b.) 5-Bromo-furan-2-carboxylic acid {(S)-3-methyl-1-[3-oxo-1-(1-oxy-pyridine-2-
sulfonyl)-azepana4-ylcarbamoyl]-butyl}amide
Following the procedure of Example 1i except substituting 5-bromo-furan-2-
carboxylic acid {(S)-3-methyl-1-[3-hydroxy-1-(1-oxy-pyridine-2-sulfonyl)-
azepan-4-
ylcarbamoyl]-butyl}amide of Example 86a the title compound was prepared: 'H
NMR
(CDC13): 8 1.0 (m, 6H), 1.5-2.1 (m, 5H), 2.2 (m, 2H), 2.7 (m, 1H), 3.8 (q,
1H). 4.0 (m, 1H),
4.7 (m, 1H), 4.8 (m, 1H), 5.0 (m, 1H), 7.0 (m, 2H), 7.4 (m, 2H), 8.1-8.2 (m,
2H); MS(EI):
570 (M+,100%) .
I5I
CA 02412353 2002-12-13
WO 01/95911 PCT/USO1/19062
The diastereomeric mixture vas separated b~~HPI;C to provide the faster
eluting
i
diastereoemer; MS(EI): 572 (M+H~,100%), and the slows eluting diastereomer;
MS(EI):
572 (M+H+,100%).
Example 87
Preparation of 5,6-Dimetho~benzofuran-2-carboxylic acid t(S)-3-methyl-1-f3-oxo-
1-(1-
ox~pyridine-2-sulfonyl)-azepan-4-ylcarbamo 1y ]butyl~amide
a.) 5,6-Dimethoxybenzofuran-2-carboxylic acid {(S)-3-methyl-1-[3-hydroxy-I-(1-
oxy-
pyridine-2-sulfonyl)-azepan-4-ylcarbamoyl]-butyl } amide
Following the procedure of Example 85c except substituting 5,6-
dimethoxybenzofuran-2-carboxylic acid for benzo[b]thiophene-2-carboxylic acid
the title
compound was prepared: MS(EI) 604 (M+H+).
b.) 5,6-Dimethoxybenzofuran-2-carboxylic acid { (S)-3-methyl-1-[3-oxo-I-( 1-
oxy-
pyridine-2-sulfonyl)-azepan-4-ylcarbamoyl]-butyl } amide
Following the procedure of Example 1i except substituting 5,6-
dimethoxybenzofuran-2-carboxylic acid {(S)-3-methyl-1-[3-hydroxy-1-(1-oxy-
pyridine-2-
sulfonyl)-azepan-4-ylcarbamoyl]-butyl}amide of Example 87a the title compound
was
prepared: 'H NMR (CDC13): 8 1.0 (m, 6H), 1.5-2.1 (m, 5H), 2.2 (m, 2H), 2.7 (m,
1H), 3.8
(m, 7H). 4.0 (m, 1H), 4.7 (m, 1H),
4.8 (m, 1H), 5.0 (m, IH), 7.0-7.5 (m, 5H), 8.1-8.2 (m, 2H); MS(EI): 602
(M+,100%) .
The diastereomeric mixture was separated by HPLC to provide the faster eluting
diastereoemer; MS(EI): 602 (M+,100%), and the slower eluting diastereomer;
MS(EI): 602
(M+,100%).
152
CA 02412353 2002-12-13
WO 01/95911 PCT/USO1/19062
Example 88
Preparation of 1-Ox~pyridine-2-carboxylic acid ~(S)-3-methyl-1-f3-oxo-1-
(pyridine-2-
sulfon~)-azepan-4-ylcarbamo 1Y 1-butyl)amide
a.) 1-Oxy-pyridine-2-carboxylic acid { (S)-3-methyl-1-[3-hydroxy-1-(pyridine-2-
sulfonyl)-azepan-4-ylcarbamoyl]-butyl } amide
Following the procedure of Example 28b except substituting picolinic acid N-
oxide
for benzofuran-2-carboxylic acid the title compound was prepared: MS(EI) 505
(M+H+)
b.) 1-Oxy-pyridine-2-carboxylic acid { (S)-3-methyl-1-[3-oxo-1-(pyridine-2-
sulfonyl)-
azepan-4-ylcarbamoyl]-butyl } amide
Following the procedure of Example 1i except substituting 1-oxy-pyridine-2-
carboxylic acid {(S)-3-methyl-1-[3-hydroxy-1-(pyridine-2-sulfonyl)-azepan-4-
ylcarbamoyl]-butyl}amide of Example 88a the title compound was prepared: 'H
NMR
(CDC13): 8 1.0 (m, 6H), 1.5-2.1 (m, 5H), 2.2 (m, 2H), 2.7 (m, 1H), 3.8 (q,
1H). 4.1 (m, 1H),
4.7 (m, 2H), 5.0 (m, 1H), 7.5 (m, 3H), 7.9 (m 2H), 8.3-8.4 (m, 2H), 8.6 (m,
1H); MS(EI):
503 (M~,100°~0) .
Example 89
Preparation of (S)-4-Methyl-2-(pyridine-2-sulfonylamino)-pentanoic acid f3-oxo-
1-
(pyridine-2-sulfon~)-azepan-4-yll-amide
a.) (S)-4-Methyl-2-(pyridine-2-sulfonylamino)-pentanoic acid [3-hydroxy-1-
(pyridine-
2-sulfonyl)-azepan-4-yl]-amide
To a solution of (S)-2-amino-4-methyl-pentanoic acid [3-hydroxy-1-(pyridine-2-
sulfonyl)-azepan-4-yl]-amide of Example 28a (0.25 g) in dichloromethane was
added
triethylamine (0.27 mL) and 2-pyridinesulfonyl chloride (0.15 g). The reaction
was stirred
until complete. Workup and column chromatography (5% methanol:dichloromethane)
provided the title compound (0.09 g): MS(EI) 525 (M+H+).
153
CA 02412353 2002-12-13
WO 01/95911 PCT/USO1/19062
b.) (S)-4-Methyl-2-(pyridine-2-sulfonylamino)-pentanoic acid [3-hydroxy-1-
(pyridine-
2-sulfonyl)-azepan-4-yl]-amide
Following the procedure of Example 1i except substituting (S)-4-methyl-2-
(pyridine-2-sulfonylamino)-pentanoic acid [3-hydroxy-1-(pyridine-2-sulfonyl)-
azepan-4-
yl]-amide of Example 89a the title compound was prepared: 'H NMR (CDC13): 8
1.0 (m,
6H), 1.5-2.1 (m, 5H), 2.2 (m, 2H), 2.7 (m, 1H), 3.8 (q, 1H). 4.0 (m, 1H), 4.7
(m, 1H), 5.0
(m, 1H), 5.5 (m, 1H), 7.0 (m 1H), 7.5 (m, 2H), 7.9 (m 3H), 8.6 (m, 2H).
MS(EI): 523
(M+,100%) .
Example 90
Preparation of (S)-2-(3-Benzyl-ureido)-4-meth r~l-pentanoic acid f3-oxo-1-
(pyridine-2-
sulfon 1)-azepan-4-yll-amide
a.) (S)-2-(3-Benzyl-ureido)-4-methyl-pentanoic acid [3-hydroxy-1-(pyridine-2-
sulfonyl)-azepan-4-yl]-amide
To a solution of (S)-2-amino-4-methyl-pentanoic acid [3-hydroxy-1-(pyyridine-
sulfonyl)-azepan-4-yl]-amide of Example 28a (0.25 g) in dichloromethane was
added
triethylamine (0.17 mL) and benzyl isocyanate (0.088g). The reaction was
stirred until
complete. Workup and column chromatography (5% methanol:dichloromethane)
provided
the title compound (0.12 g).
b.) (S)-2-(3-Benzyl-ureido)-4-methyl-pentanoic acid [3-oxo-1-(pyridine-2-
sulfonyl)-
azepan-4-yl]-amide
Following the procedure of Example 1i except substituting (S)-2-(3-benzyl-
ureido)-
4-methyl-pentanoic acid [3-hydroxy-1-(pyridine-2-sulfonyl)-azepan-4-yl]-amide
of
Example 89a the title compound was prepared: 'H NMR (CDC13): b 1.0 (m, 6H),
1.5-2.1
(m, 5H), 2.2 (m, 2H), 2.7 (m, 1H), 3.8 (q, 1H). 4.0 (m, 3H), 4,5 (t, 1H), 4.7
(m, 1H), 5.0 (m,
1H), 7.2 (, 5H), 7.5 (m, 1H), 7.9 (m, 2H), 8.6 (m, 1H); MS(EI): 515 (M+, 60%).
The diastereomeric mixture was separated by HPLC to provide the faster eluting
diastereoemer; MS(EI): 516 (M+H+,100%), and the slower eluting diastereomer;
MS(EI):
516 (M+H+,100%).
154
CA 02412353 2002-12-13
WO 01/95911 PCT/USO1/19062
Exam In a 91
Preparation of (S)-2-(3-Phenyl-uriedo)-4-meth~pentanoic acid f3-oxo-1
~pyridine-2-
sulfon~)-azepan-4-yll-amide
a.) (S)-2-(3-Phenyl-ureido)-4-methyl-pentanoic acid [3-hydroxy-1-(pyridine-2-
sulfonyl)-azepan-4-yl]-amide
Following the procedure of Example 90a except substituting phenyl isocyante
for
benzyl isocyanate the title compound was prepared: : MS(EI) 503 (M+H+).
b.) (S)-2-(3-Phenyl-ureido)-4-methyl-pentanoic acid [3-oxo-1-(pyridine-2-
sulfonyl)-
azepan-4-yl]-amide
Following the procedure of Example 1i except substituting (S)-2-(3-phenyl-
ureido)-4-methyl-pentanoic acid [3-hydroxy-1-(pyridine-2-sulfonyl)-azepan-4-
yl]-amide of
Example 91a the title compound was prepared: 'H NMR (CDCl3): ~ 1.0 (m, 6H),
1.5-2~1
(m, 5H), 2.2 (m, 2H), 2.7 (m, 1H), 3.8 (q, 1H). 4.0 (m, 1H), 4,5 (t, 1H), 4.7
(m, 1H), 5.0 (m,
1H), 7.0-7.9 (m, 8H), 8.6 (m, 1H). MS(EI): 501 (M*, 60%).
Example 92
Preparation of Benzofuran-2-carbox lic acids (S)-1-f 6 6-dimethyl-3-oxo-1 (p
rid
sulphonyl)-azepan-4-ylcarbamoyll-3-methyl-butyl ~-amide
a.) Allyl-(2,2-dimethyl-pent-4-enylidene)-amine
2,2-Dimethyl-4-pentenal (2.8 g, 25 mmol) was dissolved in 15 mL benzene. To
this
solution allylamine (2.85 g, 50 mmol) was added. A few molecular sieves were
used to
absorb water generated during the reaction. The mixture was stirred at room
temperature
overnight. Removal of the solvent and excess amount of allylamine on rotavapor
provided
3.76 g of the title compound as clear liquid (yield 100%). 1H-NMR (400 MHz,
CDC13):
7.52(s, 1H), 5.99-5.90(m, 1H), 5.80-5.70(m, 1H), 5.15-4.99(m, 4H), 4.OI-
3.99(m, 2H),
2.17(d, 2H), 1.06(s, 6H).
155
CA 02412353 2002-12-13
WO 01/95911 PCT/USO1/19062
b.) Allyl-(2,2-dimethyl-pent-4-enyl)-amine
Allyl-(2,2-dimethyl-pent-4-enylidene)-amine of Example 92a (3.76g, 25mmo1) was
diluted in 5m1 MeOH. To the solution NaBH4 (0.95g, 25mmo1) was added at
0°C. After
addition the mixture was stirred at r.t. for 5h. Methanol was removed on
rotavapor and the
residue was partitioned between EtOAc/ 20% NaOH. The organic layer was dried
over
Na SO , fitered and evaperated to give 2.26 g of the title compound: MS
(M+H+): 154.0;
2 4
H-NMR (400 MHz, CDC13): 5.93-5.76(m, 2H), 5.29-4.99(m, 4H), 3.22(d, 2H),
2.34(s,
2H), 2.01 (d, 2H), 0.94(s, 6H).
c.) Pyridine-2-sulfonic acid allyl-(2,2-dimethyl-pent-4-enyl)-amide
Allyl-(2,2-dimethyl-pent-4-enyl)-amine (0.43 g, 2.8 mmol) and NMM (0.57g,
5.6mmo1) were mixed in 30 mL CH2C12. 2-pryridinesulphonyl chloride was added
slowly
to the solution while it was cooled in an ice-water bath. After addition, the
reaction mixture
was stirred at r.t. overnight. Washed by 10% NaHC03 and the brine. Purified by
column
chromatography gave 0.6 g colorless oil in 73% yield. MS (M+H+): 295.2; 1H-NMR
(400
MHz, CDC13): ~ 8.71-8.70(d, 1H), 7.98-7.86(m, 2H), 7.48-7.46(m, 1H), 5.88-
5.77(m, 1H),
5.55-5.45(m; 1H), 5.13-5.00(m, 4H), 4.05-4.04(d, 2H), 3.24(s, 2H), 2.07-
2.05(d, 2H),
0.96(s, 6H)
d.) .3,3-Dimethyl-1-(pyridine-2-sulfonyl)-2,3,4,7-tetrahydro-1H-azepine
Pyridine-2-sulfonic acid allyl-(2,2-dimethyl-pent-4-enyl)-amide (0.6g, 2mmo1)
was
diluted in CH2C12 (50m1)_ After carefully degass by Ar, Grubbs catalyst
(0.17g, 0.2mmo1)
was added under Ar protection. The mixture was then refluxed for 2h before the
solvent
was removed on rotavapor. The crude product was purified by column
chromatography
(5%-20% E/H) to give 0.47g of the title compound in 87% yield. MS (M+H+):
267.0; 1H-
NMR (400 MHz, CDC13): ~ 8.70-8.69(d, 1H), 7.96-7.88(m, 2H), 7.49-7.46(m, 1H),
5.81-
5.70(m, 2H), 3.93-3.92(d, 2H), 3.26(s, 2H), 2.13-2.12(d, 2H), 1.00(s, 6H)
e.) 5,5-Dimethyl-3-(pyridine-2-sulfonyl)-8-oxa-3-aza-bicyclo[5.1.0]octane
To the solution of the compound of Example 92d (1.2 g, 4.5 mmol) in 50 mL
CH2C12 was added NaHC03 (2.4 g, 13.5 mmol) and then MCPBA (1.2 g, 13.5 mmol)
in
portions.. The reaction was stirred at r.t. for 4h before it was worked up by
washing with
15% NaOH, saturated K2C03, brine and dried (Na2S04) to give 1.0g crude product
in 79
156
CA 02412353 2002-12-13
WO 01/95911 PCT/USO1/19062
% yield ( good enough for next reaction without further purification.) MS
(M+H+): 283.0;
1H-NMR (400 MHz, CDCl3): ~ 8.68-8.67(d, 1H), 8.03-7.87(m, 2H), 7.49-7.40(m,
1H),
4.44-3.89(q, 1H), 3.62-3.59(d, 1H), 3.50(m, 1H), 3.00(m, 1H), 2.78-2.62(m,
2H), 2.12-
2.06(m, 1H), 1.52-1.46(q, 1H), 1.20(s, 3H), 0.89(s, 3H).
f.) 4-Azido-6,6-dimethyl-1-(pyridine-2-sulfonyl)-azepan-3-of
5,5-Dimethyl-3-(pyridine-2-sulfonyl)-8-oxa-3-aza-bicyclo[5.1.0]octane from
Example 92e (1.2 g, 4.3 mmol) was dissolved in the mixture of 7 ml MeOH and 1
ml H20.
NaN3 (0.83 g, 13 mmol) and NH4C1 (0.7 g, 13 mmol) were added to the solution.
The
resulting mixture was refluxed overnight. After the removal of MeOH, the
residue was
diluted in EtOAc and washed with 10% NaHC03 and brine. Purified on column
chromatography gave 0.4g 4-azido-6,6-dimethyl-1-(pyridine-2-sulfonyl)-azepan-3-
of (yield
29%); MS (M+H+): 326.2; 1H-NMR (400 MHz, CDCl3): ~ 8.68-8.67(m, 1H), 8.05-
7.90(m,
2H), 7.53-7.50(m, 1H), 3.75-3.60(m, 3H), 3.49-3.30(m, 3H), 1.73-1.66(m, 1H),
1.56-
1.52(d, 1H), 1.07(s, 3H), 0.99(s, 3H)
g.) 4-Amino-6,6-dimethyl-1-(pyridine-2-sulfonyl)-azepan-3-of
4-Azido-6,6-dimethyl-1-(pyridine-2-sulfonyl)-azepan-3-of from Example 92f (0.4
g, 1.23 mmol) was dissolved in THF (50 ml) and H20 (0.2 ml). PPh3 (0.48 g,
1.85 mmol)
was added to this solution. The reaction mixture was stirred at 45°C
over night. TLC
showed no starting material left. THF was evaporated, azeotroped with toluene
(2x's). The
resulting thick oil was dissolved in MeOH, treated with HCl in ether to adjust
pH to acidic.
More ether was added and the solution turned cloudy. 0.22 g white precipitate
of the title
compound was collected. (45% yield); 1H-NMR (400 MHz, CD30D): ~ 8.68(m, 1H),
8.10-
7.93(m, 2H), 7.62(m, 1H), 3.90(m, 1H), 3.68(m,lH), 3.40-2.90(m, 4H), 1.82(m,
1H),
1.53(d, 1H), 1.05(s, 6H)
h.) {(S)-1-[3-Hydroxy-6,6-dimethyl-1-(pyridine-2-sulfonyl)-azepan-4-
ylcarbamoyl]-3-
methyl-butyl}-carbamic acid tert-butyl ester
4-Amino-6,6-dimethyl-1-(pyridine-2-sulfonyl)-azepan-3-of HCl salt from Example
92g (0.22 g, 0.6 mmol) was dissolved in 5m1 DMF. To this solution, was added
Boc-Leu-
OH (0.22 g, 0.9 mmol)and HBTU (0.34 g, 0.9 mmol) and then NMM (0.24 g, 2.4
mmol).
The mixture was stirred at r.t. overnight. DMF was removed under high vacuum.
The
157
CA 02412353 2002-12-13
WO 01/95911 PCT/USO1/19062
residue was diluted with EtOAc and washed with H20, 10% NaHC03 and brine.
Purification by column chromatography gave 0.22 g of the title compound (72%
yield);
MS (M+H+): 512.9; 1H-NMR (400 MHz, CDCl3): ~ 8.68-8.67(d, 1H), 7.97-7.88(m,
2H),
7.69-7.64(m, 1H), 6.62-6.53(m, 1H), 5.06-5.00(m, 1H), 4.03-3.18(m, 7H), 1.80-
1.42(m,
15H), 1.04-0.92(m, 12H).
i.) Benzofuran-2-carboxylic acid {(S)-1-[3-hydroxy-6,6-dimethyl-1-(pyridine-2-
sulfonyl)-azepan-4-ylcarbamoyl]-3-methyl-butyl }-amide
To {(S)-1-[3-Hydroxy-6,6-dimethyl-1-(pyridine-2-sulfonyl)-azepan-4-
ylcarbamoyl]-3-methyl-butyl}-carbamic acid tert-butyl ester of Example 92h
(0.22g,
0.43mmol) was added HCl/dioxane (4M, 20 ml, 80 mmol). The mixture was stirred
at r.t.
for 2h before solvents and excess amount of HCl was removed on rotavapor. The
resulting
white solid was dissolved in 5 ml DMF. To the solution was added 2-
benzofurancarboxylic
acid (84 mg, 0.52 mmol), HBTU (0.2 g, 0.52 mmol) and NMM (0.2 g, 2 mmol). The
mixture was stirred at r.t. overnight. DMF was then removed and the residue
was re-
dissolved in EtOAc (50 ml), washed with 10% NaHC03 (50 ml x 2) and brine (50
ml).
Evaporation of the solvent gave crude product 0.26 g. Purification by column
chromatograghy gave the title compound 0.15 g in 63% total yield; MS (M+H+):
556.8;
1H-NMR (400 MHz, CDC13): ~ 8.66-8.63(m, 1H), 7.94-7.11(m, 10H), 4.72(m, 1H),
4.01-
2.98(m, 7H), 1.78-1.39(m, 5H), 1.02-0.85(m, 12H).
j.) Benzofuran-2-carboxylic acid {(S)-1-[3-oxo-6,6-dimethyl-1-(pyridine-2-
sulfonyl)-
azepan-4-ylcarbamoyl]-3-methyl-butyl }-amide
To a solution of benzofuran-2-carboxylic acid { (S)-1-[3-hydroxy-6,6-dimethyl-
1-
(pyridine-2-sulfonyl)-azepan-4-ylcarbamoyl]-3-methyl-butyl}-amide from Example
92i
(100 mg, 0.18mmol) in 2 ml CHZClZ, was added Dess-Martin reagent (76 mg, 0.18
mmol) at
r.t.. The solution was stirred for 2h when 20 ml CH2C12 was added and then
washed with
NaHC03 and brine. Purification by column chromatograghy (50% ethyl acetate in
hexane)
gave 70 mg of the title compound in 70% yield. MS (M+H+): 555.4; 1H-NMR (400
MHz,
CDC13): ~ 8.68-8.67(d, 1H), 7.97-7.93(m, 2H), 7.69-7.28(m, 6H), 7.32-6.92(m,
ZH), 5.24(m,
1H), 4.79-4.69(m, 2H), 3.80-3.71(m, 2H), 2.54-2.50(d, 1H), 1.92-1.76(m, 4H),
1.45
1.40(m, 4H), 1.01-0.91(m, 9H).
158
CA 02412353 2002-12-13
WO 01/95911 PCT/USO1/19062
The diastereomeric mixture was separated by HPLC to provide the faster eluting
diastereoemer; MS (M+H+): 555.2, and the slower eluting diastereomer; MS
(M+H+):
555.2.
Example 93
Preparation of 5-MethoxXbenzofuran-2-carboxylic acid 1(S)-3-methyl-1-f3-oxo-1-
(1-oxy-
pyridine-2-sulfon 1y )-azepan-4 sylcarbamoyll-butyl amide
a.) 5-Methoxybenzofuran-2-carboxylic acid {(S)-3-methyl-1-[3-hydroxy-1-(1-oxy-
pyridine-2-sulfonyl)-azepan-4-ylcarbamoyl]-butyl } amide
Following the procedure of Example 85c except substituting 5-methoxybenzofuran-
2-carboxylic acid for benzo[b]thiophene-2-carboxylic acid the title compound
was
prepared: MS(EI) 574 (M+H+).
b.) 5-Methoxybenzofuran-2-carboxylic acid {(S)-3-methyl-1-[3-oxo-1-(1-oxy-
pyridine-
2-sulfonyl)-azepan-4-ylcarbamoyl]-butyl } amide
Following the procedure of Example 1i except substuting 5-methoxybenzofuran-2-
carboxylic acid {(S)-3-methyl-1-[3-hydroxy-1-(1-oxy-pyridine-2-sulfonyl)-
azepan-4-
ylcarbamoyl]-butyl}amide of Example 93a the title compound was prepared:'H NMR
(CDC13): 8 1.0 (m, 6H), 1.5-2.1 (m, 5H), 2.2 (m, 2H), 2.7 (m, 1H), 3.8 ( m,
4H). 4.0 (m,
1H), 4,5 (t, 1H), 4.7 (m, 1H), 5.0 (m, 1H), 7.4-8.6 (m, 8H) 8.0-8.2 (m, 2H);
MS(EI): 572
(M+, 30%).
The diastereomeric mixture was separated by HPLC to provide the faster eluting
diastereoemer; 'HNMR (CDC13): 8 1.0 (m, 6H), 1.5-2.1 (m, 5H), 2.2 (m, 2H), 2.7
(t, 1H),
3.7 (s, 3H), 3.8 (d, 1H). 4.0 (d, 1H), 4,7 (m, 1H), 4.8 (d, 1H), 5.0 (m, 1H),
7.4-8.6 (m, 8H)
8.0-8.2 (m, 2H); MS(EI): 573 (M+H+,100%) and the slower eluting diastereomer;
MS(EI):
573 (M+H+,100%).
159
CA 02412353 2002-12-13
WO 01/95911 PCT/USO1/19062
Example 94
Preparation of Thienof3,2-blthiophene-2-carboxylic acid ~(S)-3-methyl-1-f3-oxo-
1-(1-oxy-
pyridine-2-sulfonyl)-azepan-4-ylcarbamoyll-butyl } amide
a.) Thieno[3,2-b]thiophene-2-carboxylic acid {(S)-3-methyl-1-[3-hydroxy-1-(1-
oxy-
pyridine-2-sulfonyl)-azepan-4-ylcarbamoyl]-butyl } amide
Following the procedure of Example 85c except substituting thieno[3,2-
b]thiophene-2-carboxylic acid for benzo[b]thiophene-2-carboxylic acid the
title compound
was prepared: MS(EI) 566 (M+H+).
b.) Thieno[3,2-b]thiophene-2-carboxylic acid {(S)-3-methyl-1-[3-oxo-1-(1-oxy-
pyridine-2-sulfonyl)-azepan-4-ylcarbamoyl]-butyl } amide
Following the procedure of Example 1i except substuting thieno[3,2-b]thiophene-
2-
carboxylic acid {(S)-3-methyl-1-[3-hydroxy-1-(1-oxy-pyridine-2-sulfonyl)-
azepan-4-
ylcarbamoyl]-butyl}amide of Example 94a the title compound was prepared: 'H
NMR
(CDC13): 8 1.0 (m,6H), 1.5-2.1 (m, 5H), 2.2 (m, 2H), 2.7 (m, 1H), 3.8 (q, 1H).
4.0 (m, 1H),
4,5 (t, 1H), 4.7 (m, 1H), 5.0 (m, 1H), 7.4-7.5 (m, 6H), 7.7 (d, 1H), 8.0-8.2
(m, 2H). MS(EI):
564 (Mk,100%) .
The diastereomeric mixture was separated by HPLC to provide the faster eluting
diastereoemer; 'HNMR (CDCl3): 8 1.0 (m, 6H), 1.5-2.1 (m, 5H), 2.2 (m, 2H), 2.7
(t, 1H),
3.8 (d, 1H). 4.0 (d, 1H), 4,5 (m, 1H), 4.7 (d, 1H), 5.0 (m, 1H), 7.4-7.5 (m,
6H), 7.7 (d, 1H),
8.0-8.2 (m, 2H); MS(EI): 565 (M+H+,100%) and the slower eluting diastereomer;
MS(EI):
565 (M+H+,100%).
160
CA 02412353 2002-12-13
WO 01/95911 PCT/USO1/19062
Exam In a 95
Preparation of Quinoxaline-2-carboxylic acid 1(S)-3-methyl-1-(3-oxo-1-(1-oxy-
pyridine-2-
sulfonyl)-azepan-4-ylcarbamoyll-butyl ~ amide
a.) Quinoxaline-2-carboxylic acid {(S)-3-methyl-1-[3-hydroxy-1-(1-oxy-pyridine-
2-
sulfonyl)-azepan-4-ylcarbamoyl]-butyl } amide
Following the procedure of Example 85c except substituting quinoxaline-2-
carboxylic acid for benzo[b]thiophene-2-carboxylic acid the title compound was
prepared:
MS(EI) 556 (M+H+).
b.) Quinoxaline-2-carboxylic acid {(S)-3-methyl-1-[3-oxo-1-(1-oxy-pyridine-2-
sulfonyl)-azepan-4-ylcarbamoyl]-butyl } amide
Following the procedure of Example 1i except substuting quinoxaline-2-
carboxylic
acid {(S)-3-methyl-1-[3-hydroxy-1-(1-oxy-pyridine-2-sulfonyl)-azepan-4-
ylcarbamoyl]-
butyl}amide .
of Example 95a the title compound was prepared: 'H NMR (CDC13): 8 1.0 (m, 6H),
1.5-2.1
(m, 5H), 2.2 (m, 2H), 2.7 (m, 1H), 3.8 (q, 1H). 4.0 (m, 1H), 4,5 (t, 1H), 4.7
(m, 1H), 5.0 (m,
1H), 7.4-7.5 (m, 2H), 7.9 (m, 1H), 8.0-8.4 (m, 4H, 9.6 (d, 1H); MS(EI): 554
(M+,100%) .
The diastereomeric mixture was separated by HPLC to provide the faster eluting
diastereoemer; MS(EI): 555 (M+H+,100%) and the slower eluting diastereomer;
MS(EI):
555 (M+H+,100%).
Example 96
Preparation of Quinoline-2-carboxylic acid ~S)-3-methyl-1-f3-oxo-1-(1-oxy-
p~idine-2-
sulfon~ -azepan-4-ylcarbamoyll-butyl~amide
a.) Quinoline-2-carboxylic acid {(S)-3-methyl-1-[3-hydroxy-1-(1-oxy-pyridine-2-
sulfonyl)-azepan-4-ylcarbamoyl]-butyl}amide
Following the procedure of Example 85c except substituting quinoline-2-
carboxylic
acid for benzo[b]thiophene-2-carboxylic acid the title compound was prepared:
MS(EI)
555 (M+H+)
161
CA 02412353 2002-12-13
WO 01/95911 PCT/USO1/19062
b.) Quinoline-2-carboxylic acid, {(S)-3-methyl-1-[3-oxo-1-(1-oxy-pyridine-2-
sulfonyl)-
azepan-4-ylcarbamoyl]-butyl } amide
Following the procedure of Example 1i except substuting quinoline-2-carboxylic
acid {(S)-3-methyl-1-[3-hydroxy-1-(1-oxy-pyridine-2-sulfonyl)-azepan-4-
ylcarbamoyl]-
butyl}amide of Example 96a the title compound was prepared: 1H NMR (CDC13): b
1.0
(m, 6H), 1.5-2.1 (m, 5H), 2.2 (m, 2H), 2.7 (m, 1H), 3.8 (q, 1H). 4.0 (m, 1H),
4,5 (t, 1H), 4.7
(m, 1H), 5.0 (m, 1H), 7.4-8.6 (m, 10H); MS(EI): 553 (M+,100%) .
The diastereomeric mixture was separated by HPLC to provide the faster eluting
diastereoemer; MS(EI): 554 (M+H+,100%) and the slower eluting diastereomer;
MS(EI):
554 (M+H+,100%).
Example 97
Preparation of Thio~hene-3-carboxylic acid ~(S)-3-methyl-1-f3-oxo-1-(1-oxy-
pyridine-2-
sulfonyl)-azepan-4-~carbamoyll-butyl~amide
a.) Thiophene-3-carboxylic acid {(S)-3-methyl-1-[3-hydroxy-1-(1-oxy-pyridine-2-
sulfonyl)-azepan-4-ylcarbamoyl]-butyl } amide
Following the procedure of Example 85c except substituting thiophene-3-
carboxylic acid for benzo[b]thiophene-2-carboxylic acid the title compound was
prepared:
MS(EI) 510 (M+H+)
b.) Thiophene-3-carboxylic acid {(S)-3-methyl-1-[3-oxo-1-(1-oxy-pyridine-2-
sulfonyl)-
azepan-4-ylcarbamoyl]-butyl } amide
Following the procedure of Example 1i except substuting thiophene-3-carboxylic
acid {(S)-3-methyl-1-[3-hydroxy-1-(1-oxy-pyridine-2-sulfonyl)-azepan-4-
ylcarbamoyl]-
butyl}amide of Example 97a the title compound was prepared:'H NMR (CDCl3): 8
1.0 (m,
6H), 1.5-2.1 (m, 5H), 2.2 (m, 2H), 2.7 (m, 1H), 3.8 (q, 1H). 4.0 (m, 1H), 4,5
(t, 1H), 4.7 (m,
1H), 5.0 (m, 1H), 7.4-8.0 (m, 4H), 7.8 (m, 1H), 8.1-8.2 (m, 2H); MS(EI): 508
(M+, 80%).
162
CA 02412353 2002-12-13
WO 01/95911 PCT/USO1/19062
Example 98
Preparation of 1H-Indole-5-carboxylic acid ((S)-3-methyl-1-f3-oxo-1-(1-oxy-
pyridine-2-
sulfon, l~)-azepan-4-ylcarbamo, l~t~lamide
a.) 1H-Indole-5-carboxylic acid {(S)-3-methyl-1-[3-hydroxy-1-(1-oxy-pyridine-2-
sulfonyl)-azepan-4-ylcarbamoyl]-butyl } amide
Following the procedure of Example 85c except substituting 1H-indole-5-
carboxylic acid for benzo[b]thiophene-2-carboxylic acid the title compound was
prepared:
MS(EI) 543 (M+).
b.) 1H-Indole-5-carboxylic acid {(S)-3-methyl-1-[3-oxo-1-(1-oxy-pyridine-2-
sulfonyl)-
azepan-4-ylcarbamoyl]-butyl } amide
Following the procedure of Example 1i except substuting of 1H-indole-5-
carboxylic acid {(S)-3-methyl-1-[3-hydroxy-1-(1-oxy-pyridine-2-sulfonyl)-
azepan-4-
ylcarbamoyl]-butyl}amide of Example 98a the title compound was prepared:'H NMR
(CDC13): 8 1.0 (m, 6H), 1.5-2.1 (m, 5H), 2.2 (m, 2H) , 2.7 (m, 1H), 3.8 (q,
1H); 4.0 (m, 1H),
4,5 (t, 1H), 4.7 (m, 1H), 5.0 (m, 1H), 7.4-8.0 (m, 7H), 8.1-8.2 (m, 2H), 8.6
(b, 1H); MS(EI):
541 (M~,100%) .
The diastereomeric mixture was separated by HPLC to provide the faster eluting
diastereoemer; MS(EI): 542 (M+H+,80%) and the slower eluting diastereomer;
MS(EI): 542
(M+H+,80%).
Example 99
Preparation of Benzof1,31dioxole-5-carbox lic acid (S)-3-methyl-1-f3-oxo-1-(1-
ox~
pyridine-2-sulfonyl)-azepan-4-ylcarbamoyll-butyl ) amide
a.) Benzo[1,3]dioxole-5-carboxylic acid {(S)-3-methyl-1-[3-hydroxy-1-(1-oxy-
pyridine-2-sulfonyl)-azepan-4-ylcarbamoyl]-butyl}amide
Following the procedure of Example 85c except substituting Benzo[1,3]dioxole-5-
carboxylic acid for benzo[b]thiophene-2-carboxylic acid the title compound was
prepared:
MS(EI) 548 (M+).
163
CA 02412353 2002-12-13
WO 01/95911 PCT/USO1/19062
b.) Benzo[1,3]dioxole-5-carboxylic acid {(S)-3-methyl-1-[3-oxo-1-(1-oxy-
pyridine-2-
sulfonyl)-azepan-4-ylcarbamoyl]-butyl } amide
Following the procedure of Example 1i except substuting benzo[1,3]dioxole-5-
carboxylic acid {(S)-3-methyl-1-[3-hydroxy-1-(1-oxy-pyridine-2-sulfonyl)-
azepan-4-
ylcarbamoyl]-butyl}amide of Example 99a the title compound was prepared: 'H
NMR
(CDCl3): S 1.0 (m, 6H), 1.5-2.1 (m, 5H), 2.2 (m, 2H), 2.7 (m, 1H), 3.8 (q,
1H); 4.0 (m, 1H),
4.5 (t, 1H), 4.7 (m, 1H), 5.0 (m, 1H), 6.0 (s, 2H), 7.4-8.0 (m, 5H), 8.1-8.2
(m, 2H);
MS(EI): 546 (M+,100%) .
The diastereomeric mixture was separated by HPLC to provide the faster eluting
diastereoemer; MS(EI): 547 (M+H+,100%) and the slower eluting diastereomer;
MS(EI):
547 (M+H+,100%).
Example 100
Preparation of Furan-2-carboxylic acid ((S)-3-methyl-1-f3-oxo-1-(1-oxy-
pyridine-2-
sulfon~)-azepan-4-ylcarbamoyll-butyl ~ amide
a.) Furan-2-carboxylic acid {(S)-3-methyl-1-[3-hydroxy-1-(1-oxy-pyridine-2-
sulfonyl)-
azepan-4-ylcarbamoyl]-butyl } amide
Following the procedure of Example 85c except substituting furoic acid for
benzo[b]thiophene-2-carboxylic acid the title compound was prepared: MS(EI)
494 (M+)
b.) Furan-2-carboxylic acid {(S)-3-methyl-1-[3-oxo-1-(1-oxy-pyridine-2-
sulfonyl)-
azepan-4-ylcarbamoyl]-butyl }amide
Following the procedure of Example 1i except substuting furan-2-carboxylic
acid
{(S)-3-methyl-1-[3-hydroxy-1-(1-oxy-pyridine-2-sulfonyl)-azepan-4-ylcarbamoyl]-
butyl}amide of Example 100a the title compound was prepared: 1H NMR (CDCl3): 8
1.0
(m, 6H), 1.5-2.1 (m, 5H), 2.2 (m, 2H), 2.7 (m, 1H), 3.8 (q, 1H); 4.0 (m, 1H),
4,5 (t, 1H), 4.7
(m, 1H), 5.0 (m, 1H), 7.4-8.0 (m, 5H), 8.1-8.2 (m, 2H); MS(EI): 492 (M~,100%)
.
The diastereomeric mixture was separated by HPLC to provide the faster eluting
diastereoemer MS(EI): 493 (M+H+,100%) and the slower eluting diastereomer;
MS(EI):
493 (M+H+,100%).
164
CA 02412353 2002-12-13
WO 01/95911 PCT/USO1/19062
Example 101
Preparation of (S)-4-Methyl-2-(2-thionhen-2-yl-acetylaminol-pentanoic acid [3-
oxo-1 ~1-
ox~pyridine-2-sulfon~)-azepan-4-yll-amide
a.) (S)-4-Methyl-2-(2-thiophen-2-yl-acetylamino)-pentanoic acid [3-hydroxy-1-
(1-oxy-
pyridine-2-sulfonyl)-azepan-4-yl]-amide
Following the procedure of Example 85c except substituting thiophene-2-acetic
acid for benzo[b]thiophene-2-carboxylic acid the title compound was prepared.
b.) (S)-4-Methyl-2-(2-thiophen-2-yl-acetylamino)-pentanoic acid [3-oxo-1-(1-
oxy-
pyridine-2-sulfonyl)-azepan-4-yl]-amide
Following the procedure of Example 1i except substuting (S)-4-methyl-2-(2-
thiophen-2-yl-acetylamino)-pentanoic acid [3-hydroxy-1-(1-oxy-pyridine-2-
sulfonyl)-
azepan-4-yl]-amide of
Example 101a the title compound was prepared: 'H NMR (CDCl3): 8 1.0 (m, 6H),
1.5-2.1
(m, 5H), 2.2 (m, 2H), 2.7 (m, 1H), 3.8 (m, 3H); 4.0 (m, 1H), 4,5 (t, 1H), 4.7
(m, 1H), 5.0
(m, 1H), 7.4-8.0 (m, 5H), 8.1-8.2 (m, 2H); MS(EI): 522 (M~, 20°Io).
Example 102
Preparation of 1H-Indole-2-carboxylic acid ~(S)-3-methyl-1-f3-oxo-1-(1-oxy-
pyridine-2-
sulfon l~)-azepan-4-ylcarbamoyll-butyl amide
a.) 1H-Indole-2-carboxylic acid {(S)-3-methyl-1-[3-hydroxy-1-(1-oxy-pyridine-2-
sulfonyl)-azepan-4-ylcarbamoyl]-butyl } amide
Following the procedure of Example 85c except substituting 1H-indole-2-
carboxylic acid for benzo[b]thiophene-2-carboxylic acid the title compound was
prepared:
MS(EI) 543 (M+).
b.) 1H-Indole-2-carboxylic acid {(S)-3-methyl-1-[3-oxo-1-(1-oxy-pyridine-2-
sulfonyl)-
azepan-4-ylcarbamoyl]-butyl } amide
Following the procedure of Example 1i except substuting 1H-indole-2-carboxylic
acid {(S)-3-methyl-1-[3-hydroxy-1-(1-oxy-pyridine-2-sulfonyl)-azepan-4-
ylcarbamoyl]-
165
CA 02412353 2002-12-13
WO 01/95911 PCT/USO1/19062
butyl}amide of Example 102a the title compound was prepared: 'H NMR (CDCl3): 8
1.0
(m, 6H), 1.5-2.1 (m, 5H), 2.2 (m, 2H), 2.7 (m, 1H), 3.8 (q, 1H); 4.0 (m, 1H),
4,5 (t, 1H), 4.7
(m, 1H), 5.0 (m, 1H),7.4-8.0 (m, 7H), 8.1-8.2 (m, 2H), 9.4 (b, 1H); MS(EI):
541
(M+,100%) .
The diastereomeric mixture was separated by HPLC to provide the faster eluting
diastereomer: MS(EI): 542 (M+H+,100%) and the slower eluting diastereomer;
MS(EI):
542 (M+H+,100%).
Example 103
Preparation of 4-Fluoro-1(S)-3-methyl-1-f3-oxo-1-(1-ox~pyridine-2-sulphonyl)-
azepan-4-
carbamo l~yli-benzamide
a.) 4-Fluoro-{(S)-3-methyl-1-[3-hydroxy-1-(1-oxy-pyridine-2-sulphonyl)-azepan-
4-
carbamoyl]-butyl}-benzamide
Following the procedure of Example 85c except substituting 4-fluorobenzoic
acid
for benzo[b]thiophene-2-carboxylic acid the title compound was prepared:
MS(EI) 522
(M+).
b.) 4-Fluoro-{(S)-3-methyl-1-[3-oxo-1-(1-oxy-pyridine-2-sulphonyl)-azepan-4-
carbamoyl]-butyl }-benzamide
Following the procedure of Example 1i except substuting 4-fluoro-{(S)-3-methyl-
1-
[3-hydroxy-1-(1-oxy-pyridine-2-sulphonyl)-azepan-4-carbamoyl]-butyl}-benzamide
of
Example 103a the title compound was prepared: 1H NMR (CDCl3): 8 1.0 (m, 6H),
1.5-2.1
(m, 5H), 2.2 (m, 2H), 2.7 (m, 1H), 3.8 (q, 1H); 4.0 (m, 1H), 4,5 (t, 1H), 4.7
(m, 1H), 5.0 (m,
1H),7.4-8.0 (m, 6H), 8.1-8.2 (m, 2H); MS(EI): 520 (M+,100%) .
The diastereomeric mixture was separated by HPLC to provide the faster eluting
diastereomer: MS(EI): 521 (M+H+,100%) and the slower eluting diastereomer
MS(EI):
521 (M+H+,100%).
166
CA 02412353 2002-12-13
WO 01/95911 PCT/USO1/19062
Example 104
Preparation of 5-(2-Morpholin-4-yl-ethoxy)-benzofuran-2-carboxylic acid (S)-3-
methyl-1-
j3-oxo-(1-oxy-pyridine2-sulphonyl)-azepan-4-ylcarbamo 1~-butt' -amide
a.) 5-(2-Morpholin-4-yl-ethoxy)-benzofuran-2-carboxylic acid { (S)-3-methyl-1-
[3-
hydroxy-(1-oxy-pyridine2-sulphonyl)-azepan-4-ylcarbamoyl]-butt' }-amide
Following the procedure of Example 85c except substituting 5-(2-morpholin-4-yl-
ethyloxy)benzofuran-2-carboxylic acid for benzo[b]thiophene-2-carboxylic acid
the title
compound was prepared: MS(En 673 (M+)
b.) 5-(2-Morpholin-4-yl-ethoxy)-benzofuran-2-carboxylic acid { (S)-3-methyl-1-
[3-oxo-
( 1-oxy-pyridine2-sulphonyl)-azepan-4-ylcarbamoyl]-butt' }-amide
Following the procedure of Example 1i except substuting 5-(2-morpholin-4-yl-
ethoxy)-benzofuran-2-carboxylic acid {(S)-3-methyl-1-[3-hydroxy-(1-oxy-
pyridine2-
sulphonyl)-azepan-4-ylcarbamoyl]-butt'}-amide of Example 104a the title
compound was
prepared: 'H NMR (CDCl3): 8 1.0 (m, 6H), 1.5-2.1 (m, 5H), 2.2 (m, 2H), 2.5 (m,
4H), 2.7
(m, 3H), 3.7 (m, 4H); 3.9 (m, 1H), 4,5 (m, 3H), 4.7 (m, 1H), 5.0 (m, 1H), 7.4-
8.0 (m, 6H),
8.1-8.2 (m, 2H); MS(EI): 671 (M+,100%) .
The diastereomeric mixture was separated by HPLC to provide the faster eluting
diastereomer: MS(EI): 672 (M+H+,100%) and the slower eluting diastereomer
MS(EI):
672 (M+H+,100%).
Example 105
Preparation of Thiophene-2-carboxylic acid ((S)-3-methyl-1-f3-oxo-1-(1-oxy-
pyridine-2-
sulfonyl)-azepan-4-ylcarbamoyll-butyl 1 amide
a.) Thiophene-2-carboxylic acid {(S)-3-methyl-1-[3-hydroxy-1-(1-oxy-pyridine-2-
sulfonyl)-azepan-4-ylcarbamoyl]-butyl } amide
Following the procedure of Example 85c except substituting thiophene-2-
carboxylic acid for benzo[b]thiophene-2-carboxylic acid the title compound was
prepared:
MS(EI) 510 (M+).
167
CA 02412353 2002-12-13
WO 01/95911 PCT/USO1/19062
b.) Thiophene-2-carboxylic acid {(S)-3-methyl-1-[3-oxo-1-(1-oxy-pyridine-2-
sulfonyl)-
azepan-4-ylcarbamoyl]-butyl } amide
Following the procedure of Example 1i except substuting thiophene-2-carboxylic
acid {(S)-3-methyl-1-[3-hydroxy-1-(1-oxy-pyridine-2-sulfonyl)-azepan-4-
ylcarbamoyl]-
butyl}amide of Example 105a the title compound was prepared:'H NMR (CDCl3): 8
1.0
(m, 6H), 1.5-2.1 (m, 5H), 2.2 (m, 2H), 2.7 (m, 1H), 3.8 (q, 1H); 4.0 (m, 1H),
4,5 (t, 1H), 4.7
(m, 1H), 5.0 (m, 1H), 7.4-8.0 (m, 5H), 8.1-8.2 (m, 2H); MS(EI): 508 (M+,100%)
.
The diastereomeric mixture was separated by HPLC to provide the faster eluting
diastereomer: MS(EI): 509 (M+H+,100%) and the slower eluting diastereomer
MS(EI):
509 (M+H+,100%).
Exam 1p a 106
Preparation of 3-Methylbenzofuran-2-carboxylic acid ((S)-3-methyl-1-f3-oxo-1-
(1-ox~
pyridine-2-sulfonyl)-azepan-4-ylcarbamoyll-butyl ~ amide
a.) 3-Methylbenzofuran-2-carboxylic acid {(S)-3-methyl-1-[3-hydroxy-1-(1-oxy-
pyridine-2-sulfonyl)-azepan-4-ylcarbamoyl]-butyl } amide
Following the procedure of Example 85c except substituting 3-methylbenzofuran-
2-
carboxylic acid for benzo[b]thiophene-2-carboxylic acid the title compound was
prepared:
MS(EI) 558 (M+)
b.) 3-Methylbenzofuran-2-carboxylic acid {(S)-3-methyl-1-[3-oxo-1-(1-oxy-
pyridine-2-
sulfonyl)-azepan-4-ylcarbamoyl]-butyl } amide
Following the procedure of Example 1i except substuting 3-methylbenzofuran-2-
carboxylic acid {(S)-3-methyl-1-[3-hydroxy-1-(1-oxy-pyridine-2-sulfonyl)-
azepan-4-
ylcarbamoyl]-butyl } amide of Example 106a the title compound was prepared: 'H
NMR
(CDC13): 8 1.0 (m, 6H), 1.5-2.1 (m, 5H), 2.2 (m, 2H), 2.5 (d, 3H), 2.7 (m,
1H), 3.8 (q, 1H);
4.0 (m, 1H), 4,5 (t, 1H), 4.7 (m, 1H), 5.0 (m, 1H), 7.4-8.0 (m, 6H), 8.1-8.2
(m, 2H);
MS(EI): 556 (M+,100%) .
The diastereomeric mixture was separated by HPLC to provide the faster eluting
diastereoemer: 'H NMR (CDCl3): 8 1.0 (m, 6H), 1.5-2.1 (m, 5H), 2.2 (m, 2H),
2.6 (s, 3H),
2.7 (t, 1H), 3.8 (d, 1H); 4.1 (d, 1H), 4,7 (m, 1H), 4.7 (d, 1H), 5.0 (m, 1H),
7.0 (m, 2H), 7.3
168
CA 02412353 2002-12-13
WO 01/95911 PCT/USO1/19062
(m, 2H), 7.4 (m, 4H), 8.1 (d, 1H), 8.2 (d, 1H); MS(EI): 557 (M+H+,100%) and
the slower
eluting diastereomer MS(EI): 557 (M+H+,100%).
Example 107
Preparation of 6-Methyl-N-~(S)-3-methyl-1-[3-oxo-1-(1-ox~pyridine-2-sulfonyl)-
azepan-4-
ylcarbamoyll-butyl ~-nicotinamide
a.) 6-Methyl-N-{(S)-3-methyl-1-[3-hydroxy-1-(1-oxy-pyridine-2-sulfonyl)-azepan-
4-
ylcarbamoyl]-butyl }-nicotinamide
Following the procedure of Example 85c except substituting 6-methylnicotinic
acid
for benzo[b]thiophene-2-carboxylic acid the title compound was prepared:
MS(EI) 519
(M+).
b.) 6-Methyl-N-{(S)-3-methyl-1-[3-oxo-1-(1-oxy-pyridine-2-sulfonyl)-azepan-4-
ylcarbamoyl]-butyl }-nicotinamide
Following the procedure of Example 1i except substuting of 6-methyl-N-{ (S)-3-
methyl-1-[3-hydroxy-1-(1-oxy-pyridine-2-sulfonyl)-azepan-4-ylcarbamoyl]-butyl}-
nicotinamide Example 107a the title compound was prepared: : 'H NMR (CDC13): 8
1.0
(m, 6H), 1.5-2.1 (m, 5H), 2.2 (m, 2H), 2.6 (s, 3H), 2.7 (m, 1H), 3.8 (q, 1H);
4.0 (m, 1H), 4,5
(t, 1H), 4.7 (m, 1H), 5.0 (m, 1H), 7.4-8.0 (m, 3H), 8.1-8.2 (m, 3H), 9.0 (m,
1H); MS(EI):
517 (M+,100%) .
The diastereomeric mixture was separated by HPLC to provide the faster eluting
diastereoemer: MS(EI): 518 (M+H+,100%) and the slower eluting diastereomer
MS(EI):
518 (M+H+,100%).
169
CA 02412353 2002-12-13
WO 01/95911 PCT/USO1/19062
Example 108
Preparation of (S)-4-Methyl-2-(2-thiophen-yl-acet~amino)-pentanoic acid-f3-oxo-
1-
(pyridine-2-sulfon l~pan-4-X11-buty~amide
a.) (S)-4-Methyl-2-(2-thiophen-yl-acetylamino)-pentanoic acid-[3-hydroxy-1-
(pyridine-
2-sulfonyl)-azepan-4-yl]-butyl } amide
Following the procedure of Example 28b except substituting thiophene-2-acetic
acid for benzofuran-2-carboxylic acid the title compound was prepared: MS(ESn
508.8
(M+H+).
b.) (S)-4-Methyl-2-(2-thiophen-yl-acetylamino)-pentanoic acid-[3-oxo-1-
(pyridine-2-
sulfonyl)-azepan-4-yl]-butyl } amide
Following the procedure of Example 1i except substuting (S)-4-methyl-2-(2-
thiophen-yl-acetylamino)-pentanoic acid-[3-hydroxy-1-(pyridine-2-sulfonyl)-
azepan-4-yl]-
butyl}amide of Example 108a the title compound was prepared: MS(ESI) 506.8 (M-
~-H+).
Example 109
Preparation of 1H-Indole-6-carbox lic acid (S)-3-meth'rl-1-f3-oxo-1-(pyridine-
2-sulfonyl)-
azepan-4-ylcarbamoyll-butyl ) amide
a.) 1H-Indole-6-carboxylic acid {(S)-3-methyl-1-[3-hydroxy-1-(pyridine-2-
sulfonyl)-
azepan-4-ylcarbamoyl]-butyl } amide
Following the procedure of Example 28b except substituting 1H-indole-6-
carboxylic acid for benzofuran-2-carboxylic acid the title compound was
prepared: MS(E)]
527 (M+H+).
b.) 1H-Indole-6-carboxylic acid {(S)-3-methyl-1-[3-oxo-1-(pyridine-2-sulfonyl)-
azepan-4-ylcarbamoyl]-butyl}amide
Following the procedure of Example 1i except substuting 1H-indole-6-carboxylic
acid {(S)-3-methyl-1-[3-hydroxy-1-(pyridine-2-sulfonyl)-azepan-4-ylcarbamoyl]-
butyl}amide of Example 109a the title compound was prepared: MS(E)] 525
(M+H+).
170
CA 02412353 2002-12-13
WO 01/95911 PCT/USO1/19062
Example 110
Preparation of Benzof 1,31dioxole-5-carbox lic acid (S)-3-methyl-1-f3-oxo-1-
(pyridine-2-
sulfon l~pan-4-ylcarbamo l~t~ amide
a.) Benzo[1.3]dioxole-5-carboxylic acid {(S)-3-methyl-1-[3-hydroxy-1-(pyridine-
2-
sulfonyl)-azepan-4-ylcarbamoyl]-butyl}amide
Following the procedure of Example 28b except substituting piperonylic acid
for
benzofuran-2-carboxylic acid the title compound was prepared: MS(EI) 532.7
(M+H+)
b.) Benzo[1,3]dioxole-5-carboxylic acid {(S)-3-methyl-1-[3-oxo-1-(pyridine-2-
sulfonyl)-azepan-4-ylcarbamoyl]-butyl } amide
Following the procedure of Example 1i except substuting benzo[1,3]dioxole-5-
carboxylic acid { (S)-3-methyl-1-[3-hydroxy-1-(pyridine-2-sulfonyl)-azepan-4-
ylcarbamoyl]-butyl}amide of Example 110a the title compound was prepared:
MS(EI)
530.8 (M+H+)
Example 111
Preparation of 3,4-Dihydro-2H-benzofblfl,4ldioxepine-7-carboxylic acid ~(S)-3-
methyl-1-
f 3-oxo-1-( 1-ox~pyridine-2-sulfonXl)-azepan-4-ylcarbamoyll-butyl l amide
a.) 3,4-Dihydro-2H-benzo[b][1,4]dioxepine-7-carboxylic acid {(S)-3-methyl-1-[3-
hydroxy-1-( 1-oxy-pyridine-2-sulfonyl)-azepan-4-ylcarbamoyl]-butyl }amide
Following the procedure of Example 85c except substituting 3,4-dihydro-2H-1,5-
benzodioxepine-7-carboxylic acid for benzo[b]thiophene-2-carboxylic acid the
title
compound was prepared: MS(EI) 576 (M+).
b.) 3,4-Dihydro-2H-benzo[b][1,4]dioxepine-7-carboxylic acid {(S)-3-methyl-1-[3-
oxo-
1-( 1-oxy-pyridine-2-sulfonyl)-azepan-4-ylcarbamoyl]-butyl } amide
Following the procedure of Example 1i except substuting 3,4-dihydro-2H-
benzo[b][1,4]dioxepine-7-carboxylic acid {(S)-3-methyl-1-[3-hydroxy-1-(1-oxy-
pyridine-2-
sulfonyl)-azepan-4-ylcarbamoyl]-butyl}amide of Example 111a the title compound
was
prepared: 'H NMR (CDC13): 8 1.0 (m, 6H), 1.5-2.1 (m, SH), 2.2 (m, 4H), 2.5 (d,
3H), 2.7
171
CA 02412353 2002-12-13
WO 01/95911 PCT/USO1/19062
f!~
(m, 1H), 3.8 (q, 1H); 4.0 (m, 1H), 4.2 (m, 4H), 4,5 (t, 1H), 4.7 (m, 1H), 5.0
(m, 1H), 7.4-8.0
(m, 5H), 8.1-8.2 (m, 2H); MS(EI): 575 (M+H+,100%) .
The diastereomeric mixture was separated by HPLC to provide the faster eluting
diastereoemer: MS(EI): 575 (M+H+,100%) and the slower eluting diastereomer
MS(EI):
575 (M+H+,100%).
Example 112
Preparation of 5-Meth 1-thiophene-2-carboxylic acids(S)-3-methyl-1-f3-oxo-1-(1-
oxy-
pyridine-2-sulfon ly_)-azepan-4-xlcarbamoyll-butyl amide
a.) 5-Methyl-thiophene-2-carboxylic acid {(S)-3-methyl-1-[3-hydroxy-1-(1-oxy-
pyridine-2-sulfonyl)-azepan-4-ylcarbamoyl]-butyl } amide
Following the procedure of Example 85c except substituting 5-methyl thiophene-
2-
carboxylic acid for benzo[b]thiophene-2-carboxylic acid the title compound was
prepared:
MS(EI) 524 (M+).
b.) 5-Methyl-thiophene-2-carboxylic acid {(S)-3-methyl-1-[3-oxo-1-(1-oxy-
pyridine-2-
sulfonyl)-azepan-4-ylcarbamoyl]-butyl } amide
Following the procedure of Example 1i except substuting 5-methyl-thiophene-2-
carboxylic acid {(S)-3-methyl-1-[3-hydroxy-1-(1-oxy-pyridine-2-sulfonyl)-
azepan-4-
ylcarbamoyl]-butyl } amide of Example 112a the title compound was prepared: 'H
NMR
(CDC13): 8 1.0 (m, 6H), 1.5-2.1 (m, 5H), 2.2 (m, 2H), 2.5 (d, 3H), 2.7 (m,
1H), 3.8 (q, 1H);
4.0 (m, 1H), 4,5 (t, 1H), 4.7 (m, 1H), 5.0 (m, 1H), 7.4-8.0 (m, 4H), 8.1-8.2
(m, 2H);
MS(EI): 523 (M+H+,100%) .
The diastereomeric mixture was separated by HPLC to provide the faster eluting
diastereoemer: MS(EI): 523 (M+H+,100%) and the slower eluting diastereomer
MS(EI):
523 (M+H+,100%).
172
CA 02412353 2002-12-13
WO 01/95911 PCT/USO1/19062
Example 113
Preparation of 4,5-Dibromo-thiophene-2-carboxylic acids(S)-3-methyl-1-f3-oxo-1-
(1-ox~
pyridine-2-sulfonyl)-azepan-4-ylcarbamoyll-but~~ amide
a.) 4,5-Dibromo-thiophene-2-carboxylic acid {(S)-3-methyl-1-[3-hydroxy-1-(1-
oxy-
pyridine-2-sulfonyl)-azepan-4-ylcarbamoyl]-butyl } amide
Following the procedure of Example 85c except substituting 4,5-dibromb-
thiophene-2-carboxylic acid for benzo[b]thiophene-2-carboxylic acid the title
compound
was prepared: MS(EI) 668 (M+)
b.) 4,5-Dibromo-thiophene-2-carboxylic acid {(S)-3-methyl-1-[3-oxo-1-(1-oxy-
pyridine-2-sulfonyl)-azepan-4-ylcarbamoyl]-butyl } amide
**Following the procedure of Example 1i except substuting 4,5-dibromo-
thiophene-2-carboxylic acid {(S)-3-methyl-1-[3-hydroxy-1-(1-oxy-pyridine-2-
sulfonyl)-
azepan-4-ylcarbamoyl]-butyl}amide of Example 113a the title compound was
prepared: 'H
NMR (CDC13): ~ 1.0 (m, 6H), 1.5-2.1 (m, 5H), 2.2 (m, 2H), 2.7 (m, 1H), 3.8 (q,
1H); 4.0
(m, 1H), 4,5 (t, 1H), 4.7 (m, 1H), 5.0 (m, 1H), 7.4-8.0 (m, 3H), 8.1-8.2 (m,
2H); MS(EI):
665 (M+H+,100°70) .
Example 114
Preparation of 3,5-Dimethyl-isoxazole-4-carboxylic acid ((S)-3-methyl-1-f3-oxo-
1-(1-oxy-
pyridine-2-sulfon l~pan-4-~carbamo 1~-butyl]amide
a.) 3,5-Dimethyl-isoxazole-4-carboxylic acid {(S)-3-methyl-1-[3-hydroxy-1-(1-
oxy-
pyridine-2-sulfonyl)-azepan-4-ylcarbamoyl]-butyl } amide
Following the procedure of Example 85c except substituting 3,5-dimethyl-
isoxazole-4-carboxylic acid for benzo[b]thiophene-2-carboxylic acid the title
compound
was prepared: MS(EI) 524 (M+H+)
173
CA 02412353 2002-12-13
WO 01/95911 PCT/USO1/19062
b.) 3,5-Dimethyl-isoxazole-4-carboxylic acid {(S)-3-methyl-1-[3-oxo-1-(1-oxy-
pyridine-2-sulfonyl)-azepan-4-ylcarbamoyl]-butyl } amide
Following the procedure of Example 1i except substuting 3,5-dimethyl-isoxazole-
4-carboxylic acid {(S)-3-methyl-1-[3-hydroxy-1-(1-oxy-pyridine-2-sulfonyl)-
azepan-4-
ylcarbamoyl]-butyl}amide of Example 114a the title compound was prepared: 'H
NMR
(CDC13): ~ 1.0 (m, 6H), 1.5-2.1 (m, 5H), 2.2 (m, 2H), 2.4 (m, 3H), 2.6 (m,
3H), 2.7 (m, 1H),
3.8 (q, 1H); 4.0 (m, 1H), 4,5 (t, 1H), 4.7 (m, 1H), 5.0 (m, 1H), 7.4-8.0 (m,
5H), 8.1-8.2 (m,
2H); MS(EI): 521 (M+,100%) .
Example 115
Preparation of (S)-2-(2-Benzyloxy-acetylamino)-4-methyl-pentanoic acidll-(4-
methox~
benzenesulfonyl)-3-oxo-azepan-4w11-amide
a.) {(S)-1-[3-Hydroxy-1-(4-methoxy-benzenesulfonyl)-azepan-4-ylcarbamoyl]-3-
methyl-butyl }-carbamic acid-tert-butyl ester
[(S)-1-(3-Hydroxy-azepan-4-ylcarbamoyl)-3-methyl-butyl]-carbamic acid-tert-
butyl ester (compound 2g, 0.8 g, 2.33 mmol) was dissolved in 1,2-
dichloroethane (DCE, 20
ml). Then, morpholinemethyl polystyrene resin beads (1.26 g, 3.7 mmol/g, Nova)
were
added and the solution was shaken for 5 minutes. Then, p-
methoxybenzenesulfonyl
chloride (0.48 g, 2.33 mmol) was dissolved in DCE (10 ml), and this solution
was added to
the reaction mixture. The reaction was shaken overnight, filtered, washed with
DCE (2 x
10 ml), then CHzCIz (10 ml). The combined organics were concentrated i~z
vacuo, and used
in the next reaction without further purification: M+H+ = 514.2.
b.) (S)-2-Amino-4-methyl-pentanoic acid [3-hydroxy-1-(4-methoxy-
benzenesulfonyl)-
azepan-4-yl]-amide-HCl salt
{ (S)-1-[3-Hydroxy-1-(4-methoxy-benzenesulfonyl)-azepan-4-ylcarbamoyl]-3-
methyl-butyl}-carbamic acid-tert-butyl ester (compound 207a, 0.59 g, 1.15
mmol) was
dissolved in CHZClz (8 ml), then a solution of 4 M HCl in dioxane (8 ml) was
added and the
reaction was stirred at RT for 4h. The reaction mixture was concentrated zrz
vacazo,
azeotroped from toluene twice (10 ml) irz vacuo, and was used in the next
reaction without
further purification: M+H~ = 413.8.
174
CA 02412353 2002-12-13
WO 01/95911 PCT/USO1/19062
c.) (S)-2-(2-Benzyloxy-acetylamino)-4-methyl-pentanoic acid [3-hydroxy-1-(4-
methoxy-benzenesulfonyl)-azepan-4-yl]-amide
(S)-2-Amino-4-methyl-pentanoic acid [3-hydroxy-1-(4-methoxy-benzenesulfonyl)-
azepan-4-yl]-amide-HCl salt (crude product from reaction mixture of 115b) was
dissolved
in MeOH (10 ml) and was treated with carbonate-polystyrene resin beads (1.75
g, 2.63
mmol/g, 4.6 mmol) and was shaken for 2h, filtered, washed with MeOH (10 ml)
and the
combined organics were concentrated in vacuo. The product was then dissolved
in DCE (2
ml) and morpholinemethyl polystyrene resin beads (0.25 g, 3.77 mmol/g, 0.91
mmol,
Nova) were added and the reaction was shaken for 5 minutes. Then, benzylacetyl
chloride
(0.081 g, 0.44 mmol) was added and the reaction mixture was shaken overnight.
Then,
trisamine polystyrene beads (0.1g, 3.66 mmol/g, 0.366 mmol) was added and the
reaction
mixture was shaken for 1.5 h. The reaction mixture was then filtered, washed
with DCE
(2x10 ml) and CHzClz (10 ml), and the combined organics were concentrated ira
vacuo. The
crude product was used in the next reaction without further purification: M+H+
= 562.2.
d.) (S)-2-(2-Benzyloxy-acetylamino)-4-methyl-pentanoic acid [1-(4-methoxy-
benzenesulfonyl)-3-oxo-azepan- 4-yl]-amide
(S)-2-(2-Benzyloxy-acetylamino)-4-methyl-pentanoic acid [3-hydroxy-1-(4-
methoxy-benzenesulfonyl)-azepan-4-yl]-amide (compound 207c, 0.24 g, 0.44 mmol)
was
dissolved in CHZCIz (5 ml), then Dess-Martin periodinane (0.3 g, 0.7 mmol) was
added and
the reaction was stirred for 30 min. The reaction was diluted with CH2Clz (20
ml), then was
extracted With aqueous 10% Na2SZO5 (10 ml), then aqueous 10% NaHC03 (10 ml),
water
(10 ml), brine (10 ml). The combined organics were concentrated i~a vacaco.
The residue
was purified by HPLC (50:50 Ethanol: hexanes, 20mL/min, 25min, WhelkO-1(R,R)
21x250mm column, LTV detection at 280nm and 305nm) to yield the first elution
as a white
solid (47 mg, 43 %): MS 560.4 (M+H+).1H NMR (400Hz,CDCl3): 8 7.73 (d, 2H),
7.40-
7.30 (m, 5H), 7.05 (d, 2H), 3.99 (s, 2H), 3.88 (s, 3H), 2.28-2.10 (m, 2H),
0.95 (t, 6H) and
second eluting diastereomer: MS 560.2 (M+H+).
175
CA 02412353 2002-12-13
WO 01/95911 PCT/USO1/19062
Example 116
Preparation of 5-(3-Trifluoromethyl-phenyl)-furan-2-carboxylic acid ~ (S)-3-
methyl-1-13-
oxo-1-(1-oxy-pyridine-2-sulfonyl)-azepan-4-ylcarbamoyll-butyllamide
"
a.) 5-(3-Trifluoromethyl-phenyl)-furan-2-carboxylic acid { (S)-3-methyl-1-[3-
hydroxy-
1-( 1-oxy-pyridine-2-sulfonyl)-azepan-4-ylcarbamoyl]-butyl } amide
Following the procedure of Example 85c except substituting 5-(3-
trifluoromethyl-
phenyl)-furan-2-carboxylic acid for benzo[b]thiophene-2-carboxylic acid the
title
compound was prepared: MS(El) 638 (M+)
b.) 5-(3-Trifluoromethyl-phenyl)-furan-2-carboxylic acid {(S)-3-methyl-1-[3-
oxo-1-(1-
oxy-pyridine-2-sulfonyl)-azepan-4-ylcarbamoyl]-butyl } amide
Following the procedure of Example 1i except substuting 5-(3-trifluoromethyl-
phenyl)-furan-2-carboxylic acid {(S)-3-methyl-1-[3-hydroxy-1-(1-oxy-pyridine-2-
sulfonyl)-azepan-4-ylcarbamoyl]-butyl}amide of Example 116a the title compound
was
prepared: 'H NMR (CDCn3): ~ 1.0 (m, 6H), 1.5-2.1 (m, 5H), 2.2 (m, 2H), 2.6 (d,
3H), 2.7
(m, 1H), 3.8 (q, 1H); 4.1 (m, 1H), 4,7 (t, 1H), 4.8 (m, 1H), 5.0 (m, 1H), 7.4-
8.0 (m, 9H),
8.1-8.2 (m, 2H); MS(EI): 637 (M+H+,100°0) .
The diastereomeric mixture was separated by HPLC to provide the faster eluting
diastereoemer: MS(EI): 637 (M+H+, 100%) and the slower eluting diastereomer
MS(EI):
637 (M+H+, 100%) .
Examine 117
Preparation of 5-Methyl-2-phenyl-oxazole-4-carboxylic acid ~(S)-3-methyl-1-f3-
oxo-1-(1-
ox~pyridine-2-sulfonyl)-azepan-4-ylcarbamo l~~~amide
a.) 5-Methyl-2 -phenyl-oxazole-4-carboxylic acid { (S)-3-methyl-1-[3-hydroxy-1-
(1-
oxy-pyridine-2-sulfonyn)-azepan-4-ylcarbamoyl]-butyl } amide
Following the procedure of Example 85c except substituting 5-methyl-2-phenyl-
oxazole-4-carboxylic acid for benzo[b]thiophene-2-carboxylic acid the title
compound was
prepared: MS(EI) 585 (M+).
176
CA 02412353 2002-12-13
WO 01/95911 PCT/USO1/19062
b.) 5-Methyl-2 -phenyl-oxazole-4-carboxylic acid { (S)-3-methyl-1-[3-oxo-1-( 1-
oxy-
pyridine-2-sulfonyl)-azepan-4-ylcarbamoyl]-butyl } amide
Following the procedure of Example 1i except substuting 5-methyl-2 -phenyl-
oxazole-4-carboxylic acid {(S)-3-methyl-1-[3-hydroxy-1-(1-oxy-pyridine-2-
sulfonyl)-
azepan-4-ylcarbamoyl]-butyl}amide of Example 117a the title compound was
prepared: IH
NMR (CDC13): 8 1.0 (m, 6H), 1.5-2.1 (m, 5H), 2.2 (m, 2H), 2.6 (d, 3H), 2.7 (m,
1H), 3.8 (q,
1H); 4.0 (m, 1H), 4,5 (t, 1H), 4.7 (m, 1H), 5.0 (m, 1H), 7.4-8.0 (m, 7H), 8.1-
8.2 (m, 2H);
MS(EI): 584 (M+H+, 100%).
The diastereomeric mixture was separated by HPLC to provide the faster eluting
diastereoemer: MS(EI): 584 (M+H+, 100%) and the slower eluting diastereomer
MS(EI):
584 (M+H~, 100%) .
Example 118
Preparation of Benzofuran-2-carboxylic acid {(S)-1-f 1-(3 4-dimethoxy-
benzenesulfon~
oxo-azepan-4-ylcarbamo 1~-butyl-amide
a.) Benzofuran-2-carboxylic acid {(S)-1-[ 1-(3,4-dimethoxy-benzenesulfonyl)-3-
hydroxy-azepan-4-ylcarbamoyl]-butyl }-amide
To a solution of benzofuran-2-carboxylic acid { (S)-1-[ 1-(3,4-dimethoxy-
benzenesulfonyl)-3-oxo-azepan-4-ylcarbamoyl]-butyl }-amide of Example 78c
(0.175 g) in
dichloromethane was added triethylamine (0.1 mL) and 3,4-
dimethoxybenzenesulfonyl
chloride (0.12 g). The reaction was stirred until complete. Workup and column
chromatography (5% methanol:dicloromethane) provided the title compound (0.21
g):
MS(EI) 587 (M+)
b.) Benzofuran-2-carboxylic acid {(S)-1-[ 1-(3,4-dimethoxy-benzenesulfonyl)-3-
oxo-
azepan-4-ylcarbamoyl]-butyl }-amide
Following the procedure of Example 1i except substuting benzofuran-2-
carboxylic
acid { (S)-1-[ 1-(3,4-dimethoxy-benzenesulfonyl)-3-hydroxy-azepan-4-
ylcarbamoyl]-butyl }-
amide of Example 118a the title compound was prepared: : 1H NMR (CDCl3): 8 1.0
(m,
6H), 1.5-2.1 (m, 6H), 2.6 (m, 1H), 3.5 (d, 1H); 3.7 (t, 6H), 4.0 (m, 1H), 4,5
(t, 1H), 4.7 (m,
1H), 5.0 (m, 1H), 7.4-8.0 (m, 8H); MS(EI): 586 (M+H+, 100%).
177
CA 02412353 2002-12-13
WO 01/95911 PCT/USO1/19062
Example 119
Preparation of Benzofuran-2-carboxylic acid (S)-1-f 1-(4-bromo-
benzenesulfonyl)-3-oxo-
azepan-4-ylcarbamoyll-3-methyl-butyl -amide
a.) Benzofuran-2-carboxylic acid {(S)-1-[1-(4-bromo-benzenesulfonyl)-3-hydroxy-
azepan-4-ylcarbamoyl]-3-methyl-butyl }-amide
Following the procedure of Example 118a except substituting 4-
bromobenzenesulfonyl chloride for 3,4-dimethoxybenzenesulfonyl chloride the
title
compound was prepared: MS(EI] 606 (M+)
b.) Benzofuran-2-carboxylic acid {(S)-1-[1-(4-bromo-benzenesulfonyl)-3-oxo-
azepan-
4-ylcarbamoyl]-3-methyl-butyl }-amide
Following the procedure of Example 1i except substituting benzofuran-2-
carboxylic
acid {(S)-1-[1-(4-bromo-benzenesulfonyl)-3-hydroxy-azepan-4-ylcarbamoyl]-3-
methyl-
butyl}-amide of Example 119a the title compound was prepared:'H NMR (CDCl3): 8
1.0
(m, 6H), 1.5-2.1 (m, 6H), 2.6 (m, 1H), 3.5 (d, 1H); 4.0 (m, 1H), 4,5 (t, 1H),
4.7 (m, 1H), 5.0
(m, 1H), 7.4-8.0 (m, 9H); MS(EI): 604 (M+, 100%).
Example 120
Preuaration of Benzofuran-2-carboxylic acid (S)-1-f 1-(benzo f 1 2
5loxadiazole-4-sulfonXlL
3-oxo-azenan-4-ylcarbamoyll-3-methyl-but~~-amide
a.) Benzofuran-2-carboxylic acid {(S)-1-[1-(benzo[1,2,5]oxadiazole-4-sulfonyl)-
3-
hydroxy-azepan-4-ylcarbamoyl]-3-methyl-butyl }-amide
Following the procedure of Example 118a except substituting benzofurazan-4-
sulfonyl chloride for 3,4-dimethoxybenzenesulfonyl chloride the title compound
was
prepared: MS(EI) 569 (M+).
b.) Benzofuran-2-carboxylic acid {(S)-1-[1-(benzo[1,2,5]oxadiazole-4-sulfonyl)-
3-oxo-
azepan-4-ylcarbamoyl]-3-methyl-butyl }-amide
Following the procedure of Example 1i except substituting Benzofuran-2-
carboxylic acid {(S)-1-[1-(benzo[1,2,5]oxadiazole-4-sulfonyl)-3-hydroxy-azepan-
4-
178
CA 02412353 2002-12-13
WO 01/95911 PCT/USO1/19062
ylcarbamoyl)-3-methyl-butyl }-amide of Example I20a the title compound was
prepared:
'H NMR (CDC13): 8 1.0 (m, 6H), 1.5-2.1 (m, 6H), 2.6 (m, 1H), 3.7 (m, 1H); 4.1
(m, 1H),
4.7 (m, 2H), 5.2 (m, IH), 7.4-8.0 (m, 8H); MS(EI): 568 (M+H+, 100°l0).
Example 121
Preparation of Benzofuran-2-carboxylic acid 1 (S)-1-f 1-(3 5-dimethyl-oxazole-
4 -sulfon.
3-oxo-azepan-4-ylcarbamoyll-3-methyl-butt)-amide
a.) Benzofuran-2-carboxylic acid {(S)-1-[1-(3,5-dimethyl-oxazole-4 -sulfonyl)-
3-
hydroxy-azepan-4-ylcarbamoyl]-3-methyl-butyl }-amide
Following the procedure of Example 118a except substituting 3,5-
dimethyloxazole-
4-sulphonyl chloride for 3,4-dimethoxybenzenesulfonyl chloride the'title
compound was
prepared: MS(EI) 546 (M+).
b.) Benzofuran-2-carboxylic acid {(S)-1-[1-(3,5-dimethyl-oxazole-4 -sulfonyl)-
3-oxo-
azepan-4-ylcarbamoyl]-3-methyl-butyl }-amide
Following the procedure of Example 1i except substituting benzofuran-2-
carboxylic acid {(S)-1-[1-(3,5-dimethyl-oxazole-4-sulfonyl)-3-hydroxy-azepan-4-
ylcarbamoyl]-3-methyl-butyl}-amide of Example 121a the title compound was
prepared:
'H NMR (CDCl3): 8 1.0 (m, 6H), 1.5-2.2 (m, 6H), 2.2 (m, 2H), 2.4 (d, 3H), 2.7
(t, 3H), 3.6
(d, 1H), 4.1 (m, 1H), 4.4 (t, 1H), 4.7 (m, 1H), 5.2 (m, 1H), 7.4-8.0 (m, 5H);
MS(EI): 544
(M+, 100%).
Example 122
Preparation of 3-Methylbenzofuran-2-carboxylic acid ~ (S)-3-methyl-1-f 3-oxo-1-
(~yridine-
2-sulfonyl)-r azepan-4-ylcarbamo l~~lamide
a.) 3-Methylbenzofuran-2-carboxylic acid {(S)-3-methyl-1-[3-hydroxy-1-
(pyridine-2-
sulfonyl)-azepan-4-ylcarbamoyl]-butyl } amide
Following the procedure of Example 28b except substituting 3-methylbenzofuran-
2-carboxylic acid for benzofuran-2-carboxylic acid the title compound was
prepared:
MS(EI) 542 (M+).
179
CA 02412353 2002-12-13
WO 01/95911 PCT/USO1/19062
b.) 3-Methylbenzofuran-2-carboxylic acid {(S)-3-methyl-1-[3-oxo-1-(pyridine-2-
sulfonyl)-azepan-4-ylcarbamoyl]-butyl } amide
Following the procedure of Example 1i except substituting 3-methylbenzofuran-2-
carboxylic acid {(S)-3-methyl-1-[3-hydroxy-1-(pyridine-2-sulfonyl)-azepan-4-
ylcarbamoyl]-butyl}amide of Example 122a the title compound was prepared:'H
NMR
(CDC13): 8 1.0 (m, 6H), 1.5-2.2 (m, 6H), 2.2 (m, 2H), 2.6 (d, 3H), 2.7 (m,
1H), 3.8 (m,
1H), 4.1 (m, 1H), 4.7 (m, 2H), 5.2 (m, 1H), 7.4-8.0 (m, 7H); 8.7 (m, 1H);
MS(EI): 540
(M+, 100%).
The diastereomeric mixture was separated by HPLC to provide the faster eluting
diastereoemer: 'H NMR (CDC13): 8 1.0 (m, 6H), 1.5-2.2 (m, 6H), 2.2 (m, 2H),
2.6 (s, 3H),
2.7 (m, 1H), 3.8 (d, 1H); 4.1 (d, 1H), 4.7 (m, 2H), 5.2 (m, 1H), 7.4-8.0 (m,
7H); 8.7 (m,
1H); MS(EI): 541 (M+H+,100%) and the slower eluting diastereomer MS(EI): 541
(M+H+,
100%) .
Example 123
Preparation of Thienof3 2-blthiophene-2-carboxylic acid (S)-3-methyl-1-f3-oxo-
1-
nyridine-2-sulfonyl)-azepan-4-ylcarbamo l~yl)amide
a.) Thieno[3,2-b]thiophene-2-carboxylic acid {(S)-3-methyl-1-[3-hydroxy-1-
(pyridine-
2-sulfonyl)-azepan-4-ylcarbamoyl]-butyl } amide
Following the procedure of Example 28b except substituting thieno[3,2-
b]thiophene-2-carboxylic acid for benzofuran-2-carboxylic acid the title
compound was
prepared: MS(EI) 550 (M+).
b.) Thieno[3,2-b]thiophene-2-carboxylic acid {(S)-3-methyl-1-[3-oxo-1-
(pyridine-2-
sulfonyl)-azepan-4-ylcarbamoyl]-butyl } amide
Following the procedure of Example 1i except substituting thieno[3,2-
b]thiophene-
2-carboxylic acid {(S)-3-methyl-1-[3-hydroxy-1-(pyridine-2-sulfonyl)-azepan-4-
ylcarbamoyl]-butyl}amide of Example 123a the title compound was prepared:'H
NMR
(CDCI~): 8 1.0 (m, 6H), 1.5-2.2 (m, 6H), 2.2 (m, 2H), 2.7 (m, 1H), 3.8 (m,
1H); 4.1 (m, 1H),
4.7 (m, 2H), 5.2 (m, 1H), 7.4-8.0 (m, 8H); 8.7 (m, 1H); MS(EI): 548 (M+,
100%).
180
CA 02412353 2002-12-13
WO 01/95911 PCT/USO1/19062
The diastereomeric mixture was separated by HPLC to provide the faster eluting
diastereoemer: 'HNMR (CDCl3): 8 1.0 (m, 6H), 1.5-2.2 (m, 6H), 2.2 (m, 2H) 2.7
( t, 1H),
3.8 (d, 1H); 4.1 (d, 1H), 4.7 (m, 2H), 5.2 (m, 1H), 7.4-8.0 (m, 8H); 8.7 (d,
1H); MS(EI):
549 (M+H+,100°Io) and the slower eluting diastereomer MS(EI): 549
(M+H+, 100%) .
Example 124
Preparation of 5-tart-Butyl-3-methyl-thienof3,2-blthiophene-2-carboxylic acid
{(S)-3-
methyl-1-f3-oxo-1-(pyridine-2-sulfonyl)-azepan-4-ylcarbamo l~-butyl~amide
a.) 5-tar-t-Butyl-3-methyl-thieno[3,2-b]thiophene-2-carboxylic acid {(S)-3-
methyl-1-[3-
hydroxy-1-(pyridine-2-sulfonyl)-azepan-4-ylcarbamoyl]-butyl } amide
Following the procedure of Example 28b except substituting 5-tart-butyl-3-
methyl-
thieno[3,2-b]thiophene-2-carboxylic acid for benzofuran-2-carboxylic acid the
title
compound was prepared: MS(EI) 620 (M+).
b.) 5-tart-Butyl-3-methyl-thieno[3,2-b]thiophene-2-carboxylic acid {(S)-3-
methyl-1-[3-
oxo-1-(pyridine-2-sulfonyl)-azepan-4-ylcarbamoyl]-butyl } amide
Following the procedure of Example 1i except substituting 5-tart-butyl-3-
methyl-
thieno[3,2-b]thiophene-2-carboxylic acid {(S)-3-methyl-1-[3-hydroxy-1-
(pyridine-2-
sulfonyl)-azepan-4-ylcarbamoyl]-butyl } amide of Example 124a the title
compound was
prepared: 'H NMR (CDC13): 8 1.0 (m, 6H), 1.45 (s, 9H), 1.5-2.2 (m, 6H), 2.2
(m, 2H) 2.4
(d, 3H), 2.7 (m, 1H), 3.8 (m, 1H); 4.1 (m, 1H), 4.7 (m, 2H), 5.2 (m, 1H), 7.4-
8.0 (m, 4H);
8.7 (m, 1H); MS(EI): 618 (M+, 100°l0).
181
CA 02412353 2002-12-13
WO 01/95911 PCT/USO1/19062
Exam 1p a 125
Preparation of 5-Methyl-2-phenyl-oxazole-4-carboxylic acid ~S)-3-methyl-1-f3-
oxo-1-
(pyridine-2-sulfon l~pan-4-ylcarbamo.l~yllamide
a.) 5-Methyl-2-phenyl-oxazole-4-carboxylic acid { (S)-3-methyl-1-[3-hydroxy-1-
(pyridine-2-sulfonyl)-azepan-4-ylcarbamoyl]-butyl } amide
Following the procedure of Example 28b except substituting 5-methyl-2-phenyl-
oxazole-4-carboxylic acid for benzofuran-2-carboxylic acid the title compound
was
prepared: MS(EI) 569 (M+)
b.) 5-Methyl-2-phenyl-oxazole-4-carboxylic acid { (S)-3-methyl-1-[3-oxo-1-
(pyridine-
2-sulfonyl)-azepan-4-ylcarbamoyl]-butyl } amide
Following the procedure of Example 1i except substituting 5-methyl-2-phenyl-
oxazole-4-carboxylic acid { (S)-3-methyl-1-[3-hydroxy-1-(pyridine-2-sulfonyl)-
azepan-4-
ylcarbamoyl]-butyl}amide of Example 125a the title compound was prepared: 'H
NMR
(CDC13): 8 1.0 (m, 6H), 1.5-2.2 (m, 6H), 2.2 (m, 2H), 2.7 (m, 1H), 2.6 (m,
3H), 3.8 (m, 1H);
4.1 (m, 1H), 4.7 (m, 2H), 5.2 (m, 1H), 7.4-8.0 (m, 8H); 8.7 (m, 1H); MS(EI):
567 (M+,
100%).
The diastereomeric mixture was separated by HPLC to provide the faster eluting
diastereoemer: MS(EI): 568 (M+H+,100%) and the slower eluting diastereomer
MS(EI):
568 (M+H+,100%)
Exam 1p a 126
Preparation of 2-Phenyl-5-trifluoromethyl-oxazole-4-carbox lic acid (S)-3-
methyl-1-f3-
oxo-1-(pyridine-2-sulfonyl)-azepan-4-ylcarbamoyll-butyl 1 amide
a.) 2-Phenyl-5-trifluoromethyl-oxazole-4-carboxylic acid {(S)-3-methyl-1-[3-
hydrox-1-
(pyridine-2-sulfonyl)-azepan-4-ylcarbamoyl]-butyl}amide
Following the procedure of Example 28b except substituting 2-phenyl-5-
trifluoromethyl-oxazole-4-carboxylic acid for benzofuran-2-carboxylic acid the
title
compound was prepared: MS(EI) 623 (M+)
182
CA 02412353 2002-12-13
WO 01/95911 PCT/USO1/19062
b.) 2-Phenyl-5-trifluoromethyl-oxazole-4-carboxylic acid {(S)-3-methyl-1-[3-
oxo-1-
(pyridine-2-sulfonyl)-azepan-4-ylcarbamoyl]-butyl } amide
Following the procedure of Example 1i except substituting 2-phenyl-5-
trifluoromethyl-oxazole-4-carboxylic acid {(S)-3-methyl-1-[3-hydrox-1-
(pyridine-2-
sulfonyl)-azepan-4-ylcarbamoyl]-butyl}amide of Example 126a the title compound
was
prepared: 'H NMR (CDCl3): 8 1.0 (m, 6H), 1.5-2.2 (m, 6H), 2.2 (m, 2H), 2.7 (m,
1H), 3.8
(m, 1H); 4.1 (m, 1H), 4.7 (m, 2H), 5.2 (m, 1H), 7.4-8.0 (m, 8H); 8.7 (m, 1H);
MS(EI): 621
(M+, 100%).
The diastereomeric mixture was separated by HPLC to provide the faster eluting
diastereoemer: MS(EI): 622 (M+H+,100%) and the slower eluting diastereomer:
MS(EI):
622 (M+H+,100%).
Example 127
Preuaration of Quinoline-2-carboxylic acid f(S)-1-(1-methanesulfonyl-3-oxo-
azepan-4-
ylcarbamoyl)-3-methyl-butyll-amide
Following the procedure of Example 75, except substituting methanesulfonyl
chloride for thiazole-2-sulfonyl chloride and 2-quinoline carboxylic acid for
benzofuran-2
carboxylic acid, the title compound Was prepared. The residue was purified by
HPLC. First
eluting diastereomer; MS (M+H+): 475.2; 1H-NMR (400 MHz, CDC13): ~ 8.65(d,
1H),
8.35-8.28(q, 2H), 8.20-8.18(d, 1H), 7.91-7.89(d, 1H), 7.80-7.78(t, 1H), 7.67-
7.65(t, 1H),
7.10(d, 1H), 5.08(m, 1H), 4.73 (m, 1H), 4.56-4.51(d, 1H), 4.00(m, 1H), 3.67-
3.62(d, 1H),
2.91(s, 3H), 2.70(m, 1H), 2.32-2.10(m, 2H), 1.95-1.40(m, 5H), 1.02-1.00(m,
6H); and the
second eluting diastereomer: MS (M+H+): 475.2
Example 128
Preparation of 1-Methyl-1H-indole-2-carboxylic acid f(S)-1-(1-methanesulfonyl-
3-oxo-
azepan-4-ylcarbamoyl)-3-methyl-butyll-amide
Following the procedure of Example 75, except substituting methanesulfonyl
chloride for thiazole-2-sulfonyl chloride and N-methylindole-2-carboxylic acid
for
183
CA 02412353 2002-12-13
WO 01/95911 PCT/USO1/19062
benzofuran-2-carboxylic acid, the title compound was prepared. The residue was
purified
by HPLC. First eluting diastereomer; MS (M+H+): 477.2; 1H-NMR (400 MHz,
CDC13):
7.65-7.63(d, 1H), 7.39-7.33(m, 2H), 7.17-7.14(t, 1H), 6.98-6.95(m, 2H),
6.65(d, 1H),
5.08(m, 1H), 4.68 (m, 1H) 4.56-4.52(d, 1H), 4.03(m, 4H), 3.67-3.63(d, 1H),
2.92(s, 3H),
2.71(m, 1H), 2.32-2.10(m, 2H), 1.95-1.40(m, 5H), 1.02-1.00(d, 6H); and the
second eluting
diastereomer: MS (M+H+): 477.2
Example 129
Preparation of Furan-2-carboxylic acid 11(S)-1-(1-methanesulfonyl-3-oxo-azenan-
4-
ylcarbamoyl)-3-meth~ylcarbamoyll-methyl-amide
Following the procedure of Example 75, except substituting methanesulfonyl
chloride for thiazole-2-sulfonyl chloride and N-(2-furan-carbonyl)-glycine for
benzofuran-
2-carboxylic acid, the title compound was prepared. The residue was purified
by HPLC.
First eluting diastereomer; MS (M+H+): 471.2; 1H-NMR (400 MHz, CDC13): ~
7.50(m,
1H), 7.15(m, 1H), 7.05(m, 1H), 6.90(d, 1H), 6.55(m, 2H), 5.08(m, 1H), 4.55 (m,
2H),
4.12(m, 2H), 4.05(m, 1H), 3.70(d, 1H), 2.92(s, 3H), 2.75(m, 1H), 2.20-1.40(m,
7H), 0.95
(m, 6H); and the second eluting diastereomer: MS (M+H+): 471.4.
Example 130
Preparation of 5-Methoxybenzofuran-2-carboxylic acid ((S)-1-(1-methanesulfonyl-
3-oxo-
azepan-4-ylcarbamoyl)-3-meth~yll-amide
Following the procedure of Example 75, except substituting methanesulfonyl
chloride for thiazole-2-sulfonyl chloride and 5-methoxybenzofuran-2-carboxylic
acid for
benzofuran-2-carboxylic acid, the title compound was prepared. The residue was
purified
by HPLC. First eluting diastereomer; MS (M+H+): 494.2; 1H-NMR (400 MHz,
CDC13):
7.42-7.40(d, 2H), 7.08-6.94(m, 4H), 5.10(m, 1H), 4.71(m, 1H), 4.56-4.52(d,
1H), 4.02(m,
IH), 3.86(s, 3H), 3.68-3.63(d, IH), 2.92(s, 3H), 2.72(m, 1H), 2.30-1.I5(m,
2H), 1.95-
1.40(m, 5H), 0.99 (d, 6H); and the second eluting diastereomer: MS (M+H+):
494.2.
184
CA 02412353 2002-12-13
WO 01/95911 PCT/USO1/19062
Example 131
Preparation of Quinoxaline-2-carbolic acid f(S)-1-(1-methanesulfonyl-3-oxo-
azepan-4-
Ylcarbamoyl)-3-methyl-butyll-amide
Following the procedure of Example 75, except substituting methanesulfonyl
chloride for thiazole-2-sulfonyl chloride and quinoxaline-2-carboxylic acid
for benzofuran-
2-carboxylic acid, the title compound was prepared. The residue was purified
by HPLC.
First eluting diastereomer; MS (M+H+): 476.2; 1H-NMR (400 MHz, CDC13): ~
9.66(s,
1H), 8.38(d, 1H), 8.20-8.18(m, 2H), 7.88(m, 2H), 7.01(d, 1H), 5.10(m, 1H),
4.77(m, 1H),
4.57-4.52(d, 1H), 4.08-4.00(m, 1H), 3.69-3.64(d, 1H), 2.92(s, 3H), 2.71(m,
1H), 2.42-
2.15(m, 2H), 1.95-1.42(m, 5H), 1.02-1.01(d, 6H); and the second eluting
diastereomer:
MS (M+H+): 476.2.
Exam 1p a 132
Preparation of 5-(4-Chloro-phenyl)-furan-2-carboxylic acid ~ (S)-3-methyl-1-f
3-oxo-1-
(pyridine-2-sulfonyl)-azepan-4-ylcarbamoyll-butyl amide
a.) 5-(4-Chloro-phenyl)-furan-2-carboxylic acid {(S)-3-methyl-1-[3-hydroxy-1-
(pyridine-2-sulfonyl)-azepan-4-ylcarbamoyl]-butyl } amide
Following the procedure of Example 28b except substituting 5-(4-chlorophenyl)-
2-
furoic acid for benzofuran-2-carboxylic acid the title compound was prepared:
MS(EI) 590
(M+H+).
b.) 5-(4-Chloro-phenyl)-furan-2-carboxylic acid { (S)-3-methyl-1-[3-oxo-1-
(pyridine-2-
sulfonyl)-azepan-4-ylcarbamoyl]-butyl } amide
Following the procedure of Example 1i except substituting 5-(4-chloro-phenyl)-
furan-2-carboxylic acid { (S)-3-methyl-1-[3-hydroxy-1-(pyridine-2-sulfonyl)-
azepan-4-
ylcarbamoyl]-butyl}amide of Example 132a the title compound was prepared: 'H
NMR
(CDCl3): 8 1.0 (m, 6H), 1.5-2.1 (m, 5H), 2.2 (m, 2H), 2.7 (m, 1H), 3.7 (d,
1H), 4.0 (m, 1H),
4.7 (m, 2H), 5.0 (m, 1H), 6.7 (m, 1H), 7.2 (m, 1H), 7.3 (m, 2H), 7.5 (m, 1H),
7.7 (m, 2H),
8.0 (m, 2H), 8.7 (m, 1H); MS(EI): 587 (M+, 80%)
185
CA 02412353 2002-12-13
WO 01/95911 PCT/USO1/19062
The diastereomeric mixture was separated by HPLC to provide the faster eluting
diastereoemer: MS(EI): 587 (M+H+,100%) and the slower eluting diastereomer:
MS(EI):
587 (M+H+,100%).
Example 133
Preparation of (S)-2-f2-(4-Methox~ hen l~ylamino)-4-methyl-pentanoic acid (1-
methanesulfonyl-3-oxo-aze~an-4-yl)-amide
Following the procedure of Example 75, except substituting 4- methanesulfonyl
chloride for thiazole-2-sulfonyl chloride and 2-(4-methoxyphenyl)-acetic acid
for
benzofuran-2-carboxylic acid, the title compound was prepared. The residue was
purified
by HPLC. First eluting diastereomer; MS (M+H+): 468.2; 1H-NMR (400 MHz,
CDCl3):
7.19-7.17(d, 2H), 6.90-6.88(d, 3H), 5.83-5.81(d, 1H), 5.00(m, 1H), 4.53-
4.40(m, 2H), 4.03-
3.99(m, 1H), 3.81(s, 3H), 3.66-3.61(d, 1H), 3.53(s, 2H), 2.91(s, 3H), 2.73(t,
1H), 2.22-
2.10(m, 2H), 1.99( m, 1H), 1.62-1.35(m, 4H), 0.90-0.88(d, 6H); and the second
eluting
diastereomer: MS (M+H+): 468.2.
Example 134
.
Preparation of Ouinoline-2-carboxylic acid ( ((S)-1-f 1-(2-cyano-
benzenesulfon~)-3-oxo-
azepan-4-ylcarbamoyll-3-methyl-butyl -amide
Following the procedure of Example 75, except substituting 2-
cyanobenzenesulfonyl chloride for thiazole-2-sulfonyl chloride and quinoline-2-
carboxylic
acid for benzofuran-2-carboxylic acid, the title compound was prepared. The
residue was
purified by HPLC. First eluting diastereomer; MS (M+H+): 562.2; 1H-NMR (400
MHz,
CDC13): ~ 8.65(d, 1H), 8.48-8.40(q, 2H), 8.25-8.10(q, 2H), 7.91-7.65(m, 6H);
and the
second eluting diastereomer:, 7.12(d, 1H), 5.10(m, 1H), 4.73 (m, 1H) 4,61-
4.56(d,
1H),4.20(m, 1H),3.73-3.68(d, 1H), 2.80(m, 1H), 2.27(m, 2H), 1.91-1.40(m, 5H),
1.03-
1.01(m, 6H); and the second eluting diastereomer: MS (M+H+): 562.2.
186
CA 02412353 2002-12-13
WO 01/95911 PCT/USO1/19062
Example 135
Preparation of 1-Methyl-1H-indole -2-carboxylic acid {j(S)-1-f 1-(2-c
benzenesulfonyl)-3-oxo-azepan-4-ylcarbamoyll-3-methyl-butyl l-amide
Following the procedure of Example 75, except substituting 2-
cyanophenylsulfonyl chloride for thiazole-2-sulfonyl chloride and N-
methylindole-2-
carboxylic acid for benzofuran-2-carboxylic acid, the title compound was
prepared. The
residue was purified by HPLC. First eluting diastereomer; MS (M+H+): 564.2; 1H-
NMR
(400 MHz, CDC13): ~ 8.13(d, 1H), 7.89(d, 1H), 7.77-7.67(m, 3H), 7.38-7.16(m,
4H), 6.97(s,
1H), 6.70(d, 1H), 5.05(m, 1H), 4.70-4.60 (m, 1H), 4.55-4.50(d, 1H), 4.07(m,
1H), 4.05(s,
3H), 3.76-3.71(d, 1H), 2.75(m, 1H), 2.30(m, 2H), 2.00-1.45(m, 5H), 1.00(d,
6H); and the
second eluting diastereomer: MS (M+H+) 564.2.
Example 136
Preparation of Furan-2-carboxylic acid (((S)-1-f 1-(2-cyano-benzenesulfon~)-3-
oxo-azepan-
4-ylcarbamoyll-3-methyl-butylcarbamoyl }-methyl)-amide
Following the procedure of Example 75, except substituting 2-
cyanophenylsulfonyl chloride for thiazole-2-sulfonyl chloride and N-(2-furan-
carbonyl)-
glycine for benzofuran-2-carboxylic acid, the title compound was prepared. The
residue
was purified by HPLC. First eluting diastereomer; MS (M+H+): 558.2; 1H-NMR
(400
MHz, CDCl3): ~ 8.14-8.12(d, 1H), 7.91-7.90(d, 1H), 7.80-7.72(m, 2H), 7.48(s,
1H), 7.14(d,
2H), 6.98(d, 1H), 6.80(d, 1H), 6.52-6.51(t, 1H), 5.03(m, 1H), 4.60-4.53 (m,
2H), 4.17-
4.14(m, 3H), 3.74-3.69(d, 1H), 2.80(m, 1H), 2.25(m, 2H), 2.00-1.40(m, 5H),
1.03-1.01(m,
6H); and the second eluting diastereomer: MS (M+H+) 558.2.
187
CA 02412353 2002-12-13
WO 01/95911 PCT/USO1/19062
Example 137
Preparation of 5-Methoxybenzofuran-2-carboxylic acid 1(S)-1-f 1-(2-cyano-
benzenesulfonyl)-3-oxo-azepan-4-ylcarbamoyll-3-meth ~~1-butyl -amide
Following the procedure of Example 75, except substituting 2-
cyanophenylsulfonyl chloride for thiazole-2-sulfonyl chloride and 5-
methoxybenzofuran-2-
carboxylic acid for benzofuran- 2-carboxylic acid, the title compound was
prepared. The
residue was purified by HPLC. First eluting diastereomer; MS (M+H+): 581.4; 1H-
NMR
(400 MHz, CDC13): ~ 8.15-8.13(d, 1H), 7.92-7.90(d, 1H), 7.81-7.74(m, 2H), 7.42-
7.40(m,
2H), 7.08-7.03(m, 3H), 6.96(d, 1H), 5.10(m, 1H), 4.72-4.60 (m, 2H), 4.17 (d,
1H), 3.85(s,
3H), 3.75-3.70(d, 1H), 2.83-2.76(t, 1H), 2.27(m, 2H), 1.92-1.51(m, 5H), 1.02-
1.01(m, 6H);
and the second eluting diastereomer: MS (M+H+) 581.2.
Example 138
Preparation of Quinoxaline-2-carboxylic acid d (S)-1-f 1-(2-cyano-
benzenesulfon~)-3-oxo-
azepan-4-ylcarbamoyll-3-methyl-butyll-amide
Following the procedure of Example 75, except substituting 2-
cyanophenylsulfonyl chloride for thiazole-2-sulfonyl chloride and quinoxaline-
2-carboxylic
acid for benzofuran-2-carboxylic acid, the title compound was prepared. The
residue was
purified by HPLC. First eluting diastereomer; MS (M+H+): 563.2; 1H-NMR (400
MHz,
CDCl3): ~ 9.65(s, 1H), 8.40(m, 1H), 8.22-8.10(m, 3H), 7.90-7.22(m, 5H),
7.00(d, 1H),
5.10(m, 1H), 4.75(m, 1H), 4.65-4.60(d, 1H), 4.20-4.10(m, 1H), 3.72-3.70(d,
1H), 2.70(m,
1H), 2.38(m, 2H), 1.95-1.40(m, 5H), 1.02(d, 6H); and the second eluting
diastereomer:
MS (M+H+) 563.2.
188
CA 02412353 2002-12-13
WO 01/95911 PCT/USO1/19062
Example 139
Preparation of (S)-2-f 2-(4-Methoxy-phenyl)-acetylamino)-4-methyl-pentanoic
acid f 1-(2-
cyano-benzenesulfonyl)-3-oxo-azepan-4-y11-amide
Following the procedure of Example 75, except substituting 2-
cyanophenylsulfonyl
chloride for thiazole-2-sulfonyl chloride and 2-(4-methoxyphenyl)-acetic acid
for
benzofuran-2-carboxylic acid, the title compound was prepared. The residue was
purified
by HPLC. First eluting diastereomer; MS (M+H+): 555.2; 1H-NMR (400 MHz,
CDC13):
8.14-8.12(d, 1H), 7.91-7.89(d, 1H), 7.79-7.73(m, 2H), 7.19-7.17(d, 2H), 6.90-
6.88(d, 3H),
5.80(d, 1H), 5.02(m, 1H), 4.59-4.55(d, 1H), 4.45-4.42(m, 1H), 4.18-4.15(m,
1H), 3.82(s,
3H), 3.72-3.67(d, 1H), 3.53(s, 2H), 2.82-2.79(t, 1H), 2.22(m, 2H), 1.92( m,
1H), 1.60-
1.30(m, 4H), 0.91-0.89(d, 6H); and the second eluting diastereomer: MS (M+H+)
555.2.
Example 140
Preparation of Quinoline-2-carboxylic acid ( f (S)-1-f 1-(4-methoxy-
benzenesulfonyl)-3-oxo-
azepan-4-ylcarbamoyll-3-methyl-butyl ~-amide
Following the procedure of Example 75, except substituting 4-
methoxybenzenesulfonyl chloride for thiazole-2-sulfonyl chloride and 2-
quinoline
carboxylic acid for benzofuran-2-carboxylic acid, the title compound was
prepared. The
residue was purified by HPLC. First eluting diastereomer; MS (M+H+): 567.2; 1H-
NMR
(400 MHz, CDCl3): ~ 8.72-8.61(d, 1H), 8.35-8.28(q, 2H) 8.21-8.18(d, 1H), 7.91-
7.60(m,
5H), 7.10-6.99(m, 3H), 5.05(m, 1H), 4.73 (m, 1H) 4,59-4.52(d, 1H),4.00(m, 1H),
3.88(s,
3H), 3.45-3.38(d, 1H), 2.42(m, 1H), 2.30-1.35 (m, 7H), 1.03-1.01(m, 6H); and
the second
eluting diastereomer: MS (M+H+) 567.2.
189
CA 02412353 2002-12-13
WO 01/95911 PCT/USO1/19062
Example 141
Preparation of 1-Methyl-1H-indole-2-carbox, lic acid j(S)-1-f 1-(4-methox~
benzenesulfonyl)-3-oxo-azepan-4-ylcarbamoyll-3-methXl-butyl ~-amide
Following the procedure of Example 75, except substituting 4-
methoxyphenylsulfonyl chloride for thiazole-2-sulfonyl chloride and N-methyl-
indole-2-
carboxylic acid for benzofuran-2-carboxylic acid, the title compound was
prepared. The
residue was purified by HPLC. First eluting diastereomer; MS (M+H+): 569.2; 1H-
NMR
(400 MHz, CDC13): ~ 7.78-7.72(d, 2H), 7.70-7.65(d, 1H), 7.42-7.30(m, 2H), 7.17-
7.14(t,
1H), 7.05-6.95(m, 4H), 6.65(d, 1H), 5.05(m, 1H), 4.70-4.50 (m, 2H), 4.03(s,
3H), 3.88(s,
3H), 3.45-3.40(d, 1H), 2.45(m, 1H), 2.30-2.10(m, 2H), 1.90-1.35(m, 6H); and
the second
eluting diastereomer:, 1.00(d, 6H); and the second eluting diastereomer: MS
(M+H+)
569.2.
Example 142
Preparation of Furan-2-carboxylic acid (( (S)-1-f 1-(4-methoxy-
benzenesulfonyl)-3-oxo-
azepan-4-ylcarbamoyll-3-methyl-butylcarbamoyl ~-methyl)-amide
Following the procedure of Example 75, except substituting 4-
methoxyphenylsulfonyl chloride for thiazole-2-sulfonyl chloride and N-(2-furan-
carbonyl)-
glycine for benzofuran-2-carboxylic acid, the title compound was prepared. The
residue
was purified by HPLC. First eluting diastereomer; MS (M+H+): 563.2; 1H-NMR
(400
MHz, CDC13): ~ 7.74-7.72(d, 2H), 7.47 (s, 1H), 7.15-6.99(m, 4H), 6.91(d, 1H),
6.70(d, 1H),
6.52-6.51(m, 1H), 5.01(m, 1H), 4.53-4.49 (m, 2H), 4.17-4.14(m, 2H), 4.00-
3.90(m, 1H),
3.88(s, 3H), 3.45-3.41(d, 1H), 2.47(m, 1H), 2.17(m, 2H), 1.85-1.40(m, 5H),
0.95(m, 6H);
and the second eluting diastereomer: MS (M+H+) 563.2.
190
CA 02412353 2002-12-13
WO 01/95911 PCT/USO1/19062
Example 143
Preparation of 5-Methoxybenzofuran-2-carboxylic acid ( f (S)-1-f 1-(4-methoxy-
benzenesulfonyl)-3-oxo-azepan-4-ylcarbamoyll-3-methyl-butyl ~-amide
Following the procedure of Example 75, except substituting 4-
methoxyphenylsulfonyl chloride for thiazole-2-sulfonyl chloride and 5-
methoxybenzofuran-2-carboxylic acid for benzofuran-2-carboxylic acid, the
title compound
was prepared. The residue was purified by HPLC. First eluting diastereomer; MS
(M+H+): 586.2; 1H-NMR (400 MHz, CDC13): ~ 7.75-7.73(d, 2H), 7.42-7.40(m, 2H),
7.08-
6.99(m, 5H), 6.91(d, 1H), 5.05(m, 1H), 4.70-4.55(m, 2H), 4.05-4.00(m, 1H),
3.89(s, 3H),
3.86(s, 3H), 3.45-3.40(d, 1H), 2.50-2.40(m, 1H), 2.30-2.10(m, 2H), 1.90-
1.35(m, 5H),
1.01(m, 6H); and the second eluting diastereomer: MS (M+H+) 586.2.
Example 144
Preparation of Quinoxaline-2-carboxylic acid ( f (S)-1-f 1-(4-methoxy-
benzenesulfonyl)-3-
oxo-azepan-4-ylcarbamoyll-3-methyl-butyl }-amide
Following the procedure of Example 75, except substituting 4-
methoxyphenylsulfonyl chloride for thiazole-2-sulfonyl chloride and
quinoxaline-2-
carboxylic acid for benzofuran-2-carboxylic acid, the title compound was
prepared. The
residue was purified by HPLC. First eluting diastereomer; MS (M+H+): 568.2; 1H-
NMR
(400 MHz, CDC13): ~ 9.66(s, 1H), 8.40-8.35(m, 1H), 8.19(m, 2H), 7.88(m, 2H),
7.75-
7.73(d, 2H), 7.02-6.90(m, 3H), 5.10-5.05(m, 1H), 4.75(m, 1H), 4.60-4.55(d,
1H), 4.05-
3.95(m, 1H), 3.89(s, 3H), 3.45-3.41(d, 1H), 2.45(m, 1H), 2.30-2.10(m, 2H),
1.95-1.40(m,
5H), 1.04-1.02(d, 6H); and the second eluting diastereomer: MS (M+H+) 568.2.
191
CA 02412353 2002-12-13
WO 01/95911 PCT/USO1/19062
Example 145
Preparation of (S)-2-f 2-(4-Methoxy-phe~l)-acetylamino)-4-meth ~~1-pentanoic
acid f 1-(4-
methoxy-benzenesulfon~)-3-oxo-azepan-4-~l-amide
Following the procedure of Example 75, except substituting 4-
methoxyphenylsulfonyl chloride for thiazole-2-sulfonyl chloride and 2-(4-
methoxyphenyl)-
acetic acid for benzofuran-2-carboxylic acid, the title compound was prepared.
The
residue was purified by HPLC. First eluting diastereomer; MS (M+H+): 560.4; 1H-
NMR
(400 MHz, CDCl3): ~ 7.74-7.71(d, 2H), 7.19-7.17(d, 2H), 7.01-6.99(d, 2H), 6.90-
6.88(d,
2H), 6.85(d, 1H), 5.81(d, 1H), 4.99(m, 1H), 4.55-4.44(m, 2H), 3.97(m, 1H),
3.88(s, 3H),
3.81(s, 3H), 3.53(s, 2H), 3.43-3.38(d, 1H), 2.43(t, 1H), 2.14(m, 2H), 1.85-
1.35(m, 5H),
0.90-0.89(d, 6H); and the second eluting diastereomer: MS (M+H+) 560.2.
Example 146
Preparation of 1-Methyl-1H-indole-2-carboxylic acid i f S)-1-f 1-(4-fluoro-
benzenesulfon~)-3-oxo-azepan-4-ylcarbamoyll-3-meth~~1-amide
Following the procedure of Example 75, except substituting 4-
fluorophenylsulfonyl chloride for thiazole-2-sulfonyl chloride and N-methyl-
indole-2-
carboxylic acid for benzofuran-2-carboxylic acid, the title compound was
prepared. The
residue was purified by HPLC. First eluting diastereomer; MS (M+H+): 557.2; 1H-
NMR
(400 MHz, CDC13): ~ 7.84-7.80(m, 2H), 7.66-7.65(d, 1H), 7.40-7.14(m, 5H),
6.95(m, 2H),
6.65-6.63(d, 1H), 5.07(m, 1H), 4.68-4.55 (m, 2H), 4.04(s, 3H), 3.48-3.43(d,
1H), 2.49(m,
1H), 2.25(m, 2H), 1.89-1.38(m, 6H); and the second eluting diastereomer:,
1.01(d, 6H);
and the second eluting diastereomer: MS (M+H+) 557.4.
192
CA 02412353 2002-12-13
WO 01/95911 PCT/USO1/19062
Example 147
Preparation of Furan-2-carboxylic acid (; (S)-1-f 1-(4-fluoro-benzenesulfonyl)-
3-oxo-
azepan-4-ylcarbamoyll-3-meth~tl-butylcarbamoyl -methyl)-amide
Following the procedure of Example 75, except substituting 4-
fluorophenylsulfonyl chloride for thiazole-2-sulfonyl chloride and N-(2-furan-
carbonyl)-
glycine for benzofuran-2-carboxylic acid, the title compound was prepared. The
residue
was purified by HPLC. First eluting diastereomer; MS (M+H+): 551.4; 1H-NMR
(400
MHz, CDC13): 7.81(m, 2H), 7.48(s, 1H), 7.27-7.16(m, 3H), 7.05(m, 1H), 6.90(d,
1H),
6.52(m, 2H), 5.00(m, 1H), 4.60-4.48 (m, 2H), 4.14(m, 2H), 4.00-3.90(d, 1H),
3.48-3.44(d,
1H), 2.50(m, 1H), 2.20(m, 2H), 1.90-1.40(m, 5H), 0.95(m, 6H); and the second
eluting
diastereomer: MS (M+H+) 551.2.
Example 148
Preparation of 5-Methoxybenzofuran-2-carboxylic acid f (S)-1-f 1-(4-fluoro-
benzenesulfonyl)-3-oxo-azepan-4-ylcarbamoyll-3-methyl-butyl ~-amide
Following the procedure of Example 75, except substituting 4-
fluorophenylsulfonyl chloride for thiazole-2-sulfonyl chloride and 5-
methoxybenzofuran-2-
carboxylic acid for benzofuran-2-carboxylic acid, the title compound was
prepared. The
residue was purified by HPLC. First eluting diastereomer; MS (M+H+): 574.2; 1H-
NMR
(400 MHz, CDC13): ~ 7.84-7.81(m, 2H), 7.42-7.40(m, 2H), 7.27-7.22(m, 2H), 7.08-
7.04(m,
3H), 6.93(d, 1H), 5.10-5.02(m, 1H), 4.69-4.55(m, 2H), 4.05-4.00(m, 1H),
3.86(s, 3H), 3.47-
3.43(d, 1H), 2.49(m, 1H), 2.24(m, 2H), 1.90-1.40(m, 5H), 1.01(m, 6H); and the
second
eluting diastereomer: MS (M+H+): 574.2
193
CA 02412353 2002-12-13
WO 01/95911 PCT/USO1/19062
Example 149
Preparation of Quinoxaline-2-carboxylic acid f (S)-1-f 1-(4-fluoro-
benzenesulfon~)-3-oxo-
azepan-4-ylcarbamoyll-3-methyl-butyl l-amide
Following the procedure of Example 75, except substituting 4-
fluorophenylsulfonyl chloride for thiazole-2-sulfonyl chloride and quinoxaline-
2-
carboxylic acid for benzofuran-2-carboxylic acid, the title compound was
prepared. The
residue was purified by HPLC. First eluting diastereomer; MS (M+H+): 556.2; 1H-
NMR
(400 MHz, CDCl3): ~ 9.66(s, 1H), 8.40-8.35(d, 1H), 8.21-8.18(m, 2H), 7.90-
7.81(m, 4H),
7.27-7.22(m, 2H), 6.97(d, 1H), 5.10-5.02(m, 1H), 4.75(m, 1H), 4.59-4.55(d,
1H), 4.05-
4.39(m, 1H), 3.48-3.44(d, 1H), 2.49(m, 1H), 2.32-2.10(m, 2H), 1.90-1.40(m,
5H), 1.03-
1.02(d, 6H); and the second eluting diastereomer: MS (M+H+) 556.2.
Example 150
Preparation of (S)-2-f2-(4-Methoxy-phen 1~)-acetylamino)-4-metal-pentanoic
acid f 1-(4-
fluoro-benzenesulfonyl)-3-oxo-azepan-4-yll-amide
Following the procedure of Example 75, except substituting 4-
fluorophenylsulfonyl chloride for thiazole-2-sulfonyl chloride and 2-(4-
methoxyphenyl)-
acetic acid for benzofuran-2-carboxylic acid, the title compound was prepared.
The
residue was purified by HPLC. First eluting diastereomer; MS (M+H+): 548.2; 1H-
NMR
(400 MHz, CDCl3): ~ 7.83-7.80(m, 2H), 7.27-7.17(m, 4H), 6.90-6.88(d, 3H),
5.85(d, 1H),
4.98(m, 1H), 4.55-4.43(m, 2H), 4.00-3.97(m, 1H), 3.81(s, 3H), 3.53(s, 2H),
3.45-3.41(d,
1H), 2.48(t, 1H), 2.17-2.14(m, 2H), 1.90-1.30(m, 5H), 0.90-0.88(d, 6H); and
the second
eluting diastereomer: MS (M+H+): 548.4.
194
CA 02412353 2002-12-13
WO 01/95911 PCT/USO1/19062
Example 151
Preparation of Benzofuran-2-carboxylic acid- (S)-1-f 1-(3-chloro-
benzenesulphonyl)-3-oxo-
aze ap n-4-ylcarbamoyll-3-methyl-butyl -amide
a.) {(S)-1-[1-(3-Chloro-benzenesulfonyl)-3-hydroxy-azepan-4-ylcarbamoyl]-3-
methyl-
butyl}-carbamic acid tart-butyl ester
To a solution of the compound of Example 2g (2.50g, 7.29mmo1) in DCE (100m1)
was added P-NMM (4.0g) and 3-chlorobenzenesulphonyl chloride (1.85g,
8.75mmo1).
After shaking at room temperature overnight, the solution was filtered. The
filtrate was
concentrated to yield the title compound as white solid (3.13g, 83.3%). MS:
539.78
(M+Na)+.
b.) (S)-2-Amino-4-methyl-pentanoic acid [1-(3-chloro-benzenesulfonyl)-3-
hydroxy-
azepan-4-yl]-amide
To a stirring solution of the compound of Example 151a (1.0g, 1.93mmo1) in
methnol ( 10 ml) was added HCl (4M in Dioxane) ( 10 ml). After stirring at
room
temperature for 3 hr the solution was concentrated to provide a white solid.
To a solution
of the white solid (0.68 g, 1.50 mmol, 78%) in methnol (37 ml) was added P-C03
(2.85g,
2.63mmo1/g). After shaking for 2hr, the solution was filtered and concentrated
to yield the
title compound as white solid (0.59 g, 1.42 mmol, 95%). MS: 417.86 (M+H)+.
c.) Benzofuran-2-carboxylic acid-{(S)-1-[1-(3-chloro-benzenesulphonyl)-3-
hydroxy-
azepan-4-ylcarbamoyl]-3-methyl-butyl }-amide
To a solution of the compound of Example 151b (0.14 g, 0.33 mmol) in CHZClz
(20
mL) was added benzofuran-2-carboxylic acid (0.81, 0.50 mmol), 1-
hydroxybenzotriazole
(0.77 g, 0.57 mmol), and P-EDC (0.67g, 1 mmol/g) in CHZC12 (10 mL) . After
shaking at
room temperature overnight, the solution was treated with tisamine (0.45 g,
3.75 mmol/g).
After shaking for another 2 hr, the solution was filtered and concentrated to
yield the title
compound as a white solid (122 mg, 65%). MS (ESI): 562.2 (M+H)+.
195
CA 02412353 2002-12-13
WO 01/95911 PCT/USO1/19062
d.) Benzofuran-2-carboxylic acid-{(S)-1-[1-(3-chloro-benzenesulphonyl)-3-oxo-
azepan-4-ylcarbamoyl]-3-methyl-butyl }-amide
To a stirring solution of the compound of Example 151c (122 mg, 0.22 mmol) in
dichloromethane (4 mL) was added Dess-Martin reagent (185 mg, 0.44 mmol).
After
, stirring at room temperature for 2 h, solutions of sodium thiosulfate (2 mL
of IO% in
water) and saturated aqueous sodium bicarbonate (2 mL) were added
simultaneously to the
solution. The aqueous layer was extracted with dichloromethane (2x). The
organic phases
were combined, washed with saturated brine, dried (MgS04), filtered and
concentrated. The
residue was purified by HPLC to yield the first eluting diastereomer as a
white solid (62.7
mg, 51.6 %), MS (ESI): 560.2 (M+H)+ and the second eluting diastereomer as a
white
solid (40.2 mg, 33.1 %). MS (ESI): 560.2 (M+H)+
Example 152
Preparation of 5-Methoxybenzofuran-2-carboxylic acid- (S)-1-f 1-(3-chloro-
benzenesulphonyl)-3-oxo-azepan-4-ylcarbamoyll-3-methyl-butyl~~-amide
Following the procedure of Example 151c-d, except substituting 5-
methoxybenzofuran-2-carboxylic acid for benzofuran-2-carboxylic acid of
Example 151c
provided the title compound which was separated by HPLC to give the first
eluting
diastereomer as a white solid (64.4 mg, 50.3%): MS (ESI): 590.2 (M+H)+ and the
second
eluting distereomer as a white solid (44.4 mg, 34.7%): MS (ESI): 590.2 (M+H)+
Example 153
Preparation of 7-Methoxybenzofuran-2-carboxylic acid-d (S)-1-f 1-(3-chloro-
benzenesulphonyl)-3-oxo-azepan-4-ylcarbamoyll-3-methyl-butyl }-amide
Following the procedure of Example 151c-d except substituting 7-
methoxybenzofuran-2-carboxylic acid for benzofuran-2-carboxylic acid of
Example 151c
provided the title compound which was separated by HPLC to give first eluting
diastereomer as a white solid (5l.lmg, 39.9%), MS (ESI): 590.2 (M+H)+ and the
second
eluting diastereomer as a white solid (36.7 mg, 28.7%): MS (ESI): 590.2 (M+H)+
196
CA 02412353 2002-12-13
WO 01/95911 PCT/USO1/19062
Example 154
Preparation of 5,6-Dimethoxybenzofuran-2-carboxylic acid- (S)-1-f I~3-chloro-
benzenesulphonyl)-3-oxo-azepan-4 ylcarbamoyll-3-methyl-butyll-amide
Following the procedure of Example 151c-d except substituting 5,6-
dimethoxybenzofuran-2-carboxylic acid for benzofuran-2-carboxylic acid of
Example 151c
provided the title compound which was separated by HPLC to give first eluting
diastereomer as a White solid (5l.lmg, 39.9%), MS (ESI): 622.2 (M+H)+ and the
second
eluting diastereomer as a white solid (36.7 mg, 28.7%): MS (ESI): 622.2 (M+H)+
Example 155
Preparation of 3-Methylbenzofuran-2-carboxylic acid- (S)-1-f 1-(3-chloro-
benzenesulphonyl)-3-oxo-azepan-4-ylcarbamoyll-3-methyl-butyl l-amide
Following the procedure of Example 151c-d except substituting 3-
methylbenzofuran-2-carboxylic acid for benzofuran-2-carboxylic acid in step
151c
provided the title compound which was separated by HPLC to give the first
eluting
diastereomer as a white solid (78.6mg, 63.1%), MS (ESI): 574.2 (M+H)+ and the
second
eluting diastereomer as a white solid (40.7mg, 32.6%). MS (ESI): 574.2 (M+H)+
Example 156
Preparation of Benzofblthiophene-2-carboxylic acid~(S)-1-f 1-(3-chloro-
benzenesulphonyl)-3-oxo-azepan-4-ylcarbamoyll-3-methyl-bull l-annide
Following the procedure of Example 151c-d except substituting
benzo[b]thiophene-
2-carboxylic acid for benzofuran-2-carboxylic acid in step 151c provided the
title
compound which was separated by HPLC to give the first eluting diastereomer as
a white
solid (41.0 mg, 32.8%), MS (ESI): 576.2 (M+H)+ and the second eluting
diastereomer as a
white solid (31.0 mg, 24.8%). MS (ESI): 576.4 (M+H)+
197
CA 02412353 2002-12-13
WO 01/95911 PCT/USO1/19062
Example 157
Preparation of 1-Methyl-1H-indole-2-carboxylic acid-((S)-1-fl-(3-chloro-
benzenesul honyl)-3-oxo-azepan-4-ylcarbamoyll-3-methyl-bu~l~-amide
Following the procedure of Example 151c-d except substituting 1-methylindole-2-
carboxylic acid for benzofuran-2-carboxylic acid in step 151c provided the
title compound
which was separated by HPLC to give the first eluting diastereomer as a white
solid (28.5
mg, 22.9%), MS (ESI): 573.2 (M+H)+ and the second eluting diastereomer as a
white
solid (28.5mg, 22.9%). MS (ESI): 573.2 (M+H)+
Example 158
Preparation of Ouinoxaline-2-carboxylic acid- (S)-1-f 1-(3-chloro-
benzenesulphon~l)-3-
oxo-azepan-4-ylcarbamoyll-3-metl~l-butyl -amide
Following the procedure of Example 151c-d except substituting quinoxaline-2-
carboxylic acid for benzofuran-2-carboxylic acid in step 151c provided the
title compound
which was separated by HPLC to give the first eluting diastereomer as a white
solid (63.1
mg, 50.8%), MS (ESI): 572.2 (M+H)+ and the second eluting distereomer as a
White solid
(43.2 mg, 34.8%), MS (ESI): 572.2 (M+H)+
Exam 1p a 159
Preparation of Benzofuran-2-carboxylic acid- (S)-1-f 1-(2-fluoro-
benzenesulphonyl)-3-oxo-
azepan-4-ylcarbamoyll-3-methyl-butyll-amide
a.) {(S)-1-[1-(2-Fluoro-benzenesulfonyl)-3-hydroxy-azepan-4-ylcarbamoyl]-3-
methyl-
butyl}-carbamic acid ter-t-butyl ester
To a solution of the compound of Example 2g (1.03 g, 3.00 mmol) in DCE (20 ml)
was added P-NMM (1.65 g, 3.64 mmol/g) and 2-fluorobenzenesulphony lchloride
(0.70 g,
3.60 mmol). After shaking at room temperature overnight, the solution was
filtered. The
198
CA 02412353 2002-12-13
WO 01/95911 PCT/USO1/19062
filtrate was concentrated to yield the title compound as white solid (1.13 g,
75.1%): MS:
523.88 (M+Na)+,
b.) (S)-2-Amino-4-methyl-pentanoic acid [1-(2-fluoro-benzenesulfonyl)-3-
hydroxy-
azepan-4-yl]-amide
To a stirring solution of the compound of Example 159a (1.13 g, 2.25 mmol) in
methnol (15 ml) was added HCl (4M in dioxane) (15 ml). After stirring at room
temperature for 3 hr, the solution was concentrated to get white solid. To a
solution of the
white solid (1.11 g, 2.60 mmol, 75%) in methnol (50 ml) was added P-C03 (5.70
g, 2.63
mmol/g). After shaking for 2hr, the solution was filtered and concentrated to
yield the title
compound as white solid (0.868g, 2.16mmo1, 96%): MS: 401.96 (M+H)+.
c.) Benzofuran-2-carboxylic acid-{(S)-1-[1-(2-fluoro-benzenesulphonyl)-3-
hydroxy-
azepan-4-ylcarbamoyl]-3-methyl-butyl }-amide
To a solution of the compound of Example 159b (0.11 g, 0.26 mmol) in CHZC12
(10
mL) was added benzofuran-2-carboxylic acid (64.7 mg, 0.39 mmol), 1-
hydroxybenzotriazole (61.1g, 0.45 mmol), and P-EDC (0.53 g, 1 mmol/g) in
CHZCIz (10
mL). After shaking at room temperature overnight, the solution was treated
with tisamine
(0.35 g, 3.75 mmol/g). After shaking for another 2 hr, the solution was
filtered and
concentrated to yield the title compound as a white solid (103.5 mg, 70%): MS
(ESI)
546.2 (M+H)+.
d.) Benzofuran-2-carboxylic acid-{(S)-1-[1-(2-fluoro-benzenesulphonyl)-3-oxo-
azepan-4-ylcarbamoyl]-3-methyl-butyl }-amide
To a stirring solution of the compound of Example 159c (103.5 mg, 0.19 mmol)
in
dichloromethane (4 mL) was added Dess-Martin reagent (164.7 mg, 0.39 mmol).
After
stirring at room temperature for 2 h, solutions of sodium thiosulfate (2 mL of
10% in
water) and saturated aqueous sodium bicarbonate (2 mL) were added
simultaneously to the
solution. The aqueous was extracted with dichloromethane (2x). The organic
phases were
combined, washed with saturated brine, dried (MgSOø), filtered and
concentrated. The
residue was purified by HPLC to yield the first eluting diastereomer as a
white solid (76.2
mg, 73.6 %): MS (ESI) 544.2 (M+H)+ and the second eluting diastereomer as a
white
solid (20.7mg, 20.0%) MS (ESI) 544.4 (M+H)+
199
CA 02412353 2002-12-13
WO 01/95911 PCT/USO1/19062
Example 160
Preparation of 5-Methoxybenzofuran-2-carboxylic acid-d (S)-1-f 1-(2-fluoro-
benzenesulphonyl)-3-oxo-azepan-4-ylcarbamoyll-3-methyl-butyl -amide
Following the procedure of Example 159c-d, except substituting 5-
methoxybenzofuran-2-carboxylic acid for benzofuran-2-carboxylic acid in step
159c
provided the title compound which was separated by HPLC to give the first
eluting
diastereomer as a white solid (48.3 mg, 59.2%) MS (ESI): 574.2 (M+H)+ and the
second
eluting diastereomer as a white solid (24.2mg, 29.6%) MS (ESI): 574.2 (M+H)+
Example 161
Preparation of 7-Methoxybenzofuran-2-carboxylic acid-1 (S)-1-f 1-(2-fluoro-
benzenesulphonyl)-3-oxo-azepan-4-ylcarbamoyll-3-methyl-butyll-amide
Following the procedure of Example 159c-d except substituting 7-
methoxybenzofuran-2-carboxylic acid for benzofuran-2-carboxylic acid in step
159c
provided the title compound which was separated by HPLC to give the first
eluting
° diastereomer as a white solid (47.7 mg, 58.5%): MS (ESI) 574.2 (M+H)+
and the second
eluting diastereomer as a white solid (27.7 mg, 33.9%).
Example 162
Preparation of 5,6-Dimethoxybenzofuran-2-carbox, lic acid-f (S)-1-f 1-(2-
fluoro-
benzenesulphonyl)-3-oxo-azepan-4-ylcarbamoyll-3-methyl-butyll-amide
Following the procedure of Example 159c-d except substituting 5,6-
dimethoxybenzofuran-2-carboxylic acid for benzofuran-2-carboxylic acid in step
159c
provided the title compound which was separated by HPLC to give the first
eluting
diastereomer: MS (ESI) 606.4 (M+H)+ and the second eluting diastereomer as a
white
solid MS(ESI) 606.4 (M+H+).
200
CA 02412353 2002-12-13
WO 01/95911 PCT/USO1/19062
Example 163
Preparation of 3-Methylbenzofuran-2-carbox lic acid- ,~S)-1-f 1-(2-fluoro-
benzenesulphonyl)-3-oxo-azepan-4-ylcarbamoyll-3-methyl-but~~-amide
S
Following the procedure of Example 159c-d except substituting 3-
methylbenzofuran-2-carboxylic acid for benzofuran-2-carboxylic acid in step
160c
provided the title compound which was separated by HPLC to give the first
eluting
diastereomer as a white solid (SO.S mg, 63.7%): MS (ESI) SS8.2 and the second
elutinfg
diastereoemer as a white solid (20.6 mg); MS 558.2 (M+H)+.
Exam In a 164
Preparation of Benzo~blthiophene-2-carboxylic acid- (S)-1-f 1-(2-fluoro-
1S benzenesulphonyl)-3-oxo-azepan-4-ylcarbamoyll-3-methyl-butyll-amide
Following the procedure of Example lS9c-d except substituting
benzo[b]thiophene-
2-carboxylic acid for benzofuran-2-carboxylic acid in step 159c provided the
title
compound which was separated by HPLC to give the first eluting diastereomer as
a white
solid (52.5 mg, 65.9%): MS (ESI) 560.2 (M+H)+ and the second eluting
diastereomer as a
white solid (20.7mg, 26.0%): MS(ESI) 560.2 (M+H)+.
Example 16S
Preparation of 1-Methyl-1H-indole-2-carboxylic acid- (S)-1-f 1-(2-fluoro-
benzenesulphonyl)-3-oxo-azepan-4-ylcarbamoyll-3-methyl-butyl )-amide
Following the procedure of Example 159c-d except substituting 1-methylindole-2-
carboxylic acid for benzofuran-2-carboxylic acid in step lS9c provided the
title compound
which was separated by HPLC to give the first eluting diastereomer as a white
solid (S 1.4
mg, 64.9%): MS (ESI) SS7.2 (M+H)+ and the seond eluting diastereoemer as a
white solid
(21.0 mg, 26.5%): MS 557.2 (M+H)+.
201
CA 02412353 2002-12-13
WO 01/95911 PCT/USO1/19062
Exam 1p a 166
Preparation of (S)-4-Methyl-2-(1-oxy-pyridine-2-sulfonylamino)-pentanoic acid
[3-oxo-1-
(pyridine-2-sulfonyl)-aze ap n-4-yll-amide
a.) (S)-4-Methyl-2-(1-oxy-pyridine-2-sulfonylamino)-pentanoic acid [3-hydroxy-
1-
(pyridine-2-sulfonyl)-azepan-4-yl]-amide
To a solution of the compound of Example 28a (0.1 g) in dichlorormethane (10
mL) and saturated NaHC03 was added 2-pryridinesulfonyl chloride N-oxide (0.9
mL) in a
dropwise fashion over 3 minutes. The reaction was stirred at room temperature
for 30
minutes. Workup and columnn chromatography provided 9.2 mg of the title
compound:
MS (ESI) 541 (M+H+).
b.) (S)-4-Methyl-2-(1-oxy-pyridine-2-sulfonylamino)-pentanoic acid [3-oxo-1-
(pyridine-2-sulfonyl)-azepan-4-yl]-amide
Following the procedure of Example 1i except substituting the compound of
Example 166a the title compound was prepared: MS (ESI) 539 (M+H+).
Example 167
Preparation of Ouinoxaline-2-carboxylic acid- (S)-1-f 1-(2-fluoro-
benzenesulpho~l)-3-oxo-
azepan-4-ylcarbamoyll-3-methyl-butyl)-amide
Following the procedure of Example 159c-d except substituting quinoxaline-2-
carboxylic acid for benzofuran-2-carboxylic acid in step 159c provided the
title compound
which was purified by HPLC to give the first eluting diastereomer as a white
solid (49.7
mg, 62.9%): MS (ESI) 556.2 (M+H)+ and the second eluting diastereomer as a
white solid
(19.9 mg, 25.1°70): MS 556.4 (M+H)+.
Example 168
Preparation of 5-Methoxybenzofuran-2-carboxylic acid-1(S)-3-methyl-1-f3-oxo-1-
(thiophene-2-sulfonyl)-azepan-4-ylcarbamoyll-butyll-amide
Following the procedure of Example 75a-d except substituting 2-
thiophensulfonyl
chloride for 2-thiazolesupfonyl chloride of Example 75a and 5-
methoxybenzofuran-2-
202
CA 02412353 2002-12-13
WO 01/95911 PCT/USO1/19062
carboxylic acid for benzofuran-2-carboxylic acid in step 75c provided the
title compound
which was purified by HPLC to give the first eluting diastereomer as a white
solid (71 mg,
65%): MS (ESI) 562.2 (M+H)+ and the second eluting diastereomer as a white
solid (21.6
mg, 20.0%) MS (ESI): 562.2 (M+H)+.
Example 169
Preparation of 7-Methoxybenzofuran-2-carboxylic acid~(S)-3-methyl-1-f3-oxo-1-
(thiophene-2-sulfonyl)-azepan-4 ylcarbamoyll-butyl -amide
Following the procedure of Example 168 except substituting 7-
methoxybenzofuran-2-carboxylic acid for 5-methoxybenzofuran-2-carboxylic acid
provided the title compound which ws purified by HPLC to give the first
eluting
diastereomer as a white solid (88 mg, 80%): MS (ESI) 562.2 (M+H)+ and the
second
eluting diastereomer as a white solid (18 mg, 16%) MS (ESI): 562.2 (M+H)+.
15'
Example 170
Preparation of 5,6-Dimethoxybenzofuran-2-carboxylic acid-((S)-3-methyl-1-f3-
oxo-1-
(thiophene-2-sulfonyl)-azepan-4-ylcarbamoyll-butt -amide
Following the procedure of Example 168 except substituting 5,6-
dimethoxybenzofuran-2-carboxylic acid for 5-methoxybenzofuran-2-carboxylic
acid
provided the title compound which was purified by HPLC to give the first
eluting
diastereomer MS (ESI) 594.2 (M+H)+ and the second eluting diastereomer.
Example I71
Preparation of 3-Methylbenzofuran-2-carboxylic acid- (S)-3-methyl-1-f3-oxo-1-
(thiophene-
2-sulfonyl)-azepan-4-ylcarbamo l~yl ~-amide
Following the procedure of Example 168 except substituting 3-methybenzofuran-2-
carboxylic acid for 5-methoxybenzofuran-2-carboxylic acid provided the title
compound
which was purified by HPLC to give the first eluting diastereomer as a white
solid (88 mg,
83%): MS (ESI) 546.2 (M+H)+ and the second eluting diastereomer as a white
solid (16
mg, 15%): MS (ESI) 546.2 (M+H)+.
203
CA 02412353 2002-12-13
WO 01/95911 PCT/USO1/19062
Exam In a 172
Preparation ofBenzofblthiophene-2-carboxylic acid-~(S)-3-methyl-I-f3-oxo-1-
(thio hp ene-
2-sulfonyl)-azepan-4-ylcarbamoyll-butyl -
Following the procedure of Example 168 except substituting benzo[b]thiophene-2-
carboxylic acid 5-methoxybenzofuran-2-carboxylic acid provided the title
compound which
was purified by HPLC to give the first eluting diastereomer as a white solid
(43.4 mg,
41%): MS (ESI) 548.4 (M+H)+ and the second eluting diastereomer as a white
solid (33.4
mg, 31.5%): MS (EST) 548.2 (M+H)+.
Example 173
Preparation of 1-Methyl-1H-indole-2-carbox lic acid- (S)-3-meth-1-f3-oxo-1-
(thiophene-
2-sulfon l~pan-4-ylcarbamo 1y 1butyll-amide
Following the procedure of Example 168 except substituting 1-methylindole-2-
carboxylic acid for 5-methoxybenzofuran-2-carboxylic acid provided the title
compound
which was separated by HPLC to give the first eluting diastereomer as a white
solid (35.8
mg, 34.0%): MS (ESI) 545.2 (M+H)+ and the second eluting diastereomer as a
white solid
(45.8 mg, 43%): MS (ESI) 545.2 (M+H)+.
Example 174
Preparation of (~uinoxaline-2-carboxylic acid-((S)-3-methyl-1-f3-oxo-1-
(thiophene-2-
sulfonyl)-azepan-4-ylcarbamoyll-butyl ~-amide
Following the procedure of Example 168 except substituting quinoxaline-2-
carboxylic acid for 5-methoxybenzofuran-2-carboxylic acid provided the title
compound
which was separated by HPLC to give the first eluting diastereomer as a white
solid (60
mg, 56%): MS (ESI) 544.4 (M+H)+ and the second eluting diastereomer as a white
solid
(38.7 mg, 37%): MS (ESI) 544.4 (M+H)+.
204
CA 02412353 2002-12-13
WO 01/95911 PCT/USO1/19062
Example 175
Preparation of Benzofuran-2-carbox lic acid- (S)-1-f 1 ~4-chloro-benzenesul
honyl)-3-oxo-
azepan-4-ylcarbamoyll-3-methyl l-amide
a.) {(S)-1-[1-(3-Chloro-benzenesulfonyl)-3-hydroxy-azepan-4-ylcarbamoyl]-3-
methyl-
butyl}-carbamic acid tent-butyl ester
To a solution of the compound of Example 2g (2.50 g, 7.29mmo1) in DCE (100 ml)
was added P-NMM (4.0g) and 4-chlorobenzenesulphonyl chloride (1.85g,
8.75mmo1).
After shaking at room temperature for over night, the solution was filtered.
The filtrate was
concentrated to yield the title compound as white solid (3.13g, 83.3%). MS:
539.78
(M+Na)+.
b.) (S)-2-Amino-4-methyl-pentanoic acid [1-(3-chloro-benzenesulfonyl)-3-
hydroxy-
azepan-4-yl]-amide
To a stirring solution of the compound of example 175a (1.0 g, 1.93mmo1) in
methnol ( 10 ml) was added HCl (4M in dioxane) ( 10 ml). After stirring at
room
temperature for 3 hr, the solution was concentrated to provide a white solid.
To a solution
of the white solid (0.68 g, 1.50 mmol, 78%) in methnol (37 ml) was added P-C03
(2.85 g,
2.63 mmol/g). After shaking for 2hr, the solution was filtered and
concentrated to yield the
title compound as white solid (0.59 g, 1.42 mmol, 95%): MS: 417.86 (M+H)'.
c.) Benzofuran-2-carboxylic acid-{(S)-1-[1-(4-chloro-benzenesulphonyl)-3-
hydroxy-
azepan-4-ylcarbamoyl]-3-methyl-butyl }-amide
To a solution of the compound of Example 175b (0.14 g, 0.335 mmol) in CHZC12
(20 mL) was added benzofuran-2-carboxylic acid (0.81, 0.50 mmol), 1-
hydroxybenzotriazole (0.77g, 0.569mmo1), and P-EDC (0.67g, lmmol/g) in CHzCIz
(10
mL) . After shaking at room temperature overnight, the solution was treated
with tisamine
(0.446 g, 3.75 mmol/g). After shaking for another 2 hr, the solution was
filtered and
concentrated to yield the title compound as a white solid (122.2 mg, 65%). MS
(ESI):
562.2 (M+H)+.
205
CA 02412353 2002-12-13
WO 01/95911 PCT/USO1/19062
d.) Benzofuran-2-carboxylic acid-{(S)-1-[1-(4-chloro-benzenesulphonyl)-3-oxo-
azepan-4-ylcarbamoyl]-3-methyl-butyl }-amide
To a stirring solution of the compound of Example 175c (122.2mg, 0.217mmol) in
dichloromethane (4 mL) was added Dess-Martin reagent (184.8mg, 0.436mmol).
After
stirring at room temperature for 2 h, solutions of sodium thiosulfate (2 mL of
10% in
water) and saturated aqueous sodium bicarbonate (2 mL) were added
simultaneously to the
solution. The aqueous was extracted with dichloromethane (2x). The organic
phases were
combined, washed with saturated brine, dried (MgSO~), filtered and
concentrated. The
residue was purified by HPLC to yield the first eluting diastereomer as a
white solid
(62.7mg, 51.6 %): MS (ESI) 560.2 (M+H)+ and the second elution as a white
solid
(32.7mg, 26.9 %): MS (ESI) 560.2 (M+H)+.
Example 176
. Preparation of 5-Methoxybenzofuran-2-carboxylic acid- (S)-1-f 1-(4-chloro-
benzenesulphonyl)-3-oxo-azepan-4-ylcarbamoyll-3-metal-butyl ~-amide
Following the procedure of Example 175c-d except substituting 5-
methoxybenzofuran-2-carboxylic acid for benzofuran-2-carboxylic acid in step
175c
provided the title compound which was separated by HPLC to give the first
eluting
diastereomer as a white solid (64.4 mg, 50%): MS (ESI) 590.2 (M+H)+ and the
second
eluting diastereoemer as a white solid (32.2 mg, 25.2%): MS (ESI) 590.0
(M+H)+.
Example 177
Preparation of 7-Methoxybenzofuran-2-carboxylic acid-~(S)-1-fl-(4-chloro-
benzenesulphonyl)-3-oxo-azepan-4-Ylcarbamoyll-3-methyl-butyl ~-amide
Following the procedure of Example 175c-d except substituting 7-
methoxybenzofuran-2-carboxylic acid for benzofuran-2-carboxylic acid in step
175c
provided the title compound which was separated by HPLC to give the first
eluting
diastereomer as a white solid (51.1 mg, 40%): MS (ESI) 590.2 (M+H)+ and the
second
eluting diastereoemer as a white solid (41 mg, 32%): MS (ESI) 590.2 (M+H)+.
206
CA 02412353 2002-12-13
WO 01/95911 PCT/USO1/19062
Exam 1p a 178
Preparation of 5,6-Dimethoxybenzofuran-2-carboxylic acid- (S)-1-f 1-(4-chloro-
benzenesulphonyl)-3-oxo-azepan-4-ylcarbamoyl -3-metal-butyl -amide
Following the procedure of Example 175c-d except substituting 5,6-
dimethoxybenzofuran-2-carboxylic acid for benzofuran-2-carboxylic acid in step
175c
provided the title compound which was separated by HPLC to give the first
eluting
diastereomer: MS (ESI) 622.2 (M+H)+ and the second eluting diastereoemer: MS
(ESI)
622.2 (M+H)+.
Example 179
Preparation of 3-Methylbenzofuran-2-carboxylic acid- (S)-1-f 1-(4-chloro-
benzenesulphonyl)-3-oxo-azepan-4-ylcarbamoyll-3-methyl-butyl ~-amide
Following the procedure of Example 175c-d except substituting 3-
methylbenzofuran-2-carboxylic acid for benzofuran-2-carboxylic acid in step
175c
provided the title compound which was separated by HPLC to give the first
eluting
diastereomer as a white solid (78.6 mg, 63%): MS (ESI) 574.2 (M+H)+ and the
second
eluting diastereoemer as a white solid (27.6 mg, 22%): MS (ESI) 574.2 (M+H)+.
Example 180
Preparation of Benzo~blthiophene-2-carboxylic acid-( (~-1-f 1-(4-chloro-
benzenesulphony~-3-oxo-azepan-4-ylcarbamoyll-3-methyl-butyl l-amide
Following the procedure of Example 175c-d except substituting
benzo[b]thiophene-
2-carboxylic acid for benzofuran-2-carboxylic acid in step 175c provided the
title
compound which was separated by HPLC to give the first eluting diastereomer as
a white
solid (41 mg, 33 %): MS (ESI) 576.2 (M+H)+ and the second eluting
diastereoemer as a
white solid (32.6 mg, 26%): MS (ESI) 576.2 (M+H)+.
207
CA 02412353 2002-12-13
WO 01/95911 PCT/USO1/19062
Example 181
Preparation of 1-Methyl-1H-indole-2-carboxylic acid-~(S)-1-f 1-(4-chloro-
benzenesulphonyl)-3-oxo-azepan-4-ylcarbamoyll-3-methyl-butyl-amide
Following the procedure of Example 175c-d except substituting 1-methylindole-2-
carboxylic acid for benzofuran-2-carboxylic acid in step 175c provided the
title compound
which was separated by HPLC to give the first eluting diastereomer as a white
solid (28.5
mg, 23%): MS (ESI) 573.2 (M+H)+ and the second eluting diastereoemer as a
white solid
(38.5 mg, 31%): MS (ESI) 573.2 (M+H)+.
Example 182
Preparation of Quinoxaline-2-carboxylic acid- ~S)-1-f 1-(4-chloro-
benzenesulphon 1~)-3-
oxo-azepan-4-ylcarbamoyll-3-methyl-but l~~-amide
Following the procedure of Example 175c-d except substituting quinoxaline-2-
carboxylic acid for benzofuran-2-carboxylic acid in step 175c provided the
title compound
which was separated by HPLC to give the first eluting diastereomer as a white
solid (63
mg, 51%): MS (ESI) 572.2 (M+H)+ and the second eluting diastereoemer as a
white solid
(44.5 mg, 36%): MS (ESI) 572.2 (M+H)+.
Example 183
Preparation of Benzofuran-2-carboxylic acid-{ (S)-1-f 1-(3-methoxy-
benzenesulphonyl)-3-
oxo-azepan-4-ylcarbamo~l-3-methyl-butyl l-amide
a.) {(S)-1-[1-(3-Methoxy-benzenesulfonyl)-3-hydroxy-azepan-4-ylcarbamoyl]-3-
methyl-butyl}-carbamic acid tart-butyl ester
To a solution of the compound of Example 2g (I.60g, 4.66mmo1) in DCE (50m1)
was added P-NMM (2.56g, 3.64mmol/g ) and 3-methoxy-benzenesulphonyl chloride
(1.15g, 5.59mmol). After shaking at room temperature for over night, the
solution was
208
CA 02412353 2002-12-13
WO 01/95911 PCT/USO1/19062
filtered. The filtrate was concentrated to yield the title compound as white
solid (1.70g,
71.1%): MS 535.8 (M+Na)~.
b.) (S)-2-Amino-4-methyl-pentanoic acid [1-(3-methoxy-benzenesulfonyl)-3-
hydroxy-
azepan-4-yl]-amide
To a stirring solution of the compound of example 1$3a (1.70 g, 3.31mmol) in
methnol (22 ml) was added HCl (4M in dioxane) (22 ml). After stirring at room
temperature for 3 hr, the solution was concentrated to get white solid. To a
solution of the
white solid (1.19 g, 2.64 mmol, 80%) in methnol (50 ml) was added P-C03 (5.02
g, 2.63
mmol/g). After shaking for 2 hr the solution was filtered and concentrated to
yield the title
compound as white solid (1.03 g, 2.49 mmol, 96%): MS 413.90 (M+H)+.
c.) Benzofuran-2-carboxylic acid-{(S)-1-[1-(3-methoxy-benzenesulphonyl)-3-
hydroxy-azepan-4-ylcarbamoyl]-3-methyl-butyl }-amide
To a solution of the compound of Example 183b (0.11 g, 0.26 mmol) in CHZCIZ
(10
mL) was added benzofuran-2-carboxylic acid (64.69mg, 0.399 mmol), 1-
hydroxybenzotriazole (61.1g, 0.452mmol), and P-EDC (0.532g, lmmol/g) in CHZCIz
(10
mL) . After shaking at room temperature for over night, the solution was
treated with
tisamine (0.355g, 3.75mmo1/g). After shaking for another 2hr, the solution was
filtered and
concentrated to yield the title compound as a white solid (103.5 mg, 70%): MS
(ESI) 558.2
(M+H)+.
d.) Benzofurau-2-carboxylic acid-{(S)-1-[1-(3-methoxy-benzenesulphonyl)-3-oxo-
azepan-4-ylcarbamoyl]-3-methyl-butyl }-amide
To a stirring solution of the compound of Example 183c (103 mg, 0.19 mmol) in
dichloromethane (4 mL) was added Dess-Martin reagent (157 mg, 0.37 mmol).
After
stirnng at room temperature for 2 h, solutions of sodium thiosulfate (2 mL of
10% in
water) and saturated aqueous sodium bicarbonate (2 mL) were added
simultaneously to the
solution. The aqueous was extracted with dichloromethane (2x). The organic
phases were
combined, washed with saturated brine, dried (MgSO~), filtered and
concentrated. The
residue was purified by HPLC to yield the first eluting diastereomer as a
white solid (76.2
mg, 73.6 %): MS (ESI: 556.2 (M+H)+ and the second eluting diastereomer as a
white
solid (24.1 mg, 23.3 %): MS (ESI) 556.2 (M+H)+
209
CA 02412353 2002-12-13
WO 01/95911 PCT/USO1/19062
Exam In a 184
Preparation of 5-Methoxybenzofuran-2-carboxylic acid-1 (S)-1-f 1-(3-methoxy-
benzenesulphonyl)-3-oxo-azepan-4-ylcarbamoyll-3-methyl-butyl ~-amide
Following the procedure of Example 183c-d except substituting 5-
methoxybenzofuran-2-carboxylic acid for benzofuran-2-carboxylic acid in step
183c
provided the title compound which was separated by HPLC to give the first
eluting
diastereomer as a white solid (33 mg, 31%): MS (ESI) 586.2 (M+H)+ and the
second
eluting diastereoemer as a white solid (35.2 mg, 32%): MS (ESI) 586.2 (M+H)+.
Example 185
Preparation of 7-Methoxybenzofuran-2-carboxylic acid-; (S)-1-f 1-(3-methox~
benzenesulphonyl)-3-oxo-azepan-4-ylcarbamoyll-3-meths utyl 1-amide
Following the procedure of Example 183c-d except substituting 7-
methoxybenzofuran-2-carboxylic acid for benzofuran-2-carboxylic acid in step
183c
provided the title compound which was separated by HPLC to give the first
eluting
diastereomer as a white solid (41 mg, 38%): MS (EST) 586.4 (M+H)+ and the
second
eluting diastereoemer as a white solid (39.5 mg, 36%): MS (ESI) 586.2 (M+H)+.
Exam In a 186
Preparation of 4,5-Dimethoxybenzofuran-2-carboxylic acid-1 (S)-1-f 1-(3-
methox~
benzenesulphonyl)-3-oxo-azepan-4-ylcarbamoyll-3-methyl-butyl l-amide
Following the procedure of Example 183c-d except substituting 5,6-
dimethoxybenzofuran-2-carboxylic acid for benzofuran-2-carboxylic acid in step
183c
provided the title compound which was separated by HPLC to give the first
eluting
diastexeomer: MS (ESI) 618.4 (M+H)+ and the second eluting diastereoemer.
210
CA 02412353 2002-12-13
WO 01/95911 PCT/USO1/19062
Example 187
Preparation of 3-Methylbenzofuran-2-carboxylic acid-~(S)-1-f 1-(3-methox~
benzenesulphonyl)-3-oxo-azepan-4-ylcarbamoyll-3-methyl-butyl -amide
Following the procedure of Example 183c-d except substituting 3-
methylbenzofuran-2-carboxylic acid for benzofuran-2-carboxylic acid in step
183c
provided the title compound which was separated by HPLC to give the first
eluting
diastereomer as a white solid (76 mg, 72%): MS (ESI) 570.2 (M+H)+ and the
second
eluting diastereoemer as a white solid (23.2 mg, 22%): MS (ESI) 570.2 (M+H)+.
Example 188
Preparation of Benzo(blthiophene-2-carboxylic acid-~ (S)-1-f 1~3-methox~
benzenesulphonyl)-3-oxo-azepan-4-Ylcarbamoyll-3-meth-bull-amide
Following the procedure of Example 183c-d except substituting
benzo[b]thiophene-
2-carboxylic acid for benzofuran-2-carboxylic acid in step 183c provided the
title
compound which was separated by HPLC to give the first eluting diastereomer as
a white
solid (37 mg, 35%): MS (ESI) 572.2 (M+H)+ and the second eluting diastereoemer
as a
white solid (31 mg, 29%): MS (ESI) 572.2 (M+H)+.
Example 189
Preparation of 1-Methyl-1H-indole-2-carboxylic acid- ~S)-1-f 1-(3-methoxy-
benzenesulphonyl)-3-oxo-azepan-4-ylcarbamoyll-3-meth~ut~ ~-amide
Following the procedure of Example 183c-d except substituting 1-methylindole-2-
carboxylic acid for benzofuran-2-carboxylic acid in step 183c provided the
title compound
which was separated by HPLC to give the first eluting diastereomer as a white
solid (34
mg, 32%): MS (ESI) 569.2 (M+H)+ and the second eluting diastereoemer as a
white solid
(38 mg, 38%): MS (ESI) 569.4 (M+H)+.
211
CA 02412353 2002-12-13
WO 01/95911 PCT/USO1/19062
Example 190
Preparation of ~inoxaline-1 (S)-1-f 1-(3-methoxy-benzenesulphonvl)-3-oxo-
azepan-4-
ylcarbamoyll-3-methyl-but~~-amide
Following the procedure of Example 183c-d except substituting quinoxaline-2-
carboxylic acid for benzofuran-2-carboxylic acid in step 183c provided the
title compound
which was separated by HPLC to give the first eluting diastereomer as a white
solid (71
mg, 67%): MS (ESI) 568.2 (M+H)+ and the second eluting diastereoemer as a
white solid
(27 mg, 24%): MS (ESI) 568.2 (M+H)+. '
Example 191
Preparation of Benzofuran-2-carboxylic acid- (S)-3-methyl-1-f3-oxo-1-
(thiophene-2-
sulfonyl)-azepan-4-ylcarbamoyll-butyl }-amide
Following the procedure of Example 168 except substituting benzofuran-2-
carboxylic acid for 5-methoxybenzofuran-2-carboxylic acid provided the title
compound
which ws purified by HPLC to give the first eluting diastereomer as a white
solid (76 mg,
73%): MS (ESI) 532.2 (M+H)+ and the second eluting diastereomer as a white
solid (25
mg, 23%) MS (ESI): 532.2 (M+H)+.
Example 192
Preparation of Benzofuran-2-carbox~ic acid ((S)-3-methyl-1-f(2 2' 4-
trideuterio)-3-oxo-1-
(pyridine-2-sulfon 1y )iazepan-4-ylcarbamoyll-butyl amide
To a solution of benzofuran-2-carboxylic acid {(S)-3-methyl-1-[3-oxo-1-
(pyridine-
2-sulfonyl)-azepan-4-ylcarbamoyl)-butyl}amide of Example 28c (0.03 g) in
DzO:CD30D
(0.4:4 mL) was added triethylamine (0.04 mL). The reaction was heated to
reflux for 2
hours whereupon it was concentrated and dried under vacuum. The residue was
the
redissolved in the same mixture and heated to reflux overnight. The reaction
was
concentrated and the residue purified by column chromatography (5%
methanol:dichloromethane) to provide the title compound (0.02 g): 'HNMR: 81.0
(m, 6H),
212
CA 02412353 2002-12-13
WO 01/95911 PCT/USO1/19062
1.5-2.2 (m, 6H), 2.7 (m, 1H), 4.1 (m, 1H), 4.7 (m, 2H), 7.4-8.0 (m, 8H), 8.7
(m, 1H);
MS(EI): 529 (M+, 45%).
The diastereomeric mixture was separated by HPLC to provide the faster eluting
diastereoemer: MS(EI): 530 (M+H+,100%) and the slower eluting diastereomer:
MS(EI):
530 (M+H+,100°Io).
Example 193
Preparation of Benzofuran-2-carboxylic acid ((S)-2-methyl-1-f3-oxo-1-(pyridine-
2-
sulfon 1 -azepan-4-ylcarbamoyll-butyl ~-amide
a.) 4-tent-Butoxycarbonylamino-3-hydroxy-azepane-1-carboxylicacid benzyl ester
To a stirring solution of compound of Example 2e (1.04 g, 3.92mmo1) in THF was
added di-tart-butyldicarbonate (0.864 g). After stirring at room temperature
for 30 minutes,
the reaction mixture was diluted with diethylether and extracted with
saturated NaHC03.
The organic layer was dried over anhydrous Na2S04, filtered, concentrated, and
purified by
silica gel column to give the title compound as a yellow oil (0.963 g, 2.64
mmol, 67%). MS
(ESI): 365.03 (M+H)+.
b.) (3-Hydroxy-azepan-4-yl)-carbamic acid tart-butyl ester
To a solution of compound of Example 193a (0.963g, 2.64mmo1) in ethyl acetate
(16 ml) was added 10% palladium on carbon (500 mg). After stirring the
solution at room
temperature for 48 hours, the mixture was filtered through celite. The
filterate was
concentrated to yield the title compound ( 0.529 g, 2.29mmo1, 87%): MS(ESI):
231.92
(M+H)+.
c.) [3-Hydroxy-1-(pyridine-2-sulfonyl)-azepan-4-yl]-carbamic acid tart butyl
ester
To a solution of the compound of Example 193b (0.53, 2.29 mmol) in
dichloromethane (20 ml) was added triethylamine (232 mg) and pyridine-2-
sulfonyl
chloride (410 mg, 2.32 mmol). After stirring at room temperature for 30
minutes, the
mixture was washed with saturated NaHC03. The. organic layer was dried,
filtered,
concentrated and purified on a silica gel column to give the title compound as
a solid ( 0.58
g, 1.57 mmol, 68%): MS(ESI): 372.95 (M+H)~.
213
CA 02412353 2002-12-13
WO 01/95911 PCT/USO1/19062
d.) 4-Amino-1-(pryidine-2-sulfonyl)-azepan-3-of
To a stirring solution of the compound of Example 193c (0.583 g, 1.57mmo1) in
ethyl acetate (0.5 ml) was added HCl (4M in dioxane, 3.9 nnl). After stirring
the reaction
mixture for 30 minutes at room temperature, the mixture was concentrated to
yield a white
solid. The solid was treated with NaOH and then extracted with ethylacetate.
The organic
layer was dried, filtered, and concentrated to yield a yellow solid (0.35 g,
1.28 mmol, 81%):
MS (ESI) 272.93 (M+H)+.
e.) {(S)-1-[3-Hydroxy-1-(pryidine-2-sulfonyl)-azepan-4-ylcarbamoyl]-2-meth-
butyl}-
carbamic acid tert-butyl ester
To a solution of the compound of example 1934 (19 mg, 0.070 mmol) in CHZC12
was added N-Boc-isoleucine (24.5 mg, 0.10 mmol), 1-hydroxybenzotriazole (16.1
mg, 0.12
mmol), and P-EDC (140 mg, 0.14 mmol ) in CHZC12 . After shaking at room
temperature
overnight, the mixture was treated with PS-Trisamine. After shaking for
another 2 hours,
the mixture was filtered and concentrated to yield the title compound as a
solid. MS (ESI)
484.97 (M+H)+.
f.) (S)-2-Amino-3-methyl-penatanoic acid [3-hydroxy-1-(pyridine-2-sulfonyl)-
azepan-
4-yl]-amide
To a stirring solution of the compound of example 193e (34 mg, 0.07 mmol) in
CHZCl2 (0.50 ml) was added HCl (4M in dioxane) (0.165 ml). After stirring at
room
temperature for 30 minutes, the mixture was concentrated, giving a white
solid. The white
solid was azeotroped with toluene then treated with MP-carbonate (0.35 mmol)
in
methanol. After four hours of shaking, the mixture was filtered and
concentrated to give the
title compound as a solid.: MS(ESI) 384.9 (M+H)+.
g.) Benzofuran-2-carboxylic acid {(S)-2-methyl-1-[3-hydroxy-1-(pyridine-2-
sulfonyl)-
azepan-4-ylcarbamoyl]-butyl }-amide
To a solution of the compound of example 193f (27 mg, 0.070 mmol) in CHzCIz
was added 2-benzofurancarboxylic acid (17.0 mg, 0.106mmo1), 1-
hydroxybenzotriazole
(16.1 mg, 0.12 mmol), and P-EDC (140 mg, 0.14 mmol ) in CHZCIZ . After shaking
at
room temperature overnight, the mixture was treated with PS-Trisamine. After
shaking for
214
CA 02412353 2002-12-13
WO 01/95911 PCT/USO1/19062
another 2 hours, the mixture was filtered and concentrated to yield the title
compound as a
solid: MS (ESI) 528.9 (M+H)+.
h.) Benzofuran-2-carboxylic acid {(S)-2-methyl-1-[3-oxo-1-(pyridine-2-
sulfonyl)-azepan-
4-ylcarbamoyl]-butyl }-amide
To a stirring solution of the compound of example 193g (37 mg, 0.07 mmol) in
CHZCIZ (0.5 ml) was added Dess-Martin reagent (45 mg, 0.105 mmol). After
stirring for 30
minutes, solutions of sodium thiosulfate (10% in water, 0.50 ml) and saturated
aqueous
sodium bicarbonate (0.50 ml) were added simultaneously to the reaction. The
mixture was
then extracted with dichloromethane (2 times). The organic layer was dried,
filtered, and
concentrated. The residue was purified by HPLC to yield the two diastereomers
of the title
compound as solids (first eluting: 7mg, second eluting: 5.5 mg): MS (ESI)
526.91
(M+H)~.
Example 194
Preparation of Benzofuran-2-carboxylic acid (S)-1-f3-oxo-1-(pyridine-2-
sulfonyl)-azepan-
4-ylcarbamo~pro~yl )-amide
Following the procedure of Example 193e-h, except substituting N-Boc-alpha-
aminobutyric acid in step 193e the title compound was purified to yield two
diastereomers
as solids (first eluting: 5 mg, second eluting: 5 mg) MS(ESI) 543.8 (M+H)+.
Example 195
Preparation of Benzofuran-2-carboxylic acid ~S)-2-cyclohex~l-1-f3-oxo-1-
(pyridine-2-
sulfon~)-azepan-4-ylcarbamoyll-ethyl l-amide
Following the procedure of Example 193e-h, except substituting N-Boc-
cyclohexylalanine in step 193e, the title compound was purified to yield two
diastereomers
as solids (first eluting: 4.5 mg second eluting: 4.5 mg): MS(ESI): 566.87
(M+H)+.
215
CA 02412353 2002-12-13
WO 01/95911 PCT/USO1/19062
Example 196
Preparation of Benzofuran-2-carboxylic acid (S)-1-_ f3-oxo-1-(pyridine-2-
sulfonXl)-azepan-
4-vlcarbamoyll-ethyl ~-amide
Following the procedure of Example 193e-h, except substituting N-Boc-alanine
for
step 193e, the title compound was purified to yield two diastereomers as
solids (first
eluting: 5.5 mg, second eluting: 5 mg).
Example 197
Preparation of Benzofuran-2-carboxylic acid ~(S)-3-methanesulfinyl-1-f3-oxo-1-
(pyridine-
2-sulfonyl)-azepan-4-ylcarbamoyli-propyl )-amide
Following the procedure of Example 193e-h, except substituting N-Boc-L-
methionine for step 1(f), the title compound was purified to yield two
diastereomers as
solids (first eluting: 3 mg, second eluting: 3 mg). MS(ESI): 560.7 (M+H)+.
Example 198
Preparation of Benzofuran-2-carboxylic acid f3-oxo-1-(pyridine-2-sulfon~)-
azepan-4-
ylcarbamoyll-methxl l-amide
Following the procedure of Example 193e-h, except substituting N-Boc-glycine
for step 193e, the title compound was purified to yield two diastereomers as
solids (first
eluting: 3mg ,second eluting: 3 mg). MS(ESI): 470.81 (M+H)+.
216
CA 02412353 2002-12-13
WO 01/95911 PCT/USO1/19062
Example 199
Preparation of Benzofuran-2-carboxylic acid (S)-1-f3-oxo-1-(pyridine-2-
sulfonyl)-azepan-
4-ylcarbamo~pentyl -amide
Following the procedure of Example 193e-h, except substituting N-Boc-
norleucine
for step 193e, the title compound was purified to yield two diastereomers as
solids (first
eluting: 4 mg, second eluting: 5 mg). MS(ESI): 526.85 (M+H)+.
Exam 1p a 200
Preparation of Benzofuran-2-carboxylic acid (S)-1-f3-oxo-1-(pyridine-2-
sulfonyl)-azepan-
4-ylcarbamoyll-butyl)-amide
Following the procedure of Example 193e-h, except substituting N-Boc-norvaline
for step 193e, the title compound was purified to yield two diastereomers as
solids (first
eluting: 7.5 mg, second eluting: 3.5 mg). MS(ESI): 512.8 (M+H)+.
Example 201
Preparation of Benzofuran-2-carbox lic acid (S)-2-methyl-1-f3-oxo-1-(pyridine-
2-
sulfon 1 -azepan-4-ylcarbamoyll-propyl ~-amide
Following the procedure of Example 193e-h, except substituting N-Boc-valine
for
step 193e, the title compound was purified to yield two diastereomers as
solids (first
eluting: 6 mg, second eluting: 4.5 mg). MS(ESI): 512.8 (M+H)+.
217
CA 02412353 2002-12-13
WO 01/95911 PCT/USO1/19062
Example 202
Preparation of Benzofuran-2-carboxylic acid 1(S)-2-hydrox~-1-(3-oxo-1-
(pyridine-2-
sulfon~)-azepan-4-ylcarbamoyll-propyl -amide
Following the procedure of Example 193e-h, except substituting N-Boc-L-
threonine for step 193e, the title compound was purified to yield two
diastereomers as
solids (first eluting: 3 mg, second eluting: 3 mg).
Example 203
Preparation of Benzofuran-2-carboxylic acid (S)-1-f3-oxo-1-(pyridine-2-
sulfonyl)-azepan-
4-ylcarbamoyll-2-phenyl-ethyl -amide
Following the procedure of Example 193e-h, except substituting N-Boc-
phenylalanine for step 193e, the title compound was purified to yield two
diastereomers as
solids (first eluting:5mg, second eluting: 5mg). MS(ESI): 560.8 (M+H)+.
Example 204
Preparation of 1(Benzofuran-2-carbonyl)-pyrrolidine-2-carboxylic acid f3-oxo-1-
(pyridine-
2-sulfon~)-azepan-4-yll-amide
Following the procedure of Example 193e-h, except substituting N-Boc-L-proline
for step 193e, the title compound was purified to yield two diastereomers as
solids (first
eluting: 4 mg, second eluting: 5mg). MS(ESI): (M+H)+.
Exam 1p a 205
Preparation of 3,4-Dimethoxy-~ (S)-1-f 1-(4-imethoxy-benzenesulfonyl)-3-oxo-
azepan-4-
ylcarbamoyll-3-metal-butyl ~-benzamide
Following the procedure of Example 115, except substituting 3,4-
dimethoxybenzoyl chloride for benzyloxyacetyl chloride, the title compound was
prepared.
218
CA 02412353 2002-12-13
WO 01/95911 PCT/USO1/19062
The residue was purified by HPLC. First eluting diastereomer: MS
576.4(M+H+).1H
NMR (500 MHz,CDCl3): 8 7.68 (d, 2H),7.00 (d,lH), 6.89 (s, 2H),3.84 (s,
3H),3.77 (s, 6H),
2.38 (t,lH), 0.94 (d, 6H): MS 576.4 (M+H+).
Example 206
Preparation of Benzo f blthiophene-2-carboxylic acid- (S)-1-f 1-(4-imethox~
benzenesulfonyD-3-oxo-aze~an-4-ylcarbamoyll-3-methyl-butt)-amide
Following the procedure of Example 115, except substituting 2-thiophene-
carbonyl
chloride for benzyloxyacetyl chloride, the title compound was prepared. The
residue was
purified by HPLC. First eluting diastereomer: MS 572.2 (M+H+).1H NMR (500
MHz,CDCl3): 8 7.80-7.68 (m, SH), 7.38-7.34 (m, 2H), 7.01-6.93 (m, 4H), 3.83
(s, 3H),
2.38 (t, 1H), 0.97 (d, 6H). Second eluting diastereomer: MS 572.2 (M+H+)
Exam 1p a 207
Preparation of Benzof 1,31dioxole-5-carboxylic acid (S)-1-f 1~4-fluoro-
benzenesulfonyl)-3-
oxo-azepan-4-ylcarbamoyll-3methyl-butyl ~-amide
Following the procedure of Example 115, except substituting 4-
fluorobenzenesulphonyl chloride for 4-methoxybenzenesulfonyl chloride and 3,4-
methylenedioxybenzoyl chloride for benzyloxyacetyl chloride, the title
compound was
prepared. The residue was purified by HPLC. First eluting diastereomer; MS
548.2
(M+H+); 1H NMR (400Hz,CDCl3): ~ 7.85-7.78 (m, 2H), 7.38-7.20 (m, 4H), 7.05 (d,
1H),
2.52-2.40 (m,lH), 1.0 (d, 6H). Second eluting diastereomer: MS 548.2 (M+H+)
219
CA 02412353 2002-12-13
WO 01/95911 PCT/USO1/19062
Example 208
Preparation of (S)-2-(2-Benzylox~acet~amino)-4-methyl-pentanoic acidf 1-(4-
fluoro-
benzenesulfonyl)-3-oxo-azepan-4-yll-amide
Following the procedure of Example I I5, except substituting 4-
fluorobenzenesulphonyl chloride for 4-methoxybenzenesulfonyl chloride, the
title
compound was prepared. The residue was purified by HPLC. First eluting
diastereomer:
MS 548.2 (M+H+).1H NMR (400Hz,CDCl3-CD30D) ~ 7.88-7.80 (m, 2H), 7.45-7.30 (m,
5H), 7.30-7.20 (m, 2H), 4.00 (s, 2H), 2.60-2.48 (m,lH), 0.96 (t, 6H): MS 548.2
(M+H+).
Example 209
Preparation of Benzo~blthiophene-2-carboxylic acid- j~S)-1-f 1-(4-fluoro-
benzenesulfonyl)-
3-oxo-azepan-4-yl carbamoyll-3-methyl-butyl-amide
Following the procedure of Example 115, except substituting 4-
fluorobenzenesulphonyl chloride for 4-methoxybenzenesulfonyl chloride and
benzo[b]thiophenecarbonyl chloride for benzyloxyacetyl chloride, the title
compound was
prepared. The residue was purified by HPLC. First eluting diastereomer: MS
560.2
(M+H+).IH NMR (500 MHz,CDCl3): b 7.80-7.72 (m, 5H).7.37-7.34 (m, 2H), 7.33-
7.15
(m, 4H), 2.43 (t, 1H), 0.96 (d, 6H). Second eluting diastereomer: MS 560.2
(M+H+)
Example 210
Preparation of Benzofuran-2-carboxylic acid ( (S)-1-C 1-benzoyl-3-oxo-azepan-4-
ylcarbamoyll-3-methyl-butyl ~-amide
a.) Benzofuran-2-carboxylic acid {(S)-1-[1-benzoyl-3-hydroxy-azepan-4-
ylcarbamoyl]-
3-methyl-butyl }-amide
To a solution of benzofuran-2-carboxylic acid [(S)-1-(3-hydroxy-azepan-4-
ylcarbamoyl)-3-methyl-butyl]-amide of Example 78c (0.2 g) in dichloromethane
was added
benzoic acid (0.12 g), HOBt (0.07 g) and EDC (0.99 g). The reaction was
stirred until
220
CA 02412353 2002-12-13
WO 01/95911 PCT/USO1/19062
complete. Workup and column chromatography (5% methanol:dichloromethane)
provided
the title compound (0.2 g): 'H NMR (CDC13): ~ 1.0 (m, 6H), 1.5-2.2 (m, 6H),
2.7 (m, 1H),
3.8 (m,lH), 4.1 (m, 1H), 4.7 (m, 2H), 5.1 (m, 1H), 7.0-7.7 (m, 10H), 8.7 (nn,
1H); MS(EI):
492 (M+H+, 100%).
b.) Benzofuran-2-carboxylic acid {(S)-1-[1-benzoyl-3-oxo-azepan-4-ylcarbamoyl]-
3-
methyl-butyl}-amide
Following the procedure of Example 1i except substituting benzofuran-2-
carboxylic acid {(S)-1-[1-benzoyl-3-hydroxy-azepan-4-ylcarbamoyl]-3-methyl-
butyl}-
amide of Example 210a the title compound was prepared: 'H NMR (CDCl3): 8 1.0
(m, 6H),
1.5-2.2 (m, 6H), 2.7 (m, 1H), 3.7 (m,lH), 4.0 (m, 1H), 4.7 (m, 2H), 5.1 (m,
1H), 7.4-8.0 (m,
8H); MS(EI): 490 (M+H+, 100%).
Example 211
Preparation of (S)-4-Methyl-2-(quinoline-8-sulfonylamino)-pentanoic acid (3-
oxo-1-
(pyridine-2-sulfonyl)-azepan-4-y11-amide
a.) (S)-4-Methyl-2-(quinoline-8-sulfonylamino)-pentanoic acid [3-hydroxy-1-
(pyridine-2-sulfonyl)-azepan-4-yl]-amide
Following the procedure of Example 89a except substituting 8-quinolinesulfonyl
chloride for 2-pyridinesulfonyl chloride the title compound Was prepared:
MS(E~ 576
(M+H+).
b.) (S)-4-Methyl-2-(quinolir<e-8-sulfonylamino)-pentanoic acid [3-oxo-1-
(pyridine-2-
sulfonyl)-azepan-4-yl]-amide
Following the procedure of Example 1i except substituting (S)-4-methyl-2-
(quinoline-8-sulfonylamino)-pentanoic acid [3-hydroxy-1-(pyridine-2-sulfonyl)-
azepan-4-
yl]-amide of Example 21 la the title compound was prepared: 'H NMR (CDC13): 8
0.5-0.8
(m, 6H), 1.4-1.8 (m, 7H), 2.5 (m, 1H), 3.5-3.9 (m, 3H), 4.4 (m, 1H), 4.6 (m,
1H), 5.5 (m,
1H), 6.7 -7.0 (m, 2H), 7.5 (m, 3H), 8.0 (m, 2H), 8.3 (m, 2H), 8.6 (m, 1H), 9.0
(m, 1H);
MS(EI): 674 (M+H+, 100%).
221
CA 02412353 2002-12-13
WO 01/95911 PCT/USO1/19062
Example 212
Preparation of (S)-4-Methyl-2-(na~hth~lene-2-sulfonylamino)-pentanoic acid f3-
oxo-1-
(pyridine-2-sulfon l~)-azepan-4-yll-amide
a.) (S)-4-Methyl-2-(naphthylene-2-sulfonylamino)-pentanoic acid [3-hydroxy-1-
(pyridine-2-sulfonyl)-azepan-4-yl]-amide
Following the procedure of Example 89a except substituting 2-
naphthylenesulfonyl
chloride for 2-pyridinesulfonyl chloride the title compound was prepared:
MS(EI) 575
(M+H+).
b.) (S)-4-Methyl-2-(naphthylene-2-sulfonylamino)-pentanoic acid [3-oxo-1-
(pyridine-
2-sulfonyl)-azepan-4-yl]-amide
Following the procedure of Example 1i except substituting (S)-4-methyl-2-
(naphthylene-2-sulfonylamino)-pentanoic acid [3-hydroxy-1-(pyridine-2-
sulfonyl)-azepan-
4-yl]-annide of Example 212a the title compound was prepared: 'H NMR (CDCl3):
8 0.5-
0.8 (m, 6H), 1.4-1.8 (m, 7H), 2.5 (m, 1H), 3.5-3.9 (m, 3H), 4.5 (m, 1H), 4.6
(m, 1H), 5.5
(m, 1H), 6.7 (m, 1H), 7.5-8.0 (m, 9H), 8.5-8.6 (m, 2H); MS(EI): 673 (M+H+,
100%).
Example 213
Preparation of Benzofuran-2-carbolic acid-i(S)-1-( 1-(4-fluoro-benzenesulfon~)-
3-oxo-
azepan-4-yl carbamoyll-3-methyl-butyl ~-amide
Following the procedure of Example 115, except substituting 4-
fluorobenzenesulphonyl chloride for 4-methoxybenzenesulfonyl chloride and 2-
benzofurancarbonyl chloride for benzyloxyacetyl chloride, the title compound
was
prepared. The residue was purified by HPLC. First eluting diastereomer: MS
544.2.(M+H+).1H NMR (500 MHz,CDCl3): 8 7.79-7.77 (m, 2H), 7.61 (d, 1H), 7.46-
7.38
(m, 3H), 7.25-7.06 (m, 5H), 2.43 (t, 1H), 0.95 (d, 6H). Second eluting
diastereomer: MS
544.4 (M+H+).
222
CA 02412353 2002-12-13
WO 01/95911 PCT/USO1/19062
Example 2I4
Preparation of N-1 (S)-1-f 1-(4-Fluoro-benzenesulfon~)-3-oxo-azepan-4-
ylcarbamo 1
meth-butyll-3,4-dimethoxy-benzamide
Following the procedure of Example 115, except substituting 4-
fluorobenzenesulphonyl chloride for 4-methoxybenzenesulfonyl chloride and 3,4-
dimethoxybenzoyl chloride for benzyloxyacetyl chloride, the title compound was
prepared.
The residue was purified by HPLC. First eluting diastereomer: MS 564.2.(M+H+).
1H
NMR (500 MHz,CDCl3): 8 7.80-7.76 (m, 2H),7.19 (t, 2H),7.05 (d, 1H), 6.88 (s,
2H), 6.78
(d, 1H), 6.53 (s, 1H), 3.77 (s, 6H), 2.43 (t, 1H), 0.94 (d, 6H). Second
eluting diastereomer:
MS 546.2 (M+H+).
Exam In a 215
Preparation of Cyclohexanecarboxylic acid ; (S)-1-f 1-(4-fluoro-
benzenesulfonyl)-3-oxo-
azepan-4-ylcarbamoyl l-3-methyl-butyl l-amide
Following the procedure of Example 115, except substituting 4-
fluorobenzenesulphonyl chloride for 4-methoxybenzenesulfonyl chloride and
cyclohexylcarbonyl chloride for benzyloxyacetyl chloride, the title compound
was
prepared. The residue was purified by HPLC. First eluting diastereomer: MS
510.4.(M+H+).1H NMR (400Hz,CDCl3): 8 7.83-7.80 (m, 2H), 7.27-7.20 (m, 2H),
6.92 (d,
1H), 6.95 (d, 1H). 2.50 (t, 1H), 1.90-1.20 (m, 15H), 0.94 (t, 6H). Second
eluting
diastereomer: MS 510.2 (M+H+).
Exam 1u a 216
Preparation of (S)-2~2-Benzyloxy-acetylamino)-4-methyl-pentanoic acidf 1-
(methanesulfonyl)-3-oxo-azepan-4-yll-amide
Following the procedure of Example 115, except substituting methanesulphonyl
chloride for 4-methoxybenzenesulfonyl chloride, the title compound was
prepared. The
223
CA 02412353 2002-12-13
WO 01/95911 PCT/USO1/19062
residue was purified by HPLC. First eluting diastereomer: MS 468.2 (M+H+).1H
NMR
(500 MHz,CDCl3): ~ 7.37-7.24 (m, 4H), 6.93-6.91 (m, 2H), 5.02-5.00 (m, 1H),
2.88 (s,
3H), 2.70 (t, 1H), 0.92 (t, 6H). Second eluting diastereomer: MS 468.2 (M+H+)
Example 217
Preparation of Benzo~blthiophene-2-carboxylic acid-~~)-1-(1-methanesulfonyl-3-
oxo-
azepan-4-yl carbamoyl)-3-methyl-butyll-amide
Following the procedure of Example 115, except substituting methanesulphonyl
chloride for 4-methoxybenzenesulfonyl chloride and benzo[b]thiophenecarbonyl
chloride
for benzyloxyacetyl chloride, the title compound was prepared. The residue was
purified
by HPLC. First eluting diastereomer: MS 480.2 (M+H+).1H NMR (500 MHz,CDCl3):
S 7.83-7.78 (m, 3H),7.42-7.37 (m, 2H),6.94 (d, 1H), 6.75 (d, 1H), 2.89 (s,
3H), 2.68 (t, 1H),
0.97 (d, 6H). Second eluting diastereomer: MS 480.2 (M+H+).
Exam In a 218
Preparation of Benzof 1,31dioxole-5-carboxylic acid- (S)-1-(1-methanesulfonyl-
3-oxo-
azepan-4-yl carbamoyl)-3-methyl-butyll-amide
Following the procedure of Example 115, except substituting methanesulphonyl
chloride for 4-methoxybenzenesulfonyl chloride and piperonylcarbonyl chloride
for
benzyloxyacetyl chloride, the title compound was prepared. The residue was
purified by
HPLC. First eluting diastereomer: MS 468.2 (M+H+).1H NMR (500 MHz,CDCl3): 8
7.31-7.24 (m, 2H), 6.91 (d, 1H), 6.00 (s, 2H), 2.89 (s, 3H), 2.67 (t, 1H),
0.95 (d, 6H).
Second eluting diastereomer: MS 468.2 (M+H+).
224
CA 02412353 2002-12-13
WO 01/95911 PCT/USO1/19062
Example 219
Preparation of Benzofuran-2-carboxylic acid- (S)-1-(1-methanesulfonyl-3-oxo-
azepan-4-yl
carbamoyl)-3-meth~yll-amide
Following the procedure of Example 115, except substituting methanesulphonyl
chloride for 4-methoxybenzenesulfonyl chloride and 2-benzofurancarbonyl
chloride for
benzyloxyacetyl chloride, the title compound was prepared. The residue was
purified by
HPLC. First eluting diastereomer: MS 464.2 (M+H+).1H NMR (500 MHz,CDCl3): 8
7.64 (d, 1H), 7.51-7.37 (m, 3H), 7.29-7.28 (m, 1H), 2.89 (s, 3H), 2.67 (t,
1H), 0.97 (d, 6H).
Second eluting diastereomer: MS 464.2 (M+H+).
Example 220
Preparation of N-f(S)-1-(1-Methanesulfon~)-3-oxo-azepan-4-ylcarbamoyl)-3-
methyl-
butyl )-3,4-dimethoxy-benzamide
Following the procedure of Example 115, except substituting methanesulphonyl
chloride for 4-methoxybenzenesulfonyl chloride and 3,4-dimethoxybenzoyl
chloride for
benzyloxyacetyl chloride, the title compound was prepared. The residue was
purified by
HPLC. First eluting diastereomer: MS 484.2 (M+H+).1H NMR (500 MHz,CDCl3): 8
6.94-6.88 (m, 3H), 6.58-6.55 (m, 2H), 3.80 (s, 6H), 2.89 (s, 3H), 0.95 (d,
6H). Second
eluting diastereomer: MS 484.2 (M+H+)
Example 221
Preparation of (S)-2-(2-Benzyloxy-acetylamino)-4-methyl-pentanoic acidf 1-(2-
cyano-
benzensulfonyl)-3-oxo-azepan-4-yli-amide
Following the procedure of Example 115, except substituting 2-
cyanophenylsulphonyl chloride for 4-methoxybenzenesulfonyl chloride, the title
compound
was prepared. The residue was purified by HPLC. First eluting diastereomer: MS
555.2
(M+H+).1H NMR (500 MHz,CDCl3): b 8.10 (d, 1H), 7.86 (d, 1H), 7.76-7.70 (m,
2H),
225
CA 02412353 2002-12-13
WO 01/95911 PCT/USO1/19062
7.35-7.31 (m, 5H), 6.93 (d, 2H), 4.61-4.47 (m, 4H), 2.77 (t, 1H), 0.92 (t,
6H). Second
eluting diastereomer: MS 555.2 (M+H+).
Example 222
Preparation of N-( (S)-1-f 1-(2-C~ano-benzenesulfon~)-3-oxo-azepan-4-ylcarbamo
l~l-3-
methyl-butyl ~-4-methanesulfonyl-1-benzamide
Following the procedure of Example 115, except substituting 2-
cyanophenylsulphonyl chloride for 4-methoxybenzenesulfonyl chloride and 4-
methanesulfonylbenzoyl chloride for benzyloxyacetyl chloride, the title
compound was
prepared. The residue was purified by HPLC. First eluting diastereomer: MS
589.2
(M+H+).1H NMR (500 MHz,CDCl3): 8 8.10 (d,lH), 7.96 (s, 4H), 7.88 (d, 1H), 7.78-
7.71
(m, 2H), 3.05 (s, 3H), 2.79 (t, 1H), 0.97 (t, 6H). Second eluting
diastereomer: MS 589.2
(M+H+).
Example 223
Preparation of Benzofblthiophene-2-carboxylic acid-((S)-1-f 1-(2-cyano-
benzenesulfonyl)-
3-oxo-azepan-4-yl carbamoyl)-3-methyl-butyll-amide
Following the procedure of Example 115, except substituting 2-
cyanophenylsulphonyl chloride for 4-methoxybenzenesulfonyl chloride and
benzo[b]thiophene-2-carbonyl chloride for benzyloxyacetyl chloride, the title
compound
was prepared. The residue was purified by HPLC. First eluting diastereomer: MS
567.2
(M+H+).1H NMR (500 MHz,CDCl3): 8 8.10 (d, 1H), 7.86-7.70 (m, 6H), 7.37-7.30
(m,
2H), 2.76 (t, 1H), 0.98 (d; 6H). Second eluting diastereomer: MS 567.2 (M+H+)
226
CA 02412353 2002-12-13
WO 01/95911 PCT/USO1/19062
Example 224
Preparation of Benzof 1,31dioxole-5-carbolic acid-~S)-1-f 1-(2-cyano-
benzenesulfon 1~)-3-
oxo-azepan-4-ylcarbamoyl)-3-methyl-butyll-amide
Following the procedure of Example 115, except substituting 2-
cyanophenylsulphonyl chloride for 4-methoxybenzenesulfonyl chloride and
piperonyloyl
chloride for benzyloxyacetyl chloride, the title compound was prepared. The
residue was
purified by HPLC. First eluting diastereomer: MS 555.2 (M+H+).1H NMR (500
MHz,CDCl3): 8 8.1I (d, 1H), 7.87 (d, 1H), 7.76-7.71 (m, 2H), 7.3I-7.24 (m,
ZH), 6.00 (s,
2H), 2.77 (t, 1H), 0.97 (d, 6H). Second eluting diastereomer: MS 555.4 (M+H+)
Exam 1p a 225
Preparation of (S)-4-Methyl-2-f 4-oxo-4-((4-phenoxy_phenxl)-but~rylamino }-
pentanoic acid
f 3-oxo-1-(pyridine-2-sulfonyl)-azepan-4-yll-amide
Following the procedure of Example 75, except substituting 2-pyridylsulfonyl
chloride for thiaxole-2-sulfonyl chloride and 4-phenoxyphenyl-carboxylic acid
for
benzofuran-2-carboxylic acid, the title compound was prepared. The residue was
purified
by HPLC. First eluting diastereomer; MS (M+H+) 635.4; 1H-NMR (400 MHz, CDC13):
8.69(d, 1H), 7.99-7.94(m, 4H), 7.53-7.39(m, 3H), 7.23-6.95(m, 7H), 6.20(d,
1H), 5.07(m,
1H), 4.77-4.72(d, 1H), 4.46(m, 1H), 4.13-4.09(m, 1H), 3.85-3.80(d, 1H),
3.33(m, 2H), 2.70-
2.64(m, 3H), 2.20-1.40(m, 6H); and the second eluting diastereomer:, 0.96-
0.92(m, 6H);
and the second eluting diastereomer: MS (M+H+) 635.4.
Exam 1u a 226
Preparation of N-d(S)-1-f(1-(2-cyano-benzenesulfon~l)-3-oxo-azepan-4-
ylcarbamo~~-3-
methyl-butyl ~-3,4-dimethoxy-benzamide
Following the procedure of Example 115, except substituting 2-
cyanophenylsulphonyl chloride for 4-methoxybenzenesulfonyl chloride and 3,4-
227
CA 02412353 2002-12-13
WO 01/95911 PCT/USO1/19062
dimethoxybenzoyl chloride for benzyloxyacetyl chloride, the title compound was
prepared.
The residue was purified by HPLC. First eluting diastereomer: MS 571.4
(M+H+).1H
NMR (500 MHz,CDCl3): 8 8.10 (d, 1H), 7.87 (d, 1H), 7.76-7.70 (m, 2H), 6.98 (s,
2H), 6.89
(s, 2H), 3.79 (s, 6H), 2.76 (t, 1H), 0.96 (d, 6H). Second eluting
diastereomer: MS 571.4
(M+H+)
Example 227
Preparation of Cyclohexanecarboxylic acid (S)-1-f 1~4-methoxy-benzenesulfonyl)-
3-oxo-
azepan-4-ylcarbamoyl~-3-metal-butyl-amide
Following the procedure of Example 115, except substituting cyclohexylcarbonyl
chloride for benzyloxyacetyl chloride, the title compound was prepared. The
residue was
purified by HPLC. First eluting diastereomer: MS 522.4 (M+H+).1H NMR (500
MHz,CDCl3): 8 7.70 (d, 2H), 6.97 (d, 2H), 2.40 (t, 1H), 1.90-1.20 (m, 16H),
0.92 (d, 6H).
Second eluting diastereomer: MS 522.4 (M+H+)
Example 228
Preparation of 4-Methansulfonyl-N~(S)-1-f4-method-benzenesulfon~)-3-oxo-azepan-
4-
carbamoyll-3-methyl-butyl-benzamide
Following the procedure of Example 115, except substituting 4-
methanesulfonylbenzoyl chloride for benzyloxyacetyl chloride, the title
compound was
prepared. The residue was purified by HPLC. First eluting diastereomer: MS
594.2
(M+H+).1H NMR (500 MHz,CDCl3): 8 7.96 (s, 4H), 7.69 (d, 2H), 7.25 (d,lH), 6.98
(d,3H), 3.85 (s, 3H), 3.04 (d, 3H), 2.42 (t, 1H), 0.95 (d, 6H). Second eluting
diastereomer:
MS 594.2 (M+H+).
228
CA 02412353 2002-12-13
WO 01/95911 PCT/USO1/19062
Example 229
Preparation of 4-Methansulfonyl-N-i(S)-1-f4-fluoro-benzenesulfon~)-3-oxo-
azepan-4-
carbamoyll-3-methyl-butyl-benzamide
Following the procedure of Example 115, except substituting 4-
fluorophenylsulphonyl chloride for 4-methoxybenzenesulfonyl chloride and
substituting 4-
methanesulfonylbenzoyl chloride for benzyloxyacetyl chloride, the title
compound was
prepared. The residue was purified by HPLC. First eluting diastereomer: MS
582.2
(M+H+).1H NMR (500 MHz,CDCl3): 8 7.94 (s, 4H), 7.80-7.77 (m, 2H), 7.25-7.19
(m,
3H), 7.00 (d, 1H), 3.04 (s, 3H), 0.96 (d, 6H). Second eluting diastereomer: MS
582.2
(M+H+)
Exam 1p a 230
Preparation of (~(S)-3-Methyl-1-f3-oxo-1-(pyridine-2-sulfonXl)-azepan-4-
ylcarbamoyll-
butylcarbamoyl ~-carbamic acid benzyl ester
Following the procedure of Example 75, except substituting 2-pyridylsulfonyl
chloride for benzenesulfonyl chloride and N-carbobenzyloxycarbonyl-glycine for
benzofuran-2-carboxylic acid, the title compound was prepared. The residue was
purified
by HPLC. First eluting diastereomer; MS (M+H+): 574.2; 1H-NMR (400 MHz,
CDC13):
8.60(d, 1H), 7.97-7.90(m, 2H), 7.50(m, 1H), 7.42-7.25(m, 5H), 6.90(m, 1H),
6.42(m, 1H),
5.38(m, 1H), 5.18-5.10(m, 4H), 4.78-4.72(d, 1H), 4.50(m, 1H), 4.12-4.05(m,
1H), 3.95-
3.85(m, 2H), 2.72(m, 1H), 2.25-2.10(m, 2H), 1.90-1.40(m, 5H), 0.92(m, 6H); and
the
second eluting diastereomer: MS (M+H+) 574.2.
229
CA 02412353 2002-12-13
WO 01/95911 PCT/USO1/19062
Example 231
Preparation of (S)-2-f5-(4-Methoxy- henyD-pentanoylamniol-4-methyl-pentanoic
acid f3-
oxo-1-(pyridine-2-sulfon 1)-azepan-4-yll-amide
Following the procedure of Example 75, except substituting 2-pyridylsulfonyl
chloride for benzenesulfonyl chloride and 5-(4-methoxyphenyl)-pentanoic acid
for
benzofuran-2-carboxylic acid, the title compound was prepared. The residue was
purified
by HPLC. First eluting diastereomer; MS (M+H+): 573.4; 1H-NMR (400 MHz,
CDCl3):
8.59(d, 1H), 7.97-7.94(m, 2H), 7.53(m, 1H), 7.09-7.07(d, 2H), 6.89-6.81(m,
3H), 5.90(m,
1H), 5.12(m, 1H), 4.79-4.74(d, 1H), 4.48(m, 1H), 4.12(m, 1H), 3.86-3.81(d,
1H), 3.79(s,
3H), 2.69(m, 1H), 2.59-2.57(m, 2H), 2.23-2.10(m, 3H), 1.75-1.45(m, 10H), 0.96-
0.95(m,
6H); and the second eluting diastereomer: MS (M+H+) 573.4.
Example 232
Preparation of (S)-2-f2-(3-Benzyloxy-4-methox~phenyl -acetylamniol-4-
methylpentanoic
acid f3-oxo-1-(pyridine-2-sulfonyl)-azepan-4-yll-amide
Following the procedure of Example 75, except substituting 2-pyridylsulfonyl
chloride for benzenesulfonyl chloride and (3-benzyloxy-4-methoxy-phenyl)-
acetic acid for
benzofuran-2-carboxylic acid, the title compound was prepared. The residue was
purified
by HPLC. First eluting diastereomer; MS (M+H+): 637.4; 1H-NMR (400 MHz,
CDCl3):
8.69(d, 1H), 7.98-7.91(m, 2H), 7.53-7.30(m, 6H); and the second eluting
diastereomer:,
6.89-6.82(m, 4H), 5.82(m, 1H), 5.14-5.07(m, 3H), 4.78-4.73(d, 1H), 4.43(m,
1H), 4.09(m,
1H), 3.89(s, 3H), 3.82(d, 1H), 3.49(s, 2H), 2.69(m, 1H), 2.14(m, 2H), 1.82-
1.40(m, 5H),
0.89(d, 6H); and the second eluting diastereomer: MS (M+H+) 637.4.
230
CA 02412353 2002-12-13
WO 01/95911 PCT/USO1/19062
Example 233
Preparation of 5,6-Difluoro-benzofuran-2-carbox~ acid (S)-3-methyl-1-f 1-
(pyridine-2-
sulfonyl)-3-oxo-azepan-4-ylcarbamoyll-bull amide
a.) 5,6-Difluoro-benzofuran-2-carboxylic acid {(S)-3-methyl-1-[1-(pyridine-2-
sulfonyl)-3-hydroxy-azepan-4-ylcarbamoyl]-butyl } amide
Following the procedure of Example 28b except substituting 5,6-
difluorobenzofuran-2-carboxylic acid for bernzofuran-2-carboxylic acid
provided the title
compound: MS (M+H+): 564
b.) 5,6-Difluoro-benzofuran-2-carboxylic acid {(S)-3-methyl-1-[1-(pyridine-2-
sulfonyl)-3-oxo-azepan-4-ylcarbamoyl]-butyl } amide
Following the procedure of Example 1i except substituting the compound
of Example 233a provided the title compound. The residue was purified by HPLC.
First
eluting diastereomer; MS (M+H~): 562; and the second eluting diastereomer: MS
(M+H+)
562.
Example 234
Preparation of (S)-4-Methyl-2-(5-oxo-hexanoylamino)-pentanoic acid f 3-oxo-1-
(pyridine-2-
sulfon~)-azepan-4w11-amide
Following the procedure of Example 115, except substituting 2-
pyridinesulphonyl
chloride for 4-methoxybenzenesulfonyl chloride and substituting 5-oxo-hexanoyl
chloride
for benzyloxyacetyl chloride, the title compound was prepared. The residue was
purified
by HPLC. First eluting diastereomer: MS 495.4 (M+H+); Second eluting
diastereomer:
MS 495.4 (M+H+).
231
CA 02412353 2002-12-13
WO 01/95911 PCT/USO1/19062
Example 235
Preparation of Benzofuran-2-carbox lic acid (S)-3-methyl-1 jl-(6-metal-
pyridine-2-
sulfonyl)-3-oxo-azepan-4-ylcarbamoyll-butt amide
a.) 6-methyl-pyridine-2-sulphonyl chloride
The title compound was prepared in a similar fashion as that described in
Example
85a for the preparation of 2-pyridinesulfonyl chloride-N-oxide.
b.) { (S)-1-[3-Hydroxy-1-(6-methyl-pyridine-2-sulfonyl)-azepan-4-ylcarbamoyl]-
3-
methyl-butyl}-carbamic acid tert-butylester
To a solution of [(S)-1-(3-hydroxy-azepan-4-ylcarbamoyl)-3-methyl-butyl]-
carbamic acid tert-butyl ester of Example 2g (1.0 g) in dichloromethane (20
mL) was added
saturated sodium bicarbonate (50 mL). To this solution was added 6-methyl-
pyridine-2-
sulphonyl chloride (6.44 mL of a 0.13 glmL solution in 9M HCl). The reaction
was stirred
until complete. Workup and column chromatography (5% methanol:dichloromethane)
provided the title compound (1.2 g).
c.) (S)-2-Amino-4-methyl-pentanoic acid [3-hydroxy-1-(6-methyl-pyridine-2-
sulfonyl)-azepan-4-yl]-amide
To a solution of (S)-2-amino-4-methyl-pentanoic acid [3-hydroxy-1-(6-methyl-
pyridine-2-sulfonyl)-azepan-4-yl]-amide of Example 235a (1.2 g) in methanol
(20 xnL,)
was added 4M HCl in diopxane (20 mL). The reaction was stirred until complete
whereupon it was concentrated to provide the title compound (1 g).
d.) Benzofuran-2-carboxylic acid {(S)-3-methyl-1-[1-(6-methyl-pyridine-2-
sulfonyl)-3-
hydroxy-azepan-4-ylcarbamoyl]-butyl } amide
Following the procedure of Example 28b except substituting (S)-2-amino-4-
methyl-pentanoic acid [3-hydroxy-1-(6-methyl-pyridine-2-sulfonyl)-azepan-4-yl]-
amide of
Example 235c the title compound was prepared: MS(EI) 542 (M+)
232
CA 02412353 2002-12-13
WO 01/95911 PCT/USO1/19062
e.) Benzofuran-2-carboxylic acid {(S)-3-methyl-1-[1-(6-methyl-pyridine-2-
sulfonyl)-3-
oxo-azepan-4-ylcarbamoyl]-butyl } amide
Following the procedure of Example 1i except substituting benzofuran-2-
carboxylic acid {(S)-3-methyl-1-[1-(6-methyl-pyridine-2-sulfonyl)-3-hydroxy-
azepan-4-
ylcarbamoyl]-butyl}amide of Example 235d the title compound was prepared:'H
NMR
(CDC13): 8 1.0 (m, 6H), 1.5-2.2 (m, 6H), 2.6 (m, 3H), 2.7 (m, 1H), 4.1 (m,
1H), 4.7 (m, 2H),
5.3 (m, 1H), 7.4-8.0 (m, 8H); MS(EI); 540 (M+, 100%).
Example 236
IO
Preparation of 5-Methoxybenzofuran-2-carboxylic acid ( (S)-3-meth-1-f 1-(6-
meth ~~l-
pyridine-2-sulfonyl)-3-oxo-azepan-4-ylcarbamo~l-butyl ~~ amide
a.) 5-Methoxybenzofuran-2-carboxylic acid {(S)-3-methyl-1-[1-(6-methyl-
pyridine-2-
sulfonyl)-3-hydroxy-azepan-4-ylcarbamoyl]-butyl}amide
Following the procedure of Example 28b except substituting 5-methoxybenzofuran-
2-carboxylic acid for benzofuran-2-carboxylic acid and (S)-2-amino-4-methyl-
pentanoic
acid [3-hydroxy-1-(6-methyl-pyridine-2-sulfonyl)-azepan-4-yl]-amide of Example
235c for
(S)-2-amino-4-methyl-pentanoic acid [3-hydroxy-1-(pyridine-2-sulfonyl)-azepan-
4-yl]-
amide of Example 28b the title compound was prepared: MS(EI] 572 (M+)
b.) 5-Methoxybenzofuran-2-carboxylic acid {(S)-3-methyl-1-[1-(6-methyl-
pyridine-2-
sulfonyl)-3-oxo-azepan-4-ylcarbamoyl]-butyl } amide
Following the procedure of Example 1i except substituting 5-methoxybenzofuran-
2-carboxylic acid {(S)-3-methyl-1-[1-(6-methyl-pyridine-2-sulfonyl)-3-hydroxy-
azepan-4-
ylcarbamoyl]-butyl}amide of Example 236a the title compound was prepared: 'H
NMR
(CDC13): 8 1.0 (m, 6H), 1.5-2.2 (m, 6H), 2.6 (m, 3H), 2.7 (m, 1H), 3.8 (s,
3H); 4.1 (m, 1H),
4.7 (m, 2H), 5.3 (m, 1H), 7.4-8.0, (m, 7H); MS(EI): 570 (M+, 100°Io).
233
CA 02412353 2002-12-13
WO 01/95911 PCT/USO1/19062
Exam lt~ a 237
Preparation of 3-Methylbenzofuran-2-carboxylic acid ~S)-3-methyl-1-f 1-(6-
methy_l-
pyridine-2-sulfonyl)-3-oxo-azepan-4-ylcarbam~ll-butyl ~ amide
a.) 3-Methylbenzofuran-2-carboxylic acid {(S)-3-methyl-1-[1-(6-methyl-pyridine-
2-
sulfonyl)-3-hydroxy-azepan-4-ylcarbamoyl]-butyl } amide
Following the procedure of Example 236a except substituting 3-methylbenzofuran-
2-carboxylic acid for S-methoxybenzofuran-2-carboxylic acid the title compound
was
prepared: MS(EI) S56 (M+)
b.) 3-Methylbenzofuran-2-carboxylic acid {(S)-3-methyl-1-[1-(6-methyl-pyridine-
2-
sulfonyl)-3-oxo-azepan-4-ylcaxbamoyl]-butyl } amide
Following the procedure of Example 1i except substituting 3-methylbenzofuran-2-
carboxylic acid {(S)-3-methyl-1-[1-(6-methyl-pyridine-2-sulfonyl)-3-hydroxy-
azepan-4-
ylcarbamoyl]-butyl}amide of Example 237a the title compound was prepared: 'H
NMR
(CDC13): 8 1.0 (m, 6H), 1.5-2.2 (m, 6H), 2.6 (m, 3H), 2.7 (m, 1H), 3.8 (s,
1H); 4.1 (m, 1H),
4.7 (m, 2H), 5.3 (m, 1H), 7.4-8.0 (m, 6H); MS(EI): 564 (M+, 100°l0).
Exam 1~ a 238
Preparation of 7-Methoxybenzofuran-2-carboxylic acid (S)-3-methyl-1-f 1-
(pyridine-2-
sulfonyl)-3-oxo-azepan-4-ylcarbamoyll-butyl amide
a.) 7-Methoxybenzofuran-2-carboxylic acid {(S)-3-methyl-1-[1-(6-methyl-
pyridine-2-
sulfonyl)-3-hydroxy-azepan-4-ylcarbamoyl]-butyl } amide
Following the procedure of Example 28b except substituting 7-
methoxybenzofuran-2-carboxylic acid for benzofuran-2-carboxylic acid the title
compound
was prepared: MS(EI) 559 (M+H+).
b.) 7-Methoxybenzofuran-2-carboxylic acid {(S)-3-methyl-1-[1-(6-methyl-
pyridine-2-
sulfonyl)-3-oxo-azepan-4-ylcarbamoyl]-butyl } amide
Following the procedure of Example 1i except substituting 7-methoxybenzofuran-
2-carboxylic acid {(S)-3-methyl-1-[1-(6-methyl-pyridine-2-sulfonyl)-3-hydroxy-
azepan-4-
234
CA 02412353 2002-12-13
WO 01/95911 PCT/USO1/19062
ylcarbamoyl]-butyl}amide of Example 238a the title compound was prepared:
MS(EI) 557
(M+H+).
Example 239
Preparation of 5,6-Dimethoxy-benzofblthiophene-2-carboxylic acid L)-3-methyl-1-
~l-
~pyridine-2-sulfonyl)-3-oxo-azepan-4-ylcarbamo 1v 1-butt amide
a.) 5,6-Dimethoxy-benzo[b]thiophene-2-carboxylic acid {(S)-3-methyl-1-[1-(6-
methyl-
pyridine-2-sulfonyl)-3-hydroxy-azepan-4-ylcarbamoyl]-butyl}amide
Following the procedure of Example 28b except substituting 5,6-dimethoxy-
benzo[b]thiophene-2-carboxylic acid for benzofuran-2-carboxylic acid the title
compound
was prepared: MS(EI) 604 (M+)
b.) 5,6-Dimethoxy-benzo[b]thiophene-2-carboxylic acid {(S)-3-methyl-1-[1-(6-
methyl-
pyrid'ine-2-sulfonyl)-3-oxo-azepan-4-ylcarbamoyl]-butyl } amide
Following the procedure of Example 1i except substituting 5,6-dimethoxy-
benzo[b]thiophene-2-carboxylic acid {(S)-3-methyl-1-[1-(6-methyl-pyridine-2-
sulfonyl)-3-
hydroxy-azepan-4-ylcarbamoyl]-butyl}amide of Example 239a the title compound
was
prepared: MS(EI) 602.9 (M+H+).
Exam 1p a 240
Preparation of (R)-1-Benzyl-5-oxo-pymolidine-2-carboxylic acid 1 (S)-3-methyl-
1-{ 3-oxo-
(pyridine-2-sulfonyl)-azepan-4-ylcarbam~ll-butyl~amide
Following the procedure of Example 75, except substituting 2-pyridylsulfonyl
chloride for thiazole-2-sulfonyl chloride and (R)-1-benzyl-5-oxo-pyrrolidine-2-
carboxylic
acid for benzofuran-2-carboxylic acid, the title compound was prepared. The
residue was
purified by HPLC. First eluting diastereomer; MS (M+H+): 584.4; 1H-NMR (400
MHz,
CDC13): ~ 8.69(d, 1H), 7.99-7.92(m, 2H), 7.52(m, 1H), 7.32-7.22(m, 5H),
6.92(d, 1H),
6.38(d, 1H), 5.15-5.08(m, 2H), 4.80-4.75(d, 1H), 4.47-4.44(m, 1H), 4.14-
4.10(m, 1H),
3.89-3.80(m, 3H), 2.75-2.63(m, 2H), 2.46-1.44(m, 10H), 0.95(d, 6H); and the
second
eluting diastereomer: MS (M+H+) 584.4.
235
CA 02412353 2002-12-13
WO 01/95911 PCT/USO1/19062
Example 241
Preparation of (S)-1-Benzyl-5-oxo-pyrrolidine-2-carboxXlic acid (S)-3-methy~3-
oxo-
pyridine-2-sulfonyl)-azepan-4-ylcarbamoyll-butyllamide
Following the procedure of Example 75, except substituting 2-pyridylsulfonyl
chloride for benzenesulfonyl chloride and (S)-1-benzyl-5-oxo-pyrrolidine-2-
carboxylic
acid for benzofuran-2-carboxylic acid, the title compound was prepared. The
residue was
purified by HPLC. First eluting diastereomer; MS (M+H+): 584.4; 1H-NMR (400
MHz,
CDC13): ~ 8.69(d, 1H), 7.98-7.92(m, 2H), 7.52(m, 1H), 7.32-7.22(m, 5H),
6.92(d, 1H),
6.38(d, 1H), 5.22-5.18(d, 1H), 5.10(m, 1H), 4.80-4.75(d, 1H), 4.51(m, 1H),
4.12-4.08 (m,
1H), 3.91-3.79(m, 3H), 2.71-1.38(m, 12H), 0.97(d, 6H); and the second eluting
diastereomer: MS (M+H+): 584.4.
Example 242
Preparation of Benzofuran-2-carboxylic acid (S)-2-cyclopro~yl-1-f3-oxo-1-
(~yridine-2-
sulfon~)-azepan-4ylcarbamo~)-ethyll-amide
Following the procedure of Example 193e-h except substituting N-Boc-
cyclopropylalanine for step 193e, the title compound was purified to yield two
diastereomers as solids (first eluting: 8 mg, second eluting: 8 mg): MS(ESI):
525 (M+H)+.
Example 243
Preparation of Benzofuran-2-carboxylic acid (S)-3-methylsulfanyl-1-f3-oxo-1-
(pyridine-2-
sulfonyl)-azepan-4-ylcarbamoyl)-propyll-amide
Following the procedures of Examples 193e-g except substituted N-Boc-L-
methionine in step 193e. The oxidation of Example 193g was performed by adding
sulfur
trioxide-pyridine complex (34mg, 0.211 mmol ) and triethylamine ( 0.077 ml) to
the
alcohol intermediate in DMSO solvent (0.200 ml). After stirring at room
temperature for
two hours, the mixture was diluted with water and extracted with ethyl
acetate. The organic
236
CA 02412353 2002-12-13
WO 01/95911 PCT/USO1/19062
layer was dried, filtered, concentrated, and purified by HPLC to yield two
diastereomers of
the title compound as solids (first eluting: 8mg, second eluting: 5 mg).
MS(ESI): 545
(M+H)+.
Example 244
Preparation of Benzofuran-2-carboxylic acid ~(S)-2-naphthylen-2-yl-1-f3-oxo-1-
(pyridine-
2-sulfonyl)-azepan-4-ylcarbamoyl)-ethyll-amide
Following the procedure of Example 193e-h except substituting except
substituting
N-(t-butoxycarbonyl)-3-(2-naphthyl)-L-alanine, the title compound was purified
to yield
two diastereomers as solids (first eluting: 5.3 mg, second eluting: 3.3 mg):
MS(ESI): 610.8
(M+H)+ .
Example 245
Preparation of Thienof3,2-blthiophene-2-carbolic acid (S)-3-methyl-1-f 1-(6-
meth ~~I-
pyridine-2-sulfonyD-3-oxo-azepan-4-ylcarbamoyll-butyl 1 amide
a.) Thieno[3,2-b]thiophene-2-carboxylic acid {(S)-3-methyl-1-[1-(6-methyl-
pyridine-2-
sulfonyl)-3-hydroxy-azepan-4-ylcarbamoyl]-butyl } amide
Following the procedure of Example 236a except substituting thieno[3,2-
b]thiophene-2-carboxylic acid for 5-methoxybenzofuran-2-carboxylic acid the
title
compound was prepared: MS(EI) 564 (M+).
b.) Thieno[3,2-b]thiophene-2-carboxylic acid {(S)-3-methyl-I-[1-(6-methyl-
pyridine-2-
sulfonyl)-3-oxo-azepan-4-ylcarbamoyl]-butyl } amide
Following the procedure of Example 1i except substituting thieno[3,2-
b]thiophene-
2-carboxylic acid {(S)-3-methyl-1-[1-(6-methyl-pyridine-2-sulfonyl)-3-hydroxy-
azepan-4-
ylcarbamoyl]-butyl}amide of Example 245a the title compound was prepared: 'H
NMR
(CDC13): 8 1.0 (m, 6H), 1.5-2.2 (m, 6H), 2.6 (m, 3H) 2.7 (m, 1H), 3.8 (s, 1H);
4.1 (m, 1H),
4.7 (m, 2H), 5.3 (m, 1H), 7.4-8.0 (m, 6H); MS(EI): 562 (M+, I00%).
237
CA 02412353 2002-12-13
WO 01/95911 PCT/USO1/19062
Example 246
Preparation of Thienof3,2-blthiophene-2-carboxylic acid ((S)-3-methyl-1-f 1-(3-
methxl-
pyridine-2-sulfonyl)-3-oxo-azepan-4-ylcarbamoyll-butyl amide
a.) (S)-2-Amino-4-methyl-pentanoic acid [3-hydroxy-1-(3-methyl-pyridine-2-
sulfonyl)-azepan-4-yl]-amide
Following the procedure of Examples 235b-c except substituting 3-methyl-
pyridine-2-sulfonyl chloride for 6-methyl-pyridine-2-sulfonyl chloride the
title compound
was prepared: MS(En 399 (M+).
b.) Thieno[3,2-b]thiophene-2-carboxylic acid {(S)-3-methyl-1-[1-(3-methyl-
pyridine-2-
sulfonyl)-3-hydroxy-azepan-4-ylcarbamoyl]-butyl } amide
To a solution of (S)-2-amino-4-methyl-pentanoic acid [3-hydroxy-1-(3-methyl-
pyridine-2-sulfonyl)-azepan-4-yl]-amide of Example 246a (0.25 g) in
dichloromethane was
added thieno[3,2-b]thiophene (0.10 g), triethylamine (0.12 mL), HOBt (0.085 g)
and EDC
(0.12 g). The reaction was stirred until complete. Workup and column
chromatography
(5% methanol: dichloromethane) provided the title compound (0.18 g): MS(EI)
564 (M+).
c.) Thieno[3,2-b]thiophene-2-carboxylic acid {(S)-3-methyl-1-[1-(3-methyl-
pyridine-2-
sulfonyl)-3-oxo-azepan-4-ylcarbamoyl]-butyl } amide
Following the procedure of Example 1i except substituting thieno[3,2-
b]thiophene-
2-carboxylic acid {(S)-3-methyl-1-[1-(3-methyl-pyridine-2-sulfonyl)-3-hydroxy-
azepan-4-
ylcarbamoyl]-butyl}amide of Example 245a the title compound was prepared:'H
NMR
(CDCl3): 8 1.0 (m, 6H), 1.5-2.2 (m, 6H), 2.6 (m, 3H) 3.0 (m, 1H), 3.8 (s, 3H);
4.1 (m, 2H),
4.7 (m, 2H), 5.3 (m, 1H), 7.4-8.0 (m, SH), 8.4 (m, 1H); MS(EI): 562 (M+,
100%).
238
CA 02412353 2002-12-13
WO 01/95911 PCT/USO1/19062
Example 247
Preparation of 3-Methylbenzofuran-2-carboxylic acid ~S)-3-methyl-1-f 1-(3-
methyl-
pyridine-2-sulfonyl)-3-oxo-azepan-4-~carbamoyl]-bull amide
a.) 3-Methylbenzofuran-2-carboxylic acid {(S)-3-methyl-1-[1-(3-methyl-pyridine-
2-
sulfonyl)-3-hydroxy-azepan-4-ylcarbamoyl]-butyl } amide
Following the procedure of Example 246c except substituting 3-methylbenzofuran-
2-carboxylic acid for thieno[3,2-b]thiophene the title compound was prepared:
MS(EI) 556
(M+)
b.) 3-Methylbenzofuran-2-carboxylic acid {(S)-3-methyl-1-[1-(3-methyl-pyridine-
2-
sulfonyl)-3-oxo-azepan-4-ylcarbamoyl]-butyl } amide
Following the procedure of Example 1i except substituting 3-methylbenzofuran-2-
carboxylic acid {(S)-3-methyl-1-[1-(3-methyl-pyridine-2-sulfonyl)-3-hydroxy-
azepan-4-
ylcarbamoyl]-butyl}amide of Example 247a the title compound was prepared: 'H
NMR
(CDC13): 8 1.0 (m, 6H), 1.5-2.2 (m, 6H), 2.6 (d, 3H), 2.6 (m, 3H), 3.0 (m,
1H), 4.1 (m,
2H), 4.7 (m, 2H), 5.3 (m, 1H), 7.4-8.0 (m, 6H), 8.4 (m, 1H); MS(EI): 554 (M+,
100%).
Example 248
Preparation of 5-Methoxybenzofuran-2-carboxylic acid ~S)-3-methyl-1-f 1-(3-
methyl-
pyridine-2-sulfonyl)-3-oxo-azepan-4-ylcarbamo l~-butyl~amide
a.) 5-Methoxybenzofuran-2-carboxylic acid {(S)-3-methyl-1-[1-(3-methyl-
pyridine-2-
sulfonyl)-3-hydroxy-azepan-4-ylcarbamoylJ-butyl } amide
Following the procedure of Example 246c except substituting 5-
methoxybenzofuran-2-carboxylic acid for thieno[3,2-b]thiophene the title
compound was
prepared: MS(EI) 572 (M+).
b.) 5-Methoxybenzofuran-2-carboxylic acid {(S)-3-methyl-1-[1-(3-methyl-
pyridine-2-
sulfonyl)-3-oxo-azepan-4-ylcarbamoyl]-butyl } amide
Following the procedure of Example 1i except substituting 5-methoxybenzofuran-
2-carboxylic acid {(S)-3-methyl-1-[1-(3-methyl-pyridine-2-sulfonyl)-3-hydroxy-
azepan-4-
239
CA 02412353 2002-12-13
WO 01/95911 PCT/USO1/19062
ylcarbamoyl]-butyl}amide of Example 247a the title compound was prepared: 'H
NMR
(CDC13): 8 1.0 (m, 6H), 1.5-2.2 (m, 6H), 2.6 (d, 3H), 3.0 (m, 1H), 3.8 (s,
3H); 4.1 (m, 2H),
4.7 (m, 2H), 5.3 (m, 1H), 7.4-8.0 (m, 6H), 8.4 (m, 1H); MS(EI): 570 (M+,
100%).
Example 249
Preparation of 5,6-Difluoro-benzofuran-2-carboxylic acid (S)-3-methyl-1-f3-oxo-
1-(1-oxy-
pyridine-2-sulfon~)-azepan-4-ylcarbamoyll-butyl 1 amide
a.) 5,6-Difluoro-benzofuran-2-carboxylic acid {(S)-3-methyl-1-[3-hydroxy-1-(1-
oxy-
pyridine-2-sulfonyl)-azepan-4-ylcarbamoyl]-butyl } amide
Following the procedure of Example 85c exept substituting 5,6-
difluorobenzofuran-
2-carboxylic acid for benzo[b]thiophene-2-carboxylic acid the title compound
was
prepared: MS(ESI) 580.9 (M+H~).
b.) 5,6-Difluoro-benzofuran-2-carboxylic acid {(S)-3-methyl-1-[3-oxo-1-(1-oxy-
pyridine-2-sulfonyl)-azepan-4-ylcarbamoyl]-butyl } amide
Following the procedure of Example 1i exept substituting the compound of
Example 249a the title compound was prepared: MS(ESI) 578.87 (M+H+)
Exam 1p a 250
Preparation of 5-(3-Trifluoromethyl-phenXl)-furan-2-carboxylic acid (S~2-
cyclohexvl-1-1-
~3-oxo-1- pyridine-2-sulfonyl)-azepan-4-ylcarbamoyll-ethyll-amide
a.) 4-((S)-2-tart-Butoxycarbonylamino-3-cyclohexyl-proprionylamino)-3-hydroxy-
azepane-1-carboxylic acid benzyl ester
To a solution of the compound of Example 2e (3.2 g, 12.2 mmol) in DMF (35 mL)
was added N-Boc-cyclohexylalanine (3.3 g), HOBt (1.8 g) and EDC (2.56 g). The
reaction
was stirred until complete. Workup and column chromatography of the residue
(65%
hexanes:ethyl acetate) provided 5.5 g of the title compound.
240
CA 02412353 2002-12-13
WO 01/95911 PCT/USO1/19062
b.) [(S)-Cyclohexyl-1-(3-hydroxy-azepan-4-ylcarbamoyl)-ethyl]-carbamic acid
tert-
butyl ester
To a solution of the compound of Example 250a (5.5 g) in etyhl
acetate:methanol
(185 mL:40 mL) was added 10% Pd/C. This mixture was stirred under an
atmosphere of
hydrogen until complete consumption of the starting material was observed. The
reaction
was filtered and concentrated to provide 3.75 g of the title compound.
c.) {(S)-2-Cyclohexyl-1-[3-hydroxy-1-(pyridine-2-sulfonyl)-azepan-4-
ylcarbamoyl]-
ethyl}-carbamic acid tert-butyl ester
To a solution of the compound of Example 250 b (1.0 g, 1.91 mmol) in
dichloromethane (5 mL) was added water (10 mL) and sodium bicarbonate (1 g).
To this
mixture was added 2-pryidinesulfonyl chloride (0.55 g in 5 mL dichloromethane)
dropwise.
The mixture was stirred for 20 minutes whereupon the organic layer was
separated and
washed with Water, brine, dried filtered and concentrated. Column
chromatography (2%
methanol:dichloromethane) of the residue provided 1.0 g of the title compound:
MS (ESI]
525 (M+H+)
d.) (S)-2-Amino-3-cyclohexyl-N-[3-hydroxy-(pyridine-2-sulfonyl)-azepan-4-yl]-
proprionanude
To a solution of the compound of Example 250c (1.0 g) in methanol (10 mL) was
added HCl ( 10 mL of 4M HCl in dioxane). The reaction was stirred until
complete
consumption of the starting material whereupon it was concentrated. The
residue was
azeotroped with toluene then washed with ether to provide 0.95 g of the title
compound.
e.) 5-(3-Trifluoromethyl-phenyl)-furan-2-carboxylic acid{(S)-2-cyclohexyl-1-{3-
hydroxy-1-(pyridine-2-sulfonyl)-azepan-4-ylcarbamoyl]-ethyl }-amide
To a solution of the compound of Example 250d (0.20 g, 0.4 mmol) in DMF (0.5
mL) was added diisopropylethylamine (0.16 mL), HOBt (0.06 g), EDC (0.084 g)
and 5-[3-
(trifluoromethyl)phenyl]-2-furoic acid (0.11 g). ). The reaction was stirred
until complete
consumption of the starting material. Workup and column chromatography 4%
methanol:dichloromethane) provided 0.23 g of the title compound.
241
CA 02412353 2002-12-13
WO 01/95911 PCT/USO1/19062
f.) 5-(3-Trifluoromethyl-phenyl)-furan-2-carboxylic acid{(S)-2-cyclohexyl-1-{3-
oxo-
1-(pyridine-2-sulfonyl)-azepan-4-ylcarbamoyl]-ethyl }-amide
Following the procedure of Example 75d except substituting the compound of
Example 250e the title compound was prepared. Separation of the diastereomers
by HPLC
provided the first eluting disatereomer (52 mg): MS (ESl) 661.4 and the second
eluting
diastereomer (45.8 mg): MS (ESI] 661.6.
Example 251
Preparation of 5-(4-Chloro-phenxl)-furan-2-carboxylic acid((S)-2-cyclohexyl-1-
I3-oxo-1-
(pyridine-2-sulfonyl)-azepan-4 ylcarbamo l~eth~ -amide
Following the procedures of Example 250e-f except substituting 5-(4-
chlorophenyl)-2-furoic acid for 5-[3-(trifluoromethyl)phenyl]-2-furoic acid of
Example
252e the title compound was prepared. Separation of the diastereomers by HPLC
provided
the first eluting diastereomer (57 mg): MS (ESI] 627.4 and the second eluting
diastereomer
(53 mg): MS (ESI) 627.4.
Example 252
Preparation of Benzofuran-2-carboxylic acid {(S)-3-methyl-1-f6-methyl-3-oxo-1-
(~yridine-
sulphon~)-azepan-4-ylcarbam X11-butyl )-amide
Following the procedure of Example 92, except substituting, 2-methyl-4-
pentenal
for 2,2-dimethyl-4-pentenal the title compound was prepared. The residue was
purified by
HPLC. First eluting diastereomer; MS (M+H+): 541.2; 1H-NMR (400 MHz, CDCl3):
8.71-8.66(m, 1H), 7.98-7.93(m, 2H), 7.91(d, 1H), 7.67-7.29(m, 5H), 7.15-
6.92(m, 2H),
5.28-5.20(m, 1H), 4.82-4.47(m, 2H), 3.97-3.78(m, 1H), 3.65-2.98(m, 1H), 2.37-
2.34(m,
1H), 2.20-1.55(m, 3H), 1.22-1.I9(m, 3H), I.00-0.86(m, 9H).
242
CA 02412353 2002-12-13
WO 01/95911 PCT/USO1/19062
Exam 1p a 253
Preparation of 5-(4-Chloro-phenyl)-furan-2-carboxylic acidd S)-2-cyclohexyl-1-
f3-oxo-1-
1-ox~-pyridine-2-sulfonyl)-azepan-4-ylcarbamoyll-ethyl ~-amide
Following the procedures of Example 250c-f except substituting 2-
pyridinesulfonyl
chloride N-oxide for 2-pyridinesulfonyl chloride of Example 250c and
substituting 5-(4-
chlorophenyl)-2-furoic acid for 5-[3-(trifluoromethyl)phenyl]-2-furoic acid of
Example
252e the title compound was prepared. Separation of the diastereomers by HPLC
provided
the first eluting diastereomer: MS (ESI) 643.4 and the second eluting
diastereomer: MS
(ESI) 643.2.
Exam ' 1p a 254
Preparation of 5-(3-Trifluoromethyl-phenyl)-furan-2-carboxylic aci ~ (S)-2-
cyclohexyl-1-j3-
oxo-1-(1-oxy-pyridine-2-sulfon,~l)-azepan-4-ylcarbamoyll-ethyl -amide
Following the procedures of Example 250c-f except substituting 2-
pyridinesulfonyl
chloride N-oxide for 2-pyridinesulfonyl chloride of Example 250c the title
compound was
prepared. Separation of the diastereomers by HPLC provided the first eluting
diastereomer:
MS (ESI) 677.2 and the second eluting diastereomer: MS (ESI) 677.4.
Example 255
Preparation of 5-Fluoro-benzofuran-2-carboxylic acid ~S)-3-methyl-1-f3-oxo-1-
(p, rydine-
2-sulfonyl)-azepan-4-ylcarbamoyll-butt}-amide
a.) 5-Fluoro-benzofuran-2-carboxylic acid {(S)-3-methyl-1-[3-hydroxy-1-
(pyridine-2-
sulfonyl)-azepan-4-ylcarbamoyl]-butyl }-amide
Following the procedure of Example 28b except substituting 5-fluorobenzofuran-
2-
carboxylic acid for benzofuran-2-carboxylic acid the title compound was
prepared: MS
(ES>7 547 (M+H+).
243
CA 02412353 2002-12-13
WO 01/95911 PCT/USO1/19062
b.) 5-Fluoro-benzofuran-2-carboxylic acid {(S)-3-methyl-1-[3-oxo-1-(pyridine-2-
sulfonyl)-azepan-4-ylcarbamoyl]-butyl }-amide
Following the procedure of Example 1i except substituting the compound of
Example 255a the title compound was prepared: MS(ESI) 544.9 (M+H+)
Example 256
Preparation of 5,6-Dimethoxybenzofuran-2-carboxylic acids (S)-2-cyclohexyl-1-
(3-oxo-1-
(1-oxy-pyridine-2-sulfon~)-azepan-4-ylcarbamo l~yl~-amide
Following the procedures of Example 250c-f except substituting 2-
pyridinesulfonyl
chloride N-oxide for 2-pyridinesulfonyl chloride of Example 250c and
substituting 5,6-
dimethoxybenzofuran-2-carboxylic acid for 5-[3-(trifluoromethyl)phenyl]-2-
furoic acid of
Example 252e the title compound was prepared. Separation of the diastereomers
by HPLC
provided the first eluting diastereomer: MS (ESI) 643.4 and the second eluting
diastereomer: MS (ESI) 643.2.
Example 257
Preparation of 5,5-Bis-(4-methox~phen~)-pent-4-enoic acid ( (S)-3-methyl-1-f 3-
oxo-1-
pyridine-2-sulfonyl)-azepan-4-ylcarbamoyll~-butyl }-amide
Following the procedure of Example 75 except substituting 2-pyridylsulfonyl
chloride for thiazole-2-sulfonyl chloride and 5,5-bis-(4-methoxy-phenyl)-pent-
4-enoic acid
for benzofuran-2-carboxylic acid, the title compound was prepared. The residue
was
purified by HPLC. First eluting diastereomer; MS (M+H+) 677.4; 1H-NMR (400
MHz,
CDC13): ~ 8.69(d, 1H), 7.98-7.92(m, 2H), 7.53-7.50(m, 1H), 7.27-6.77(m, 10H),
6.00-
5.87(m, 2H), 5.08(m, 1H), 4.76-4.72(d, 1H), 4.48(m, 1H), 4.08(m, 1H), 3.83(s,
3H), 3.78(s,
3H), 2.70-1.35(m, 12H), 0.91(d, 6H); and the second eluting diastereomer: MS
(M+H+)
677.4.
244
CA 02412353 2002-12-13
WO 01/95911 PCT/USO1/19062
Example 258
Preparation of Ouinoline-8-carboxylic acid ~ (S)-2-na~hthylen-2-yl-1-f 3-oxo-1-
(pyridine-2-
sulfonxl)-azepan-4-ylcarbamoyl)-ethyll-amide
a.) 4-Amino-1-(pyridine-2-sulfonyl)-azepan-3-of
To a solution of the compound of Example 193c (1.5 g) in methanol (10 xnL,)
was
added HCl (10 mL of 4M HCl in dioxane). The reaction was stirred until
complete by TLC
analysis whereupon it was concentrated to provide 1.2 g of the title compound
as a white
solid.
b.) . {(S)-1-[3-hydroxy-1-(pyridine-2-sulfonyl)-azepan-4-ylcarbamoyl]-2-
napthylene-2-
yl-ethyl}-carbamic acid tert-butyl ester
To a solution of the compound of Example 258a (225 mg) in dichloromethane was
added TEA (0.15 mL), HOBt (99 mg), EDC (140 mg) and N-Boc-L-2-naphthylalanine
(230
mg). The reaction was stirred until complete. Workup and column chromatography
of the
residue (3% methanol:dichloromethane) provided 0.35g of the title compound:
MS(ESI)
569 (M+H+).
c.) (S)-2-Amino-N-[3-hydroxy-1-(pyridine-2-sulfonyl)-azepan-4-yl]-3-naphthylen-
2-yl-
proprionamide
To a solution of the compound of Example 258b (0.35 g) in methanol (5 mL) was
added HCl (5 mL of 4M HCl in dioxane). The reaction was stirred until complete
by TLC
analysis whereupon it was concentrated to provide 0.31 g of the title compound
as a white
solid.
d.) Quinoline-8-carboxylic acid { (S)-2-naphthylen-2-yl-1-[3-hydroxy-1-
(pyridine-2-
sulfonyl)-azepan-4-ylcarbamoyl)-ethyl]-amide
To a solution of the compound of Example 258c (131 mg) in dichloromethane was
added TEA, HOBt (39 mg), EDC (55 mg) and quinoline-8-carboxylic acid (51 mg).
The
reaction was stirred until complete. Workup and column chromatography of the
residue
(5% methanol:dichloromethane) provided 0.35g of the title compound: MS(ESI)
574
(M+H+).
245
CA 02412353 2002-12-13
WO 01/95911 PCT/USO1/19062
e.) Quinoline-8-carboxylic acid {(S)-2-naphthylen-2-yl-1-[3-oxo-1-(pyridine-2-
sulfonyl)-azepan-4-ylcarbamoyl)-ethyl]-amide
Following the procedure of Example 1i except substituting the compound of
Example 258d the title compound was prepared.
Example 259
Preparation of Naphthylene-1-carboxylic acid ((S)-2-naphth lien-2-yl-1-(3-oxo-
1-(pyridine-
2-sulfonyl)-azepan-4-ylcarbamoyl)-ethyll-amide
Following the procedures of Examples 258d-a except substituting 1-naphthoic
acid
for quinoline-8-carboxylic acid the title compound was prepared.
Example 260
Preparation of Quinoline-8-carbox lic acid ~~S)-1-f3-oxo-1-(pyridine-2-
sulfonyl)-azepan-4-
ylcarbamoyll-2-phenyl-ethyll-amide
Following the procedures of Examples 258a-a except substituting N-Boc-
phenylalanine for N-Boc-L-2-naphthylalanine the title compound was prepared.
Example 261
Preparation of Naphthyridine-2-carboxylic acid {(S)-3-meth-1-f3-oxo-1-
(pyridine-2-
sulfonyl)-azepan-4-ylcarbamo l~yll-amide
Following the procedure of Example 28b-c exept subsituting 1,6-naphthyridine-2-
carboxylic acid for benzofuran-2-carboxylic acid the title compound was
prepared.
246
CA 02412353 2002-12-13
WO 01/95911 PCT/USO1/19062
Exam 1p a 262
Preparation of Naphthylene-1-carboxylic acid 1~S)-I-f3-oxo-1-(pyridine-2-
sulfonyl)-
azepan-4-ylcarbamoyll-2-phenyl-ethyl-amide
Following the procedure of Example 260 except substituting 1-naphthoic acid
for
quinoline-8-carboxylic acid the title compound was prepared.
Exam 1u a 263
Preparation of 3-Methylbenzofuran-2-carboxylic acid ((S)-3-methyl-I-f3-oxo-1-
~cyclohexyl-proprionyl)-azepan-4~lcarbamoyl -butyll-amide
a.) 4-{(S)-2-[(3-Methylbenzofuran-2-carbonyl)-amino]-4-methyl-pentanoylamino}-
3-
hydroxy-azepane-1-carboxylic acid benzyl ester
To a solution of the compound of Example 72a (1.2 g, 2.67 mmol) was added EDC
(0.56 g), HOBt (0.36 g), TEA (0.67 g) and 3-methylbenzofuran-2-carboxylic acid
(0.47 g).
The reaction was stirred until complete consumption of the starting material
was observed.
Workup and colum chromatography (4:1 hexanes:ethyl acetate) provided 1.05 g of
the title
compound: MS (ESI) 536 (M+H+).
b.) 3-Methylbenzofuran-2-carboxylic acid [(S)-1-(3-hydroxy-azepan-4-
ylcarbamoyl)-3-
methyl-butyl]-amide
Following the procedure of Example 2g except substituting the compound of
Example 263a the title compound was prepared: MS (ESI) 402 (M+H+).
c.) 3-Methylbenzofuran-2-carboxylic acid {(S)-3-methyl-I-[3-hydroxy-I-
(cyclohexyl-
proprionyl)-azepan-4-ylcarbamoyl]-butyl }-amide
Following the procedure of Example 263a except substituting the compound of
Example 263b and 3-cyclohexylpropionic acid for 3-methylbenzofuran-2-
carboxylic acid
the title compound was prepared: MS (EST) 540 (M+H~).
247
CA 02412353 2002-12-13
WO 01/95911 PCT/USO1/19062
d.) 3-Methylbenzofuran-2-carboxylic acid { (S)-3-methyl-1-[3-oxo-1-(cyclohexyl-
proprionyl)-azepan-4-ylcarbamoyl]-butyl }-amide
Following the procedure of Example 1i except substituting the compound of
Example 263c the title compound was prepared: MS (ESI) 538 (M+H+)
Example 264
Preparation of 3-Methylbenzofuran-2-carboxylic acid (S)-3-methyl-1-f3-oxo-1-(4-
methyl-
pentanoyl)-azepan-4-ylcarbamo l~yll-amide
Following the procedures of Example 263c-d except substituting 4-
methylpentanoic
acid for 3-cyclohexylpropionic acid the title compound was prepared: MS (ESI)
498
(M+H+).
Example 265
Preparation of 3-Methylbenzofuran-2-carboxylic acid (S)-3-methyl-1-f 3-oxo-1-(
1-ox~
pyridine-2-carbon 1~ )-azepan-4-ylcarbamoyll-butyl l-amide
Following the procedures of Example 263c-d except substituting picolinic acid
N-
oxide for 3-cyclohexylpropionic acid the title compound was prepared: MS (EST)
498
(M+H~).
Example 266
Preparation of (S)-Acetylamino-4-methyl-pentanoic acid f 3-oxo-1-(pyridine-2-
sulfon~)-
azepan-4-yll-amide
Following the procedure of Example 75c-d except substituting acetic acid for
benzofuran-2-carboxylic acid in step 75c provided the title compound which was
separated
by HPLC to give the first eluting diastereoemer: MS (M+H+) 425.2; 1H-NMR
(400Hz,
CDC13): ~ 8.69(d, 1H), 7.96-7.94(m, 2H), 7.53-7.52(m, 1H), 7.05(m, 1H),
5.92(m, 1H),
5.08(m, 1H), 4.69-4.53(m, 2H), 4.05-3.90(m, 2H), 2.80(m, 1H), 2.25-2.12(m,
2H), 1.64(s,
248
CA 02412353 2002-12-13
WO 01/95911 PCT/USO1/19062
3H), 1.90-I.40(m, 5H), 0.95(m, 6H); and the second eluting distereomer: MS
(M+H+):
425.2
Example 267
Preparation of Ouinoline-2-carboxylic acid 1(S)-1-f3-oxo-1-(pyridine-2-sulfon
l~pan-4-
ylcarbamoyll-pentyl ~-amide
a.) 4-((S)-2-tart-Butoxycarbonylamino-hexanoylamino)-3-hydroxy-azepane-1-
carboxylic acid benzyl ester
To a stirring solution of compound of the amino alcohol of Example 2e (200 mg,
0.74mmo1) in DMF (4 ml) was added N-Boc-norleucine (175 mg, 0.76mmol), EDC-HCl
(145 mg, 0.76mmol), and 1-hydroxybenzotriazole (21 mg, 0.16mmol). Reaction
allowed to
proceed overnight at room temperature. The following morning the mixture was
diluted
with ethyl acetate, washed with~sat. NaHC03, HZO, and brine. Dried on MgSOø,
filtered and
purified by column chromatography to give 300 mg of the title compound:
MS(ESI)
478.11 (M+H)+.
b.) [(S)-1-(3-Hydroxy-azepan-4-ylcarbamoyl)-pentyl]-carbamic acid ter-t-butyl
ester
To a solution of compound of Example 267a (300 mg, 0.6 3mmol) in ethyl acetate
(5 ml) was added IO% palladium on carbon (160 mg) and Hz from a filled
balloon. After
stirring the solution at room temperature for 48 hours, the mixture was
filtered through
celite. The filterate was concentrated to yield the title compound (crude,
161mg,
0.47mmo1): MS(ESI): 344.19 (M+H)+.
c.) { (S)-1-[3-Hydroxy-I-(pyridine-2-sulfonyl)-azepan-4-ylcarbamoyl]-pentyl }-
carbamic acid tart-butyl ester
To a solution of the compound of Example 267b (161 mg,0.47 mmol) in
dichloromethane (6 ml) was added triethylamine (0.065 ml, 0.47mmo1) and
pyridine-2-
sulfonyl chloride (83mg, 0.47 mmol). After stirring at room temperature for 1
hr the
mixture was washed with saturated NaHC03. The organic layer was dried,
filtered,
concentrated and purified on a silica gel column to give the title compound
(142mg,
0.29mmo1): MS(ESI):485.10 (M+H)+.
249
CA 02412353 2002-12-13
WO 01/95911 PCT/USO1/19062
d.) (S)-2-Amino-hexanoic acid {3-hydroxy-1-(pyridine-2-sulfonyl)-azepan-4-yl]-
amide
To a stirring solution of the compound of Example 267c (142mg, 0.29mmo1) in
ethyl acetate was added HCl (4M in dioxane) (0.760 ml, 3.0 mmol). After
stirring the
reaction mixture for 1 hr at room temperature, the mixture was concentrated to
yield a
white solid. The solid was azeotroped with toluene twice on rotavap and then
treated with a
resin bound carbonate (1.47 mmol) in methanol and placed on a shaker. After 4
hr the
suspension was filtered and concentrated to yield 104 mg crude product: MS
(ESI) 385.08
(M+H)+.
e.) Quinoline-2-carboxylic acid { (S)-1-[3-hydroxy-1-(pyridine-2-sulfonyl)-
azepan-4-
ylcarbamoyl]-pentyl }-amide
To a solution of the compound of Example 267d (104 mg, 0.27mmo1) in CHZCIz
was added quinaldic acid (47mg, 0.27 mmol), 1-hydroxybenzotriazole (7.4, .055
mmol),
EDC-HCL (52 mg, 0.27 mmol) in DMF (2 ml). After stirring at room temperature
overnight, the mixture was diluted with ethylacetate, washed with sat. NaHC03,
H20, dried
on MgS04, and filtered to obtain 172mg crude product: MS(ESI) 539.90 (M+H)+.
f.) Quinoline-2-carboxylic acid {(S)-1-[3-oxo-1-(pyridine-2-sulfonyl)-azepan-4-
ylcarbamoyl]-pentyl }-amide
To a stirring solution of the compound of Example 267e (172mg crude, 0.32mmol)
in 1 ml DMSO was added sulfur trioxide-pyridine complex ( 260mg, 1.6 mmol) )
and
triethylamine (0.88 ml, 3.2mmo1). After stirring at room temperature for two
hours, the
mixture was diluted with water and extracted with ethyl acetate. The organic
layer was
dried, filtered, concentrated, and purified by HPLC to yield two diastereomers
of the title
compound as solids (first: 40 mg: second:43mg): MS(ESI) 537.86 (M+H)+.
250
CA 02412353 2002-12-13
WO 01/95911 PCT/USO1/19062
Example 268
Preparation of Benzofuran-2-carboxylic acid ~ (S)-3-methyl-1-f 3-oxo-1-(c
clohex ~~l-
proprionyl)-azepan-4-ylcarbamoyll-butyl l-amide
Following the procedures of Example 263a-d except substituting benzofuran-2-
carboxylic acid for 3-methylbenzofuran-2-carboxylic acid of Example 263a the
title
compound was prepared: MS(ESI) 524 (M+H~).
Example 269
Preparation of Benzofuran-2-carboxylic acid ~(S)-3-methyl-I-f3-oxo-I-(4-met~l-
pentanoyl)-azepan-4-ylcarbamo l~yll-amide
Following the procedures of Example 263a-d except substituting benzofuran-2-
carboxylic acid for 3-methylbenzofuran-2-carboxylic acid of Example 263a and 5-
methyl
pentanoic aicd for cyclohexyl propionic acid the title compound was prepared:
MS(ESn
484 (M+H+).
Example 270
Preparation of Quinoline-2-carboxylic acid i(S)-1-f3-oxo-1-(pyridine-2-
sulfonyl)-azepan-4-
ylcarbamoyll-2-phen~-ethyl -amide
Following the procedure of Example 267a-f except substituting N-Boc-
phenylalanine for N-Boc-norleucine in step 267a the title compound was
prepared.
Separation of the mixture by HPLC provided two diastereomers as solids (first
eluting: 20.5
mg; second eluting: 27 mg ): MS(ESI) 571.95 (M+H)+.
251
CA 02412353 2002-12-13
WO 01/95911 PCT/USO1/19062
Example 271
Preparation of Benzofuran-2-carboxylic acid(S)-2-benzyloxy-1-f3-oxo-1-
(pyridine-2-
sulfonyl)-azepane-4-ylcarbamoyll-ethyl ~-amide
Following the procedure of Example 193e-h, except substituting N-Boc-O-benzyl-
L-serine in step 193e the title compound was prepared as a mixture of
distereoemers. To a
solution of benzofuran-2-carboxylic acid { (S)-2-benzyloxy-1-[3-oxo-1-
(pyridine-2-
sulfonyl)-azepane-4-ylcarbamoyl]-ethyl}-amide (90 mg) in ethyl acetate (2 mL)
was added
10°Io PdIC (50 mg). Upon hydrogenolysis of approximately 50% of the
starting benzyl
ether the reaction was filtered and concentrated. Purification of this 4
component mixture
by HPLC provided the first eluting diastereomer of the title compound (1 mg)
and the
second eluting diastereomer of the title compound (0.3 mg): MS(ESI):
590.94(M+H)+.
Additionally the two individual diastereoemers of benzofuran-2-carboxylic
acid{(S)-2-
hydroxy-1-[3-oxo-1-(pyridine-2-sulfonyl)-azepane-4-ylcarbamoyl]-ethyl}-amide
were also
isolated as described below in Example 272.
Example 272
Preparation of Benzofuran-2-carboxylic acid ~ (S)-2-hydroxy-1-f 3-oxo-1-
(pyridine-2-
sulfon~)-azepane-4-ylcarbam~ll-ethyl -amide
The title compound was obtained as discussed above in Example 271.
Purification of the mixture by HPLC provided the two diastereomers in solid
form (first
eluting: 1.6 mg; second eluting 2.1 mg): MS(ESI): 500.9 (M+H)+.
Example 273
Preparation of 5-Methoxybenzofuran-2-carboxylic acid ~S)-3-methyl-1-f3-oxo-1-
(thiazole-
2-sulfonyl)-azepan-4-ylcarbamoyll-butyl amide
Following the procedure of Example 75c-d except substituting 5-
methoxybenzofuran-2-carboxylic acid for benzofuran-2-carboxylic acid in step
75c
provided the title compound which was separated by HPLC to give the first
eluting
252
CA 02412353 2002-12-13
WO 01/95911 PCT/USO1/19062
diastereoemer as a white solid (144.3 mg, 85.1%): MS (ESI) 563.2 (M+H)+ and
the
second eluting diastereomer as a white solid (16.9mg, 10.0%) MS (ESI): 563.0
(M+H)+
Example 274
Preparation of 7-Methoxybenzofuran-2-carboxylic acid (S)-3-methyl-1-f3-oxo-1-
(thiazole-
2-sulfonyl)-azepan-4-ylcarbamoyll-butyll amide
Following the procedure of Example 75c-d except substituting 7-
methoxybenzofuran-2-carboxylic acid for benzofuran-2-carboxylic acid in step
75c
provided the title compound which was separated by HPLC to give the first
eluting
diastereoemer as a white solid (75 mg, 47%): MS (ESI) 563.2 (M+H)+ and the
second
eluting diastereomer as a white solid (57 mg, 35%): MS (ESI) 563.0 (M+H)+
Example 275
Preparation of 3-Methylbenzofuran-2-carboxylic acid d (S)-3-methyl-1-f 3-oxo-1-
(thiazole-2-
sulfon l~pan-4-ylcarbamoyll-butyllamide
Following the procedure of Example 75c-d except substituting 3-
methylbenzofuran-2-carboxylic acid for benzofuran-2-carboxylic acid in step
75c provided
the title compound which was separated by HPLC to give the first eluting
diastereoemer as
a white solid (69.5 mg, 42%): MS (ESI) 547.2 (M+H)+ and the second eluting
diastereomer as a white solid (65 mg, 40%): MS (ESI) 547.2 (M+H)+
Example 276
Preparation of Benzofblthiophene-2-carboxylic acid(S)-3-methyl-1-f3-axo-
l~thiazole-2-
sulfon 1~)-azepan-4-ylcarbamoyll-but~lamide
Following the procedure of Example 75c-d except substituting benzo[b]thiophene-
2-carboxylic acid for benzofuran-2-carboxylic acid in step 75c provided the
title compound
which was separated by HPLC to give the first eluting diastereoemer as a white
solid (79.5
253
CA 02412353 2002-12-13
WO 01/95911 PCT/USO1/19062
mg, 48%): MS (ESI) 549.3 (M+H)+ and the second eluting diastereomer as a white
solid
(50.5 mg, 3I %): MS (ESI) 549.2 (M+H)+
Example 277
Preparation of 1-Methyl-1H-indole-2-carboxylic acid d(S)-3-methyl-1-f3-oxo-
l~thiazole-2-
sulfonyl)-azepan-4-ylcarbam~ll-butyl amide
Following the procedure of Example 75c-d except substituting 1-methylindole-2-
carboxylic acid for benzofuran-2-carboxylic acid in step 75c provided the
title compound
which was separated by HPLC to give the first eluting diastereoemer as a white
solid (75
mg, 47%): MS (ESI) 563.2 (M+H)+ and the second eluting diastereomer as a white
solid
(57 mg, 35%): MS (ESI) 563.0 (M+H)+
Example 278
Preparation of Quinoxaline-2-carboxylic acid ~S)-3-methyl-1-f 3-oxo-1-
(thiazole-2-
sulfon~)-azepan-4-ylcarbamoyll-butyl l amide
Following the procedure of Example 75c-d except substituting quinoxaline-2-
carboxylic acid for benzofuran-2-carboxylic acid in step 75c provided the
title compound
which was separated by HPLC to give the first eluting diastereoemer as a white
solid (126
mg, 77%): MS (ESI) 545.2 (M+H)+ and the second eluting diastereomer as a white
solid
(25 mg, 15%): MS (ESI) 545.2 (M+H)+
254
CA 02412353 2002-12-13
WO 01/95911 PCT/USO1/19062
Example 279
Preparation of Quinoline-2-carboxylic acid f f (S)-1'f 1-(4-fluoro-
benzenesulfonyl)-3-oxo-
azepan-4-ylcarbamoyll-3-meth~utyll-amide
Following the procedure of Example 75, except substituting 4-
fluorophenylsulfonyl
chloride for benzenesulfonyl chloride and 2-quinoline carboxylic acid for
benzofuran-2-
carboxylic acid, the title compound was prepared. The residue was purified by
HPLC.
First eluting diastereomer; MS (M+H+): 555.2; 1H-NMR (400Hz, CDC13): ~ 8.62(d,
1H),
8.34-8.23(q, 2H) 8.19-8.17(d, 1H), 7.90-7.88(d, 1H), 7.88-7.80(m, 3H), 7.66-
7.64(t, 1H),
7.25-7.07(m, 3H), 5.08(m, 1H), 4.72 (m, 1H), 4.58-4.53(d, 1H),4.00(m, 1H),
3.46-3.42(d,
1H), 2.47(m, 1H), 2.27-2.12(m, 2H), 1.90-1.40(m, 5H), 1.03-1.01(m, 6H); and
the second
eluting diastereomer: MS (M+H+): 555.4.
, Example 280
Preparation of Benzofuran-2-carboxylic acid ~~S)-1-f-(3-fluoro-benzensulfonyD-
3-oxo-
azepan-4-ylcarbamoyll-3-methyl-1-butt - amide
a.) Allyl-pent-4-enyl-carbamic acid benzyl ester
To a suspension of NaH (1.83 g, 76.33 mmol of 90% NaH) in DMF was added
allyl-carbamic acid benzyl ester (7.3 g, 38.2 mriiol) in a dropwise fashion.
The mixture was
stirred at room temperature for approximately 10 minutes whereupon 5-bromo-1-
pentene
(6.78 mL, 57.24 mmol) was added in a dropwise fashion. The reaction was heated
to 40°C
for approximately 4 hours whereupon the reaction was partitioned between
dichloromethane and water. The organic layer was washed with water (2x's),
brine, dried
(MgS04), filtered and concentrated. Column chromatography of the residue (10%
ethyl
acetate:hexanes) provided 10.3 grams of the title compound as an oil: MS(ES)
260
(M+H+).
255
CA 02412353 2002-12-13
WO 01/95911 PCT/USO1/19062
b.) 2,3,4,7-Tetrahydro-azepine-1-carboxylic acid benzyl ester
To a solution of compound of Example 280a (50 g) in dichloromethane was added
bis(tricyclohexylphosphine)benzylidine ruthenium (IV) dichloride (5.0 g). The
reaction
was heated to reflux until complete as determined by TLC analysis. The
reaction was
concentrated ira vacuo. Column chromatography of the residue (50%
dichloromethane:hexanes) gave 35 g of the title compound: MS(ES) 232 (M+H+).
c.) 8-Oxa-3-aza-bicyclo[5.1.0]octane-3-carboxylic acid benzyl ester
To a solution of the compound of Example 280b (35 g, 1.5 mol) in CHZCIz was
added m-CPBA (78 g, 0.45 mol). The mixture was stirred overnight at room
temperature
whereupon it was filtered to remove the solids. The filtrate was washed with
saturated
water and saturated NaHC03 (several times). The organic layer was dried
(MgS04), filtered
and concentrated to give 35 g of the title compound which was of sufficient
purity to carry
on to the next step: MS(ES) 248 (M+H+), 270 (M+Na+)
d.) 4-Azido-3-hydroxy-azepane-1-carboxylic acid benzyl ester
To a solution of the epoxide from Example 280c (2.0 g, 8.1 mmol) in
methanol:water (8:1 solution) was added NHQCl (1.29 g, 24.3 mmol) and sodium
azide
(1.58 g, 24.30 mmol). The reaction was heated to 40°C until complete
consumption of the
starting epoxide was observed by TLC analysis. The majority of the solvent was
removed
in vacuo and the remaining solution was partitioned between ethyl acetate and
pH 4 buffer.
The organic layer was washed with sat. NaHC03, water, brine dried (MgSO~,
filtered and
concentrated. Column chromatography (20% ethyl acetate:hexanes) of the residue
provided 1.3 g of the title compound: MS(ES) 291 (M+H+) plus 0.14 g of trans-4-
hydroxy-3-azido-hexahydro-1H-azepine
e.) 4-Amino-3-hydroxy-azepane-1-carboxylic acid benzyl ester
To a solution of the azido alcohol of Example 280d (1.1 g, 3.79 mmol) in
methanol
was added triethyamine (1.5 mL, 11.37 mmol) and 1,3-propanedithiol (1.l mL,
11.37
mmoL). The reaction was stirred until complete consumption of the starting
material was
observed by TLC analysis whereupon the reaction was concentrated in vacuo.
Column
chromatography of the residue. (20% methanol:dichloromethane) provided 0.72 g
of the
title compound: MS(ES) 265 (M+H+)
256
CA 02412353 2002-12-13
WO 01/95911 PCT/USO1/19062
f.) 4-((S)-2-tert-Butoxycarbonylamino-4-methyl-pentanoylamino)-3-hydroxy-
azepan-1-
carboxylic acid benzyl ester
To a solution of the amino alcohol of Example 280e (720 mg, 2.72 mmol) in
CHzCIz was added EDC (521 mg), HOBt (368 mg) and N-Boc-leucine (630 mg). The
reaction was maintained at room temperature until complete consumption of the
starting
material was observed by TLC analysis. The reaction was diluted with ethyl
acetate and
washed with 1N HCI, sat. I~C03, water, brine, dried (MgS04), filtered and
concentrated.
Column chromatography of the residue (3% methanol:dichloromethane) gave 1.0 g
of the
title compound: MS(ES) 478 (M+H+).
g.) [(S)-1-(3-Hydroxy-azepan-4-ylcarbamoyl)-3-methyl-butyl]-carbamic acid tert
butyl ester
To a solution of the compound of Example 280f (1.0 g) and 10% Pd/C (catalytic)
in
ethyl acetate:methanol (2:1 solution) was affixed a balloon of hydrogen. The
reaction was
stirred until complete consumption of the starting material was observed by
TLC analysis.
The reaction was filtered to remove the catalyst and the filtrate was
concentrated to provide
0.82 g of the title compound: MS(ES) 344 (M+H+).
h.) (S)-2-Amino-4-methyl-pentanoic acid [1-(3-fluoro-benzenesulfonyl)-3-
hydroxy-
azepan-4-yl]-amide
To a solution of the compound of Example 280g (0.2 g) in dichloroethane (20
mL)
was added p-NMM (0.32 g) and 3-fluorobenzenesulfonyl chloride (0.11 g). The
reaction
was stirred until complete as determined by MS analysis whereupon it was
filtered,
concentrated. The residue was dissolved in methanol (10 mL) and 4M HCl in
dioxane (10
mL) was added. The reaction was maintained at room temperature until complete
consumption of the starting material whereupon it was concentrated. The
residue was
dissolved in methanol whereupon p-carbonate resin was added. The mixture was
shaken at
room temperature for 4 hours then filtered and concentrated to provide 0.64 g
of the title
compound.
257
CA 02412353 2002-12-13
WO 01/95911 PCT/USO1/19062
i.) Benzofuran-2-carboxylic acid {(S)-1-[1-(3-fluoro-benzenesulfonyl)-3-
hydroxy-
azepan-4-ylcarbamoyl] 3-methyl-butyl }-amide
To a solution of the compound of Example 280h (0.15 g) in CHzCl2 was added
benzofuran-2-carboxylic acid (0.56 mmol), HOBt (0.09 mg), and p-EDC (0.75 mg).
The
reaction was stirred overnight whereupon trisamine (0.50 g) was added and
stirred an
additional 1.5 hours. The reaction was filtered and concentrated to provide
the title
compound.
j.) Benzofuran-2-carboxylic acid {(S)-1-[1-(3-fluoro-benzenesunfonyl)-3-oxo-
azepan-
4-ylcarbamoyl]3-methyl-butyl}-amide
To a solution of the compound of Example 2801 (0.3 mmol) in CHZC12 was added
Dess-Martin periodinane (0.25 g). The reaction was stirred until complete as
determined
by MS analysis. Workup and HPLC chromatography provided diastereomer 1: MS(ES)
543.2 (M+H)+ and diastereomer 2: MS(ES) 543.2 (M+H)k.
Examine 281
Preparation of (S)-4-Meth 1-~-(3-piperidin-1-yl-propanoylamino)-pentanoic acid
[3-oxo-1-
(pyridine-2-sunfonyl)-azepan-4-ynl-amide
Following the general procedures of Examples 280h j except substituting 2-
pyridinesulfonyl chloride for 3-fluorobenzenesulfonyl chloride and 1-
piperidinepropionoic
acid for benzofuran-2-carboxylic acid the title compound was prepared: MS(ES)
521.9
(M+H)+.
Example 282
Preparation of Benzofuran-2-carbox~rlic acid ~[(S)-1-f-(4-ether-
benzensulfon~l)-3-oxo-
azepan-4-yncarbamo~3-methyl-1-butt - amide
Following the general procedures of Examples 280h-j except substituting 4-
ethylnezenesulfonyn chloride for 3-fluorobenzenesunfonyl chloride the title
compound was
258
CA 02412353 2002-12-13
WO 01/95911 PCT/USO1/19062
prepared: Separation of the diastereomers provided diastereomer I MS(ES) 554.4
(M+H)+
and distereomer 2 MS(ES) 554.4 (M+H)+.
Example 283
Preparation of 5-(3-Trifluoromethyl-phenyl)-furan-2-carboxylic acid ((S)-3-
methyl 3-
oxo-1-f 1-(1-oxy-pyridin-2-yl)-methanoyll-azepan-4-ylcarbamoyll-butt)-amide
a.) 4-((S)-2-Amino-4-methyl-pentanoylamino)-3-hydroxy-azepane-1-carboxylic
acid
benzyl ester
To a solution of the compound of Example 280f (7.32 g) in methanol was added
4M HCl in dioxane (38 mL). The reaction was stirred until complete whereupon
it was
concentrated to give 6.9 g of the title compound as a white solid.
b.) 3-Hydroxy-4-[(S)-4-methyl-2-({ 1-[5-(3-trifluoromethyl-phenyl)-furan-2-yl]-
methanoyl}-amino)-pentanoylamino]azepane-1-carboxylic acid benzyl ester
To a solution of the compound of Example 283a (1.2 g) in dichloromethane was
added TEA (0.93 mL), EDC (0.56 g), HOBt (0.36 g) and 5-[3-(trifluoromethyl)
phenyl]-2-
furoic acid (0.68 g). The reaction was stirred at room temperature until
complete as
determined by TLC analysis. Workup and column chromatography provided 1.35 g
of the
title compound: MS (ES) 616 (M+H)~'.
c.) 5-[3-(Trifluoromethyl)phenyl]-furan-2-carboxylic acid [(S)-1-(3-hydroxy-
azepan-
4-ylcarbamoyl)-3-methyl-butyl]-amide
. To a solution of the compound of Example 283b (I.3 g) in ethyl
acetate:methanol
(20 mL of an 8:1 mixture) was added 10% Pd\C. The mixture was stirred under a
balloon of
hydrogen gas until complete consumption of the starting material was observed
by TLC
analysis. The reaction was filtered and concentrated to provide 0.96 g of the
title
compound which was used directly in the following reaction with no further
purification.
259
CA 02412353 2002-12-13
WO 01/95911 PCT/USO1/19062
d.) 5-(3-Trifluoromethyl-phenyl)-furan-2-carboxylic acid ((S)-3-methyl-1-{3-
hydroxy-
1-[ 1-( 1-oxy-pyridin-2-yl)-methanoyl]-azepan-4-ylcarbamoyl }-butyl)-amide
To a solution of the compound of Example 283c (0.3 g) in dichloromethane was
added TEA (0.22 mL), EDC (0.13 g), HOBt (0.8 g) and picolinic acid N-oxide
(0.09 g).
The reaction was stirred at room temperature until complete as determined by
TLC
analysis. Workup and column chromatography provided 0.16 g of the title
compound: MS
(ES) 603 (M+H)+.
e.) 5-(3-Trifluoromethyl-phenyl)-furan-2-carboxylic acid ((S)-3-methyl-1-{3-
oxo-1-
[1-(1-oxy-pyridin-2-yl)-methanoyl]-azepan-4-ylcarbamoyl}-butyl)-amide
To a solution of the compound of Example 283d (0.15 g) in DMSO (1.5 mL) was
added TEA (0.37 mL) and pyridine sulfur trioxide complex (0.21 g). The
reaction was
stirred until complete as determined by LCMS. Workup and column chromatography
(10%
methanol:dichloromethane) provided 0.12 g of the title compound: MS (ES) 601
(M+H)+.
The diastereomers were separated by HPLC to provide diastereomer 1 and
diastereomer 2.
Exam 1p a 284
Preparation of Benzof 1,31-dioxole-5-carboxylic acid ((S)-3-meth~~3-oxo-1-f 1-
ox~
pyridin-2-Xl)-methanoyll-azepan-4-ylcarbamoyll-butt -amide
Following the general procedures of Examples 283b-a except substituting
piperonylic acid for 5-[3-(trifluoromethyl) phenyl]-2-furoic acid the title
compound was
prepared: MS(ES) 511 (M+H)~.
The diastereomers were separated by HPLC to provide diastereomer 1 and
diastereomer 2.
260
CA 02412353 2002-12-13
WO 01/95911 PCT/USO1/19062
Exam 1~ a 285
Preparation of 5-(3-Trifluorometh ~~1-phenyl)-furan-2-carboxylic acid (S)-1-f
1~3-
cyclohexyl-propanoyl)-3-oxo-aze~an-4-ylcarbamoyll-3-methyl-butyl amide
Following the general procedures of Examples 283b-a except substituting 3-
cyclohexylpropionic acid for picolinic acid N-oxide the title compound was
prepared:
MS(ES) 618 (M+H)+.
The diastereomers were separated by HPLC to provide diastereomer 1 and
diastereomer 2.
Example 286
Preparation of Benzof 1,31-dioxole-5-carboxylic acid i(S)-1-f 1-(3-c clohexyl-
propanoyl)-3-
oxo-azepan-4-ylcarbamoyll-3-methyl-but, )-amide
Following the general procedures of Examples 283b-a except substituting 3-
cyclohexylpropionic acid for picolinic acid N-oxide and piperonylic acid for 5-
[3-
(trifluoromethyl) phenyl)-2-furoic acid the title compound was prepared:
MS(ES) 528
(M+H)+.
The diastereomers were separated by HPLC to provide diastereomer 1 and
diastereomer 2.
Example 287
Preparation of 5-(3-Trifluoromethyl-phenyl)-furan-2-carbolic acid (S)-1-f 1-(4-
methyl-
pentanoyl)-3-oxo-azepan-4-ylcarbamoyll-3-methyl-butyl )-amide
Following the general procedures of Examples 283b-a except substituting 4-
methyl-pentanoic acid for picolinic acid N-oxide the title compound was
prepared: MS(ES)
578 (M+H)+.
261
CA 02412353 2002-12-13
WO 01/95911 PCT/USO1/19062
The diastereomers were separated by HPLC to provide diastereomer 1 and
diastereomer 2.
Example 288
Preparation of Benzof 1,31-dioxole-5-carbox~~lic acid ((S)-1-f 1-(4-methyl-
pentanoyl)-3-
oxo-azepan-4-ylcaxbamoyll-3-metl~l-butyl )-amide
Following the general procedures of Examples 283b-a except substituting 4-
methyl-pentanoic acid for picolinic acid N-oxide and piperonylic acid for 5-[3-
(trifluoromethyl) phenyl]-2-furoic acid the title compound was prepaxed:
MS(ES) 488
(M+H)+.
The diastereomers were separated by HPLC to provide diastereomer 1 and
diastereomer 2.
15,
Example 289
Preparation of Benzofuran-2-carbox lic acid ~S)1-f3-oxo-1-(propane-1-sulfon~)-
azepan-
4-ylcarbamoyll-3-methyl-1-butyl- amide
Following the general procedures of Examples 280h j except substituting
propanesulfonyl chloride for 3-fluorosulfonyl chloride the title compound was
prepared.
Separation of the diastereomers by HPLC provided diastereomer 1: MS(ES) 491.2
(M+H)+ and diastereomer 2: MS(ES) 491.2 (M+H)+.
Example 290
Preparation of Benzofuran-2-carboxylic acid f(S)-1-f3-oxo-1-(ethanesulfonyl-
azepan-4-
ylcarbamo 1 -3-methyl-1-butyll- amide
Following the general procedures of Examples 280h-j except substituting
ethanesulfonyl chloride for 3-fluorobenzenesulfonyl chloride the title
compound was
prepared.
262
CA 02412353 2002-12-13
WO 01/95911 PCT/USO1/19062
Separation of the diastereomers by HPLC provided diastereomer 1: MS(ES) 477.4
(M+H)+ and diastereomer 2: MS(ES) 477.4 (M+H)+.
Example 291
Preparation of 5-Fluoro-benzofuran-2-carboxylic acid 1(S)-3-methyl-1-f3-oxo-1-
(1-ox~
pyridine-2-sulfonyl)-azepan-4-ylcarbamoyll-butyl l-amide
a.) {(S)-1-[3-Hydroxy-1-(1-oxy-pyridine-2-sulfonyl)-azepan-4-ylcarbamoyl]-3-
methyl-butyl }-carbamic acid tart-butyl ester
Generation of 2-pyridinesulfonylchloride-N-oxide: To a 0°C
solution of 2-
mercaptopyridine-N-oxide (2.23 g, 17.55 mmol) in 9M HCl (33 mL) was bubbled
chlorine
gas for approximately 90 minutes. The dissolved chlorine was removed under
vacuum at
0°C.
To a solution of [(S)-1-(3-hydroxy-azepan-4-ylcarbamoyl)-3-methyl-butyl]-
carbamic acid tart butyl ester of Example 280g (2.5 g, 7.28 mmol) in CHZCIz
(100 mL) and
sat. NaHC03 (400 mL) was added the solution of 2-pyridinesulfonylchloride-N-
oxide (27
mL, 102 mglmL) dropwise in portions. As the addition proceeds additional sat.
NaHC03 is
added in order to maintain the pH at approximately 8-9. Upon complete addition
of the
sulfonylchloride the reaction is stirred for an additional hour whereupon the
organic layer
was removed and washed with brine. The organic layer was evaporated and the
residue
chromatographed (5% methanol:dichloromethane) to provide 2.5 g of the title
compound:
MS (ES) 500 (M+H+).
b.) (S)-2-Amino-4-methyl-pentanoic acid-[3-hydroxy-1-(1-oxy-pyridine-2-
sulfonyl)-
azepan-4-yl]-amide
To a solution of {(S)-1-[3-hydroxy-1-(1-oxy-pyridine-2-sulfonyl)-azepan-4-
ylcarbamoyl]-3-methyl-butyl}-carbamic acid tart-butyl ester of Example 291a
(2.0 g) in
methanol (20 mL) was added 4 M HCl in dioxane (20 mL). The reaction was
stirred at
room temperature for 1.5 hours whereupon it was concentrated to provide 1.8 g
of the title
compound: MS (ES) 400 (M+H+).
263
CA 02412353 2002-12-13
WO 01/95911 PCT/USO1/19062
c.) 5-Fluoro-benzofuran-2-carboxylic acid {(S)-3-methyl-1-[3-hydroxy-1-(1-oxy-
pyridine-2-sulfonyl)-azepan-4-ylcarbamoyl]-butyl }-amide
To a solution of the compound of Example 291b (0.30 g) in CHZCl2 was added 5-
fluoro-benzofuran-2-carboxylic acid (0.11 g), EDC (0.13 g), HOBt (0.086 g),
and 'TEA
(0.22 mL). The reaction was stirred until complete as determined by LCMS
whereupon it
was diluted with ethyl acetate and washed with water, sat. I~C03, IN HCI,
brine, dried
(MgSO,~, filtered and concentrated. Column chromatography (10% methanol:
dichloromethane) of the residue provided 0.27 g of the title compound: MS(ES)
563
(M+H)+.
d.) 5-Fluoro-benzofuran-2-carboxylic acid {(S)-3-methyl-1-[3-oxo-1-(1-oxy-
pyridine-
2-sulfonyl)-azepan-4-ylcarbamoyl]-butyl }-amide
To a solution of the compound of Example 291c (0.19 g) in DMSO (1.5 mL) was
added sulfur trioxide pyridine complex (0.26 g). The reaction was stirred
until complete as
determined by LCMS whereupon it was diluted with ethyl acetate and washed with
sat.
NaHC03, brine dried, filtered and concentrated. Column chromatography of the
residue
provided 0.15 g of the title compound as a mixture of diastereomers: MS(ES)
561 (M+H)+.
Separation of the diastereomers by HPLC provided diastereomer 1 and
diastereomer 2.
Example 292
Preparation of 5-Fluoro-3-methyl-benzofuran-2-carboxylic acid ((S)-3-methyl-1-
f3-oxo-1-
(1-oxy-pyridine-2-sulfonyl)-azepan-4-ylcarbamo 1~~1-butyl)-amide
Following the general procedure of Examples 291c-d . except substituting 5-
fluoro-
3-methyl benzofuran-2-carboxylic acid for 5-fluoro-benzofuran-2-carboxylic
acid provided
the title compound as a mixture of diastereomers: MS(ES) 575 (M+H)+.
Separation of the diastereomers by HPLC provided diastereomer 1 and
diastereomer 2.
264
CA 02412353 2002-12-13
WO 01/95911 PCT/USO1/19062
Example 293
Preparation of 6-Fluoro-3-methyl-benzofuran-2-carboxylic acid 1 (S)-3-methxl-1-
f 3-oxo-1-
( 1-oxy-pyridine-2-sulfonyl)-azepan-4~lcarbamoyll-butyl 1-amide
Following the general procedure of Examples 291c-d except substituting 6-
fluoro-
3-methyl benzofuran-2-carboxylic acid for 5-fluoro-benzofuran-2-carboxylic
acid provided
the title compound as a mixture of diastereomers: MS(ES) 575 (M+H)+.
Separation of the diastereomers by HPLC provided diastereomer l and
diastereomer 2.
Example 294
Preparation of 3-Methyl-benzofuran-2-carboxylic acid (R)-3-methyl-1-f3-oxo-I-
(1-ox~
pyridine-2-sulfonyl)-az~an-4-~lcarbamo~ll-butyl-amide
Following the general procedures of Examples 280f i except substituting N-Boc-
D-
leucine for N-Boc-L-leucine, 2-pyridinesulfonylchloride N-oxide for 3-
fluorobenzenesulfonyl chloride and 3-methyl-benzofuran-2-carboxylic acid for
benzofuran-
2-carboxylic acid the title compound was prepared: MS(ES) 556 (M+H)+.
Separation of the diastereomers by HPLC provided diastereomer 1 and
diastereomer 2.
265
CA 02412353 2002-12-13
WO 01/95911 PCT/USO1/19062
Example 295
Preparation of 3-Methyl-furof3,2-bl-pyridine-2-carboxylic acid 1(S)-3-methyl-1-
f-3-oxo-1-
(1-oxy-pyridine-2-sulfon~)-azepan-4-ylcarbamo 1~1-butyll-amide
Following the general procedure of Examples 291c-d except substituting 3-
methyl-
furo[3,2-b]-pyridine-2-carboxylic acid for 5-fluoro-benzofuran-2-carboxylic
acid provided
the title compound as a mixture of diastereomers: MS(ES) 558 (M+H)+.
Separation of the diastereomers by HPLC provided diastereomer 1 and
diastereomer 2.
Example 296
Preparation of 5-Methoxy-benzofuran-2-carboxylic acid f (S)-1-(1-(3-fluoro-
benzenesulfon~)-3-oxo-azepan-4-ylcarbamoyll-3-methyl-butyl -amide
Following the general procedure of Examples 280h-j except substituting 5-
methoxy-benzofuran-2-carboxylic acid for benzofuran-2-carboxylic acid provided
the title
compound as a mixture of diastereomers.
Separation of the diastereomers by HPLC provided diastereomer l: MS(ES) 574.5
(M+H)+ and diastereomer 2 574.5 (M+H)+.
Example 297
Preparation of 3-Methyl-benzofuran-2-carboxylic acid ( ~)-1-f 1-~3-fluoro-
benzenesulfonXl)-3-oxo-azepan-4-ylcarbamoyll-3-methyl )-amide
Following the general procedure of Examples 280h-j except substituting 3-
methyl-
benzofuran-2-carboxylic acid for benzofuran-2-carboxylic acid provided the
title compound
as a mixture of diastereomers.
Separation of the diastereomers by HPLC provided diastereomer 1: MS(ES) 557.4
(M+H)+ and diastereomer 2 557.4 (M+H)+.
266
CA 02412353 2002-12-13
WO 01/95911 PCT/USO1/19062
Exam In a 298
Preparation of Benzofblthiophene-2-carboxylic acid ~(S)-I-fl-(3-fluoro-
benzenesulfonxl)-
3-oxo-azepan-4-ylcarbamoyll-3-methyl-butyl ~-amide
Following the general procedure of Examples 280h j except substituting
benzo[b]thiophene-2-carboxylic acid for benzofuran-2-carboxylic acid provided
the title
compound as a mixture of diastereomers.
Separation of the diastereomers by HPLC provided diastereomer l: MS(ES) 559.4
(M+H)~ and diastereomer 2 559.4 (M+H)+.
Example 299
I5 Preparation of 3-Methyl-furan-2-carboxylic acid ~(S~-1-(I~3-fluoro-
benzenesulfonyl)-3-
oxo-azepan-4-ylcarbamoyll-3-methyl-butyll-amide
Following the general procedure of Examples 280h-j except substituting 3-
methyl-
furan-2-carboxylic acid for benzofuran-2-carboxylic acid provided the title
compound as a
mixture of diastereomers.
Separation of the diastereomers by HPLC provided diastereomer 1: MS(ES) 507.2
(M+H)+ and diastereomer 2 507.4 (M+H)+.
267
CA 02412353 2002-12-13
WO 01/95911 PCT/USO1/19062
Example 300
Preparation of Quinoline-2-carbolic acid 1(S)-1-f 1-(3-fluoro-benzenesulfonyl)-
3-oxo-
azepan-4-ylcarbamoyll-3-methyl-bu~l1-amide
Following the general procedure of Examples 280h j except substituting
quinoline-
2-carboxylic acid for benzofuran-2-carboxylic acid provided the title compound
as a
mixture of diastereomers.
Separation of the diastereomers by HPLC provided diastereomer 1: MS(ES) 554.2
(M+H)+ and diastereomer 2 MS(ES) 545.2 (M+H)+.
Example 301
Preparation of Thienof3,2-blthiophene-2-carbolic acid (S)-1-f 1-(3-fluoro-
I5 benzenesulfonyl)-3-oxo-azepan-4-ylcarbamoyl]-3-meth-butyl-amide
Following the general procedure of Examples 280h-j except substituting
thieno[3,2-b]thiophene-2-carboxylic acid for benzofuran-2-carboxylic acid
provided the
title compound as a mixture of diastereomers.
Separation of the diastereomers by HPLC provided diastereomer 1: MS(ES) 565.2
(M+H)~ and diastereomer 2 MS(ES) 565.2 (M+H)+.
Exam In a 302
Preparation of Quinoxaline-2-carboxylic acid {~S)-1-f 1-(3-fluoro-
benzenesulfonyl)-3-oxo-
azepan-4-ylcarbamoyll-3-methyl-butyl ~-amide
Following the general procedure of Examples 280h j except substituting
quinoxaline-2-carboxylic acid for benzofuran-2-carboxylic acid provided the
title
compound as a mixture of diastereomers.
Separation of the diastereomers by HPLC provided diastereomer I: MS(ES) 555.4
(M+H)+ and diastereomer 2 MS(ES) 555.4 (M+H)+.
268
CA 02412353 2002-12-13
WO 01/95911 PCT/USO1/19062
Example 303
Preparation of Thiophene-2-carboxylic acid {(S)-1-f 1-(3-fluoro-
benzenesulfonyl)-3-oxo-
azepan-4-ylcarbamoyll-3-methyl-butyl ~-amide
Following the general procedure of Examples 280h j except substituting
thiophene-
2-carboxylic acid for benzofuran-2-carboxylic acid provided the title compound
as a
mixture of diastereomers.
Separation of the diastereomers by HPLC provided diastereomer 1: MS(ES) 509.4
(M+H)+ and diastereomer 2 MS(ES) 509.2 (M+H)+.
Example 304
Preparation of 5-Meth 1-thiophene-2-carboxylic acid i (S)-1-f 1-(3-fluoro-
benzenesulfonyl)-
3-oxo-azepan-4-ylcarbamoyll-3-meth~yl -amide
Following the general procedure of Examples 280h-j except substituting 5-
methyl-
thiophene-2-carboxylic acid fox benzofuran-2-carboxylic acid provided the
title compound
as a mixture of diastereomers.
Separation of the diastereomers by HPLC provided diastereomer 1: MS(ES) 523.2
(M+H)+ and diastereomer 2 MS(ES) 523.4 (M+H)+.
269
CA 02412353 2002-12-13
WO 01/95911 PCT/USO1/19062
Example 305
Preparation of 5-Methoxy-benzofuran-2-carboxylic acid f(S)-1-(1-ethanesulfonyl-
3-oxo-
azepan-4-ylcarbamoXl)-3-methyl-butyll-amide
Following the general procedure of Examples 280h-j except substituting 5-
methoxy-benzofuran-2-carboxylic acid for benzofuran-2-carboxylic acid and
ethanesulfonyl chloride for 3-flurobenzenesulfonyl chloride provided the title
compound as
a mixture of diastereomers.
Separation of the diastereomers by HPLC provided diastereomer 1: MS(ES) 507.4
(M+H)+ and diastereomer 2 MS(ES) 507.4 (M+H)+.
Example 306
Preparation of 3-Methyl-benzofuran-2-carboxylic acid ~(S)-1-(1-ethanesulfonyl-
3-oxo-
azepan-4-ylcarbamoyl)-3-methyl-butyll-amide
Following the general procedure of Examples 280h-j except substituting 3-
methyl-
benzofuran-2-carboxylic acid for benzofuran-2-carboxylic acid and
ethanesulfonyl chloride
for 3-flurobenzenesulfonyl chloride provided the title compound as a mixture
of
diastereomers.
Separation of the diastereomers by HPLC provided diastereomer 1: MS(ES) 491.2
(M+H)+ and diastereomer 2 MS(ES) 491.2 (M+H)+.
Exam 1p a 307
Preparation of Benzo~blthiophene-2-carboxylic acid f(S)-1-(1-ethanesulfonyl-3-
oxo-
azepan-4-ylcarbamoyl)-3-methyl-butyll-amide
Following the general procedure of Examples 280h j except substituting
benzo[b]thiophene-2-carboxylic acid for benzofuran-2-carboxylic acid and
ethanesulfonyl
chloride for 3-flurobenzenesulfonyl chloride provided the title compound as a
mixture of
diastereomers.
270
CA 02412353 2002-12-13
WO 01/95911 PCT/USO1/19062
Separation of the diastereomers by HPLC provided diastereomer 1: MS(ES) 493.4
(M+H)~ and diastereomer 2 MS(ES) 493.4 (M+H)+.
Example 308
Preparation of 3-Methyl-furan-2-carboxylic acid f(S)-1-(1-ethanesulfonyl-3-oxo-
azepan-4-
ylcarbamoyl)-3-methyl-butyll-amide
Following the general procedure of Examples 280h j except substituting 3-
methyl-
furan-2-carboxylic acid for benzofuran-2-carboxylic acid and ethanesulfonyl
chloride for 3-
flurobenzenesulfonyl chloride provided the title compound as a mixture of
diastereomers.
Separation of the diastereomers by HPLC provided diastereomer 1: MS(ES) 441.2
(M+H)+ and diastereomer 2 MS(ES) 441.2 (M+H)+.
Example 309
Preparation of Quinoline-2-carboxylic acid f(S)-1-(1-ethanesulfonyl-3-oxo-aze
ap n-4-
ylcarbamoyl)-3-methyl-butyll-amide
Following the general procedure of Examples 280h-j except substituting
quinoline-
2-carboxylic acid for benzofuran-2-carboxylic acid and ethanesulfonyl chloride
for 3-
flurobenzenesulfonyl chloride provided the title compound as a mixture of
diastereomers.
Separation of the diastereomers by HPLC provided diastereomer 1: MS(ES) 488.2
(M+H)+ and diastereomer 2 MS(ES) 488.2 (M+H)+.
Example 310
Preparation of Thieno~3,2-blthiophene-2-carboxylic acid f(S)-1-(1-
ethanesulfonyl-3-oxo-
azepan-4-ylcarbamoyl)-3-methyl-butyl-amide
Following the general procedure of Examples 280h j except substituting
thieno[3,2-b]thiophene-2-carboxylic acid for benzofuran-2-carboxylic acid and
271
CA 02412353 2002-12-13
WO 01/95911 PCT/USO1/19062
ethanesulfonyl chloride for 3-flurobenzenesulfonyl chloride provided the title
compound as
a mixture of diastereomers.
Separation of the diastereomers by HPLC provided diastereomer 1: MS(ES) 499.4
(M+H)+ and diastereomer 2 MS(ES) 499.4 (M+H)+.
Example 311
Preparation of Quinoxaline-2-carboxylic acid f(S)-1-(1-ethanesulfonyl-3-oxo-
azepan-4-
ylcarbamoyl)-3-methyl-butyll-amide
Following the general procedure of Examples 280h j except substituting
quinoxaline-2-carboxylic acid for benzofuran-2-carboxylic acid and
ethanesulfonyl
chloride for 3-flurobenzenesulfonyl chloride provided the title compound as a
mixture of
diastereomers.
Separation of the diastereomers by HPLC provided diastereomer 1: MS(ES) 489.2
(M+H)+ and diastereomer 2 MS(ES) 489.2 (M+H)+.
Exam 1p a 312
Preparation of Thiophene-2-carboxylic acid f(S)-1-(1-ethanesulfonyl-3-oxo-
azepan-4-
ylcarbamoyl)-3-meth~y~-amide
Following the general procedure of Examples 280h j except substituting
thiophene-
2-carboxylic acid for benzofuran-2-carboxylic acid and ethanesulfonyl chloride
for 3-
flurobenzenesulfonyl chloride provided the title compound as a mixture of
diastereomers.
Separation of the diastereomers by HPLC provided diastereomer 1: MS(ES) 443.4
(M+H)+ and diastereomer 2 MS(ES) 443.2 (M+H)+.
272
CA 02412353 2002-12-13
WO 01/95911 PCT/USO1/19062
Example 313
Preparation of 5-Methyl-thiophene-2-carboxylic acid f(S)-1-(1-ethanesulfonyl-3-
oxo-
azepan-4-ylcarbamoyl)-3-methyl-butyll-amide
Following the general procedure of Examples 280h-j except substituting 5-
methyl-
thiophene-2-carboxylic acid for benzofuran-2-carboxylic acid and
ethanesulfonyl chloride
for 3-flurobenzenesulfonyl chloride provided the title compound as a mixture
of
diastereomers.
Separation of the diastereomers by HPLC provided diastereomer 1: MS(ES) 457.2
(M+H)+ and diastereomer 2 MS(ES) 457.4 (M+H)+.
Example 314
Preparation of 5-Methoxy-benzofuran-2-carboxylic acid 1(S)-1-f3-oxo-1-(propane-
1-
sulfonyl)-azepan-4-ylcarbamoyll-3-methyl-1-butyl l- amide
Following the general procedure of Examples 280h-j except substituting 5-
methoxy-benzofuran-2-carboxylic acid for benzofuran-2-carboxylic acid and 1-
propanesulfonyl chloride for 3-flurobenzenesulfonyl chloride provided the
title compound
as a mixture of diastereomers.
Separation of the diastereomers by HPLC provided diastereomer I: MS(ES) 521.4
(M+H)+ and diastereomer 2 MS(ES) 521.2 (M+H)+.
273
CA 02412353 2002-12-13
WO 01/95911 PCT/USO1/19062
Example 315
Preparation of 3-Methyl-benzofuran-2-carboxylic acid {(S)-1-[3-oxo-1-(propane-
1-
sulfonyl)-azepan-4-ylcarbamoyl]-3-methyl-1-butyl}- amide
Following the general procedure of Examples 280h-j except substituting 3-
methyl-
benzofuran-2-carboxylic acid for benzofuran-2-carboxylic acid and 1-
propanesulfonyl
chloride for 3-flurobenzenesulfonyl chloride provided the title compound as a
mixture of
diastereomers.
Separation of the diastereomers by HPLC provided diastereomer 1: MS(ES) 505.4
(M+H)k and diastereomer 2 MS(ES) 505.2 (M+H)+.
Example 316
Preparation of Benzofblthiophene-2-carboxylic acid (S)-1-f3-oxo-1-(propane-1-
sulfonyl)-
azepan-4-ylcarbamoyll-3-methyl-1-butt)- amide
Following the general procedure of Examples 280h-j except substituting
benzo[b]thiophene-2-carboxylic acid for benzofuran-2-carboxylic acid and 1-
propanesulfonyl chloride for 3-flurobenzenesulfonyl chloride provided the
title compound
as a mixture of diastereomers.
Separation of the diastereomers by HPLC provided diastereomer l: MS(ES) 507.4
(M+H)+ and diastereomer 2 MS(ES) 507.4 (M+H)+.
274
CA 02412353 2002-12-13
WO 01/95911 PCT/USO1/19062
Example 317
Preparation of 3-Methyl-furan-2-carboxylic acid ,;~S)-1-f3-oxo-1-(propane-1-
sulfon
azepan-4-ylcarbamoyll-3-methyl-1-but~~- amide
Following the general procedure of Examples 280h j except substituting 3-
methyl-
furan-2-carboxylic acid for benzofuran-2-carboxylic acid and 1-propanesulfonyl
chloride
for 3-flurobenzenesulfonyl chloride provided the title compound as a mixture
of
diastereomers.
Separation of the diastereomers by HPLC provided diastereomer 1: MS(ES) 455.2
(M+H)+ and diastereomer 2 MS(ES) 455.4 (M+H)+.
Example 318
Z5 Preparation of 2,5-Dimeth~-benzofuran-2-carboxylic acid~(S)-1-f3-oxo-
l~~ropane-1-
sulfonYl)-azepan-4 ylcarbam~ll-3-methyl-1-butyl- amide
Following the general procedure of Examples 280h j except substituting 2,5-
dimethyl-benzofuran-2-carboxylic acid for benzofuran-2-carboxylic acid and 1-
propanesulfonyl chloride for 3-flurobenzenesulfonyl chloride provided the
title compound
as a mixture of diastereomers.
Separation of the diastereomers by HPLC provided diastereomer 1: MS(ES) 469.4
(M+H)+ and diastereomer 2 MS(ES) 469.2 (M+H)+.
275
CA 02412353 2002-12-13
WO 01/95911 PCT/USO1/19062
Example 319
Preparation of Quinoline-2-carbolic acid ((S)-1-f3-oxo-1-(propane-1-sulfon l~)-
azepan-4-
ylcarbamoyll-3-methyl-1-butyll- amide
Following the general procedure of Examples 280h j except substituting
quinoline-
2-carboxylic acid for benzofuran-2-carboxylic acid and 1-propanesulfonyl
chloride for 3-
flurobenzenesulfonyl chloride provided the title compound as a mixture of
diastereomers.
Separation of the diastereomers by HPLC provided diastereomer l: MS(ES) 565.2
(M+H)+ and diastereomer 2 MS(ES) 565.2 (M+H)+.
Example 320
Preparation of Thieno~3 2-blthiophene-2-carboxylic acid (S)-1-f3-oxo-1-
(propane-1-
sulfonyl)-azepan-4-ylcarbamo~ -3-methyl-1-butyl amide
Following the general procedure of Examples 280h-j except substituting
thieno[3,2-b]thiophene-2-carboxylic acid for benzofuran-2-carboxylic acid and
1-
propanesulfonyl chloride for 3-flurobenzenesulfonyl chloride provided the
title compound
as a mixture of diastereomers.
Separation of the diastereomers by HPLC provided diastereomer 1: MS(ES) 513.2
(M+H)+ and diastereomer 2 MS(ES) 513.2 (M+H)+.
276
CA 02412353 2002-12-13
WO 01/95911 PCT/USO1/19062
Example 321
Preparation of Ouinoxaline-2-carboxylic acid 1(S)-1-(3-oxo-1-(propane-1-
sulfonyl)-
azepan-4-ylcarbamoyll-3-methyl-1-butyll- amide
Following the general procedure of Examples 280h j except substituting
quinoxaline-2-carboxylic acid for benzofuran-2-carboxylic acid and 1-
propanesulfonyl
chloride for 3-flurobenzenesulfonyl chloride provided the title compound as a
mixture of
diastereomers.
Separation of the diastereomers by HPLC provided diastereomer 1: MS(ES) 503.4
(M+H)+ and diastereomer 2 MS(ES) 503.4 (M+H)+.
Example 322
Preparation of Thiophene-2-carboxylic acid 1(S)-1-f3-oxo-1-(propane-1-
sulfonyl)-azepan-
4-ylcarbamoyll-3-methyl-1-butyll- amide
Following the general procedure of Examples 280h j except substituting
thiophene-
2-carboxylic acid for benzofuran-2-carboxylic acid and 1-propanesulfonyl
chloride for 3-
flurobenzenesulfonyl chloride provided the title compound as a mixture of
diastereomers.
Separation of the diastereomers by HPLC provided diastereomer 1: MS(ES) 457.4
(M+H)+ and diastereomer 2 MS(ES) 457.4 (M+H)+.
277
CA 02412353 2002-12-13
WO 01/95911 PCT/USO1/19062
Example 323
Preparation of 5-Methyl-thiophene-2-carboxylic acid~(S)-1-f3-oxo-1 propane-1-
sulfon~l~-azepan-4ylcarbamoyll-3-methyl-1-butyll- amide
Following the general procedure of Examples 280h j except substituting 5-
methyl-
thiophene-2-carboxylic acid for benzofuran-2-carboxylic acid and 1-
propanesulfonyl
chloride for 3-flurobenzenesulfonyl chloride provided the title compound as a
mixture of
diastereomers.
Separation of the diastereomers by HPLC provided diastereomer 1: MS(ES) 471.4
(M+H)+ and diastereomer 2 MS(ES) 471.4 (M+H)+.
Example 324
Preparation of 5-Methoxy-3-methyl-benzofuran-2-carboxylic acid ~ (S)-3-methyl-
1-f 3-oxo-
1-( 1-oxy-pyridine-2-sulfonyl)-azepan-4-ylcarbamo 1~~~-amide
Following the general procedure of Examples 291c-d except substituting 5-
methoxy-3-methyl-benzofuran-2-carboxylic acid for 5-fluoro-benzofuran-2-
carboxylic acid
provided the title compound as a mixture of diastereomers: MS(ES) 587 (M+H)+.
Separation of the diastereomers by HPLC provided diastereomer 1: MS(ES) 565.2
(M+H)~ and diastereomer 2 MS(ES) 565.2 (M+H)+.
Exam 1p a 325
Preparation of 3,5-Dimeth~l-benzofuran-2-carboxylic acid (S)-3-meth-1-f3-oxo-1-
(1-
ox~pyridine-2-sulfonyl)-azepan-4-ylcarbamoyll-but~~-amide
Following the general procedure of Examples 291c-d except substituting 3,5-
dimethyl-benzofuran-2-carboxylic acid for 5-fluoro-benzofuran-2-carboxylic
acid provided
the title compound as a mixture of diastereomers: MS(ES) 571 (M+H)+.
Separation of the diastereomers by HPLC provided diastereomer 1 and
diastereomer 2.
278
CA 02412353 2002-12-13
WO 01/95911 PCT/USO1/19062
Example 326
Preparation of 3-Ethyl-benzofuran-2-carboxylic acid -(S)-3-methyl-1-f3-oxo-1~1-
ox~
pyridine-2-sulfonxl)-azepan-4-ylcarbamo 1~1-b-u~l)-amide
Following the general procedure of Examples 291c-d except substituting 3-ethyl-
benzofuran-2-carboxylic acid for 5-fluoro-benzofuran-2-carboxylic acid
provided the title
compound as a mixture of diastereomers: MS(ES) 571 (M+H)+.
Separation of the diastereomers by HPLC provided diastereomer 1 and
diastereomer 2.
Example 327
Preparation of 4-Methoxy-3-methyl-benzofuran-2-carboxylic acid ~S)-3-methyl-1-
f3-oxo-
1-( 1-oxy-pyridine-2-sulfonyl)-azepan-4-ylcarbamoyll-bull ~-amide
Following the general~procedure of Examples 291c-d except substituting 4-
methoxy-3-methyl-benzofuran-2-carboxylic acid for 5-fluoro-benzofuran-2-
carboxylic acid
provided the title compound as a mixture of diastereomers: MS(ES) 587 (M+H)+.
Separation of the diastereomers by HPLC provided diastereomer 1 and
diastereomer 2.
Exam In a 328
Preparation of 1-Meth-naphthof2,1-bl-furan-2-carboxylic acid ((S)-3-methyl-1-
f3-oxo-1-
( 1-oxy-pyridine-2-sulfonyl)-azepan-4-ylcarbamoyl~-butyl -amide
Following the general procedure of Examples 291c-d except substituting 1-
methyl-
naphtho[2,1-b]-furan-2-carboxylic acid for 5-fluoro-benzofuran-2-carboxylic
acid provided
the title compound as a mixture of diastereomers: MS(ES) 607 (M+H)+.
Separation of the diastereomers by HPLC provided diastereomer 1 and
diastereomer 2.
279
CA 02412353 2002-12-13
WO 01/95911 PCT/USO1/19062
Example 329
Preparation of 6-Methoxy-3-methyl-benzofuran-2-carboxylic acid (S)-3-methyl-1-
f3-oxo-
l~- 1-ox~pyridine-2-sulfonyl)-azepan-4-ylcarbamoyll-butyll-amide
Following the general procedure of Examples 291c-d except substituting 6-
methoxy-3-methyl-benzofuran-2-carboxylic acid for 5-fluoro-benzofuran-2-
carboxylic acid
provided the title compound as a mixture of diastereomers: MS(ES) 587 (M+H)+.
Separation of the diastereomers by HPLC provided diastereomer 1 and
diastereomer 2.
Example 330
Preparation of 3-Methyl-benzofuran-2-carboxylic acid ~ 1,3-dimethyl-1-f3-oxo-1-
(1-ox~
pyridine-2-sulfon~)-azepan-4-ylcarbamoyll-butyl;~-amide
a.) 4-(2-tent-Butoxycarbonylamino-2,4-dimethyl-pentanoylamino)-3-hydroxy-
azepane-1-carboxylic acid benzyl ester
To a solution of N-[(1,1-dimethylethoxy)carbonyl]-2-methyl-(d,l)-leucine
(3.0g) in
methlene chloride was added EDC (2.34g), HOBt (1.65g), Et3N (1.7 ml) and the
compound
of Example 280e (3.23 g). After stirring at room temperature over night the
mixture was
washed with O.1N HCI, Sat. NaHC03, H20, Brine. The organic layer was
concentrated and
residue was purified by flash column chromatography eluting with CH2C12 :
CH30H
(95:5) to give the title compound as a white solid (4.0g, 66.6%). MS: 492.4
(M+H)+
b. ) [1-(3-Hydroxy-azepan-4-ylcarbamoyl)-1,3-dimethyl-butyl]-carbamic acid
tert-
butyl ester
To a solution of the compound of Example 330(a) (3.04 g, 8.00 mmol) in ethyl
acetate (50 mL) was added 10% palladium on carbon (1.5 g). After stirring at
room
temperature under a hydrogen atmosphere for 16 h, the mixture was filtered
through celite.
The filtrate was concentrated to yield the title compound as a yellow oil
(1.97 g, 100%)
MS (ESI): 358.4 (M+H)+.
280
CA 02412353 2002-12-13
WO 01/95911 PCT/USO1/19062
c.) { I-[3-Hydroxy-1-(1-hydroxy-pyridine-2-sulfonyl)-azepan-4-ylcarbamoyl]-1,3-
dimethyl-butyl }-carbamic acid tert-butyl ester
2-Mercaptane N-oxide (1.25g) was disolved in concentrated HCl (5.5m1). After.
cooled to OoC water (3m1) was added. C12 gas was bubbled through this solution
for 1.5h.
Water solution was extacted with cold CH2C12 then the combined organic layer
was
washed with Sat.NaHC03, brine. To a solution of the compound of Example 330b
(1.20 g)
and Et3N (1.3 ml) in DCE (10 ml) was added the sulfonyl chloride which was
freshly
prepared above at OoC. Stirring was kept for 1h then the reaction mixture was
washed with
brine, dried over Na2S04, concentrated and purified through flash column
chromatograpghy eluting with CH2Cl2: CH30H (95:5). The filtrate was
concentrated to
yield the title compound as white solid (1.2 g, 70%). MS: 515.4 (M+H)+.
d.) 2-Amino-2,4-dimethyl-pentanoic acid [3-hydroxy-1-(hydroxy-pyridine-2-
sulfonyl)-
azepan-4-yl]-amide
To a stirring solution of the compound of Example 330c (1.0g, 2.04 mmol) in
methanol (lOml) was added HCl (4M in Dioxane) (10 ml). After stirring at room
temperature for 3hr, the solution was concentrated to get white solide. To a
solution of the
white solid (0.81g, 1.53mmol, 75%) in methnol (30m1) was added P-C03 (2.9g,
2.63mmo1/g). After shaking for 2hr, the solution was filtered and concentrated
to yield the
title compound as white solid (0.57g, 1.45mmol, 95%). MS: 415.4 (M+H)+.
e.) 3-Methyl-benzofuran-2-carboxylic acid { 1,3-dimethyl-1-[3-hydroxy-1-(1-oxy-
pyridine-2-sulfonyl)-azepan-4-ylcarbamoyl]-butyl }-amide
To a solution of the compound of Example 330d (0.150 g, 0.448 mmol) in CHZCIz
(20 mL) was added 3-methyl benzofuran-2-carboxylic acid (0.109 g), 1-
hydroxybenzotriazole (0.106g, 0.762mmol), and P-EDC (0.85g, lmmol/g) in CHZC12
(10
mL) . After shaking at room temperature for over night, the solution was
treated with
tisamine (0.589g, 3.75mmol/g). After shaking for another 2hr, the solution was
filtered and
concentrated to yield the title compound as a white solid (166.7mg, 70%). MS
(ESI):
573.2(M+H)+.
281
CA 02412353 2002-12-13
WO 01/95911 PCT/USO1/19062
f.) 3-Methyl-benzofuran-2-carboxylic acid{ 1,3-dimethyl-1-[3-oxo-1-(oxy-
pyridine-2-
sulfonyl)-azepan-4-ylcarbamoyl]-butyl }-amide
To a stirring solution of the compound of Example 330e (140.7mg, 0.245mmo1) in
DMSO (2mL) was added Py-S03 (155.7mg, 0.98mmo1) and Et3N (0.27m1, 1.96mmo1).
After stirring at room temperature for 2 h. Sat. NaHC03 and ethyl acetate was
added to
quench the reaction. Organic layer was washed with brine, dried over Na SOQ
and
2
concentrated.The residue was purified through flash column chromatograghy
eluting with
CH2C12 :CH30H (95:5) to yield the title compound as a white solid (69.9mg,
50.8 °Io).
MS (ESI): 571.2(M+H)+ .
Example 331
Preparation of Benzofuran-2-carboxylic acid f(S)-3-methyl-1-f3-oxo-1-quinolin-
2-
ylmethyl-azepan-4-ylcarbamoyll-butyl ~-amide
a.) [(S)-1-(3-Hydroxy-1-quinoline-2-ylmethyl-azepan-4-ylcarbamoyl)-3-methyl-
butyl]-
carbamic acid tent-butyl ester
To a solution of the compound of Example 280g (1.0 g) in CHZClz was added oc-
quinoline carbaldehyde (0.68 g) and NaBH(OAc)3 (1.2 g). Workup and column
chromatography (6% methanol: dichloromethane) provided 1.4 g of the title
compound:
MS(ES) 485 (M+H)+.
b.) (S)-2-Amino-4-methyl-pentanoic acid (3-hydroxy-1-quinolin-2-methyl-azepan-
4-yl)-
amide
To a solution of the compound of Example 331a (1.4 g) in methanol (20 mL) was
added 4M HCl in dioxane (20 mL). The reaction was stirred until complete
whereupon the
reaction was concentrated to provide 1.3 g of the title compound: MS(ES) 385
(M+H)+.
282
CA 02412353 2002-12-13
WO 01/95911 PCT/USO1/19062
c. ) Benzofuran-2-carboxylic acid [(S)-3-methyl-1-[3-hydroxy-1-quinolin-2-
ylmethyl-
azepan-4-ylcarbamoyl]-butyl }-amide
Following the general procedure of Example 291c except substituting the
compound of Example 331b and benzofuran-2-carboxylic acid for 5-fluoro-
benzofuran-2-
carboxylic acid the title compound was prepared: MS(ES) 545 (M+H)+.
d.) Benzofuran-2-carboxylic acid [(S)-3-methyl-1-[3-oxo-1-quinolin-2-ylmethyl-
azepan-4-ylcarbamoyl]-butyl }-amide
Following the general procedure of Example 291d except substituting the
compound of Example 331c the title compound was prepared: MS(ES) 543 (M+H)+.
Example 332
Preparation of 3-Methyl-benzofuran-2-carbox~ic acid [(S)-3-methyl-1-f 3-oxo-1-
quinolin-
2-ylmethyl-azepan-4-ylcarbamo~l-butyl?-amide
Following the procedure of Example 331c-d except substituting 3-methyl-
benzofuran-2-carboxylic acid for benzofuran-2-carboxylic acid the title
compound was
prepared: MS(ES) 541 (M+H)+.
Example 333
Preparation of Benzofblthiophene-2-carboxylic acid f(S)-3-methyl-1-f3-oxo-1-
quinolin-2-
ylmeth 1-azepan-4-ylcarbamoyll-butyl-amide
Following the procedure of Example 331c-d except substituting
benzo[b]thiophene-
2-carboxylic acid for benzofuran-2-carboxylic acid the title compound was
prepared:
MS(ES) 541 (M+H)+.
283
CA 02412353 2002-12-13
WO 01/95911 PCT/USO1/19062
Example 334
Preparation of Benzofuran-2-carboxylic acid ((S -3-methyl-1-13-oxo-1-f 1-
toluene-2-
sulfonylamino)-methanoyll-azepan-4-~carbamoyll-butyl)-amide
a.) ((S)-1-{3-Hydroxy-1-[1-(toluene-2-sulfonylamino)-methanoyl]-azepan-4-
ylcarbamoyl}-3-methyl-butyl)-carbamic acid tert-butyl ester
To a solution of the compound of Example 280g (1.0 g) in CHzCIz was added o-
toluenesulfonyl isocyanate (0.68 g). The reaction was stirred until complete
consumption
of the starting material was observed. Workup and column chromatography (6%
methanol:dichloromethane) provided 1.28 g of the title compound: MS(ES) 541
(M+H)+.
b.) (S)-2-Amino-4-methyl-pentanoic acid {3-hydroxy-1-[1-(toluene-2-
sulfonylamino)-
methanoyl]-azepan-4-yl }-amide
Following the procedure of Example 283a except substituting the compound of
Example 334a the title compound was prepared: MS(ES) 441 (M+H)+.
c.) Benzofuran-2-carboxylic acid ((S)-3-methyl-1-{3-hydroxy-1-[1-toluene-2-
sulfonylamino)-methanoyl]-azepan-4-ylcarbamoyl }-butyl)-amide
Following the procedure of Example 280i except substituting the compound of
Example 334b the title compound was prepared: MS(ES) 585 (M+H)+.
d.) Benzofuran-2-carboxylic acid ((S)-3-methyl-1-{3-oxo-1-[1-toluene-2-
sulfonylamino)-methanoyl]-azepan-4-ylcarbamoyl }-butyl)-amide
Following the procedure of Example 2914 except substituting the compound of
Example 334c the title compound was prepared: MS(ES) 583 (M+H)+.
284
CA 02412353 2002-12-13
WO 01/95911 PCT/USO1/19062
Example 335
Preparation of 3-Methyl-benzofuran-2-carboxylic acid ((S)-3-methyl-1-(3-oxo-1-
11-
toluene-2-sulfonylamino)-methanoyl]-azepan-4-ylcarbamo 1~~-butyl)-amide
Following the procedures of Example 334c-d except substituting 3-methyl-
benzofuran-2-carboxylic acid for benzofuran-2-carboxylic acid the title
compound was
prepared: MS(ES) 597 (M+H)+.
Example 336
Preparation of Benzofblthiophene-2-carboxylic acid ((S)-3-methyl-1-~3-oxo-1-f1-
toluene-
2-sulfonylamino)-methanol-azepan-4-ylcarbamoyl ~-butyl)-amide
Following the procedures of Example 334c-d except substituting
Benzo[b]thiophene-2-carboxylic acid for benzofuran-2-carboxylic acid the title
compound
was prepared: MS(ES) 599 (M+H)+.
Example 337
Preparation of Benzofuran-2-carboxylic acid ((S)-3-methyl-1-i3-oxo-1-f2-chloro-
benzenesulfonylamino)-methanoyll-azepan-4-ylcarbamoyl ~-butt)-amide
Following the procedures of Example 334a-d except substituting 2-
chlorobenzenesulfonyl isocyanate for o-toluenesulfonyl isocyanate the title
compound was
prepared: MS(ES) 603 (M+H)+.
285
CA 02412353 2002-12-13
WO 01/95911 PCT/USO1/19062
Example 338
Preparation of 3-Methyl-benzofuran-2-carboxylic acid ((S)-3-methyl-1-j3-oxo-1-
j2-chloro-
benzenesulfonylamino)-methanoyll-azepan-4-ylcarbamoyl ~-butyl)-amide
Following the procedures of Example 334a-d except substituting 2-
chlorobenzenesulfonyl isocyanate for o-toluenesulfonyl isocyanate and 3-methyl-
benzofuran-2-carboxylic acid for benzofuran-2-carboxylic acid the title
compound was
prepared: MS(ES) 617 (M+H)+.
Example 339
Preparation of Benzofblthiophene-2-carboxylic acid ((S)-3-methyl-1-~3-oxo-1-f2-
chloro-
benzenesulfon~lamino)-methanoyll-azepan-4-ylcarbamo. 1~1-butyl)-amide
Following the procedures of Example 334a-d except substituting 2-chlorobenzene
sulfonyl isocyanate for o-toluenesulfonyl isocyanate and benzo[b]thiophene-2-
carboxylic
acid for benzofuran-2-carboxylic acid the title compound was prepared: MS(ES)
619
(M+H)+.
Example 340
Preparation of Benzofuran-2-carboxylic acid ((S)-3-methyl-1-j3-oxo-1-f4-fluoro-
benzenesulfonylamino)-methanoyll-azepan-4-ylcarbamoyl ~-butyl)-amide
Following the procedures of Example 334a-d except substituting 4-fluorobenzene
sulfonyl isocyanate for o-toluenesulfonyl isocyanate the title compound was
prepared:
MS(ES) 587 (M+H)+.
286
CA 02412353 2002-12-13
WO 01/95911 PCT/USO1/19062
Example 341
Preparation of 3-Methyl-benzofuran-2-carbox~c acid ((S)-3-methy~3-oxo-1-f4-
fluoro-
benzenesulfonylamino)-methanoyll-azepan-4-ylcarbamo~ -butyl)-amide
Following the procedures of Example 334-d except substituting 4-fluorobenzene
sulfonyl isocyanate for o-toluenesulfonyl isocyanate and 3-methyl-benzofuran-2-
carboxylic
acid for benzofuran-2-carboxylic acid the title compound was prepared: MS(ES)
601
(M+H)+.
Example 342
Preparation of Benzofblthiophene-2-carboxylic acid ((S)-3-methy~3-oxo-1-f4-
fluoro-
benzenesulfonylamino)-methanoyll-azepan-4-ylcarbamoyl -butyl)-amide
Following the procedures of Example 334a-d except substituting 4-fluorobenzene
sulfonyl isocyanate for o-toluenesulfonyl isocyanate and benzo[b]thiophene-2-
carboxylic
acid for benzofuran-2-carboxylic acid the title compound was prepared: MS(ES)
603
(M+H)+.
Example 343
Preparation of Benzofuran-2-carboxylic acid ((S)-3-methyl-1-~ 3-oxo-1-f 1-
toluene-4-
sulfonylamino)-methanoyll-azepan-4-ylcarbamo l~l-butyl)-amide
Following the procedures of Example 334a-d except substituting p-
toluenesulfonyl
isocyanate for o-toluenesulfonyl isocyanate the title compound was prepared:
MS(ES) 583
(M+H)+.
287
CA 02412353 2002-12-13
WO 01/95911 PCT/USO1/19062
Example 344
Preparation of 3-Methyl-benzofuran-2-carboxylic acid ((S)-3-methy~3-oxo-1-~1-
toluene-4-sulfonylamino)-methanoyll-azepan-4-ylcarbamoyl ~-butt)-amide
Following the procedures of Example 334a-d except substituting p-
toluenesulfonyl
isocyanate for o-toluenesulfonyl isocyanate and 3-methyl-benzofuran-2-
carboxylic acid for
benzofuran-2-carboxylic acid the title compound was prepared: MS(ES) 597
(M+H)+.
Example 345
Preparation of Benzofblthiophene-2-carboxylic acid ((S)-3-meth,; 3-oxo-1-f 1-
toluene-
4-sulfonylamino)-methano, l~-azepan-4-ylcarbamoyl ~-butyl)-amide
Following the procedures of Example 334a-d except substituting p-
toluenesulfonyl
isocyanate for o-toluenesulfonyl isocyanate and benzo[b]thiophene-2-carboxylic
acid for
benzofuran-2-carboxylic acid the title compound was prepared: MS(ES) 597
(M+H)+.
Example 346
Preparation of Benzofuran-2-carboxylic acid ~ (S)-3-methyl-1-f 1-(6-methyl-
pyridin-2-
Methyl)-3-oxo-azepan-4 ylcarbamo l~utyl~-amide
Following the general procedures of Example 331a-d except substituting 6-
methylpyridine-2-aldehyde for o~-quinoline carbaldehyde the title compound was
prepared:
MS(ES) 491 (M+H)+.
The diastereomers were separated by HPLC to provide diastereoemr 1 and
diastereomer 2.
288
CA 02412353 2002-12-13
WO 01/95911 PCT/USO1/19062
Example 347
Preparation of 3-Methyl-benzofuran-2-carboxylic acid (S)-3-methyl-1-f 1-(6-
methyl-
pyridin-2-ylmethyl)-3-oxo-azepan-4-~lcarbamoyl~-but~~mide
Following the general procedures of Example 331a-d except substituting 6-
methylpyridine-2-aldehyde for a-quinoline carbaldehyde and 3-methyl-benzofuran-
2-
carboxylic acid for benzofuran carboxylic acid the title compound was
prepared: MS(ES)
505 (M+H)+.
The diastereomers were separated by HPLC to provide diastereoemr 1 and
diastereomer 2.
Exam 1p a 348
Preparation of Benzofblthiophene-2-carboxylic acid (S)-3-methyl-1-f 1 ~6-
methyl-pyridin-
2-ylmethyl)-3-oxo-azepan-4-ylcarbamoyll-butyl l-amide
Following the general procedures of Example 331a-d except substituting 6-
methylpyridine-2-aldehyde for a-quinoline carbaldehyde and benzo[b]thiophene-2-
carboxylic acid for benzofuran carboxylic acid the title compound was
prepared: MS(ES)
507 (M+H)+.
The diastereomers were separated by HPLC to provide diastereomer 1 and
diastereomer 2.
Example 349
Preparation of Benzofblthiophene-2-carboxylic acid 1(S)-1-fl-(2-fluoro-
phenylcarbamo~)-
3-oxo-azepan-4-ylcarbamoyll-3-methyl-but~~-amide
a.) {(S)-1-[1-(2-fluorophenylcarbamoyl)-3-hydroxy-azepan-4-ylcarbamoyl]-3-
methyl-
butyl}-carbamic acid tert-butyl ester
To a solution of the compound of Example 280g (0.1 gm, 0.29mmol) dissolved in
THF was added 2-flurophenyl isocyanate (32 ml, 0.29 mmol) and stirred for lhr.
THF was
289
CA 02412353 2002-12-13
WO 01/95911 PCT/USO1/19062
removed zn vaccuo and the compound was directly used in the next step: MS(ES):
481.02(M+H)+.
b.) 4-((S)-2-Amino-4-methyl-pentanoylamino)-3-hydroxy-azepane-1-carboxylic
acid
(2-fluoro-phenyl)-amide
To a solution of the compound of Example 349a (1.96 g, 4.1 mmol) dissolved in
MeOH was added 4M HCl/ dioxane (5m1, 20.3 mmol) and allowed to stir at RT for
2hr.
Excess reagent was removed ira vaccuo and azeotroped with toluene to yield
1.84gm of the
product.
c.) Benzo[b]thiophene-2-carboxylic acid {(S)-1-[1-(2-fluoro-phenylcarbamoyl)-3-
hydroxy-azepan-4-ylcarbamoyl]-3-methyl-butyl }-amide
To a solution of the compound of Example 349b (0.11 g, 0.28 mmol) dissolved in
dichloromethane were added P-EDC (0.35 g , 1.8 mmol/g), HOBT ( 0.06 g, 0.49
mmol) and
2-benzothiophene carboxylic acid (0.077 gm, 0.432 mmol). The reaction mixture
was
shaken for 16 hr. The reaction was continued for one more hour by the addition
of
trisamine(0.38 gm, 3.7 mmol/g), followed by the filtration of the product. The
product was
purified on a silica gel column to yield 112.5 mg of the product: MS(ES):
541.2(M+H)+.
d.) Benzo[b]thiophene-2-carboxylic acid {(S)-1-[1-(2-fluoro-phenylcarbamoyl)-3-
oxo-
azepan-4-ylcarbamoyl]-3-methyl-butyl }-amide
To a solution of the compound of example 349c (0.112 g, 0.2 mmol) was
dissolved
in dichloromethane followed by the addition of Dess-Martin periodinane (0.175
g, 0.41
mmol). The reaction was stirred for lhr followed whereupon it was washed with
NaZSz03,
NaHC03 and brine. The compound was purified on a silica gel column to yield 78
mg of
the product as a mixture of diastereomers. Separation of the diastereomers by
HPLC
provided diastereomer l: MS (ES) 539 (M+H)+ and diastereomer 2: 539 MS(ES)
(M+H)+.
290
CA 02412353 2002-12-13
WO 01/95911 PCT/USO1/19062
Example 350
Preparation of 3-Methyl-benzofuran-2-carboxylic acid (S)-1-f 1-(2-fluoro-
phenylcarbamoyl)-3-oxo-azepan-4-ylcarbamoyll-3-methyl-butyl -amide
Following the general procedures of example 349c-d except substituting 3-
methyl-
benzofuran-2-carboxylic acid for benzo[b]thiophene-2-carboxylic acid the title
compound
was prepared.
Separation of the diastereomers by HPLC provided diastereomer 1: MS(ES) 537
(M+H)* and diastereomer 2: MS(ES) 537 (M+H)*.
Example 351
Preparation of 2,4-Dimethylfuran-3-carboxylic acid (S)-1-f 1-(2-fluoro-
phe~lcarbamo~l~
3-oxo-azepan-4-~lcarbamoyll-3-methyl-butyl l-amide
Following the general procedures of example 349c-d except substituting 2,4-
dimethylfuran-3-carboxylic acid for benzo[b]thiophene-2-carboxylic acid the
title
compound was prepared.
Separation of the diastereomers by HPLC provided diastereomer 1: MS(ES) 501
(M+H)* and diastereomer 2: MS(ES) 501 (M+H)*.
Example 352
Preparation of Quinoxaline-2-carboxylic acid (S)-1-f 1-(2-fluoro-
phenylcarbamoyl)-3-oxo-
azepan-4-ylcarbamoyll-3-methyl-butyll-amide
Following the general procedures of example 349c-d except substituting
quinoxaline-2-carboxylic acid for benzo[b]thiophene-2-carboxylic acid the
title compound
was prepared.
Separation of the diastereomers by HPLC provided diastereomer 1: MS(ES) 535
(M+H)* and diastereomer 2: MS(ES) 535 (M+H)*.
291
CA 02412353 2002-12-13
WO 01/95911 PCT/USO1/19062
Example 353
Preparation of Thieno~3,2-blthio~hene-2-carboxylic acid;(S)-1-tl-(2-fluoro-
phenylcarbamo~)-3-oxo-azepan-4-ylcarbamoyll-3-methyl-butyl l-amide
Following the general procedures of example 349c-d except substituting
thieno[3,2-b]thiophene-2-carboxylic acid for benzo[b]thiophene-2-carboxylic
acid the title
compound was prepared.
Separation of the diastereomers by HPLC provided diastereomer 1: MS(ES) 545
(M+H)+ and diastereomer 2: MS(ES) 545 (M+H)+.
Example 354
Preparation of Quinoline-2-carboxylic acid ( (S)-1-f 1-(2-fluoro-
phenylcarbam~l)-3-oxo-
azepan-4-ylcarbamoyll-3-methyl-butyl -amide
Following the general procedures of example 349c-d except substituting
quinoline-
2-carboxylic acid for benzo[b]thiophene-2-carboxylic acid the title compound
was
prepared.
Separation of the diastereomers by HPLC provided diastereomer 1: MS(ES) 534
(M+H)+ and diastereomer 2: MS(ES) 534 (M+H)~.
Example 355
Preparation of 4-Methyl-thiophene-2-carboxylic acid ~(S)-1-f 1-(2-fluoro-
phenylcarbamoyl)-3-oxo-azepan-4-ylcarbamoyll-3-methyl -amide
Following the general procedures of example 349c-d except substituting 4-
methyl-
thiophene-2-carboxylic acid for benzo[b]thiophene-2-carboxylic acid the title
compound
was prepared.
Separation of the diastereomers by HPLC provided diastereomer l: MS(ES) 503
(M+H)+ and diastereomer 2: MS(ES) 503 (M+H)+.
292
CA 02412353 2002-12-13
WO 01/95911 PCT/USO1/19062
Example 356
Preparation of 5-Methoxy-benzofuran-2-carboxylic acid ~ (S)-1-f 1-(2-fluoro-
phenylcarbamo~)-3-oxo-azepan-4-ylcarbamoyll-3-meth~yl ~-amide
Following the general procedures of example 349c-d except substituting 5-
methoxy-benzofuran-2-carboxylic acid for benzo[b]thiophene-2-carboxylic acid
the title
compound was prepared.
Separation of the diastereomers by HPLC provided diastereomer 1: MS(ES) 553
(M+H)+ and diastereomer 2: MS(ES) 553 (M+H)+.
Example 357
Preparation of 4-Methyl-furan-2-carboxylic acid ( (S)-1-f 1-(2-fluoro-
phenylcarbamo l~)-3-
oxo-azepan-4-ylcarbamoyll-3-methyl-butyl-amide
Following the general procedures of example 349c-d except substituting 4-
methyl-
furan-2-carboxylic acid for benzo[b]thiophene-2-carboxylic acid the title
compound was
prepared.
Separation of the diastereomers by HPLC provided diastereomer 1: MS(ES) 487
(M+H)+ and diastereomer 2: MS(ES) 487 (M+H)+.
Example 358
Preparation of Benzofuran-2-carboxylic acid f(S)-1-(1-butyl-3-oxo-azepan-4-
ylcarbamoyl)-
3-methyl-butyll-amide
Following the general procedure of Examples 331a-d except substituting
butyraldehyde for a-quinoline carbaldehyde the title compound was prepared.
Separation
of the diastereomers by HPLC provided diastereomer 1: MS(ES) 441.9 (M+H)+ and
diastereomer 2: MS(ES) 441.9 (M+H)+.
293
CA 02412353 2002-12-13
WO 01/95911 PCT/USO1/19062
Example 359
Preparation of Benzofuran-2-carboxylic acid f(S)-1-(1-propyl-3-oxo-azepan-4-
ylcarbamoyl)-3-meth~yll-amide
Following the general procedure of Examples 331a-d except substituting
propionaldehyde for a-quinoline carbaldehyde the title compound was prepared.
Separation of the diastereomers by HPLC provided diastereomer 1: MS(ES) 428
(M+H)+
and diastereomer 2: MS(ES) 428 (M+H)+.
Example 360
Preparation of Benzofuran-2-carboxylic acid {(S)-1-[1-( 494.2)-3-oxo-azepan-4-
ylcarbamoyl]-3-methyl-butyl }-amide
Following the general procedure of Examples 331a-d except substituting 2-
fluorobenzaldeyde for a-quinoline carbaldehyde the title compound was
prepared.
Separation of the diastereomers by HPLC provided diastereomer 1: MS(ES) (M+H)+
and
diastereomer 2: MS(ES) 494.2 (M+H)+.
Example 361
Pr~aration of Benzofuran-2-carbox lic acid (S)-3-methyl-1-f 1-(2-morpholin-4-
yl-thiazol-
4-ylmethyl)-3-oxo-azepan-4-ylcarbamoyll-butyl )-amide
Following the general procedure of Examples 331a-d except substituting 2-
morpholin-4-yl-thiazole-4-carbaldehyde for a-quinoline carbaldehyde the title
compound
was prepared. Separation of the diastereomers by HPLC provided diastereomer 1:
MS(ES)
568.2 (M+H)+ and diastereomer 2: MS(ES) 568.4 (M+H)+.
294
CA 02412353 2002-12-13
WO 01/95911 PCT/USO1/19062
Exam 1p a 362
Preparation of Benzofuran-2-carboxylic acid 1 (S)-1-f 1-(5-ethyl-furan-2-
ylmethxl)-3-oxo-
azepan-4-ylcarbamoyll-3-methyl-butyl l-amide
Following the general procedure of Examples 331a-d except substituting 5-ethyl-
2-
furaldehyde for a-quinoline carbaldehyde the title compound was prepared.
Separation of
the diastereomers by HPLC provided diastereomer 1: MS(ES) 549.4 (M+H)+ and
diastereomer 2: MS(ES) 549.4 (M+H)+.
Example 363
Preparation of Benzofuran-2-carboxylic acid (S)-1-f 1-(3,4-dimethyl-thienof3,2-
blthiophene-2-ylmethyl)-3-oxo-azepan-4-ylcarbamoyll-3-methyl-butyl l-amide
Following the general procedure of Examples 331a-d except substituting 3,4-
diemethylthieno[b]thiophene-2-carboxaldehyde for a-quinoline carbaldehyde the
title
compound was prepared. Separation of the diastereomers by HPLC provided
diastereomer
1: MS(ES) 566.2 (M+H)+ and diastereomer 2: MS(ES) 566.2 (M+H)+.
Example 364
Preparation of Benzofuran-2-carboxylic acid 1 (S~ 3-methyl-1-13-oxo-1-(3-
phenyl-3H-
j1,2,31triazol-4- l~thyl)-azepan-4-ylcarbamo l~yl~-amide
Following the general procedure of Examples 331a-d except substituting 2-
phenyl-
2H-pyrazole-3-carbaldehyde for a-quinoline carbaldehyde the title compound was
prepared. Separation of the diastereomers by HPLC provided diastereomer 1:
MS(ES)
543.2 (M+H)+ and diastereomer 2: MS(ES) 543.4 (M+H)+.
295
CA 02412353 2002-12-13
WO 01/95911 PCT/USO1/19062
Example 365
Preparation of Benzofuran-2-carboxylic acid ~(S)-1-f 1-(isothiazol-3-ylmethyl-
3-oxo-
azepan-4-ylcarbamo~ -3-methyl-butyll-amide
Following the general procedure of Examples 331a-d except substituting
isothiazole-3-carbaldehyde for o~-quinoline carbaldehyde the title compound
was prepared.
Separation of the diastereomers by HPLC provided diastereomer 1: MS(ES) 483.1
(M+H)+
and diastereomer 2: MS(ES) 483.1 (M+H)k.
Example 366
Preparation of Benzofuran-2-carboxylic acid f(S)-3-methyl-1-(3-oxo-1-thiophen-
2-
ylmethyl-azepan-4-ylcarbamoyl)-butyll-amide
Following the general procedure of Examples 331a-d except substituting
thiophene-2-carbaldehyde for ~-quinoline carbaldehyde the title compound was
prepared.
Separation of the diastereomers by HPLC provided diastereomer 1: MS(ES) 582
(M+H)+
and diastereomer 2: MS(ES) 582 (M+H)+.
Exa ale 367
Preparation of Benzofuran-2-carboxylic acid f(S)-3-methyl-1-(3-oxo-1-thiophen-
2-
l~thyl-azepan-4;ylcarbamoXl -butyll-amide
Following the general procedure of Examples 331a-d except substituting
benzo[b]thiophene-2-carbaldehyde for a-quinoline carbaldehyde the title
compound was
prepared. Separation of the diastereomers by HPLC provided diastereomer 1:
MS(ES) 546
(M+H)+ and diastereomer 2: MS(ES) 546 (M+H)~".
296
CA 02412353 2002-12-13
WO 01/95911 PCT/USO1/19062
Example 368
Preparation of Benzofuran-2-carboxylic acid f(S)-3-methyl-1-(3-oxo-1-pentyl-
azepan-4-
ylcarbamoyl)-butyll-amide
Following the general procedure of Examples 331a-d except substituting
pentanal
for a,-quinoline carbaldehyde the title compound Was prepared. Separation of
the
diastereomers by HPLC provided diastereomer 1: MS(ES) 556 (M+H)+ and
diastereomer 2:
MS(ES) 556 (M+H)+.
Example 369
Preparation of Benzofuran-2-carboxylic acid (S)-3-methyl-1-f 1-(1-methyl-1H-
imidazol-2-
ylmethyl)-3-oxo-azepan-4-ylcarbamo 11~-but_y)-amide
Following the general procedure of Examples 331a-d except 'substituting 3-
methyl-
3H-imidazole-4-carbaldehyde for a-quinoline carbaldehyde the title compound
was
prepared: MS(ES) 480.4 (M+H)+ .
Example 370
Preparation of 1-Oxy-pyridine-2-carboxylic acid {(S)-3-methyl-1-f3-oxo-1-
(pyridine-2-
sulfon~)-azepan-4-ylcarbamoyl 1-butyl ~ amide
Following the procedure of Example 280h-j except substituting 1-oxy-pyridine-2-
carboxylic acid for 2-benzofuran-2-carboxylic acid and 2-pyridinesulfonyl
chloride for 3-
fluorobenzenesulfonyl chloride provided the title compound. Separation of the
diastereomers by HPLC gave diastereomer 1 (ESMS: M+H+ = 504.2) and
diastereomer 2
(ESMS: M+H+ = 504.2).
297
CA 02412353 2002-12-13
WO 01/95911 PCT/USO1/19062
Example 371
Preparation of 2-Oxy-pyridine-3-carboxylic acid { (S)-3-methyl-1-(3-oxo-1-
(pyridine-2-
sulfon~)-azepan-4-ylcarbamoyl 1-butt -dam
Following the procedure of Example 280h-j except substituting 2-oxy-pyridine-3-
carboxylic acid for 2-benzofuran-2-carboxylic acid and 2-pyridinesulfonyl
chloride for 3-
fluorobenzenesulfonyl chloride provided the title compound. Separation of the
diastereomers by HPLC gave diastereomer 1 (ESMS: M+H+ = 504.2) and
diastereomer 2
(ESMS: M+H+ = 504.2).
Example 372
Preparation of 1H-Benzoimidazole-5-carboxylic acid ((S)-3-methyl-1-f3-oxo-1-(p
ridine-
2-sulfon~)-azepan-4-ylcarbamoyll-but~i-amide
Following the procedure of Example 280h j except substituting 1H-
benzoimidazole-5-carboxylic acid for 2-benzofuran-2-carboxylic acid and 2-
pyridinesulfonyl chloride for 3-fluorobenzenesulfonyl chloride provided the
title
compound. Separation of the diastereomers by HPLC gave diastereomer 1 (ESMS:
M+H+
= 504.2) and diastereomer 2 (ESMS: M+H+ = 504.2).
Example 373
Preparation of 4-{~)-2-f(1-Benzofran-2-yl-methanoyl)-aminol-4-methyl-
pentanoylamino~-1-methyl-3-oxo-1-pentyl-azepanium
A solution of the compound of Example 368 in neat methyl iodide was heated at
reflux for 48 hours whereupon the mixture was concentrated to provide the
title compound:
MS(ES) 471.6 (M+H)+.
298
CA 02412353 2002-12-13
WO 01/95911 PCT/USO1/19062
Example 374
Preparation of Benzofuran-2- carboxylic acid (S)-1-f 1-(1,2-dimethyl-1 H -
imidazole-4-
sulfonyl)-3-oxo-azepan-4-ylcarbamoyll-3-methyl-butyll-amide
Following the procedure of Example 280h-j except substituting 1,2-dimethyl-1 H
-
imidazole-4-sulfonyl chloride for 3-fluorobenzenesulfonyl chloride provided
the title
compound: MS(ES) 544.4 (M+H)+.
Example 375
Preparation of Benzofuran-2- carboxylic acid (S)-1f 1-(1-methyl-1 H -imidazole-
4-
sulfonxl)-3-oxo-azepan-4-ylcarbamoyll-3-methyl-butt -amide
Following the procedure of Example 280h j except substituting 1-methyl-1 H -
imidazole-4-sulfonyl chloride for 3-fluorobenzenesulfonyl chloride provided
the title
compound: MS(ES) 530.2 (M+H)+.
Example 376
Preparation of Benzofuran-2- carbox~ic acid 1(S)-1-f 1-(1-methyl-1 H -
imidazole-4-
sulfonyl)-3-oxo-azepan-4-~carbamoyl~-3-methyl-butyl l-amide
Following the procedure of Example 280h-j except substituting 4-
methanesulfonyl-
benzenesulfonyl chloride for 3-fluorobenzenesulfonyl chloride provided the
title
compound. Separation of the diastereomers by HPLC gave diastereomer 1: MS(ES)
604.2
(M+H)+ and diastereomer 2: MS(ES) 604.2 (M+H)+.
299
CA 02412353 2002-12-13
WO 01/95911 PCT/USO1/19062
Exam Ip a 377
Preparation of Benzofuran-2-carboxylic acid (S)-1-f 1-(2-methanesulfonyl-
benzenesulfoil)-3-oxo-azepan-4-ylcarbamoyll-3-metl~l-butyl)-amide
Following the procedure of Example 280h-j except substituting 2-
methanesulfonyl-
benzenesulfonyl chloride for 3-fluorobenzenesulfonyl chloride provided the
title
compound. Separation of the diastereomers by HPLC gave diastereomer 1: MS(ES)
604.2
(M+H)+ and diastereomer 2: MS(ES) 604.2 (M+H)+.
Example 378
Preparation of Benzofuran-2-carbox lic acid (S)-1-f 1-(3,5-dimethyl-isoxazole-
4-
sulfonyl)-3-oxo-azepan-4-ylcarbamoy 11-3-methyl-butyl)-amide
Following the procedure of Example 280h-j except substituting 3,5-dimethyl-
isoxazole-4-sulfonyl chloride for 3-fluorobenzenesulfonyl chloride provided
the title
compound. Separation of the diastereomers by HPLC gave diastereomer l: MS(ES)
545.2
(M+H)+ and diastereomer 2: MS(ES) 545.2 (M+H)+.
Example 379
Preparation of 3-Methyl-benzofuran-2-carboxylic acid ((1S,2R)-2-methyl-1-f3-
oxo-1-
(pyridine-2-sulfon l~pan-4-ylcarbamo l~yll-amide
a.) 3-Methyl-benzofuran-2-carboxylic acid {(1S,2R)-2-methyl-1-[3-hydroxy-1-
(pyridine-2-sulfonyl)-azepan-4-ylcarbamoyl]-butyl }-amide
Following the general proceures of Example 280f i except substituting N-Boc-
allo-
isoleucine for N-Boc-leucine and 2-pyridinesulfonyl chloride fox 3-
fluorobenzenesulfonyl
chloride and 3-methyl-benzofuran-2-carboxylic acid for benzofuran-2-carboxylic
acid the
title compound was prepared.
300
CA 02412353 2002-12-13
WO 01/95911 PCT/USO1/19062
b.) 3-Methyl-benzofuran-2-carboxylic acid {(1S,2R)-2-methyl-1-[3-oxo-1-
(pyridine-2-
sulfonyl)-azepan-4-ylcarbamoyl]-butyl }-amide
Following the general procedure of Example 291d except substituting the
compound of Example 105b the title compound was prepared. Separation of the
diastereomers by HPLC provided diastereomer 1: MS(ES) 541 (M+H)+ and
diastereomer
2: MS(ES) 541 (M+H)+.
Example 380
Preparation of 3-Methyl-benzofuran-2-carbox ~~lic acid ~ 1-f3-oxo-1-(pyridine-
2-sulfon~)-
azepan-4-ylcarbamoyll-cyclopent~ll-amide
Following the general procedures of Examples 379a-b except substituting N-Boc-
cycloleucine for N-Boc-alto-leucine the title compound was prepared: MS(ES)
539
(M+H)+.
Example 381
Preparation of Furof3,2-bl-pyridine-2-carboxylic acid (S)-3-methyl-1-f-3-oxo-1-
(1-ox~
pyridine-2-sulfonyl)-azepan-4-ylcarbamoyll-butyll-amide
Following the general procedure of Examples 291c-d except substituting furo
[3,2-
b]-pyridine-2-carboxylic acid for 5-fluoro-benzofuran-2-carboxylic acid
provided the title
compound as a mixture of diastereomers: MS(ES) 587 (M+H)+.
Separation of the diastereomers by HPLC provided diastereomer 1: MS(ES) 544.2
(M+H)+ and diastereomer 2: MS(ES) 544.2 (M+H)+.
The above specification and Examples fully disclose how to make and use the
compounds of the present invention. However, the present invention is not
limited to the
particular embodiments described hereinabove, but includes all modifications
thereof
within the scope of the following claims. The various references to journals,
patents and
other publications which are cited herein comprise the state of the art and
are incorporated
herein by reference as though fully set forth.
301
